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Abstract 
Targeting molecules involved in Tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) -mediated signalling has been hailed by many as a 
potential magic bullet to efficiently kill cancer cells, with little side effects on 
normal cells. Indeed, initial clinical trials showed that antibodies against TRAIL 
receptors, death receptor (DR) 4 and DR5 are well tolerated by cancer patients. 
Despite the initial efficacy issues in the clinical setting, novel approaches to 
trigger TRAIL-mediated apoptosis are being developed and its clinical potential is 
being reappraised. Unfortunately, many patients develop resistance to TRAIL-
induced apoptosis and there is thus impetus for identifying additional resistance 
mechanisms that may be targetable and usable in combination therapies. Here, 
we show that the death associated protein kinase (DAPK) 2 is a modulator of 
TRAIL signalling. DAPK2 is a serine/threonine kinase that belongs to the DAPK 
family. Like DAPK1, it has been implicated in programmed cell death, the 
regulation of autophagy and developmental processes. Ablation of DAPK2 using 
RNAi causes phosphorylation of NF-κB and its transcriptional activity in several 
cancer cell lines. This then leads to the induction of a variety of NF-κB target 
genes, which includes DR4 and DR5. DR4 and DR5 protein expression is 
correspondingly increased on the cell surface and this leads to the sensitisation 
of resistant cells to TRAIL-induced killing. As DAPK2 is a kinase, it is eminently 
druggable and our data thus offer a novel avenue to overcome TRAIL-resistance 
in the clinic. We have additionally identified a new role for DAPK2 in the 
regulation of mitochondrial integrity. RNAi-mediated depletion of DAPK2 leads to 
a number of metabolic changes, including a significantly decreased rate of 
oxidative phosphorylation in combination with an overall destabilised 
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mitochondrial membrane potential. This phenotype is further corroborated by an 
increase in the production of mitochondrial superoxide anions and general 
oxidative stress. This role of DAPK2 is completely novel and could impact 
significantly on the understanding of DAPK2’s function in physiology and disease. 
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1.1 Cancer 
 
Cancer defines a group of diseases that are caused by abnormal cellular 
proliferation and have the potential to invade and metastasise to other parts of 
the body. It is not a disease that is exclusive to humans, mammals or even 
vertebrates, but is in fact postulated to have arisen in parallel to the development 
of multi-cellular organisms (Strachan et al., 1999, Ratcliff et al., 2012, Merlo et 
al., 2006). Complexity of multi-cellular organisms seems to inversely correlate 
with their propensity to develop cancer (Domazet-Loso et al., 2014), however, 
cancer can already be found in the nematode Caenorhabditis elegans, an 
invertebrate with low organisational complexity (Kirienko et al., 2010) or the very 
well studied arthropod model Drosophila melanogaster (known as the common 
fruit fly) (Vidal and Cagan, 2006). Interestingly, with a significantly reduced 
incidence, chimpanzees (Pan troglodytes), one of our most closely related 
species have also been described to develop cancer (Puente et al., 2006). The 
earliest known description of cancer, a breast cancer, in humans (Homo sapiens) 
was found in the ‘Edwin Smith Papyrus’ that is believed to be written as early as 
3000 BC (Stiefel et al., 2006, Breasted and New-York Historical Society. Library., 
1930). Other evidence, dating back to approximately 1500 BC describes a fatty 
tumour for the first time, and gives further reference to potential cancers of the 
skin, uterus, stomach and rectum (Ebbell, 1937). The Greek physician and 
scientist Hippocrates (460 - 370 BC) used the term Karkinos (ulcerated malignant 
tumour) and Karkinoma (malignant tumour) (Greek word for crab) (Weiss, 2000) 
to describe cancer as its growth and vascularisation is said to have reminded him 
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of a moving crab. This word was later translated into the Latin word for cancer 
[thoroughly reviewed in (Hajdu, 2011)].  
 
In the last 120 years medical and specifically cancer research has led to a 
thorough understanding of the aetiology and potential treatment options for this 
disease. Today, cancer is characterised by distinct properties and differentiated 
from benign lesions that are also caused by deregulated cellular growth. In 2000 
Douglas Hanahan and Robert Weinberg published the review article ‘The 
Hallmarks of Cancer’, arguing that cancer cells share six hallmarks that pave the 
way for the transformation of normal cells to malignant (cancer) cells. These 
hallmarks are (1) self-sufficiency in growth signals, (2) insensitivity to anti-growth 
signals, (3) evading apoptosis, (4) limitless replicative potential, (5) sustained 
angiogenesis and (6) tissue invasion and metastasis (Hanahan and Weinberg, 
2000).  
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Figure 1-1. The hallmarks of cancer. 
In 2000 Douglas Hanahan and Robert Weinberg published their first model of the six hallmarks 
of cancer that are acquired during tumour development. (Taken from (Hanahan and Weinberg, 
2011)) 
 
In 2010 the authors extended their initial hallmarks and added the following: (7) 
deregulated cellular energetics and (8) avoiding immune destruction as well as 
two enabling characteristics, (1) genome instability and mutation and (2) tumour 
promoting inflammation.  
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Figure 1-2. Emerging hallmarks and enabling characteristics of cancer. 
In 2011 Douglas Hanahan and Robert Weinberg extended their initial model of six hallmarks of 
cancer with the two emerging hallmarks: (i) deregulated cellular energetics and (ii) avoiding 
immune destruction. Deregulated cellular energetics referred to the capability of tumour cells to 
re-program cellular metabolic processes in order to increase energy supply for the tumour. 
Avoiding immune destruction refers to the capability of tumour cells to change the expression 
of cytokines and surface molecules in order to actively evade destruction by the immune 
system. In addition, the authors postulated the two enabling characteristics (i) genome 
instability and mutation, which drives tumour formation and (ii) tumour promoting inflammation, 
which actively promotes tumour formation. (Taken from (Hanahan and Weinberg, 2011)) 
 
Cancer is believed to be caused by the accumulation of genetic mutations within 
a cell. Normal cells can either carry a genetic pre-disposition or acquire genetic 
alterations which then lead to the failure of growth regulation and ultimately 
cause any of the above mentioned hallmarks of cancer (Hanahan and Weinberg, 
2011). Two main groups of genes have been described to be key regulators of 
‘oncogenesis’, the development of cancer. In 1989 J. Michael Bishop and Harold 
E. Varmus received the Nobel Prize in Physiology and Medicine for the discovery 
of the first group, the so-called pro-oncogenes. In normal cells, these genes are 
responsible for the induction of cellular growth and differentiation. Upon 
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deregulation, these genes become so-called oncogenes and can then induce 
uncontrolled cellular proliferation (Varmus, 1985). Their counter players are so-
called tumour suppressor genes, which protect cells from oncogenesis. In 
contrast to oncogenes these genes need to be affected on both alleles, which in 
1971 has led to the development of the two-hit hypothesis by A.G. Knudson. He 
discovered that for the onset of retinoblastoma cancer, two genetic events were 
necessary (Knudson, 1971). In addition to genetic changes, epigenetic changes 
have been associated with the development of cancer. Germline mutations or 
inherited DNA changes and accumulated DNA damage and thereby, somatic 
mutations are fundamental to the aetiology of cancer. Somatic mutations can be 
caused by environmental factors and the inability of cells to maintain DNA 
integrity in the process of aging. Cancer has even been proposed to be the 
‘natural end-state of multicellular organisms’ (Strachan et al., 1999). From an 
evolutionary point of view, mutations are the base of genetic variation and under 
selection pressure lead to survival of the most successful organism and its 
proliferation. Equivalent to the evolution of multicellular organism, the 
accumulation of somatic mutations allows ‘normal cells’ to escape its genetic 
control and faster proliferation. However, in the evolution of multicellular 
organisms there has been strong genetic selection favouring mechanisms that 
prevent ‘normal cells’ from escaping proliferation control. At least up to the point 
that multicellular organisms were able to reproduce themselves, no selection has 
favoured a long-term suppression of oncogenic lesion. Therefore, environmental 
factors, in combination with the decreased capability of the aging multicellular 
organism to prevent somatic mutations, inherited genetic alterations and 
epigenetic changes are believed to cause the development of cancer. This is 
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strongly supported by the fact that age is the most significant risk factor for the 
development of cancer (Simpson and Camargo, 1998, Stewart and Weinberg, 
2006). 
As mentioned previously, cancer cells are derived from ‘normal cells’ hence their 
physical appearance and properties are highly variable. Cancer is also described 
as malignant neoplasms, which are classified according to the cell type of which 
they originated. Five types have been described: (1) carcinomas, derived from 
epithelial cells (2) sarcomas, derived from connective tissue (3) lymphomas, 
derived from hematopoietic cells (4) germ line tumours, derived from pluripotent 
cells and (5) blastomas which are derived from immature precursor cells or 
embryonic tissue (Weinberg, 2007). The induction of oncogenesis is not only 
caused by genomic mutations but can also be induced by pathogens such as 
viruses.  Upon integration into the host genome, these pathogens can introduce 
oncogenic genetic material, thereby favouring the development of cancer. A 
prominent example is the human papillomavirus (HPV), which upon integration 
expresses proteins that interfere with the tumour suppressors p53 and 
retinoblastoma protein (Rb), thus promoting oncogenesis (Munger and Howley, 
2002). Interestingly, in humans, cancer exclusively develops out of endogenous 
cells, which cannot be easily passed onto others. However, dogs (Canis lupus 
familiaris) and Tasmanian devils (Sarcophilus harrisii) have developed parasitic 
cancers that are transmitted between individuals, so cancer cells themselves in 
this instance are infections agents (Rebbeck et al., 2009, Murchison et al., 2010).   
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1.2 Cancer therapies  
 
As old as the description of cancer are approaches to cure this disease. Many 
routes were taken to treat cancer. In ancient Egypt cancer was treated with 
cautery, knives, salts and arsenic paste that was used until the 19th century as 
‘Egyptian ointment’ (Hajdu, 2004). Other advanced civilisations in the same 
epoch applied herbal medicine or pastes containing metallic compounds such as 
iron or copper.  In the middle ages until the beginning of the 20th century, surgery 
was the only treatment options that, under some circumstances, provided a cure 
[reviewed in (Hajdu, 2011)]. The evolutionary advantage of cancer cells 
compared to normal cells in multicellular organism, their evasion of proliferation 
control, also represents their Achilles heel and has been exploited by many 
modern therapeutic strategies. The discovery of radiation by Marie and Pierre 
Curie led to the development of radiation therapy, which specifically targets fast 
proliferating cells. This therapy was the first effective non-surgical cancer 
treatment and revolutionised cancer therapy (Slater, 2012). In the 1940s and 
1950s the first chemical therapeutics were discovered and used to treat various 
types of cancer. Similar to radiation therapy chemotherapeutic agents target 
proliferating cells, thus the faster cells proliferate the more they are affected and 
in consequence cell death is induced. Some of the drugs that were discovered 
during that period are still in clinical use and provide a powerful weapon against 
some types of cancer such as methotrexate (Hashkes et al., 2014, DeVita and 
Chu, 2008). Many more classes of chemotherapeutic drugs have been 
discovered since. They all share a common mechanism of action as they target 
proliferating cells and thereby tumour cells. However, some ‘normal cells’ display 
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high proliferation rates, too e.g. immune cells. Thus chemotherapeutic and 
radiation therapy are characterised by more or less severe side effects on those 
fast proliferating cells. Even though surgery has been one of the first cancer 
treatments that provided a cure, it has not been replaced and, as surgical 
techniques advance, is still used successfully in combination with radiation and 
chemotherapy. As described earlier, not only organisms underlie evolutionary 
pressure, but also every single cell of a multicellular organism does. The 
development of cancer can be described as the failure of the whole organism to 
control growth of its individual components. The accumulation of genetic changes 
leads to the development of cancer cells, suggesting that these cells have 
acquired an evolutionary advantage compared to ‘normal cells’ (Simpson and 
Camargo, 1998, Tian et al., 2011). Upon chemotherapeutical or radiation 
treatment cancer cells lose their advantage to ‘normal cells’ and preferentially 
undergo cell death. However, evolution does not stop here and various strategies 
of cancer cells have been described leading to the evasion of therapeutic 
intervention (Holohan et al., 2013). Extensive research has been performed in 
this area and many mechanisms have been described, from temporarily stopped 
proliferation to enhanced tolerability towards treatment. All of them share the 
common cause of on-going evolution of cancer cells and the accumulation of 
favourable genetic changes in response to the evolutionary pressure generated 
by therapeutic intervention (Gottesman, 2002, Michor et al., 2006). To overcome 
this development, so-called ‘targeted therapies’ have been developed which, in 
contrast to classical treatment options, aim to specifically target cancer cells 
whilst sparing ‘normal cells’.  !  
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1.3 Targeted cancer therapies 
 
Opposed to classical non-specific chemotherapy or radiotherapy, targeted 
therapies aim to specifically interfere with molecular structures that are believed 
to play a crucial role in the development or progression of cancer. The central 
aim of targeted therapies is to discriminate ‘normal’ and cancerous cells and 
thereby increase efficiency and reduce adverse effects of cancer therapy. The 
fundamental background for the development of targeted therapies is the 
identification of potential targets. Very often the targeted structures are involved 
in oncogenesis and can be specifically targeted in cancer cells (Sawyers, 2004). 
One of the first targeted therapies, successfully used in the clinic, is Imatinib 
(trade name Gleevac). A small molecule inhibitor, which specifically targets the 
Bcr-Abl (breakpoint cluster region - Abelson murine leukaemia viral oncogene 
homolog 1) fusion kinase. This fusion kinase, which is the product of a 
chromosomal translocation, causes 90% of cases of chronic myelogenous 
leukaemia (CML) (O'Brien et al., 2003). Many more small molecules have been 
developed since and many of them target tyrosine kinases, due to their 
druggability, (Arora and Scholar, 2005). However, others have been developed, 
that for example modulate hormone receptors (Tamoxifen) (Jordan, 2006), target 
other types of kinases (Zhang et al., 2009) or inhibit heat shock protein 90 
(HSP90) (Neckers and Workman, 2012). The other big class of targeted 
therapies are antibody-based treatments, which use monoclonal antibodies 
(mAb) to specifically target cancer cells or their secreted products. Upon binding 
of these mAb the cellular immune response may be activated and clears the 
body of tumour cells. One of the most successful antibody-based targeted 
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therapies is the mAb trastuzumab (trade name Herceptin), which interferes with 
the receptor-tyrosine-protein kinase epidermal growth factor receptor (ERBB)-2, 
also known as human epidermal growth factor receptor 2 (HER2). This receptor 
is specifically upregulated in approximately 20% of breast cancer cases and 
provides an ideal target for mAb-based therapies (Hudis, 2007, Wolff et al., 
2007). 
 
Even though the use of targeted therapies has the advantage over classic cancer 
therapies to affect ‘normal’ and cancer cells differentially, both approaches still 
face the same problem of resistance development. Evolutionary pressure and on-
going mutation events can lead to tumour cells becoming resistant to treatment 
(Holohan et al., 2013, Lackner et al., 2012). To overcome this, many targeted 
therapies are used in combination with classic cancer therapies. In addition new, 
more advanced strategies are currently being developed, which for example 
combine the cell specificity of mAb with the powerful induction of cell death by 
chemotherapeutic drugs e.g. trastuzumab emtansine (trade name Kadcyla) 
(Niculescu-Duvaz, 2010). As the name implies, for the development of targeted 
therapies there is a need to identify targets that allow differentiation between 
‘normal’ and cancer cells. Much excitement was generated in the mid-nineties 
when tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, 
also known as APO2L) was identified (Wiley et al., 1995, Pitti et al., 1996, 
Sanchez-Perez et al., 2002, Kirienko et al., 2010). This cytokine binds and 
thereby activates so-called death receptors (DRs) that then specifically induce 
the induction of cell death in cancer cells. By virtue of preferentially killing cancer 
cells, TRAIL is seen by many as a ‘magic bullet’ against cancer. Therefore, DRs 
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represent an ideal structure for targeted therapy. Extensive preclinical and clinical 
research has been performed on TRAIL as well as TRAIL receptor agonists 
(TRAs). Unfortunately, as many other targeted therapies, TRAIL-based clinical 
applications face the development of resistance, hindering their clinical success. 
Several resistance mechanisms have been described but they do not account for 
all cases of resistant cells [reviewed in (Mellier et al., 2010)]. In this work we 
describe a novel approach to overcome the resistance to TRAIL. 
 
1.4 TRAIL Signalling 
1.4.1 TRAIL ligand 
 
The molecule TRAIL was identified in the mid-nineties of the last century. Two 
research groups independently reported a novel protein with significant homology 
to the already known extracellular domain of FasL and TNF-α 47, 66. They further 
reported, that picomolar concentrations of this protein were capable of inducing 
apoptosis in a variety of cultured cell lines (Pitti et al., 1996, Wiley et al., 1995). 
The 20 kb TRAIL gene is located on chromosome 3 and is composed of five 
exons and four introns (Mellier et al., 2010). Transcriptome analysis revealed that 
TRAIL can be found in a variety of human tissues, most predominantly in spleen, 
lung and prostate 67. Immunostaining, using TRAIL specific Abs confirms this 
observation, and, interestingly reveals relatively high TRAIL expression levels in 
the brain and thyroid (Daniels et al., 2005).  Human TRAIL consist of 281 amino 
acids and the homologous protein in mice consists of 291 amino acids 66. TRAIL 
has been characterised as a type II membrane protein, which can exhibit 
biological function as membrane bound,  released in microvesicles (Martinez-
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Lorenzo et al., 1999) , or cleaved by proteases into its soluble form sTRAIL 
(Liabakk et al., 2002). To achieve full biological activity, soluble TRAIL forms a 
homotrimeric structure, stabilised by a cystein residue at position 230. Mutation 
of this residue to alanine or glycine abolished TRAILs biological activity, 
suggesting that the trimeric structure is crucial for the activity of TRAIL [reviewed 
in (El-Deiry, 2005)].  
1.4.2 TRAIL Receptors 
 
It was observed that specific types of cancer cells express death receptors (DRs) 
on their cell surface such as DR4 (death receptor 4 or TRAIL-R1) and DR5 
(death receptor 5 or TRAIL-R2) (Figure 1-3a). These receptors belong to the 
TNF superfamily, contain a conserved death domain, are triggered by TRAIL and 
lead to the induction of apoptosis (Pan et al., 1997b, Sheridan et al., 1997, 
MacFarlane et al., 1997). DR4 and DR5 are type I transmembrane polypeptides 
that, like other members of the TNF superfamily contain cysteine-rich 
pseudorepeats that are fundamentally involved in ligand binding (Smith et al., 
1994). Both receptors share a high homology in their extracellular domain (58% 
identity and 70% similarity) also the intracellular domain and death domain are 
highly homologous. (Pan et al., 1997b, Chaudhary et al., 1997). The death 
domain of both receptors has been shown to be crucially involved in the induction 
of apoptosis (Chaudhary et al., 1997, McDonald et al., 2001, Dechant et al., 
2004) and both receptors require the adaptor molecule Fas-associated protein 
with death domain (FADD) to recruit the executioner cysteinyl-aspartate specific 
proteases (caspases) caspases-8 and/or caspases-10 3, 7, 44. Besides the 
recruitment of FADD, DR4 and DR5 have further been shown to interact with the 
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adaptor molecule tumour necrosis factor receptor type 1-associated death 
domain protein (TRADD), an important adaptor molecule for TNF signalling (Hsu 
et al., 1995) and receptor-interacting serine/threonine-protein kinase 1 (RIPK1, 
also known as RIP1), a kinase that has been associated with NF-κB signalling 
and necroptosis (Jouan-Lanhouet et al., 2012, Bertrand and Vandenabeele, 
2010). In addition to their pro-apoptotic function, it has been shown that DR4 and 
DR5 can activate NF-κB (nuclear factor kappa-light-chain-enhancer of activated 
B-cells) signalling. The use of caspase inhibitors in combination with the 
activation of DR4 and/or DR5 by TRAIL has further revealed that NF-κB 
activation occurs independent of TRAIL-induced apoptosis (Chaudhary et al., 
1997). Activation of NF-κB by DR4 and DR5 has been shown to be associated 
with TNF receptor-associated factor (TRAF) 2, NF-κB-inducing kinase (NIK), IκB 
kinase (IKK) α and β. It has also been demonstrated that the execution of TRAIL-
mediated apoptosis requires the inhibition of NF-κB (Kim et al., 2002). 
 
In addition to their role in extrinsic apoptotic cell death induced by TRAIL, DR4 
and DR5 have also been involved in the modulation of intrinsic apoptosis in 
response to DNA damage. RNAi mediated inactivation of DR5 was described to 
promote tumour growth and increase resistance to 5-fluoruracil (5-FU) (Wang 
and El-Deiry, 2004).  Furthermore, it has been shown that DR4 is upregulated in 
a p53 dependent manner in response to treatment with 5-FU, and that depletion 
or down regulation of FADD or DR4 itself significantly reduced 5-FU induced cell 
death (Henry et al., 2012). Underlining the important role of TRAIL induced 
apoptosis in innate tumour surveillance, mutations of the human TRAIL receptors 
DR4 and DR5 have been reported in a variety of tumours e.g. osteosarcoma, 
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non-Hodgkin lymphoma, head/neck and lung cancer (Dechant et al., 2004, Lee et 
al., 2001, McDonald et al., 2001, Pai et al., 1998, Shin et al., 2001). 
 
In addition to DR4 and DR5, TRAIL has also been shown to interact with the 
decoy receptors DcR1 (also known as TRAIL-R3) and DcR2 (also known as 
TRAIL-R4) and to bind to a soluble receptor called osteoprotegerin (OPG) 
(Marsters et al., 1997, Pan et al., 1997a). These receptors are, similar to DR4 
and DR5, also type I transmembrane polypeptides and members of the TNF 
superfamily (Pan et al., 1997b, Sheridan et al., 1997, MacFarlane et al., 1997). 
Like other members of the TNF superfamily they also contain cysteine-rich 
pseudorepeats that are fundamentally involved in ligand binding (Smith et al., 
1994). In strong contrast to DR4 and DR5, binding of TRAIL to DcR1 and DcR2 
does not lead to the activation of apoptosis. DcR1 was described as glycosyl-
phosphatidylinositol (GPI)-anchored membrane molecule that lacks an 
intracellular domain. Moreover, DcR1 has been described to inhibit TRAIL-
induced apoptosis upon overexpression, suggesting a rather modulating effect on 
TRAIL signalling. The extracellular domain of DcR1 is highly homologous to DR4 
(60%) and DR5 (50% DR5) (Sheridan et al., 1997). Under physiological 
conditions, expression of DcR1 is mostly restricted to peripheral blood leukocytes 
(PBLs) (Degli-Esposti et al., 1997b). In contrast to DcR1, DcR2 contains a 
cytosolic domain. This cytosolic domain of DcR2 contains only a portion of the 
consensus death motif, having lost 52 of 76 amino acids that encode the death 
domain of DR4 and DR5 (Walczak et al., 1997). As described for DR4 and DR5, 
DcR2 has been shown to be capable of activating NF-κB. Since NF-κB has been 
reported to mediate pro survival cues, DcR2 is likely to regulate TRAIL-induced 
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apoptosis via competition for TRAIL and via the induction of pro-survival 
signalling (Degli-Esposti et al., 1997a). Interestingly, DcR2 has also been 
reported to negatively regulate the cellular response to chemotherapeutic agents 
(Liu et al., 2005). In contrast to DcR1, DcR2 shows a widespread tissue 
distribution and was found to be highly expressed in several cancer cell lines 
(Degli-Esposti et al., 1997a). In addition to DcR1 and DcR2, TRAIL has also been 
shown to interact with osteoprotegerin (OPG) (Emery et al., 1998). In contrast to 
all the other TRAIL receptors, OPG is not membrane bound but a secreted 
receptor of the TNF receptor superfamily and also plays a fundamental role in the 
biology of bone remodelling. OPG also acts as a decoy receptor for the 
osteoclast activator receptor activator of NF-κB ligand (RANKL), inhibiting the 
binding of RANKL to the osteoclatogenesis receptor, RANK (receptor activator of 
NF-κB) and thereby preventing the formation of multinucleated osteoclasts. The 
ratio of RANKL/OPG determines bone mass and skeletal integrity (Boyce and 
Xing, 2007). Binding of TRAIL to OPG happens, however, with a weaker affinity 
then binding to all the other receptors (Truneh et al., 2000). Overexpression of 
OPG did suppress TRAIL-induced apoptosis and TRAIL has been shown to 
release the osteoclastogenesis block by OPG in vitro (Emery et al., 1998). 
Despite its regulation of OPG in vitro, TRAIL knockout mice did provide evidence 
for aberrant bone biology, suggesting that TRAIL is not essential for maintaining 
proper bone biology under physiological conditions (Sedger et al., 2002). Of note, 
DcR1 and DcR2 do not have a higher affinity for TRAIL and are expressed at 
substantially lower levels then DR4 and DR5 (Kimberley and Screaton, 2004). 
The exact mechanisms by which decoy receptors counteract TRAIL function 
remain to be unravelled. 
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Mice, however, compared to humans only express one functional TRAIL death 
receptor (mDR5) and three TRAIL decoy receptors (mDcR1, mDcR2 and 
mOPG), whereas mDcR2 can be expressed in two splicing variants, one 
membrane bound (mDcR2L) and one secreted form (mDcR2s) (Figure 1-3) 
(Schneider et al., 2003).  
 
Four of the human TRAIL receptors, DR4, DR5, DcR1 and DcR2 are clustered 
on chromosome 8q22-q21 (Wu et al., 1997, Marsters et al., 1997, Truneh et al., 
2000, Walczak et al., 1997). Their genomic close proximity and the complete lack 
of a second death inducing TRAIL receptor in mice, suggests that the 
development of the TRAIL system is a quite recent event in evolution and that all 
receptors have arisen from duplication (Wu et al., 1999). OPG has been mapped 
more distant but to the same chromosome, to 8q24 (Tan et al., 1997) (All 
receptors are depicted in Figure 1-3).  
 
Given their potential common ancestry it is not surprising that TRAIL receptors 
share a number of transcription factors. In humans it has been shown that DR4, 
DR5, DcR1 and DcR2 can be transcriptionally activated by the tumour 
suppressor p53 (Shetty et al., 2005, Henry et al., 2012, Toscano et al., 2008, Liu 
et al., 2005). Conversely, the NF-κB transcription factor family has been shown to 
induce the transcription of DR4, DR5 and DcR1 (Mendoza et al., 2008, Shetty et 
al., 2005, Bernard et al., 2001). Remarkably, the NF-κB family member RELA, 
under certain circumstance, inhibits the expression of DR4 and DR5 thus, blocks 
TRAIL-induced apoptosis. This effect has been shown to be counter played by 
another member of the NF-κB family, cREL (Chen et al., 2003). Taken together, 
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this suggests that a balance of pro-survival and pro-apoptotic pathways is likely 
to regulate the expression of TRAIL receptors. However, the exact mechanisms 
defining whether a cell is prone to express a pro-apoptotic or pro-survival ratio of 
TRAIL-receptors has not been determined yet.  
 
 
Figure 1-3. Human and murine TRAIL receptors.  
Humans express five different receptors for TRAIL (a). DR4 and DR5 possess a fully functional 
intracellular domain and can induce apoptosis. DcR1 is a GPI-anchored membrane molecule 
without intracellular domain, DcR2 possess an intracellular domain with truncated death 
domain and has been shown to activate pro-survival cues via NF-κB. Both function as decoy 
molecules and inhibit the pro-apoptotic role of TRAIL. OPG has a lower affinity towards TRAIL 
and is involved in osteoclastogenesis. Mice express only four TRAIL receptors (b). Murine DR5 
is the only fully functional receptor, capable of inducing apoptosis in mice. Murine DcR1 is 
equivalent to the human form a GPI-anchored membrane molecule without intracellular 
domain. Murine DcR2 is present as membrane bound form (mDcR2L) with truncated 
intracellular domain and capable of activating NF-κB. The soluble form of murine DcR2 
(mDcR2S), which is cleaved of the membrane functions as soluble decoy receptor. Equivalent 
to humans, mice express OPG. 
 
1.4.3 TRAIL-induced apoptosis 
 
The induction of apoptosis in DR-expressing cells is mediated by the binding of 
TRAIL to DR4 and/or DR5. Only trimerised TRAIL is able to activate the receptor 
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complex by leading to a conformational change of their respective death domains 
(DD), receptor clustering and activation of the extrinsic apoptotic pathway. 
Activated receptors recruit Fas-associated protein with death domain (FADD) by 
interacting with their respective death domains. Subsequently, FADD, functioning 
as an adaptor protein, allows the recruitment of pro-caspase-8 and pro-caspase-
10 via death effector domain (DED)-DED interactions triggering the formation of a 
multi-protein complex called death induced signalling complex (DISC) (Medema 
et al., 1997). This formation results in the auto activation of the initiator caspases 
(Kischkel et al., 2000). Moreover, cellular FADD-like interleukin 1β-converting 
enzyme (FLICE)-like inhibitory protein (c-FLIP), another DED-containing protein, 
is also able of binding FADD. c-FLIP possesses strong homology to caspase-8 
with its two DEDs at the N-terminus and is a major inhibitor of the extrinsic cell 
death pathway. The activation of caspase-8, or caspase-10, as part of the DISC, 
leads to proteolytic cleavage of caspase-3, downstream cleavage of further 
caspases and other numerous regulatory and structural proteins (Danial and 
Korsmeyer, 2004). This results in hallmarks of apoptosis such as membrane 
blebbing, DNA fragmentation and cellular shrinkage (Galluzzi et al., 2007).  
 
Moreover, initiator caspases are able to cleave BID (BCL-2 homology domain 3 
(BH3) interacting domain death agonist), a pro-apoptotic member of the B-cell 
CLL/lymphoma 2 (BCL-2) family. It has been shown that the cell type determines 
how BID operates: (i) BID cleavage can provide an amplification loop for the 
apoptotic signal as in type I cells, where the main mechanism is mediated by 
extrinsic apoptotic signalling, or (ii) as in type II cells, it serves as the primary 
mechanism of TRAIL- induced apoptosis (Ozoren and El-Deiry, 2002). In the 
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latter, proteolytic processing of BID leads to the activation of the intrinsic 
apoptotic pathway including activation of BCL-2-associated X protein (BAX) and 
BCL-2 homologous antagonist-killer (BAK) resulting in decreased mitochondrial 
membrane potential (Δψm) and subsequent pore formation leading to 
mitochondrial outer membrane permeabilisation (MOMP) (Waterhouse et al., 
2002). In addition, MOMP leads to the release of pro-apoptotic proteins such as 
cytochrome complex (cytochrome c) and SMAC (second mitochondria-derived 
activator of caspases/direct inhibitor of apoptosis-binding protein with low pI). 
Furthermore, cytochrome c, adenosine triphosphate (ATP) and apoptotic 
peptidase activating factor 1 (APAF-1) form the so-called apoptosome, which 
activates caspase-9. Active caspase-9 then activates caspase-3, caspase-6 and 
caspase-7 (Zou et al., 1997), finally resulting in DNA fragmentation and cell 
death. 
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Figure 1-4. TRAIL-induced apoptosis signalling pathway.  
Death receptor activation by TRAIL results in the formation of homotrimeric receptor complexes 
and primarily activates the extrinsic apoptotic pathway. TRAIL activation leads to an 
intracellular conformational change of the receptor and DISC formation. The DISC is composed 
of FADD, caspase-8, caspase-10 and potentially c-FLIP. Activation of initiator caspases-8 and 
caspases-10 lead to proteolytic cleavage and activation of downstream effector caspases, such 
as caspase-3 finally leading to the cleavage of downstream substrates e.g. PARP and 
ultimately to the induction of apoptosis. Furthermore, TRAIL can also activate the intrinsic 
apoptotic pathway via BID, which activates BAK and BAX, counteracted by BCL-2 and BCL-XL 
and induces mitochondrial outer membrane permeabilisation (MOMP). Consequently, APAF-1 
and cytochrome c form the apoptosome, activating caspases-9, which further activates 
downstream caspases. IAPs counteract the activation of caspases.  
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The use of TRAIL itself, or TRAs (TRAIL receptor agonists), in experimental 
tumour therapy is frequently confronted with resistance to TRAIL-based 
treatments that often arises during the course of therapy (Mellier et al., 2010). 
Many cancer cells develop resistance to treatment after an initial good response. 
Several resistance mechanisms have been described and it is believed that 
alterations at multiple levels from the receptor to initiator caspases are 
responsible. However, a general mechanism for the development of resistance 
has not yet been found. Several other signalling pathways have been associated 
with TRAIL-resistant phenotypes including activation of transcription factor NF-
κB, mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated 
kinase (ERK) signalling pathways and the phosphatidylinositol-3-kinase (PI3K)/ 
RAC serine/threonine-protein kinase (AKT) survival axis (Mellier et al., 2010). 
Commonly known mechanisms of resistance are described as follows. 
 
The apoptotic function of TRAIL is mediated by signalling triggered by its 
receptor, which activates downstream death executor caspases. Thus, reduced 
cell surface expression, or receptor mutations leading to impaired function, can 
severely affect TRAIL-mediated signalling and thus constitute mechanisms of 
resistance. Indeed, reduced expression of DR4 caused by epigenetic silencing is 
associated with resistance to TRAIL-treatment in ovarian cancer cells (Hopkins-
Donaldson et al., 2003, Horak et al., 2005). Furthermore, deficiencies in surface 
transport, loss of function mutations or endocytosis of DR4 and DR5 have been 
reported in various carcinomas (Fisher et al., 2001, Jin et al., 2004, Zhang and 
Zhang, 2008). There are also the so-called decoy receptors, DcR1 and DcR2, 
which compete with DR4 and DR5 for ligand binding. Hence, the ratio of TRAIL 
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decoy to DRs also determines the responsiveness of cells to TRAIL (Merino et 
al., 2006). After receptor activation, the formation of the DISC and auto-
proteolytic cleavage of caspase-8 are key factors in TRAIL-induced apoptosis. 
High levels of c-FLIP, a DED-containing protein that can bind FADD, are 
associated with resistance to TRAIL. c-FLIP binds to the DISC and inhibits the 
activation of caspase-8. Thus, c-FLIP/caspase-8 ratio can also determine the 
responsiveness of cells to TRAIL-induced apoptosis and can lead to resistance in 
various types of cancer (Horak et al., 2005). Resistance can, therefore, be the 
result of c-FLIP overexpression and/or reduction of caspase-8 levels (Zhang and 
Fang, 2005). In addition, downregulation, increased turnover and mutations in 
several caspases have been linked to resistance to TRAIL-induced apoptosis 
(Crowder and El-Deiry, 2012, Lane et al., 2006, Van Geelen et al., 2010). 
 
Despite the fact that TRAIL-induced cell death triggers the classical extrinsic 
apoptotic pathway, it also involves intrinsic, mitochondrial-associated, pathways. 
MOMP formation is a key event in the activation of the intrinsic apoptotic pathway 
and inhibitors of MOMP have been shown to inhibit signalling downstream of 
TRAIL ligation. Pro-apoptotic members of the BCL-2 family mediate the decrease 
in Δψm. It was shown that the ratio of pro- versus anti-apoptotic BCL-2 members 
is also responsible for the sensitivity to TRAIL (Zhang and Fang, 2005). The 
inhibitors of apoptosis proteins (IAP) interfere with the activation of executioner 
caspases. Members of this family possess an evolutionary conserved domain 
called baculovirus IAP repeat (BIR), as well as a caspase activation and 
recruitment domain (CARD) and are, therefore, as the name indicates, inhibitors 
of cell death. After the formation of MOMP, mitochondrial proteins such as 
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SMAC/DIABLO are released thus disrupting the interactions between caspases 
and IAPs. Hence, defects in SMAC/DIABLO release alter this balance and 
counteract apoptotic stimuli. The existence of a major resistance factor 
downstream of mitochondrial activation, which could be reverted by 
overexpressing SMAC/DIABLO, has been suggested (Ng and Bonavida, 2002).  
 
 
Figure 1-5. TRAIL-induced apoptosis signalling pathway and mechanisms of resistance. 
Resistance mechanisms can occur at different stages of the cascade. The function or 
expression of the death-inducing receptors DR5 (1) and/or DR4 (2) can be altered. 
Overexpressed DcR1 (3) or DcR2 (4) can compete for TRAIL binding and DcR2 can activate 
pro survival cues via NF-κB. Upregulation of c-FLIP (5) can inhibit the activation of initiator 
caspases-8/10. Anti-apoptotic members of the BCL-2 family, such as BCL-XL and BCL-2 are 
known inhibitors of intrinsic apoptosis pathways by counteracting pro-apoptotic members of the 
family and are often upregulated (6). Mutations, downregulation or increased turnover of 
caspases has been linked to TRAIL-resistance (7). Increased expression of IAPs is capable of 
blocking the action of effector caspases (8). 
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1.4.4 Physiological roles 
 
Since the discovery of TRAIL and its corresponding receptors, much effort was 
put in elucidating the potential therapeutic role of TRAIL. However, fewer 
research groups have focused on the physiological function of TRAIL. Today, 
more and more TRAIL-receptor agonists (TRAs) have finished phase 2 clinical 
trials and have all over led to disappointing clinical outcomes. Understanding the 
physiological role of TRAIL is more important than ever and might pave new 
avenues to make TRAs a successful strategy in the end.  
 
As described earlier, TRAIL has been shown to induce tumour cell selective cell 
death in a variety of experimental setups in vitro and in vivo. As tightly regulated 
apoptosis has been demonstrated to be a crucial event during development 
(Fuchs and Steller, 2011) and, given the fact, that TRAIL has been shown to 
selectively induce apoptosis in tumour cells, several studies have focused on the 
role of TRAIL in development. The majority of these studies have been carried 
out in mouse models, but as mentioned earlier the TRAIL signalling system 
varies slightly between humans and mice (Figure 1-3). Interestingly, TRAIL and 
mDR5 knockout mouse models did not display any developmental of fertility 
defects (Sedger et al., 2002, Finnberg et al., 2005, Cretney et al., 2002). 
However, it has been described that TRAIL and/or mDR5 knockout mice show an 
enlarged thymus that contains more thymocytes than in wild type mice (Finnberg 
et al., 2005, Cretney et al., 2002). Furthermore, it has been postulated, that the 
expression of TRAIL is needed for negative selection of thymocytes and that 
TRAIL knockout mice are more susceptible to autoimmune diseases 
(Lamhamedi-Cherradi et al., 2003). Interestingly, TRAIL has further been shown 
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to play an important role in the adaptive immune system when controlling an 
infection with influenza (Ishikawa et al., 2005). In contrast, TRAIL deficient mice 
showed increased survival upon infection with the bacterium Listeria 
monocytogenes, most likely due to the abrogation of pro-apoptotic signalling in 
innate immune cells, normally induced by the bacteria (Zheng et al., 2004). 
Studies in mice and humans into the expression of TRAIL on the surface of 
isolated T cells, natural killer T cells (NKT) cells, B cells, dendritic cells (DC), 
monocytes or natural killer (NK) cells have shown that none of these cell types 
express detectable levels of TRAIL in vivo. Only a subset of mouse liver NK cells 
was found to express considerable amounts of TRAIL, in a, what appears to be, 
type II IFN-dependent manner.  However, upon stimulation with interleukin (IL) -
2, interferons (IFNs) or IL-15, most NK cells induce TRAIL expression [reviewed 
in (Smyth et al., 2003)]. TRAIL expression has been shown to increase in 
monocytes treated with lipopolysaccharide (LPS) or type I/II IFN, correlating with 
a potentiated toxicity towards tumour cells (Halaas et al., 2000, Ehrlich et al., 
2003). T cells also induce TRAIL expression in response to type I IFN stimulation 
(Kayagaki et al., 1999), and, similarly DCs increase their surface expression 
upon type I IFN stimulation, which enhances their cytotoxicity towards tumour 
cells (Liu et al., 2001, Kemp et al., 2003) [thoroughly reviewed in (Mellier et al., 
2010)].  
 
Given the fact, that TRAIL has proven to induce cell death selectively in tumour 
cells, it has been postulated to be involved in anti-tumour immune surveillance. 
Surprisingly, TRAIL knockout or mDR5 knockout mice per se, did not show an 
increased susceptibility to tumour development in younger mice (Sedger et al., 
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2002). However, an increase in lymphoid malignancies has been reported in 
mice older than 500 days (Zerafa et al., 2005). TRAIL or mDR5 deficiency has 
been shown to increase the susceptibility towards experimentally induced cancer 
and/or cancer allografts. Induction of primary fibrosarcomas by the chemical 
carcinogen methylcholanthrene (MCA) comparing TRAIL deficient and wild type 
mice revealed a greater sensitivity and increased tumour burden in TRAIL 
deficient mice. The authors further report, that TRAIL not only prevents formation 
of primary tumours, but also contributes to the NK cell-mediated protection from 
tumour metastasis (Cretney et al., 2002). Another primary tumour model using a 
multistage model for the development of primary squamous cell carcinoma 
revealed that mDR5 deficiency does not increase the number of observed 
tumours or tumour progression rate. However, mDR5 depleted cells showed a 
significantly increased number of lymph node metastasis, suggesting an 
involvement of TRAIL signalling in immune surveillance of metastasis (Grosse-
Wilde et al., 2008). Furthermore, several studies revealed that TRAIL deficiency 
in mice leads to an increased tumour burden and more severe disease 
progression upon transplantation of e.g. lymphoma cells (Sedger et al., 2002), or 
renal carcinoma cells (Cretney et al., 2002). In contrast, is has also been shown 
that the development of thymic or intestinal tumours in mice with mutated p53 
and adenomatous polyposis coli (APC) was independent of TRAIL expression 
status (Yue et al., 2005). Other studies however, have shown a clear involvement 
of monoallelic mDR5 loss in the development of c-myc-driven lymphomas 
(Finnberg et al., 2008). It has been hypothesised that exogenously introduced or 
chemically introduced tumours are highly immunogenic and activation of NK- and 
T cells might lead to bystander killing (Yue et al., 2005). Other publications 
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contradict this and have reported a protective effect of TRAIL expression on the 
induction of spontaneous tumours following the loss of one p53 allele, but report 
no protective effect of TRAIL on the development of HER2-driven breast cancer 
(Zerafa et al., 2005). It has been argued that this lack of TRAIL-induced 
protection against certain cancers could be caused by the ameliorated signalling 
of TRAIL decoy receptor, or receptor independent functions of TRAIL. Taken 
together, TRAIL-induced apoptosis has been demonstrated to be involved in 
several immunological processes. Besides a potential role in the negative 
selection of thymocytes, it can be associated with anti-tumorigenic role of NK 
cells and most likely other cells of the innate immune system. Furthermore, 
TRAIL-signalling is clearly involved in the anti-tumorigenic and anti-metastatic 
functions of the immune system, however it does not seem to be involved in the 
immune surveillance against all tumour types. It is highly likely, that TRAIL-
signalling plays a role in the innate immune response against a subset of 
tumorous lesions. However, most functional insight into the physiological role of 
TRAIL has been gained using mouse models, which show fundamental 
differences in their TRAIL receptor expression and therefore cannot be 
transferred to humans without further validation. 
 
1.4.5 Clinical success 
 
As mentioned previously, binding of TRAIL to death inducing receptors DR4 and 
DR5 has been shown to selectively induce apoptosis in tumour cells. Several 
routes have been taken to utilise this tumouricidal function of TRAIL in cancer 
therapy. Two fundamental different categories of TRAIL-receptor agonists (TRAs) 
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are currently being tested in clinical trials. The first category are recombinant 
forms of TRAIL, the second category are monoclonal antibodies that target either 
DR4 or DR5. Several recombinant forms of TRAIL have been developed in 
preclinical studies; however, dulanermin is the only recombinant TRAIL that has 
been tested in clinical trials. This molecule is a shortened form of human TRAIL 
(amino acids 114–281) and devoid of foreign sequences (Ashkenazi et al., 1999). 
Several other TRAIL-based molecules have been developed for clinical 
applications, most recently a genetically engineered molecule (APG350) that 
represents two homotrimers fused to the Fc- part of a human IgG showing 
superior induction of TRAIL induced apoptosis compared to TRAIL and DR5 
agonistic antibodies (Gieffers et al., 2013). In comparison to mAbs, use of TRAIL-
based molecules has the disadvantage that they could also trigger signalling via 
TRAIL-decoy receptors and therefore induce side effects. When using TRAIL-
receptor specific antibodies they will only target DR4 or DR5, which could also 
hinder clinical success. As mentioned before, some types of cancer express 
primarily DR4 and/or DR5. Therefore use of the therapeutic antibody would rely 
on the specific tumour type and require diagnostic testing beforehand. It has 
been shown that DR4 and/or DR5 specific Abs are capable of inducing clustering 
of TRAIL receptors and subsequent induction of extrinsic apoptosis (Belyanskaya 
et al., 2007). Opposed to recombinant TRAIL, which has a half-life of 
approximately 10 min (Lim et al., 2011) recombinant antibodies have a half-life in 
the range of days to weeks [reviewed in (Lemke et al., 2014b)]. 
 
As mentioned above, dulanermin is the only recombinant TRAIL molecule that 
has been tested in clinical trials. Initial studies confirmed its safety, however 
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phase II trials were disappointing. Treatment with dulanermin in combination with 
chemotherapy revealed no benefit over the use of chemotherapy alone (Soria et 
al., 2011). Besides dulanermin, several TRAIL receptor agonists have been 
tested in clinical trials. One of them targets DR4 (mapatumumab) whereas all 
others are directed against DR5 (conatumumab, lexatumumab, tigatuzumab, 
drozitumab and LBY-135). All of the antibodies demonstrated tumouricidal 
activity in preclinical testing and phase I studies proofed their safety in clinical 
use. However, clinical trials, comparing these TRAs with/without chemotherapy 
or the proteome inhibitor bortezomib to standard therapy, revealed no advantage 
over standard therapy [thoroughly reviewed in (Lemke et al., 2014b)]. 
Interestingly, some TRAs led to dramatic responses in some cases e.g. the DR4 
agonist lexatumumab led to the resolution of symptoms of an unresectable chest 
wall/lung osteosarcoma after 2 years of treatment and the patient remained 
stable for at least 1 year after cessation of therapy (Merchant et al., 2012). Given 
the promising results in pre-clinical models the overall result of clinical trials with 
TRAs is surprisingly disappointing. Despite anticancer effect in certain cases, no 
TRA has yet been approved for clinical use. Many reasons for these 
disappointing results have been discussed. It is highly likely that the clinical 
failure of TRAs so far is caused by a combination of reasons. TRAs that are 
based on monoclonal therapeutic antibodies for example have the disadvantage 
that they are only capable of clustering two death receptors instead of the three 
receptors usually clustered by endogenous TRAIL (Wilson et al., 2011, Haynes et 
al., 2010). As mentioned above, cancer cells are known to develop resistance 
against TRAIL-induced apoptosis, which has been shown could be overcome by 
chemotherapeutic drugs or proteasome inhibitors in vitro. However, in vivo 
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results obtained from clinical trials do not resemble these initial findings for 
reasons that are yet not fully understood. To overcome these hurdles and to 
bring TRAIL-based therapies into the clinic, several routes are taken at present. 
More efficient TRAs are in development at the moment e.g. APG350 and, more 
sophisticated therapies are tested currently to overcome TRAIL-resistance in 
vivo. These methods include Smac and BH3 mimetics, helping to overcome 
TRAIL-resistance associated with intrinsic apoptotic signalling [reviewed in 
(Fulda, 2014)], inhibition of CDK9 (Lemke et al., 2014a) as well as the 
development and search of completely novel, selective strategies to counteract 
resistance to TRAIL-induced apoptosis.  
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1.5 Fas Signalling 
 
The FAS signalling pathway is composed of FasL (also known as CD95L) and its 
corresponding receptor FasR (CD95). FasL is 40 kDa type II transmembrane 
protein and a member of the TNF family, which can be cleaved into a soluble 
form (Gregory et al., 2011). As all the other members of the TNF family, FasL 
forms a homotrimeric ligand that induces a specific cellular response upon 
binding to its corresponding receptor, FasR. FasR, a type I membrane protein, is 
a member of the TNF receptor family. Binding of FasL to FasR has been shown 
to induce receptor trimerisation and downstream activation of apoptosis 
(Krammer, 2000). FasL-induced apoptosis demonstrates a high degree of 
signalling overlap with TRAIL-induced apoptosis. Similar to TRAIL-induced cell 
death, binding of FasL and subsequent receptor trimerisation leads to the 
recruitment of FADD (Chinnaiyan et al., 1996) followed by the binding of initiator 
caspases procaspase-8 and/or procaspase-10 and the formation of a multi-
protein complex called DISC. Downstream cleavage of caspases leads to the 
induction of cell death via the extrinsic apoptotic signalling pathway, with 
activated initiator caspases cleaving effector caspases such as caspases-3. In 
so-called type I cells this pathway is sufficient to induce apoptosis. Equivalent to 
TRAIL-induced apoptosis, so-called type II cells require a mitochondrial 
amplification loop as DISC assembly might be impaired or not sufficient enough 
to trigger apoptosis (Peter and Krammer, 2003). Partial activation of initiator 
caspases leads to proteolytic processing of BID, which subsequently activates 
the intrinsic apoptotic pathway that involves the mitochondria, as described by 
Werner et al. (Werner et al., 2002). Identical to TRAIL-induced apoptosis, FasL-
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induced signalling can be very efficiently inhibited by upregulation of cFLIP or 
anti-apoptotic members of the BCL-2 family (Oyarzo et al., 2006, Srinivasan et 
al., 1998). 
 
Physiologically, Fas signalling has been linked to the immune privileged status of 
certain organs. By using FasL deficient mice, it has been shown that FasL 
expression protects the anterior chamber of the eye, an immune privileged organ, 
from an inflammatory response (Griffith et al., 1995). In addition, FasL has been 
shown to be involved in maintaining the immune privileged status of the thyroid 
gland. Normal thyrocytes constitutively express FasL, protecting the organ from 
an immune reaction by negatively regulating lymphocytes through FasL. 
Interestingly, in the autoimmune disease Hashimoto thyroiditis, thyrocytes start to 
express FasR, which subsequently leads to the destruction of thyrocytes 
(Giordano et al., 1997). Mice with either FasR or FasL mutations exhibit severe 
autoimmune diseases that resemble systemic lupus erythematosus in humans 
(Furukawa et al., 1996, McNally et al., 1997). Mutations in the human FasR gene 
have been described to cause the autoimmune lymphoproliferative syndrome or 
Canale-Smith syndrome. These patients exhibit all signs of systemic 
autoimmunity including a massive non-malignant lymphadenopathy, 
hepatosplenomegaly and altered T cell populations (Drappa et al., 1996). Similar 
to TRAIL, FasL has been associated with negative selection of thymocytes 
(Castro et al., 1996). Moreover, the association of Fas signalling with 
autoimmune disorders is linked to the impaired regulation of autoreactive 
lymphocytes.  
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In contrast to TRAIL, Fas signalling has not been associated with innate tumour 
surveillance. The regulation of cytotoxic T lymphocytes by FasL is mandatory for 
a functional immune system and the prevention of autoimmune disorders. 
However, in some types of cancer, FasL expression has been shown to be 
disadvantageous. Of interest, many cancer cells themselves are resistant to 
FasL-induced apoptosis and/or show downregulation of the corresponding FasR. 
However, FasR is rarely lost completely and some tumours exhibit particularly 
high levels of FasR. Moreover, FasL expression by tumours has been postulated 
to protect tumour tissue from an immune response (Strand et al., 1996, O'Connell 
et al., 1996, Hahne et al., 1996). Recently, it has been shown that under certain 
conditions FasR activation by FasL could act tumorigenic and promote tumour 
growth and invasion in various cancer cell lines (Chen et al., 2010). In a 
glioblastoma mouse model, FasL signalling was shown to promote tumour 
invasion and migration through the PI3K, AKT, NF-κB and MMP 
(matrix metalloproteinase) pathways (Kleber et al., 2008). These findings have 
led to the development of a fusion protein that functions as a soluble FasR, 
inhibiting Fas signalling, which has recently been clinically approved as an 
orphan drug targeting glioblastoma multiforme (GBM) (Wick et al., 2011, 
Tuettenberg et al., 2012).  Taken together, despite great similarities in the 
intracellular signalling of TRAIL and FasL, FasL does not play a role in the innate 
immune response to tumours but under certain conditions can exhibit pro-
invasive and pro-metastatic functions.  
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1.6 TNF-α Signalling 
 
Over 40 years ago, it was reported for the first time, that cytokines might be 
involved in the anti-tumour response of the immune system (Ruddle and 
Waksman, 1968, Kolb and Granger, 1968). Around 20 years later, in 1984, two 
cytokines, involved in a cytotoxic response were cloned and identified. It was 
then discovered that they bind to the same receptor (Aggarwal et al., 1985a) and 
share 50% sequence homology. They were subsequently called tumour necrosis 
factor (TNF) -α and TNF-β (also known as lymphotoxin-α) (Aggarwal et al., 1984, 
Aggarwal et al., 1985b). Identification of these cytokines led to the discovery of 
the whole TNF superfamily and their receptors. Equivalent to the other members 
of the TNF superfamily, TNF-α is a trimeric type II transmembrane protein 
(sometimes referred to as mTNF-α) (Kriegler et al., 1988). It can be shed of the 
membrane by the metalloproteinase TNF alpha converting enzyme (TACE) and 
forms soluble homotrimers as most other members of the TNF superfamily 
(sometimes referred to as sTNF-α) (Tang et al., 1996, Black et al., 1997). Both, 
membrane bound and soluble TNF-α, have been shown to exhibit biological 
activity (Decoster et al., 1995). Equivalent to the other members of the TNF 
superfamily, TNF-α exerts biological function by binding to its corresponding 
receptors. There are two receptors described for TFN-α, tumour necrosis factor 
receptor (TNFR) 1 and 2. Both of them are members of the TNF receptor 
superfamily and are capable of binding membrane bound TNF-α whereas soluble 
TNF-α only activates TNFR1 [reviewed in (Cabal-Hierro and Lazo, 2012)]. 
TNFR1 is a ubiquitously expresses 55 kDa transmembrane protein, which can be 
activated by both, membrane bound and soluble TNF-α. Ligand binding induces 
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a conformational change in its intracellular domain and receptor trimerisation. 
TNFR1 contains a death domain (DD) and can recruit other DD containing 
proteins and induce apoptosis. Moreover, TNFR1 has been shown to recruit 
members of the TNF receptor associated family (TRAF) and subsequently 
activate the NF-κB family of transcription factors (Schulze-Osthoff et al., 1998). 
The second TNF receptor, TNFR2 is a 75 kDa transmembrane protein, that has 
been shown to be mostly expressed in specific cell types such as 
oligodendrocytes (Dopp et al., 2002), astrocytes (Li et al., 2002), T cells (Ware et 
al., 1991), myocytes (Irwin et al., 1999), thymocytes (Grell et al., 1998), 
endothelial cells (Choi et al., 2005) and human mesenchymal stem 
cells(Faustman and Davis, 2010) [reviewed in (Cabal-Hierro and Lazo, 2012)]. 
TNFR2 does not contain a DD and in contrast to TNFR1 it can only be efficiently 
activated by membrane bound TNF-α. Downstream signalling in response to 
TNF-α binding differs significantly between TNFR1 and TNFR2 (for differences in 
NF-κB activation see Figure 1-8). As mentioned above, TNFR1 contains a DD 
and can subsequently activate apoptotic processes. However, dependent on the 
cellular context TNFR1 activation can also activate pro-survival and proliferative 
pathways. Upon ligation of TNF-α, two different intracellular signalling complexes 
have been described for TNFR1. The first complex (referred to as complex-I, 
Figure 1-6a) is formed by the recruitment of TRADD to TNFR1 via its DD. In the 
next step, further adaptor molecules such as TRAF2, cellular inhibitors of 
apoptosis (cIAP) -1, -2 and RIPK1 (also known as RIP1) are recruited to the 
receptor (Hsu et al., 1996a, Chen et al., 2008). This complex is referred to as 
complex I, which is capable to activating survival cues via NF-κB and activator 
protein (AP) 1 (Micheau and Tschopp, 2003, Mahoney et al., 2008, Hsu et al., 
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1996a, Chen et al., 2008). The activation of NF-κB family of transcription factors 
by TNFR1 involves the polyubiquitination of RIPK1 (Lee et al., 2004), this 
process is further described in 1.7.1.. 
 
Under certain conditions, RIPK1 can be deubiquitinated by the ubiquitin carboxyl-
terminal hydrolase (CYLD), which subsequently leads to the formation of 
complex-II (Figure 1-6b). This complex does further contain TRADD, FADD and 
pro-caspase-8 and is called DISC (Micheau and Tschopp, 2003, Hitomi et al., 
2008). Equivalent to the DISC formed upon ligation of TRAIL to DR4/DR5 this 
complex leads to the activation of the initiator caspases-8/10 and the activation of 
extrinsic apoptotic signalling.  
 
As mentioned earlier, TNFR2 does not contain a DD and can only be activated 
by membrane bound TNF-α. Binding of membrane bound TNF-α to TNFR2 
induces receptor trimerisation and subsequently recruitment of the key adaptor 
protein TRAF2. Then, TRAF2 further recruits TRAF1, TRAF3, cIAP1 and cIAP2. 
The final result is activation of the non-canonical signalling branch of NF-κB via 
the NIK (Hauer et al., 2005) and is described in more detail in 1.7.2. In addition, 
crosstalk between TNFR1 and TNFR2 has been observed under certain 
conditions. TNFR2 can increase pro-apoptotic signalling of TNFR1. As TRAF2 is 
the main adaptor molecule for TNFR2, activation of TNFR2 and subsequent 
degradation of TRAF2 leads to a cellular environment favouring the formation of 
TNFR1 complex II (Rodriguez et al., 2011), and thus, induction of apoptosis. This 
suggests that the cellular outcome of cellular TNF-α depends on a fine balance of 
intracellular events mediated by ligand binding to different receptors.  
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When first identified, TNF-α showed striking anti-tumour activity in mice (Carswell 
et al., 1975). Since its discovery extensive research has been done on the 
physiological role of TNF-α and its potential clinical application. It is commonly 
believed that the expression of TNF-α is regulated by most pattern-recognition 
receptors, including Toll-like receptors, various cytokine receptors and the T cell 
receptor (TCR). Given the ubiquitous expression of TNFR1, the consequences of 
TNF-α signalling can be local as well as systemic [reviewed in (Kruglov et al., 
2008)]. Utilising knockout mice, it was shown that TNF-α signalling is crucially 
involved in the immune response towards a variety of pathogens (Grivennikov et 
al., 2005, Deepe, 2007). However, in some cases, production of TNF-α can 
contribute to life threatening conditions such as sepsis in response to the 
exposure to bacterial endotoxins (Beutler et al., 1985). Remarkably, TNF-α 
signalling was also shown to be over-activated in a number of auto-inflammatory 
disorders such as arthritis (Keffer et al., 1991), which led to the development of 
the anti-TNF therapy, a breakthrough in the treatment of rheumatoid arthritis 
(Elliott et al., 1994). Despite its potential to induce apoptosis in certain types of 
tumours, TNF-α signalling was also found to promote tumourigenesis via 
activation of NF-κB and activator protein 1 (AP-1) survival cues and inflammation 
of the tumour (Balkwill, 2006).  
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Figure 1-6. TNF-α signalling through TNFR1. 
Ligation of TNF-α to TNFR1, induces receptor trimerisation and recruitment of TRADD, TRAF2 
and cIAPs. cIAPs function as E3 ubiquitin ligases for RIPK1 and LUBAC. These non-
degradative ubiquitination processes lead to the recruitment of the IKK complex (composed of 
IKK-α, IKK-β and IKK-γ (NEMO)). The E3 ubiquitin ligase complex LUBAC mediates 
polyubuquitination of IKK-γ, which stabilises complex-I (a). Spatial accumulation of the IKK 
complex mediates the phosphorylation of IκB proteins and subsequent polyubiquitination and 
proteasomal degradation. The IKK complex further phosphorylates NF-κB1 (p105) leading to 
proteolytic processing and increased levels of p50. RELA (p65) – p50 dimers translocate to the 
nucleus and regulate the expression of target genes, representing the canonical activation of 
NF-κB. NF-κB family members, TRAF2 and cIAPs suppress the formation of the death-
inducing complex-II (b). This complex is formed in the absence of TRAF2, cIAP or NF-κB 
signalling and depending on the cellular context contains of RIPK1, FADD and initiator 
caspases-8/10 or TRADD, FADD and initiator caspases-8/0 and leads to the induction of the 
extrinsic apoptotic pathway. 
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1.7 NF-κB Signalling 
 
All multicellular organisms face the necessity to react towards external changes 
in order to maintain integrity and survival. Such changes may require immediate 
or sustained responses. Many molecular switches can be modulated in response 
to external changes. Amongst the most powerful are transcription factors, which 
induce mRNA expression, and subsequently regulate protein levels. This 
generates an immediate, but transient molecular response towards extracellular 
changes. The NF-κB family of transcription factors is a textbook example for the 
complexity and plasticity of these molecular switches. Discovered in 1986, NF-κB 
family members were identified as proteins that bind to enhancers of the κ light 
chain in B cells (Sen and Baltimore, 1986, Singh et al., 1986, Staudt et al., 1986, 
Weinberger et al., 1986). Since then, extensive research has been done on the 
biology of the NF-κB family of transcription factors and much progress has been 
made on deciphering the extremely complex regulation of NF-κB. The 
transcriptional activation of NF-κB depends on the activation/formation of NF-κB 
dimers, their translocation to the nucleus, binding to NF-κB consensus 
sequences and activation of the transcription machinery (Wang et al., 2012a). 
DNA binding and nuclear translocation of NF-κB dimers is tightly regulated by a 
number of positive and negative regulators. Without stimulation, in a so-called 
“resting state” NF-κB dimers are prevented from entering the nucleus by 
members of the inhibitors of κ B (IκB) family (Beg and Baldwin, 1993, Hayden 
and Ghosh, 2012). NF-κB dimers are released and become transcriptional active 
upon phosphorylation of IκB, which is followed by ubiquitination and proteasomal 
degradation. Phosphorylation of IκB in response to external changes is facilitated 
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by proteins of the IκB kinase (IKK) complex, composed of IKK-α, IKK-β and the 
structural/regulatory component NF-κB essential modulator (NEMO, also known 
as IKK-γ) (Figure 1-7). The activation of the IKK complex is a very complex 
process and depending on the stimuli involves different receptors, adaptors and 
scaffolding proteins (Israel, 2010) and is described in more detail in 1.7.1. There 
are five members of the NF-κB transcription factor family in humans (Figure 1-7). 
NF-κB1 (also known as p105) and NF-κB2 (also known as p100) require 
proteolytic processing to become active. NF-κB1 (p100) is cleaved and gives rise 
to NF-κB1 (p50) and NF-κB2 (p105) forms NF-κB2 (p52) after cleavage. The 
other three members RELA (also known as p65), RELB and cREL (often referred 
to as v-rel reticuloendotheliosis viral oncogene homolog (REL) proteins) do not 
require processing (Hayden and Ghosh, 2012). It has been revealed that so-
called REL homology domains (RHDs) at the N-terminus of NF-κB members are 
required for binding to the DNA. To become functionally active, NF-κB proteins 
form homo- heterotrimers and bind to the DNA where they can either inhibit or 
promote transcription of target genes (Muller et al., 1995, Wolberger, 1998). 
Interestingly, only RELA, RELB and cREL contain so-called C-terminal 
transactivation domains (TADs), which are required for activating the 
transcription machinery. NF-κB1 (p50) and NF-κB2 (p52) do not contain TADs 
but are capable of positively regulating transcription upon formation of 
heterodimers with TAD containing NF-κB proteins or other transcription factors 
that have the ability for transactivation (Hayden and Ghosh, 2012). In addition, 
NF-κB1 (p50) and NF-κB2 (p52) homodimers have also been shown to bind 
NF-κB consensus sites, inhibiting NF-κB mediated transcription by competing 
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with TAD containing dimers (Zhong et al., 2002, Muller et al., 1995, Hayden and 
Ghosh, 2012).  
 
Prior to external activation, NF-κB proteins are inhibited by members of the IκB 
family (Figure 1-7). In humans, this protein family has eight different members: 
IκBα, IκBβ, IκBε, IκBζ, BCL3 (B-cell lymphoma 3), IκBNS (also known as 
NF-κBδ) plus the precursor proteins NF-κB1 (p105) and NF-κB2 (p100) (Basith 
et al., 2013). NF-κB1 (p105) and NF-κB2 (p100) lose their ability to inhibit NF-κB 
dimers after proteolytic processing to NF-κB1 (p50) and NF-κB2 (p52) (Basith et 
al., 2013, Hayden and Ghosh, 2012). Proteins of the IκB family share the so-
called destruction box serine residue (DSGXXS) domain. Phosphorylation of 
serine residues in this domain leads to polyubiquitination and subsequent 
proteasomal degradation and/or processing of IκB proteins (Xu et al., 2011, 
Kanarek et al., 2010). 
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Figure 1-7. Proteins of the NF-κB, IκB and IKK families. 
Protein names are depicted on the left and alternative names can be found in brackets. The 
NF-κB family members NF-κB1 (p105) and NF-κB2 (p100) function in the unprocessed form as 
IκB. When processed to NF-κB1 (p50) and NF-κB2 (p52) they function as NF-κB family 
members. The following protein domains are indicated: ANK, ankyrin repeats; CC, coiled-coil; 
DD, death domain; GRR, glycin rich region; HLH, helix-loop-helix; LZ; leucin-zipper; NBD, 
NF-κB-essential-modulator-binding domain; PEST, proline-glutamic, serine- and threonine-rich; 
RHD, REL homology domain; TAD, transactivation domain; ZF, zinc-finger. (Taken from 
(Ghosh and Hayden, 2008)) !! !
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1.7.1 Canonical activation  
 
As mentioned earlier, NF-κB becomes activated in response to phosphorylation, 
subsequent ubiquitination and proteasomal degradation of IκB proteins. This 
targeted phosphorylation is facilitated by proteins of the IKK family. A large 
number of extracellular stimuli like oxidative stress (Kratsovnik et al., 2005, 
Rupec and Baeuerle, 1995, Schreck et al., 1991), DNA damage (Janssens and 
Tschopp, 2006, McCool and Miyamoto, 2012) or cellular ligands such as TNF-α 
are capable of activating IKKs (Cabal-Hierro and Lazo, 2012). IKKs are activated 
by the formation of IKK complexes. Depending on the actual stimuli these 
complexes vary slightly in composition and can lead to different downstream 
signalling events. Activation of NF-κB has been categorised as so-called 
canonical, also known as classical activation and the non-canonical or alternative 
pathway depending on the extracellular stimuli (Hayden and Ghosh, 2008, 
Wajant and Scheurich, 2011, Hayden and Ghosh, 2012). As depicted in Figure 
1-6 and Figure 1-8, NF-κB can be canonically activated upon binding of TNF-α to 
TNFR1 and subsequent receptor trimerisation. This conformational change of the 
receptor complex induces the recruitment of the E3 ubiquitin ligase TRADD to 
TNFR1 via its DD. In addition the E3 ubiquitin ligases TRAF2, cIAP1, cIAP2 and 
the protein kinase RIPK1 are recruited to the complex, referred to as complex-I 
(Aggarwal et al., 1996, Chen et al., 2008, Hsu et al., 1996a). This interaction 
leads to the cIAP-mediated polyubiquitination of RIPK1 with non-degradative 
ubiquitin, which in the next step leads to the recruitment of the dimeric linear 
ubiquitin chain assembly complex (LUBAC). Furthermore, ubiquitination of 
complex-I members also recruits the IKK complex composed of IKK-α, IKK-β and 
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IKK-γ. Consequently, LUBAC mediates the polyubiquitination of IKK-γ, thereby 
stabilising complex-I (Haas et al., 2009, Tokunaga et al., 2009). The activated 
IKK complex subsequently phosphorylates IκB proteins and induces their 
proteasomal degradation (Ea et al., 2006, Kovalenko and Wallach, 2006) leading 
to the translocation of NF-κB (p50)/ RELA (p65) dimers into the nucleus (Basak 
et al., 2007, Wajant and Scheurich, 2011). IKK complex proteins have also been 
shown to phosphorylate NF-κB family members directly and thereby alter their 
transcriptional response, e.g. RELA pS536 (Yoboua et al., 2010, Syrovets et al., 
2005).  
 
1.7.2 Non-canonical activation 
 
A certain subset of cellular stimuli activates the NF-κB family of transcription 
factors via the so-called non-canonical or alternative NF-κB pathway. This 
pathway has been shown to be activated after binding of TNF-β, B cell activating 
factor (BAFF), RANKL or TNF-α to their corresponding receptors (Gardam and 
Brink, 2014, Madge et al., 2008, Cabal-Hierro and Lazo, 2012). TNF-α activates 
the canonical pathway after binding to the TNFR1, whereas ligation of TNF-α to 
TNFR2 activates the non-canonical pathway (Cabal-Hierro and Lazo, 2012). 
Here, ligation induced receptor trimerisation induces the recruitment of TRAF2 to 
the receptor complex, which functions as an adaptor protein to recruit TRAF1, 
TRAF3, cIAP and cIAP2 (Rothe et al., 1995a, Rothe et al., 1995b, Rothe et al., 
1994). The fundamental difference between the canonical and non-canonical 
activation of NF-κB is the involvement of NIK, which becomes recruited by the 
TRAF proteins and phosphorylates and thereby activates IKK-α (Sun, 2011). In 
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contrast to the canonical activation via TNF-α, IKK-β does not play a fundamental 
role. IKK-α mediated phosphorylation and downstream degradation of IκB 
proteins, triggers the proteolytic processing of NF-κB2 (p100) to NF-κB2 (p50). 
This event relieves the inhibition of NF-κB dimers by NF-κB2 (p100) and 
increases the number of NF-κB2 (p50) containing dimers, inducing a 
transcriptional response (Hayden and Ghosh, 2012, Sun, 2011). 
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Figure 1-8. Canonical and non-canonical activation of NF-κB via TNF-α. 
The canonical NF-κB pathway can be activated via TNFR1. Activation of the IKK complex (IKK-
α, IKK-β and IKK-γ (NEMO)) leads to the phosphorylation of IκB proteins and subsequent 
polyubiquitination and proteasomal degradation. The IKK complex further phosphorylates 
NF-κB1 (p105) leading to proteolytic processing and increased levels of p50. RELA (p65) – 
p50 dimers translocate to the nucleus and regulate the expression of target genes. When 
TNFR2 is activated this leads to the activation of NIK which phosphorylates and thereby 
activates IKK-α. Downstream of IKK-α, phosphorylation of NF-κB2 (p100) leads to an 
increased proteolytic processing towards p52 and phosphorylation of IκB proteins release the 
block of RELB. RELB - p52 dimers translocate to the nucleus and regulate the expression of 
target genes.  
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1.8 The Death-Associated Protein Kinase (DAPK) family 
 
The Death-Associated Protein Kinase (DAPK) family comprises serine/threonine 
kinases that are associated with several cell death-related signalling pathways. 
The family is formed by DAPK1 (also referred to as DAPk) and two closely 
related homologues, DAPK2 (also known as DRP-1) and DAPK3 (also known as 
ZIPK/DLK). This family also includes DAPK-related apoptosis-inducing protein 
kinase (DRAK) 1 and 2, which display a lower level of homology. DAPK2 and 
DAPK3 share 83% and 80% identity respectively with DAPK1´s catalytic domain 
at the amino acid level. Outside this domain they vary greatly in size and 
structure (Figure 1-9). DAPK1 was originally identified as a factor regulating 
apoptosis in response to the cytokine Interferon (IFN) -γ (Deiss et al., 1995). All 
family members have been shown to mediate apoptosis upon overexpression 
(Cohen et al., 1997, Kawai et al., 1998, Kawai et al., 1999). Furthermore, the 
DAPK1 gene is often methylated in tumour cells, thereby transcriptionally silent, 
supporting the hypothesis that members of the DAPK family act as tumour 
suppressors (Bialik and Kimchi, 2006). However, it has also been reported that a 
DAPK1 isoform protects cells from TNF-induced apoptosis. This cytoprotective 
effect has been shown to be mediated through intrinsic and extrinsic apoptotic 
signalling pathways (Jin et al., 2001). In addition, DAPK1 has been described as 
a sensor for Δψm (Shang et al., 2005) and a player in oxidative stress response 
pathways (Eisenberg-Lerner and Kimchi, 2007). 
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Figure 1-9. The DAPK family. 
Protein domains of the DAPK family members are shown in different colours. The percentage 
in the kinase domain depicts homology to the family founder DAPK1. Whereas the proteins 
show a strong homology at the kinase domain, the C-termini of these proteins differ 
significantly.  
 
1.8.1 DAPK2 
 
DAPK2 is a member of the DAPK family and shares a high level of homology in 
its kinase domain with the other two family members, DAPK1 and DAPK3. The 
Kimchi group also identified DAPK2, which they characterised in 1999(Kawai et 
al., 1999). Like DAPK1, it is a Ca2+/calmodulin (CaM) regulated serine/threonine 
(Ser/Thr) kinase. The kinase domain is located at its N-terminus and the CaM 
regulated domain is located after the kinase domain and inhibits catalytic activity 
by functioning as a so-called pseudosubstrate (Figure 1-9 and Figure 1-10) 
(Shani et al., 2001, Bialik and Kimchi, 2006). Similar to DAPK1, the kinase 
activity of DAPK2 can be inhibited by autophosphorylation at the Serine residue 
308 (S308), which reduces its affinity to CaM (Shani et al., 2001, Shohat et al., 
2001). Therefore, the activation of DAPK2 requires two distinct events: First, 
Ca2+-activated CaM binds to the CaM regulated domain and releases this domain 
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from the catalytic cleft. Second, unique to members of the DAPK family, S308 de-
phosphorylation increases DAPK2’s affinity towards CaM and allows low levels of 
activation even in the absence of CaM (Shani et al., 2001, Shohat et al., 2001) 
[reviewed in (Bialik and Kimchi, 2006)]. Furthermore, it has been shown that 
DAPK2 dephosphorylated at S308 tends to form dimers and higher oligomeric 
forms. Homodimerisation is facilitated by its C-terminal 40-amino acid tail. 
Remarkably, it has been shown, that homodimerisation adds another level of 
complexity to the regulation of DAPK2, as mutants that lack this tail were not only 
unable to dimerise but required higher CaM concentrations to function properly 
(Shani et al., 2001). More recent work carried out by Patel et al. shed more light 
into this complex activation process. Upon evaluating crystallised DAPK2 it was 
shown that dimerised DAPK2 itself does not resemble the activated form. 
However, dimerised CaM bound to DAPK2 is suggested to play a crucial role in 
the generation of S308 dephosphorylated, monomeric and active DAPK2 (Patel 
et al., 2011) (Figure 1-10). DAPK2 is ubiquitously expressed in several different 
cells and tissue types (Kawai et al., 1999). As mentioned above, activation of 
DAPK2 requires binding of Ca2+-activated CaM followed by the 
dephosphorylation of S308 leading to activated DAPK2 monomers. Interestingly, 
the potentially apoptotic TNF family members FasL and TNF-α were found to 
induce dephosphorylation of DAPK2 S308 and formation of DAPK2 dimers, 
required for the activation of active monomers, suggesting that DAPK2 becomes 
activated downstream of TNF receptor activation (Shani et al., 2001). It has been 
suggested, that under physiological conditions two different processes are 
capable to activate DAPK2. An increase in cellular Ca2+ levels, often associated 
with the induction of apoptosis, can induce the CaM modulated activation of 
 
Introduction 
 
! 71!
DAPK2. Alternatively, mostly independent of increased Ca2+ levels, 
phosphatases can dephosphorylate S308 in response to extracellular stimuli 
leading to the activation of DAPK2 (Bialik and Kimchi, 2006). In addition to the 
reported activation of DAPK2 in response to the activation of TNF-α, it has also 
been described to directly interact with the transforming growth factor, beta 
receptor 1 (TGFBR1) (Barrios-Rodiles et al., 2005). However, no functional work 
characterising this interaction has been carried out so far. 
 
Introduction 
 
! 72!
 
Figure 1-10. Model of DAPK2 activation. 
Structure of DAPK2 with its kinase domain in yellow, Ca2+/calmodulin (CaM) binding domain in 
dark blue and dimerization domain in light blue (a). Possible activation mechanism of DAPK2 
according to Patel et al. (b - e). CaM binding domain functions as pseudo substrate for 
DAPK2s kinase domain and pS308 reduces the affinity of DAPK2 towards CaM, leading to 
autophosphorylated, monomeric or dimeric inactive DAPK2. Homodimerisation is dependent 
on the C-terminal dimerisation domain (b). Dephosphorylation of pS308 increases the affinity of 
DAPK2 towards CaM and/or increase of cellular Ca2+ levels leads to an activation of CaM. In 
consequence, CaM binds to dephosphorylated DAPK2, leading to the formation of CaM bound 
dimeric form (d) which is required to form the CaM bound monomeric active form of DAPK2 (e) 
(Reproduced and adapted from (Patel et al., 2011)). 
 
The activation of DAPK2, as it is the case with DAPK1, has been associated with 
autophagy and caspase-independent cell death. During autophagic processes, 
DAPK2 can be found in the lumen of autophagic vesicles (Inbal et al., 2002). The 
majority of investigations into its functional role are solely based on induction of 
death related changes in overexpression studies. Interestingly, involvement in 
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death-inducing processes have often been shown to also involve DAPK1 and 
DAPK3, and the formation a so-called ‘death-associated multi-protein complex’ 
has been postulated (Gozuacik and Kimchi, 2006). Interestingly, kinase dead 
DAPK2, that contains alanine instead of lysine at the residue 42, which destroys 
the ATP binding pocket, has been shown to block TNF-α induced membrane 
blebbing (Inbal et al., 2002, Kawai et al., 1999). Together with other reports, 
linking DAPK2 expression to the induction of membrane remodelling and loss of 
matrix adherence, this suggests that DAPK2 could be partly involved in the 
induction of apoptotic features in response to extracellular stimuli (Inbal et al., 
2002). This effect on membrane remodelling by DAPK2 is likely to be modulated 
via phosphorylation of myosin light chain (MLC), which is a known target of 
DAPK2 (Inbal et al., 2000, Kawai et al., 1999). Furthermore, DAPK2 is capable of 
phosphorylating DAPK1 and DAPK3 (Shani et al., 2004), which have also been 
associated with cytoskeletal remodelling [reviewed in (Bialik and Kimchi, 2006)].  
 
In contrast to DAPK1 and DAPK3, DAPK2 has not been identified as a tumour 
suppressor in solid tumours. Interestingly, DAPK2 is emerging as a tumour 
suppressor in several types of leukaemia, especially in acute promyelocytic 
leukaemia (APL), a subtype of acute myelogenous leukaemia (AML), which 
responds to treatment with all-trans retinoic acid (ATRA) (Rizzi et al., 2007).  
 
Further insight into the physiological role of DAPK2 has been found upon 
identification of DAPK2 as a key player during granulopoiesis. It has been shown 
to be specifically expressed in normal granulocytes versus monocytes/ 
macrophages and CD34+ progenitor cells. Remarkably, the induction of 
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neutrophil differentiation by means of all-trans retinoic acid (ATRA) resulted in 
increased DAPK2 mRNA and protein expression. On the other hand, RNAi 
mediated DAPK2 depletion in an acute promyelocytic leukaemia cell line (NB4) 
resulted in reduced ATRA mediated granulocytic differentiation (Rizzi et al., 
2007). The expression of DAPK2 during neutrophil differentiation was 
demonstrated to be mediated by the myeloid master regulator PU.1. It can be 
blocked by the main driver of acute promyelocytic leukaemia (APL), the fusion 
protein, PML-RARA, linking DAPK2 function not only to neutrophil differentiation 
but the origin of leukemic disorders (Humbert et al., 2013). Recently, it has been 
shown that the role of DAPK2 in granulocytes does not seem to be restricted to 
their differentiation but is also involved in motility and response to 
chemoattractants. Pharmacological inhibition of DAPK2 in granulocytes resulted 
in decreased motility and block of an intermediary chemoattractant (e.g. IL-8, 
Leukotriene B4, platelet-activating factor) response with no effect on the 
response to end target molecules (e.g. formyl-methionyl-leucyl phenylalanine 
(fMLF) or complement component C5 (C5a)) that are secreted at the actual site 
of inflammation. This suggest a direct involvement of DAPK2 in an pro-
inflammatory response mediated by granulocytes which might be linked to 
previously described mechanism of MLC phosphorylation by DAPK2 (e.g. fMLF 
or C5a) (Geering et al., 2013).  
 
Remarkably, DAPK2 has also been associated with differentiation processes in 
the erythropoietic lineage. DAPK2 was proposed to be a new candidate 
attenuator of erythropoiesis. Interestingly, DAPK2 expression levels are 
significantly increased in early stages of erythrocyte development (bone marrow 
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stage and late stage erythroblasts). DAPK2 knock in mice failed to reverse 
induced anaemia and showed a decreased response to EPO treatment. 
Moreover, RNAi mediated depletion of UT7/Epo (erythroleukemic cells) led to 
substantial survival advantages in response to EPO treatment. These findings 
suggested that DAPK2 might exert fundamental regulatory effects on 
proerythroblast development (Fang et al., 2008). The described function of 
DAPK2 in myeloid differentiation sheds light into the so far enigmatic role of 
DAPK2's physiological function.  
 
Most recently, DAPK2 has also been linked to the induction of tubulointerstitial 
fibrosis in mice kidneys upon chronic cisplatin exposure. Interestingly, no 
malformation or increased tumour rate was reported in these mice (Guay et al., 
2014). 
 
Adding another level of complexity into the biology of DAPK proteins, an 
alternative splicing variant of DAPK2 has been identified recently. This isoform 
lacks the above-mentioned CaM regulated domain and contains a leucin zipper 
domain equivalent to DAPK3 (Figure 1-9). This isoform was named DAPK2-β 
and reported to be exclusively expressed in embryonic and early developmental 
tissues (Shoval et al., 2011). 
 
1.9 Cancer and glucose metabolism 
 
In 2011, when Hanahan and Weinberg extended their initial hallmarks of cancer 
theory, they included the ‘emerging hallmark: reprogramming energy metabolism’ 
 
Introduction 
 
! 76!
(Hanahan and Weinberg, 2011) (Figure 1-2). This hallmark of cancer 
characterises the metabolic changes in cancer cells that fundamentally contribute 
to carcinogenesis. 
 
Under physiological conditions, ATP is generated via two distinct metabolic 
pathways, depending on the cell type and environmental changes. Glycolysis is 
the first step in both pathways, degrading one molecule of glucose into two 
molecules of pyruvate, thereby producing two molecules of ATP. As depicted in 
Figure 1-11, most eukaryotic cells produce their majority of energy using the 
aerobic respiratory pathway. Here, pyruvate, as the main energy source, is 
transported into the mitochondria, where it becomes decarboxylated by enzymes 
of the pyruvate dehydrogenase complex (PDC) and enters the tricarboxylic acid 
(TCA)/Krebs cycle. The TCA/Krebs cycle is composed of a number of sequential 
reactions, that, in the end, lead to the oxidisation of two pyruvate molecules and 
production of 6 NADH, 2 FADH, as well as 2 ATP and the by-products H2O and 
CO2 [reviewed in (Zheng, 2012)]. In the next step, NADH is metabolised in the 
oxidative phosphorylation (OXPHOS), which utilises NADH to generate an 
electron gradient between the inner and outer mitochondrial membrane, in the 
so-called intermembrane space. The enzyme ATP synthase uses this electron 
gradient to produce ATP. One molecule of glucose ultimately yields 36 ATP 
molecules (Rich, 2003).  
 
The other main pathway to generate ATP is the so-called anaerobic respiration 
(Figure 1-11). When oxygen supply is limited, this pathway bypasses the 
pyruvate transport to the mitochondria. Instead an enzyme of the lactate 
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dehydrogenase family (LDH) converts pyruvate to lactate, under the expense of 
one NADH molecule, freeing NAD+ for glycolysis and leading to the accumulation 
of lactate. Under physiological conditions anaerobic respiration happens in all 
cells automatically, as pyruvate always accumulates to a certain extend. 
Accumulated lactate is transported out of the cells and can be converted back 
into pyruvate, producing NADH. (Miao et al., 2013). In addition, cells can 
increase anaerobic respiration in response to hypoxia due to intensive muscular 
work, injuries or necrosis (Miao et al., 2013, Dashty, 2013).  
 
In 2011, Hanahan and Weinberg (Hanahan and Weinberg, 2011) stated, that 
tumour cells in hypoxic environments, or even in the presence of oxygen switch 
from aerobic to anaerobic respiration. This metabolic change in cancer cells has 
been described as early as in 1930 35. However, switching towards anaerobic 
respiration forces cancer cells to cope with an approximately 18 fold reduced 
production of ATP (36 molecules after oxidative phosphorylation versus 2 
molecules after anaerobic respiration) (Hanahan and Weinberg, 2011). 
Increasing evidence suggests that this switch in metabolism is not only caused 
by hypoxia but also driven by well characterized oncogenes such as 
myelocytomatosis viral oncogene homolog (c-Myc) and rat sarcoma (RAS) or 
mutated tumour suppressors such as (p53). As mentioned above, pyruvate is 
converted into lactate by enzymes of the LDH family. Five different LDH 
isozymes play a major role in human metabolism. These isozymes are tetramers 
composed of the subunits LDH-A and/or LDH-B, encoded by two different genes 
(von Eyben, 2001). Composition of the LDH complex determines whether the 
enzyme complex favours the conversion of pyruvate to lactate or the other way 
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round. The more LDH-A subunits are present in the isozyme tetramer, the more 
the enzyme complex favours the reaction of pyruvate to lactate, whereas the 
number of LDH-B subunits correlates with the conversion of lactate to pyruvate. 
Cancer cells primarily express LDH-A, which therefore has been discussed as a 
potential biomarker for cancer (Miao et al., 2013, Girgis et al., 2014).  
 
 
Figure 1-11. Simplified cartoon of cellular metabolism pathways. 
Simplified cartoon depicting cellular metabolism pathways with glycolysis as the first step of 
glucose breakdown, and oxidative phosphorylation and anaerobic respiration as subsequent 
steps. 
 
Reprogramming of cancer cells towards anaerobic glycolysis has been shown to 
be associated with the regulation of hypoxia-inducible factors (HIFs). HIFs are a 
family of transcription factors that are activated under hypoxic conditions and 
upregulate the expression of LDH-A mRNA amongst other transcriptional targets. 
Several oncogenic lesions, such as c-myc deregulation or overactivation of 
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Her2/neu promote the expression of LDH-A via activation of HIFs [reviewed in 
(Miao et al., 2013)]. Activation of HIFs also induces the expression of glucose 
transporters (GLUT), further increasing the amount of cytosolic glucose available 
for anaerobic respiration (Fantin et al., 2006). In addition, other factors have been 
linked to HIF proteins: e.g. HIF-1α has been linked to pyruvate kinase isoenzyme 
M2 (PKM2). PKM2 is an isoenzyme of the pyruvate kinase family, which 
dephosphorylates phosphoenolpyruvate to pyruvate whilst producing ATP as the 
final step of glycolysis. Under physiological conditions, PKM2 is mostly 
expressed during embryogenesis and development. Cancer cells however have 
been shown to induce expression of this protein so that it can contribute to the 
metabolic reprogramming towards anaerobic respiration (Luo et al., 2011). 
Recently, PKM2 has also been shown to be directly regulated by DAPK1, a 
member of the DAPK family, which phosphorylates PKM2 and thereby increases 
cellular lactate production (Mor et al., 2012). 
 
Despite the obvious reason for favouring anaerobic respiration in cancer cells 
under hypoxic conditions, the described metabolic reprograming is not 
necessarily associated with a hypoxic environment. It has been postulated, that 
an increased glycolysis per se represents an advantage for rapidly dividing cells. 
Synthesis of cellular components such as nucleotides and proteins require a 
constant supply with glycolytic intermediates. Interestingly, not only cancer cells, 
but also embryonic tissues exhibit an increase in anaerobic glycolysis. This 
suggests, that an increased glycolytic rate, despite its poor metabolic efficiency, 
contributes to cellular growth (Vander Heiden et al., 2009, Potter, 1958). 
Interestingly, induction of LDH-A has not only been shown to promote the 
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conversion of pyruvate to lactate, but LDH-A inhibition or lack seems to increase 
the rate of oxidative phosphorylation (Le et al., 2010). Remarkably, LDH-A is 
upregulated in a variety of human tumours and has further been associated with 
resistance to chemotherapy (Zhou et al., 2010, Miao et al., 2013). !! !
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1.10 Mitochondria and ROS 
 
As mentioned above, there are two main pathways of glucose metabolism. 
During glycolysis, glucose is broken down into two pyruvate molecules 
generating two molecules of ATP. The anaerobic respiratory pathway further 
converts pyruvate to lactate, generating NADH. Oxidative phosphorylation is the 
far more efficient metabolic pathway, which in the end produces 36 ATP 
molecules from one molecule of glucose. Here, pyruvate is transported into the 
mitochondria and decarboxylated by enzymes of the PDC and enters the 
TCA/Krebs cycle. At the end of this cycle, composed of a series of enzymatic 
reactions, two pyruvate molecules become oxidised to 6 NADH, 2 FADH, as well 
as 2 ATP and the by-products H2O and CO2. As mentioned in 1.9, Mitochondria 
are the key compartments that, subsequently utilise NADH and FADH to 
generate ATP in processes referred to as oxidative phosphorylation or 
chemiosmosis (Mitchell and Moyle, 1967). As depicted in Figure 1-12, this 
process is driven by the generation of a proton gradient between the 
mitochondrial matrix and the intermembrane space alongside the inner 
mitochondrial membrane. NADH and FADH serve as electron donors to electron 
acceptors such as O2. Part of this process is the oxidation of NADH and FADH 
and the transport of hydrogen protons (H+) into the inner mitochondrial 
membrane space by a protein complex referred to as electron transport chain 
(ETC), which is located in the inner mitochondrial membrane. The ETC consists 
of four different protein complexes, (Complex I, II, III and IV). Each of these is 
involved in the electron transfer process and functions as electron donor and 
acceptor leading to the accumulation of H+ in the mitochondrial intermembrane 
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space. This leads to the generation of an electron potential between the 
mitochondrial intermembrane space and the mitochondrial matrix, which is also 
referred to as mitochondrial membrane potential (Δψm). Here, Complex I (NADH 
dehydrogenase), transfers two electrons from NADH to the coenzyme ubiquinone 
(CoQ10 or Q10) resulting in the production of its reduced form ubiquinol (CoQ10H2) 
and the transfer of four H+ protons into the intermembrane space. Complex II 
(succinate dehydrogenase) functions similar to Complex I, facilitating the 
reduction of CoQ10 to CoQ10H2 using FADH, which is produced during the 
oxidisation of succinate to fumarate as the last step of the TCA cycle. Note, this 
complex does not transport H+ to the intermembrane space. In the next step, 
Complex III (CoQ10 - cytochrome c reductase) removes two electrons from CoQ10 
and transfers them to the haemoprotein cytochrome c; Complex III also transfers 
four H+ into the mitochondrial intermembrane space. This reaction is followed by 
Complex IV (cytochrome c oxidase), which removes electrons from cytochrome c 
and leads to the oxidisation of O2, resulting in the formation of H2O and also 
transferring two molecules of H+ into the mitochondrial intermembrane space. 
The last step of OXPHOS is the oxidative phosphorylation of ADP, resulting in 
the production of ATP, the central energy storage unit of the cells. This is 
facilitated by Complex V, also referred to as ATP synthase, a multi-protein 
complex that functions as an ion channel allowing an influx of H+ protons, along 
the proton gradient, back into the mitochondrial matrix. The energy freed during 
this proton flux is used to phosphorylate ADP, leading to the production of ATP.  
 
During the process of oxidative phosphorylation, single protons can escape and 
reduce oxygen to the superoxide anion (•O2-), which further results in the 
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generation of a variety of reactive oxygen species (ROS) such as H2O2, and 
highly reactive hydroperoxyl radical (HO2•). Accumulation of ROS can lead to 
oxidative damage and as end consequence induction of apoptosis  [reviewed in 
(Fariss et al., 2005)]. It has been postulated that approximately 1% of consumed 
O2 contributes to the generation of ROS, the majority of which is being produced 
in the mitochondria (Petrosillo et al., 2004) [reviewed in (Fariss et al., 2005)]. 
Electron leakage has been reported for Complex I, which is usually released into 
the matrix, making Complex I an important site for the production of •O2- (Hirst et 
al., 2008, Muller et al., 2004). Interestingly, Complex II has only been associated 
with the generation of ROS when mutated or Complex I and Complex III are 
inhibited, leaving it as a minor source for mitochondrial ROS (Drose, 2013, 
Quinlan et al., 2012). Complex III has been described by many groups to be a 
major source of mitochondrial ROS and is, together with Complex I, regarded as 
the main mitochondrial site involved in the production of ROS. During the 
electron transfer by Complex III the highly reactive ubisemiquinone radical anion  
(•CoQ10-) is formed, which can induce electron leakage leading to the generation 
of •O2-. This oxygen radical is released into the matrix as well as the 
intermembrane space (Muller et al., 2004). The generation of ROS by complexes 
of the ETC can be increased by a large proton gradient during OXPHOS. Such 
increase can be caused by an increased production of NADH or a defect in 
proteins of the ETC by e.g. aging or mutations (Fariss et al., 2005). Mitochondrial 
ROS are controlled by two proteins, phospholipid-hydroperoxide glutathione 
peroxidase (PHGPx) and Mn-superoxide dismutase (MnSOD or SOD2). PHGPx 
functions as electron donor for peroxidised lipids under oxidation of glutathione, 
protecting mitochondria from toxic lipid radicals (Nakagawa, 2004). SOD2 is a 
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mitochondrial protein that can be found in the mitochondrial matrix, transforming 
•O2- into less toxic H2O2 (Muscoli et al., 2003). 
 
 
Figure 1-12. Simplified cartoon of the electron transport chain. 
NADH is generated by the TCA cycle. Complex I (depicted as green square) transfers 
electrons to the coenzyme ubiquinone (Q10) and utilises the freed energy to transfer H+ protons 
into the intermembrane space. During this process superoxide (•O2-, depicted as purple stars) 
can be generated. As part of the TCA cycle succinate is oxidised to fumarate. This reaction is 
carried out by Complex II (depicted as light purple square). During this process energy is 
stored in FADH as an intermediate and electrons are transferred to Q10. Complex III (depicted 
as yellow oval) removes electrons from Q10 and transfers them to cytochrome c (Cyt c) 
whereby H+ protons are pumped into the intermembrane space. This process bears the risk of 
•O2- generation. Complex IV (depicted as blue oval) removes electrons from Cyt c and 
oxidises O2 under generation of H2O and also utilises the generated energy to pump H+ 
protons into the intermembrane space. Complex V, also known as ATP synthase (depicted in 
brown), uses the mitochondrial membrane potential to generate ATP. H+ proton flux along the 
proton gradient frees energy, which is utilised to phosphorylate ADP to ATP. 
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2. Aims 
Previous work in Dr. Ana P. Costa-Pereira’s’ laboratory, carried out by Dr. Katrina 
M. Sutton and Dr. Ana-Violeta Fonseca, revealed that the depletion of DAPK2 
resulted in sensitisation of U2OS osteosarcoma cells to TRAIL-induced 
apoptosis, whilst having no impact on other apoptosis stimuli such as taxol and 
H2O2 (Figure 2-1a + b), and the death-inducing cytokine TNF-α  (Figure 2-1d). 
!
 
Figure 2-1. DAPK2 is a modulator and inhibitor of TRAIL-induced apoptosis in cancer 
cells. 
U2OS osteosarcoma cells were left untransfected, mock-transfected or transfected with siRNA 
oligonucleotides targeting four different regions of DAPK2 (previously validated by 
deconvolution analysis), or with a nontargeting (NT) siRNA. After 48 h, cells were counted and 
re-plated at equivalent numbers. Cells were then challenged with Taxol, H2O2, TRAIL or TNF-α 
for 24 h and cell death measured using crystal violet. All samples were set in triplicate and the 
data shown here represent the average of 3 independent experiments. * p < 0.05 two-tailed 
students t-test; ♦ Untransfected; ! Mock; Δ NT siRNA;  DAPK2 siRNA. Dr. Ana-Violeta 
Fonseca generated this figure. !
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We hypothesised that DAPK2 is a novel modulator of TRAIL-induced apoptosis. 
Therefore, the aim of this work was thus to decipher and better understand the 
underlying mechanism(s) leading to the sensitisation of TRAIL-resistant cancer 
cells to TRAIL-induced apoptosis. 
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3.1 Materials 
3.1.1 Equipment 
 
Applied Biosystems 7900HT Fast Real-Time PCR System was from Applied 
Biosystems, (Foster City, CA, USA). FACS Canto flow cytometer was from 
Becton Dickinson (Franklin Lakes, NJ, USA). Orbital shaker Stuart SSL1 was 
from Bibby Scientific (Stone, UK). Mini-PROTEAN® electrophoresis system and 
PowerPac™ Universal Power Supply were from BioRad (Hercules, CA, USA). 
PHERAstar Plus luminescence microplate reader was from BMG Labtech 
(Ortenberg, Germany). The BioMAT 2 Microbiological Safety Cabinet was from 
CAS (Manchester, UK). Centrifuge 5810, centrifuge 5411 D, –80 °C Premium 
U570 Upright Freezer and the Thermomixer Compact were from Eppendorf 
(Hamburg, Germany). PIPETMAN Classic™ pipets were from Gilson (Middleton, 
WI, USA). The water bath was from Grant Instruments (Shepreth, UK). The 
Konica SRX-101A film processor was from Konica Minolta (Marunouchi, Japan). 
The iBlot® Dry Blotting system was from Invitrogen, a brand of Life Technologies 
(Carlsberg, CA, USA) and the Veriti® 96-Well Thermal Cycler was from Life 
Technologies. Milli-Q® Integral Water Purification Systems was from Merck 
Millipore (Billerica, MA, USA). The MP225 General Purpose GLP pH /mV / T 
Meter was from Mettler-Toledo (Greifensee, Switzerland). The AutoFlow Direct 
Heat CO2 Incubator was from NuAire (Plymouth, MN, USA). The inverted 
research microscope IMT-2 was from Olympus (Tokio, Japan). The FUSION 
Solo™ quantitative luminescence system was from PEQLAB (Erlangen, 
Germany). The bacterial incubator was from Sanyo (Moriguchi, Japan). 
CERTOMAT® BS-1 Incubation-Shaking Cabinet was from B. Braun Biotech 
International, now part of Sartorius (Göttingen, Germany). Seahorse XF96 
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analyser was from Seahorse Bioscience (North Billerica, MA, USA). Films were 
scanned using an EPSON PERFECTION V500 photo scanner from Seiko Epson 
(Nagano, Japan). Freezing container, Nalgene® Mr. Frosty was from Sigma-
Aldrich (St. Louis, MO, USA). The VORTEX GENIE 2 was from Scientific 
Industries (Bohemia, NY, USA). SunriseTM microplate absorbance reader was 
from Tecan Group (Männedorf, Switzerland). Heraeus™ Fresco™ 17 
Microcentrifuge, rotamixer Denley Spiramix, magnetic stirrer IKAMAG RO 15 
POWER, Sorvall™ Legend™ T Plus/RT Plus Centrifuge, Matrix™ Equalizer 
Electronic Multichannel Pipetters and NanoDrop 1000 Spectrophotometer were 
from Thermo Fisher Scientific (Waltham, MA, USA). The gel documentation 
system was from UVITEC (Cambridge, UK).  
 
3.1.2 Software 
 
Data was analysed using Microsoft® Excel® for Mac 2011 from Microsoft 
(Redmond, WA, USA). Statistical analysis was performed and the majority of 
graphs were generated using GraphPad Prism from GraphPad software (La 
Jolla, CA, USA). Flow cytometry data was analysed and graphs were generated 
using FlowJo Version 8.8.7 (Tree Star, Ashland, OR, USA). Quantitative 
polymerase chain reaction data was analysed using the Applied Biosystems 
7900HT Fast Real-Time PCR System Software SDS v2.3 from Applied 
Biosystems. Further gene expression analysis was performed using the qbase+ 
software from Biogazelle (Ghent, Belgium). Western blot images were obtained 
using the FUSION-CAPT software from PEQLAB (Erlangen, Germany). Images 
were further analysed using the Image Studio Lite software from LI-COR 
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Biosciences (Lincoln, NE, USA). Manuscript figures were assembled using 
Microsoft® PowerPoint® for Mac 2011 (Microsoft) and Adobe Illustrator CS6 
from Adobe Systems Incorporated (San Jose, CA, USA).  
 
3.1.3 Consumable materials 
 
All pipette tips were from Starlab (Milton Keynes, UK) and VWR (Radnor, PA, 
USA). Cell scrapers, centrifuge tubes, tissue culture dishes, tissue culture flasks 
and sterile serological pipettes were from VWR. Aspiration pipettes were from 
Sarstedt (Nümbrecht, Germany). Cloning cylinders were from Sigma-Aldrich. 
Microcentrifuge tubes and all remaining plastic ware were from Starlab and XF96 
microplates were from Seahorse Bioscience. 
 
3.1.4 General reagents 
 
The NADP+/ NADPH assay kit was from Abcam (Cambridge, UK). The 
Glutathione Assay Kit was from BioAssay Systems (Hayward, CA, USA). The 
NAD+/ NADH assay kit was from BioVision (San Francisco, CA, USA). Foetal calf 
serum (FCS) was purchased from FirstLink (Wolverhampton, UK). L-glutamine, 
Lipofectamine® RNAiMax transfection reagent, Lipofectamine® 2000 
transfection reagent, OneShot® TOP10 Chemical competent cells, Proteinase K, 
Dynabeads® Protein G-magnetic beads, iBlot® nitrocellulose Transfer Stacks, 
High-Capacity cDNA Reverse Transcription Kit, Fast SYBR® Green Master Mix, 
PureLink® HiPure Plasmid Midiprep Kit, Opti-MEM® Reduced Serum Media and 
Zeocin™ were obtained from Life Technologies. 5-(and-6)-chloromethyl-2',7'- 
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dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA), 
dihydroethidium (DHE), the MitoProbe™ JC-1 Assay Kit and MitoSOX™ Red 
mitochondrial superoxide indicator were purchased from Molecular Probes®, a 
brand of Life Technologies. Glycine, nonidet-P40 (NP-40) and paraformaldehyde 
(p-FA) were from VWR (Radnor, PA, USA). Dithiothreitol (DTT) and powdered 
milk were obtained from AppliChem (Darmstadt, Germany). BioRad protein 
assay and bromophenol blue were obtained from BioRad. Ethanol, glycerol, 
isopropyl alcohol, methanol, ethylenediamine tetraacetic acid (EDTA), 
Tris(hydroxymethyl)-aminomethan (Tris), hydrochloric acid (HCl, 37% v/v), glacial 
acetic acid, phosphate buffered saline, sodium chloride (NaCl), sodium dodecyl 
sulphate (SDS), Ultrapure Protogel 30% (w/v) acrylamide, 0.8% bis-acrylamide 
(37.5:1), Fermentas PageRulerTM prestained protein markers, Pierce ECL 
Western Blotting Substrate were obtained from Thermo Fisher Scientific. All 
siGENOME siRNA sequences were obtained from Dharmacon, now a brand of 
GE Healthcare (Little Chalfont, UK). Enhanced chemiluminescence (ECL) 
detection reagents were purchased from Amersham a brand of GE Healthcare 
and aprotinin and leupeptin were purchased from Calbiochem, now a brand of 
Merck Millipore. Attractene transfection reagent, MinElute® PCR Purification Kit, 
QIAprep® Spin Miniprep Kit, RNeasy® kit and Ribonuclease A (RNase A) and 
FlexiTube siRNA were obtained from Qiagen  (Hilden, Germany). FUJI medical 
x-ray film was from FUJIFILM (Tokyo, Japan). Dual-Glo® Luciferase assay 
system was obtained from Promega (Madison, WI, USA). All restriction enzymes 
and T4 DNA Ligase were from New England Biolabs (Ipswich, MA, USA). Tet 
System Approved FBS was from Clontech a brand of Becton Dickinson. The 
cOmplete and Mini EDTA-free protease inhibitor cocktail was from Hoffmann-La 
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Roche (Basel, Switzerland). All remaining reagents were purchased from Sigma-
Aldrich. 
 
3.1.5 Antibodies and cytokines  
 
Anti-DAPK2 was purchased from Epitomics (Burlingame, CA, USA). Anti-DAPK1 
and pDAPK1 (Ser308) were from Abcam. DAPK3 antibody was from 
Calbiochem. Antibodies against Caspase-3, Caspase-8 and Caspase-9, CHOP, 
BID, BCL-XL, DR5, pERK1/2 (Thr202/Tyr204), NF-κB1 (p50, p105), NF-κB2 
(p52, p100), PARP, RELA (p65), and phosphorylated pRELA (pp65-Ser536), 
were bought from Cell Signaling Technology (Danvers, MA, USA). The 
antibodies against β-Actin, Flag, HA and α-Tubulin were obtained from Sigma-
Aldrich and the one against HSP90 from NeoMarkers (Fremont, CA, USA). The 
antibodies against ERK1/2, KEAP1, Lamin-B and NRF2 were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Anti-FAS IgM was from Merck Millipore. 
Secondary antibodies were from DAKO (Glostrup, Denmark). For flow cytometry, 
the antibody against DR5 and FAS were from eBioscience (Hatfield, UK) and the 
one against DR4 from Abcam. TRAIL and TNF-α were purchased from 
PeproTech (London, UK). 
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3.1.6 Cell lines 
 
The majority of work in this study was carried out using U2OS and A549 cells. 
U2OS is an adherent epithelial cell line derived from a moderately differentiated 
osteosarcoma from the tibia of a 15-year-old Caucasian female (Ponten and 
Saksela, 1967). A549 is an adenocarcinomic, non-small cell lung cancer 
(NSCLC) cell line derived from a 58-year-old Caucasian male (Giard et al., 1973). 
Additionally used were T24 cells, a transitional cell carcinoma, bladder cancer 
cell line derived from an 81-year-old female Caucasian (O'Toole et al., 1972) and 
PC3 cells, a prostate adenocarcinoma cell line, derived from a 62-year-old male 
Caucasian (Kaighn et al., 1979). Characteristics and p53 status of these cell lines 
are depicted in Table 3-1. All cell lines were obtained from the American Type 
Culture Collection (ATCC). 
 
Table 3-1. Cell lines used in this study and corresponding p53 status. 
Cell line Tumour type Origin p53 status 
U2OS Osteosarcoma Bone wt / wt  (Diller et al., 1990) 
A549 NSCLC, adenocarcinoma Lung wt / wt  (Lehman et al., 1991) 
T24 Transitional cell bladder carcinoma Bladder 
wt / mt 
(Y126 " Stop) 
 (Cooper et al., 1994) 
PC3 Prostate  Prostate 
- / mt (codon 138, C 
nucleotide deletion " frame 
shift)  
(Isaacs et al., 1991)  
 
For further functional studies and the generation of tetracycline (Tet) inducible 
cell lines, U2OS cells stably transfected with the Tet repressor (TetR) gene were 
used (henceforth referred to as U2OS-TetR). These cells were characterised in 
2003 (Monroe et al., 2003) and are identical to parental U2OS cells but contain a 
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stably transfected pcDNA™6/TR plasmid as part of the inducible T-REx™ 
System (Life Technologies). 
3.2 Methods 
3.2.1 Cell culture 
 
U2OS, A549, T24 and PC3 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% (v/v) foetal calf serum (FCS), 2 mM L-
glutamine, 50 units/ml penicillin and 50 µg/ml streptomycin (henceforth referred 
to as Full-DMEM) in a humidified atmosphere of 10% CO2 at 37 ˚C. U2OS-TetR 
cells were cultured in Full-DMEM (with Tet System Approved FBS) media 
supplemented with 5 µg/ml blasticidine. U2OS-TetR cells stably transfected with 
pcDNA™4/TO based constructs were cultured in Full-DMEM (with Tet System 
Approved FBS) media supplemented with 5 µg/ml blasticidine and 500 µg/ml 
Zeocin™. All cell culture work was performed under a laminar flow hood and 
materials were disinfected using 70% (v/v) ethanol. Medium and buffers were 
warmed up in a 37 °C water bath. Cells were sub-cultured at circa 80% 
confluency. For passaging, cells were rinsed generously with PBS and any 
leftover media and cellular debris were aspirated. Next, cells were incubated with 
the protease Trypsin-EDTA [2.5 mg/ml trypsin in 0.02% (w/v) EDTA, 0.09% (w/v) 
NaCl], which detaches adherent cells. Soft beating and incubation at 37 °C 
eased cell detaching. Cells were re-suspended in Full-DMEM and spun down at 
200 RCF for two min to remove any leftover PBS and trypsin. In the next step, 
cells were seeded into new culture flasks according to the experimental 
requirements, for passaging usually at a 1:10 ratio. Cells were frozen as follows: 
upon media removal and washing with PBS, cells were covered with 
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Trypsin-EDTA. The majority of liquid was aspirated instantly so that the culture 
flask was covered with a thin layer of Trypsin-EDTA. Upon incubation and cell 
detachment, cells were re-suspended into freezing media [DMEM, 30% FCS 
(v/v), DMSO 10% (v/v)], transferred into freezing vials (>1x106 cells/vial) and 
frozen at -80 ˚C using a Mr. Frosty Nalgene® freezing container. Twenty-four h 
later, freezing vials were transferred into vapour phase nitrogen in liquid nitrogen 
storage tanks.  
 
Cells were thawed in a water bath at 37 ˚C and upon thawing re-suspended drop-
wise in Full-DMEM (37 ˚C). To remove leftover DMSO from the freezing media, 
cells were spun down at 200 RCF for two min and re-suspended in Full DMEM. 
Cells were then grown in a humidified atmosphere of 10% CO2 at 37 ˚C.  
 
3.2.2 Generation of stable inducible cell lines.  
 
For functional studies of DAPK2 mutants, tetracycline inducible cell lines were 
generated. Therefore U2OS-TetR cells were stably transfected with 
pcDNA™4/TO plasmids containing N-terminal human influenza haemagglutinin 
(HA) tagged DAPK2 constructs. The different DAPK2 constructs and their sub-
cloning into pcDNA™4/TO plasmids are further described in section 3.2.14. To 
achieve higher integration efficiency, HA-DAPK2 constructs cloned into the 
pcDNA™4/TO vector, were linearised using the restriction enzyme PvuI and 
complete digest was verified using agarose gel electrophoresis. Linearised 
plasmids were transfected into U2OS-TetR cells using Lipofectamine® 2000. 
Forty-eight h later, cells were split into selection antibiotic containing media [Full-
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DMEM (with Tet System Approved FBS) supplemented with 5 µg/ml Blasticidine 
and 500 µg/ml Zeocin™] in a 1:20 and 1:40 ratio. After around four days in 
selection media, visible colonies began to form. When colonies reached an 
appropriate size they were picked using cloning cylinders and autoclavable 
silicon grease as follows. Colonies were assessed for their physical appearance 
and only those equivalent to the parental cell line were chosen and marked with a 
pen at the bottom of the cell culture plate. Next, cells were washed twice with 
PBS and the majority of liquid was aspirated. The bottom of cloning cylinders was 
covered in grease and then pressed on the surface of the cell culture plate 
enclosing a selected colony. Subsequently trypsin was added drop wise into the 
cylinder and cells were incubated at 37 °C for ca. two min. Cell were then 
transferred into a multiwell culture plate containing selection media. Cells were 
grown and expanded for further analysis. Induction of DAPK2 constructs with 
doxycycline (10 ng/ml) and background expression were assessed by SDS-
PAGE/western blotting. For each construct, at least five inducible clones were 
generated and tested. To avoid the possible loss of transgenes, cells were 
constantly cultured in selection media. 
 
3.2.3 RNA interference (RNAi) 
 
Transfection of small interfering (si) RNA oligonucleotides was performed using 
LipofectamineTM RNAiMax according to the manufacturer’s instructions. The 
concentrations of LipofectamineTM RNAiMax and siRNAs were optimised for all 
cell lines prior to each experimental procedure. Single knockdowns were 
performed at a conc. of 20 nM and for double knockdowns (knocking down two 
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different targets at once) a total siRNA conc. of 40 nM was used, by combining 
20 nM of each target siRNA. Silencing of target mRNAs was performed using 
either siGENOME pooled siRNA (Dharmacon) (containing four different siRNAs 
targeting the same mRNA), custom designed siRNA (Dharmacon) or Qiagen 
FlexiTube siRNA. The individual siGENOME siRNAs were characterised by 
Dharmacon using genome wide microarrays analyses identifying minimal off-
target signatures (Parsons et al., 2009) and further characterised throughout the 
study by deconvolution. Knockdown efficiency was assessed by qPCR and/ or 
western blotting. RNAi experiments were controlled by using two non-specific 
siRNA controls, AllStars Negative Control siRNA (Qiagen) and Luciferase GL3 
Duplex (Dharmacon), as well as untransfected cells. siRNA oligonucleotides 
used in this study are depicted in Table 3-2.  
 
Table 3-2. siRNA oligonucleotide sequences used throughout the study. 
Target gene Target sequence Manufacturer’s ID 
Non targeting 
(AllStars) Not disclosed by Qiagen Qiagen-SI03650318 
Luciferase GL3 
Duplex CUUACGCUGAGUACUUCGA Dharmacon-001400-01-20 
BID_3 GCACCUACGUGAGGAGCUU Dharmacon-004387-03  
BID_18 GAGUAAGGGCACUGACGGA Dharmacon-004387-18  
BID_19 GCCAGAAGCUACUGCGAUG Dharmacon-004387-19  
BID_20 UGCAAUACAUACCACGCUA Dharmacon-004387-20 
DAPK2_1# GAGGAGAGCUCUUCGAUUU Dharmacon-004418-01 
DAPK2_3 GGAAACGGCUCACAAUCCA Dharmacon-004418-03 
DAPK2_4 GGAAUUUGUUGCUCCAGAA Dharmacon-004418-04 
DAPK2_5# GAGAUGGGCCCAAGGAAUU Dharmacon-004418-05 
DAPK23'UTR GAGUGUGGACUUAGGAAAA Dharmacon-custom 
DAPK2 
Qiagen 11 CAGCAUUCCCAAAGCTCUU Qiagen-SI04988298 
DAPK3_1 GAACAUUCCUGGAUUAAGG Dharmacon-004947-01 
DAPK3_2 CCACGCGUCUGAAGGAGUA Dharmacon-004947-02 
DAPK3_3 GAGCCAGGCCCGUAAGUUC Dharmacon-004947-03 
DAPK3_4 GAGGAGUACUUCAGCAACA Dharmacon-004947-04 
DR4_6 UGACAAUUCUGCUGAGAUG Dharmacon-008090-06 
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DR4_15 CAACAAAACUGGACGGAAC Dharmacon-008090-15 
DR4_16 GAACAUAGCCCUUUGGGAG Dharmacon-008090-16 
DR4_17 CGGCAGAUUUGACAGGUGU Dharmacon-008090-17 
DR5_1 GGACAGAAGCUCACAACGA Dharmacon-004448-01 
DR5_2 UCAUGUAUCUAGAAGGUAA Dharmacon-004448-02 
DR5_3 ACACGAUGCUGAUAAAGUG Dharmacon-004448-03 
DR5_4 CAAGGUCGGUGAUUGUACA Dharmacon-004448-04 
NFKB1_1 GCAGGUAUUUGACAUAUUA Dharmacon-003520-01 
NFKB1_2 GCAAUAGCCUGCCAUGUUU Dharmacon-003520-02 
NFKB1_3 GAACCACGCCUCUAGAUAU Dharmacon-003520-03 
NFKB1_5 GGGCUACACCGAAGCAAUU Dharmacon-003520-05 
NFKB2_1 CCAAACAGUUCACCUAUUA Dharmacon-003918-01 
NFKB2_2 GGACGUGUCUGAUUCCAAA Dharmacon-003918-02 
NFKB2_3 GGUGAUGGAUCUGAGUAUA Dharmacon-003918-03 
NFKB2_18 GUAGACACGUACCGACAGA Dharmacon-003918-18 
RELA_3 GGAUUGAGGAGAAACGUAA Dharmacon-003533-03 
RELA_4 CUCAAGAUCUGCCGAGUGA Dharmacon-003533-04 
RELA_5 GGCUAUAACUCGCCUAGUG Dharmacon-003533-05 
RELA_18 GAUUGAGGAGAAACGUAAA Dharmacon-003533-18 
RELB_1 CAUCAGAGCUGCGGAUUUG Dharmacon-004767-01 
RELB_4 GCCCGUCUAUGACAAGAAA Dharmacon-004767-04 
RELB_5 GCACAGAUGAAUUGGAGAU Dharmacon-004767-05 
RELB_18 GUACCUGCCUCGCGACCAU Dharmacon-004767-18 
 
# Excluded from the siRNA pool following deconvolution analysis due to off-target effects. 
 
3.2.4 Protein extraction 
 
Upon treatment according to the experimental procedures, cell culture plates 
were placed on ice. When assessing apoptotic processes, the supernatant 
containing dead cell bodies was transferred into separate tubes. Both the latter 
and cells that remained attached to the plate (live cells) were washed with ice-
cold PBS and lysed using radioimmunoprecipitation assay (RIPA) buffer [50 mM 
Tris-HCL pH 7.4, 0.5% (v/v) NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4 
and ‘cOmplete and Mini, EDTA-free protease inhibitor cocktail’ (Hoffmann-La 
Roche), the latter used as instructed by the manufacturer]. Proteins isolated from 
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live and dead cells were combined, incubated on ice for 30 min and DNA was 
removed by centrifugation at 16.2 RCF for 20 min at 4 ˚C and transfer of protein 
lysate to new tubes. Protein concentrations were determined using a Bradford 
assay according to the manufacturer’s instructions. In brief, this is a dye-binding 
assay based on a differential colour change of a dye in response to different 
concentrations of protein (Bradford, 1976). For long-term storage samples were 
frozen at -80 ˚C. To prepare samples for subsequent SDS-polyacrylamide gel 
electrophoresis (PAGE) protein concentrations were equalized and samples were 
re-suspended in Laemmli buffer [0.25 M Tris HCl, pH 6.8, 8% (w/v) SDS, 40% 
glycerol, 0.042% (w/v) bromophenol blue, 10% β-mercaptoethanol] and boiled at 
95 ˚C for 5 min. 
 
3.2.5 SDS-PAGE and western blotting 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blotting were used to separate proteins according to their molecular 
weights. For that purpose 5% acrylamide stacking gels [5% (v/v) acrylamide, 
0.125 M Tris, pH 6.8, 0.1% (w/v) SDS, 0.075% (w/v) ammonium persulphate 
(APS) and 0.083% (v/v) tetramethylethylenediamine (TEMED)] together with 6%, 
10% or 12.5% acrylamide resolving gels [6%, 10%, 12.5% (v/v) acrylamide, 
0.0375 M Tris pH 8.8, 0.1% (w/v) SDS, 0.06% (w/v) APS, 0.07% (v/v) TEMED] 
were set up. The latter depended on the molecular mass of proteins being 
analysed. Gels were run at 90 V in a Tris-glycine buffer [2.5 mM Tris, 0.2 M 
glycine and 0.1% (w/v) SDS]. Separated proteins were transferred onto 
nitrocellulose membranes using the Invitrogen iBlot®-system according to 
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manufacturer’s instructions. To prevent non-specific antibody binding, 
membranes were blocked in 5% (w/v) bovine serum albumin (BSA)/ Tris-buffered 
saline/ Tween (TBST) [0.01 M Tris pH 7.4, 75 mM NaCl, 1.25 mM EDTA pH 8.0, 
0.1% (v/v) Tween 20] containing 0.02% (v/v) sodium azide at room temperature 
for 1 to 2 h. Alternatively, depending on the antibodies, blocking was performed 
in 5% (w/v) milk powder/TBST. Primary antibodies were diluted in 5% (w/v) BSA/ 
TBST, containing 0.02% (v/v) sodium azide, according to manufacturer’s 
instructions and incubated for either one h at room temperature, or o/n at 4 °C 
overnight. Before applying the secondary antibody, membranes were washed 
three times for 10 min in TBST. Secondary antibodies, conjugated to horseradish 
peroxidase (HRP), were diluted in 5% (w/v) milk powder/ TBST and incubated for 
one to two h at room temperature. Before detecting antibody binding by exposing 
to ECL reagent, membranes were washed at least six times for 5 min in TBST. If 
re-probing was necessary, antibodies were removed overnight using stripping 
buffer [2 M glycine pH 2.5, 0.1% (w/v) of SDS, 0.02% (w/v) sodium azide]. When 
phosphorylated proteins were assessed, phosphorylated forms were always 
probed first, followed by the total proteins. Western blots were analysed using the 
quantitative luminescence system FUSION Solo™. Images were analysed using 
Image Studio Lite software.  
 
3.2.6 RNA extraction 
 
Total RNA was isolated using the RNeasy® Mini kit according to the 
manufacturer’s instructions. Briefly, cells were collected in 350 µl RLT lysis buffer 
and homogenized using the QIAshredder spin column. After adding ethanol, the 
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flow-through was run through an RNeasy spin column. RNA bound to the column 
was washed with 750 µl of RW1 buffer and twice with 500 µl RPE buffer. In the 
final step, RNA was eluted using RNase free water and RNA concentration was 
determined using the NanoDrop 1000 Spectrophotometer. If RNA was not 
isolated the day of lysis, cells were stored at -80 °C in RLT lysis buffer until RNA 
was extracted. 
 
3.2.7 Quantitative polymerase chain reaction (qPCR) 
 
Gene expression analysis was done by quantitative two-step reverse 
transcription PCR. Reverse transcription was performed using total RNA and the 
High-Capacity cDNA Reverse Transcription kit, using random hexamers. qPCR 
was done using the Fast SYBR® Green Master Mix with specific primer pairs 
(Table 3-3). For each target mRNA analysed, 2.5 µl of Fast SYBR® Green 
Master Mix, 0.5 µM of each primer pair and 2 µl of cDNA in deionised water (5 
ng/µl) were mixed in 384-well plates in duplicates using Matrix™ Equalizer 
Electronic Multichannel Pipetters. qPCR was carried out on an ABI PRISM 
7900HT using the following settings: initial activation of 20 sec at 95 ˚C, 40 
cycles; denaturation for 1 min at 95 ˚C; annealling/ extension for 20 sec at 60 ˚C; 
final melting curve was carried out for 15 sec at 95 ˚C and then 15 sec at 60 ˚C. 
Quantification of target messages was performed using qbase+ software. HPRT 
and GAPDH were the reference genes used for normalisation. 
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Table 3-3. Oligonucleotide qPCR primer pair sequences used throughout this study. 
Oligonucleotide 
Name 
Oligonucleotide sequence 
(5' → 3') 
Published source 
BID fwd TCCACACATGAATCTGCACATC 
 
BID rev GGGAACCTGCACAGTGGAA 
c-FLIP fwd TCTCACAGCTCACCATCCCTG 
(Zhang et al., 2004) 
c-FLIP rev CAGGAGTGGGCGTTTTCTTTC 
c-JUN fwd TCCAAGTGCCGAAAAAGGAAG 
 
c-JUN rev CGAGTTCTGAGCTTTCAAGGT 
COX2 fwd CGGTGAAACTCTGGCTAGACAG 
(Mologni et al., 2012) 
COX2 rev GCAAACCGTAGATGCTCAGGGA 
cREL fwd AGTTGCGGAGACCTTCTGACCA 
 
cREL rev CGTGATCCTGGCACAGTTTCTG 
DAPK2 fwd TCCTGGATGGGGTGAACTAC 
 
DAPK2 rev CAGCTTGATGTGTGGAATGG 
DcR1 fwd TCCCCAAGACCCTAAAGTTCG 
 
DcR1 rev CAGTGGTGGCAGAGTAAGC 
DcR2 fwd TACCACGACCAGAGACACC 
(Cui et al., 2011) 
DcR2 rev CACCCTGTTCTACACGTCCG 
DcR3 fwd TGCAGAAGATGTAGATTGTGTGATGA 
 
DcR3 rev GGGTCCGGGTGCAGTTTATT 
DR4 fwd CATCGGCTCAGGTTGTGGA 
(Galligan et al., 2005) 
DR4 rev TGCCGGTCCCAGCAGACA 
DR5 fwd GCACTCACTGGAATGACCTC 
(Pellerito et al., 2010) 
DR5 rev GCCTTCTTCGCACTGACAC 
FasR fwd GTACGCGGAGTGGCAGAAA 
 
FasR rev CAGAGGACGTTGCAGTAGC 
GAPDH fwd AGCCACATCGCTCAGACAC 
 
GAPDH rev GCCCAATACGACCAAATCC 
HPRT fwd  TGACCTTGATTTATTTTGCATACC 
 
HPRT rev  CGAGCAAGACGTTCAGTCCT 
KEAP1 fwd CAGATTGGCTGTGTGGAGTT 
 
KEAP1 rev GCTGTTCGCAGTCGTACTTG 
NF-κB1 fwd GCAGCACTACTTCTTGACCACC  
NF-κB1 rev TCTGCTCCTGAGCATTGACGTC 
NF-κB2 fwd GGCAGACCAGTGTCATTGAGCA  
NF-κB2 rev CAGCAGAAAGCTCACCACACTC 
NRF2 fwd GAGAGCCCAGTCTTCATTGC 
(Lister et al., 2011) 
NRF2 rev TTGGCTTCTGGACTTGGAAC 
OPG fwd TCCTGGGTGGTCCACTTAAT 
 
OPG rev CTCCAAGCCCCTGAGGTT 
p21 fwd TGAGCCGCGACTGTGATG 
(Chen et al., 2013) 
p21 rev GTCTCGGTGACAAAGTCGAAGTT 
p53 fwd TAACAGTTCCTGCATGGGCGGC (Chew et al., 2012) 
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p53 rev AGGACAGGCACAAACACGCACC 
RELA fwd CCAGGTTCTGGAAACTGTGGAT 
(Higai et al., 2006) 
RELA rev CCCCACGAGCTTGTAGGAAAG 
RELB fwd TGTGGTGAGGATCTGCTTCCAG 
 
RELB rev TCGGCAAATCCGCAGCTCTGAT 
RIPK1 fwd TATCCCAGTGCCTGAGACCAAC 
 
RIPK1 rev GTAGGCTCCAATCTGAATGCCAG 
RIPK2 fwd AGACCACTCCATGCTCTTCAGC 
 
RIPK2 rev GATCCACTGCTGGGCTATACCA 
SOD1 fwd AGGGCATCATCAATTTCGAG 
 
SOD1 rev TGCCTCTCTTCATCCTTTGG 
SOD2 fwd CGACCTGCCCTACGACTACG 
 
SOD2 rev TGACCACCACCATTGAACTT 
TNFR1 fwd TCACCGCTTCAGAAAACCACC 
 
TNFR1 rev GGTCCACTGTGCAAGAAGAGA 
TNFR2 fwd CGGGCCAACATGCAAAAGTC 
 
TNFR2 rev CAGATGCGGTTCTGTTCCC 
TNF-α fwd TCTTCTCGAACCCCGAGTGA 
(Giulietti et al., 2001) 
TNF-α rev CCTCTGATGGCACCACCAG 
TRAIL fwd AAGACTGTCAGCTTCCAAACATTAA 
(Giulietti et al., 2001) 
TRAIL rev GTGATACACTACTTGAGAGATGGAT 
 
3.2.8 mRNA and protein stability assays 
 
Cells were transfected with siRNA oligonucleotides as described before. Forty-
eight h after transfection cells were treated with 5 µg/ ml actinomycin D for 1 - 4 
h. Subsequently, RNA was isolated using an RNeasy® kit following the 
manufacturer’s instructions. Gene expression analysis was performed by qPCR 
as described before, using HPRT and GAPDH as housekeeping genes. For 
protein stability, cells were incubated with cycloheximide (CHX) (1 µg/mL) for 2, 4 
or 6 h and protein measured by SDS-PAGE/western blotting using the FUSION 
Solo™ quantitative luminescence system and normalised to the housekeeping 
gene HSP90. 
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3.2.9 Flow cytometry 
3.2.9.1 Detection of surface molecules 
 
Cells were cultured and transfected with siRNA as described earlier. Forty-eight h 
later, cells were washed thoroughly with PBS and any leftover media and cellular 
debris were aspirated. Next, cells were incubated with trypsin to detach the 
adherent cells. Soft beating and incubation at 37 °C eased cell detaching. Upon 
blocking the trypsin with FCS-containing Full-DMEM and a washing step with 
PBS, cells were incubated with anti-DR4-FITC, anti-DR5-PE or anti-FAS-PE for 1 
h at 4 ˚C, washed five times with cold PBS and fixed with PBS containing 1% 
(w/v) p-FA. Cells were analysed using a FACS Canto and data was analysed 
with FlowJo Version 8.8.7. Geometric means were used for the analyses 
essentially as described earlier (Hajdu, 2011). 
 
3.2.9.2 Detection of oxidative stress and mitochondrial superoxides 
 
Cells were cultured and transfected with siRNA as described before, or treated 
with 0.5 mM H2O2 for 24 h, which was used as a positive control for ROS 
production. For the detection of general ROS using 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Molecular 
Probes®) (referred throughout the text as DCFDA) cells were incubated with 10 
µM CM-H2DCFDA dissolved in pre-warmed PBS for 30 min at 37 ˚C. Next, cells 
were trypsinised, re-suspended in Full-DMEM, washed twice with PBS and 
analysed by flow cytometry. Cellular superoxides were detected using 
dihydroethidium (DHE) (Molecular Probes®). Therefore, 48 h after transfection, 
cells were trypsinised, re-suspended in Full-DMEM, washed twice with PBS and 
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incubated in 10 µM DHE dissolved in pre-warmed PBS for 15 min, washed twice 
with pre-warmed PBS and analysed by flow cytometry.  
 
For the detection of mitochondrial superoxides, MitoSOX™ Red mitochondrial 
superoxide indicator (Molecular Probes®) was used. Briefly, cells were 
transfected as described earlier, or they were treated for 24 h with 1 mM 1-
Methyl-4-phenylpyridinium iodide (MPP+), or with 0.5 mM H2O2, which were used 
as positive controls. Forty-eight h later, cells were washed with PBS and 
incubated for 10 min at 37 ˚C in the dark with 5 µM MitoSOX™ Red reagent 
diluted in pre-warmed PBS. Samples were subsequently washed twice with PBS 
before being analysed. Depolarised mitochondria were studied using the 
MitoProbe™ JC-1 Assay Kit (Molecular Probes®) according to the 
manufacturer’s instructions. Briefly, 48 h after transfection, cells were trypsinised, 
re-suspended in Full-DMEM, washed twice with PBS and incubated in two µM 
5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) 
dissolved in pre-warmed PBS at 37 °C, 10% CO2, for 15 min and analysed by 
flow cytometry. To induce complete mitochondrial depolarisation the 
protonophore, carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (50 mM) was 
used for 5 min previous to JC-1 incubation. Cells were analysed by flow 
cytometry. 
 
All flow cytometry analyses were performed using a FACS Canto and data 
mining was done using FlowJo version 8.8.7. Fluorescence geometric means 
were used for the analyses and samples were normalised to siNS-transfected 
control cells, essentially as described earlier (Hajdu, 2011).  
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3.2.9.3 Cell cycle analysis using propidium iodide (PI) 
 
Cells were cultured and transfected with siRNA as described before. To assess 
the effect of TRAIL treatment on DNA hypoploidy, cells were treated with TRAIL 
(100 ng/ml) for six h. PI staining was carried out as follows; Cell corpses and 
cellular debris were removed and washed with pre-warmed PBS. Remaining cells 
were washed thoroughly with pre-warmed PBS and trypsinised. Detached cells 
were re-suspended in Full-DMEM, washed with pre-warmed PBS and after 
combination with cell corpses/debris, they were fixed with ice cold 70% (v/v) 
ethanol for 30 min. After two additional washing steps, cells were incubated with 
Ribonuclease A (20 µg/ml) and stained with PI (50 µg/ml) for 15 min in the dark. 
Cells were analysed using a FACS Canto and data was analysed with FlowJo 
Version 8.8.7. 
 
3.2.10 Metabolic assays 
3.2.10.1 Analysis of OCR and EACR using a Seahorse XF96 analyser 
 
Seahorse XF96 analyser was used to measure the oxygen consumption rate 
(OCR) and the extracellular acidification rate (ECAR) under basal conditions, as 
recommended by the manufacturer. A cell titration assay was used in order to 
determine a suitable cell seeding density for both A549 and U2OS cells. For the 
experiment, 0.5x106 cells were plated per 10 cm dish and reverse transfected 
with targeted siRNAs and controls on day one as detailed earlier. Forty-eight h 
post-transfection, cells were re-plated into the XF96 microplates at a density of 
4x104 cells/well (100 µl/well) in Full-DMEM and cultured overnight. In addition, 
the XF calibrant solution was added into the XF sensor cartridge and incubated 
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at 37 °C with no CO2 overnight. The next day, growth media was replaced with 
XF Assay Medium Modified DMEM (1000 µg/ml glucose, pH~ 7.4) and incubated 
at 37 °C without CO2 for one h prior to the assay. Analyses were performed 
according to the manufacturer’s instructions, using the eight measurements the 
instrument recorded for OCR (nmoles/min) and ECAR (mpH/min) pertaining to 
each well. Results were obtained using the XFe Wave software. 
 
3.2.10.2 Glutathione (GSH) colorimetric assay 
 
Cells were cultured and transfected as described earlier. As controls, cells were 
treated for 48 h with either 50 µM ethacrynic acid (EA) or 40 µM buthionine 
sulphoximine (BSO). Cell lysates were collected and sonicated in 50 mM PBS 
and 1 mM EDTA. The concentrations were determined using a Bradford assay 
according to the manufacturer’s instructions and subsequently normalised to 1 
µg/µl of protein. GSH levels in each sample were quantified using the Glutathione 
Assay Kit essentially as recommended in the manufacturer’s protocol.  
 
3.2.10.3 NADH/NADPH colorimetric assay 
 
Cells were plated and transfected as previously described. As positive control, 
cells were treated for 24 h with 1 mM MPP+. Forty-eight h after transfection 
NADP+/NADPH levels for each sample were quantified using the NADP+/NADPH 
assay kit and NAD+/NADH levels using the NAD+/NADH assay kit according to 
the manufacturer’s protocols. 
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3.2.11 Molecular cloning and plasmid propagation 
 
Molecular cloning was performed as follows. Vector and insert were cut using 
restriction enzymes under conditions according to the manufacturer’s protocol. 
Digested DNA was run on an agarose gel, cut out of the gel, purified using the 
MinElute® PCR Purification Kit and DNA concentration was quantified using the 
NanoDrop 1000 Spectrophotometer. The ligation reaction was set up as follows 
by mixing, the linearised vector (50 - 400 ng), insert DNA (1:1 to 3:1 molar ratio of 
insert DNA to vector DNA), ligation buffer, T4 DNA Ligase and nuclease free 
water according to the manufacturer’s instructions. Ligation mixtures were 
incubated at room temperature for one h. After ligation the samples were mixed 
with One Shot® TOP10 Chemically Competent Escherichia coli (E. coli) and 
incubated on ice for 10 min. Next, a heat shock was performed at 42 °C for 
exactly 30 sec followed by another incubation step of 10 min on ice. In the next 
step, the ligation mix was incubated in 250 µl of pre-warmed Super Optimal broth 
with Catabolite (SOC) (Hanahan, 1983) repression medium for one h at 37 ˚C on 
a thermal shaker. Then, cell suspension was spread on lysogeny broth (LB) 
(Bertani, 1951) agar plates supplemented with 100 µg/ml ampicillin or 50 µg/ml 
kanamycin (depending on the bacterial resistance marker) and allowed to grow 
o/n at 37 ˚C. Positive clones were picked and cultured in LB media, containing 
the appropriate antibiotics, for at least six h at 37 ˚C. DNA was isolated using the 
QIAprep® Spin Miniprep Kit and subjected to control digests and sequencing. 
Positive clones were further cultured in a larger volume of LB media containing 
the appropriate antibiotics. DNA was isolated using the PureLink® HiPure 
Plasmid Midiprep Kit and used for the experimental procedures described in this 
study. Glycerol stocks were prepared by mixing LB media containing the 
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respective plasmid carrying E. coli with an equal amount of glycerol and freezing 
the mix at -80 °C. Plasmids were propagated equal to the above mentioned 
protocol starting with the heat shock.  
 
3.2.12 Transient transfection of plasmids 
 
Plasmids were transfected using Attractene Transfection Reagent according to 
the manufacturer’s instructions. Briefly, cells were plated at density of 4x105 in 6-
well plates transfected with 1.2 µg of plasmid DNA or empty vector control. 
Protein expression was analysed by quantitative western blotting. 
 
3.2.13 Cotransfection of siRNA and plasmid DNA 
 
Cotransfection was performed using Attractene Reagent. Briefly, cells were 
plated at a density of 4x105 in 6-well plates and co-transfected with either 40 nM 
AllStars negative control siRNA, or 40 nM siDAPK2 and 1.2 µg DNA of empty 
vector control or pcDNA3 FLAG-BCL-XL plasmid. Protein expression was 
analysed by quantitative western blotting and cell death in response to TRAIL by 
using crystal violet assays. 
 
 
3.2.14 Plasmids used in this study 
 
DAPK2 pcDNA3 plasmids containing N-terminal human influenza hemaglutinin 
(HA) tagged DAPK2 were kindly provided by Professor Adi Kimchi (Weizmann 
Institute of Science, Rehovot, Israel). Five constructs were received and used in 
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this study including the HA-DAPK2 wild-type (wt) and HA-DAPK2 K42A, (K42 " 
A42) (kinase dead). Further information about these constructs can be found in 
Table 3-4. For the generation of tetracycline inducible cell lines each of these 
constructs was sub-cloned into a pcDNA™4/TO vector using BamHI and XhOI 
restriction sites. The DR5 full-length promoter pGL3 construct and DR5 promoter-
intron wild-type (wt) and NF-κB mutated (mt) pGL3 constructs were kindly 
provided by Professor Spencer Gibson (University of Manitoba, Canada). pNF-
κB-Luc reporter vector was from Clontech (Mountain View, CA, USA). The pRL 
Renilla Luciferase Control Reporter Vector was from Promega. The N-terminal 
FLAG tagged BCL-XL pcDNA3 expression plasmid was a gift from Dr Ingram 
Iaccarino (Institute of Human Genetics, University Hospital Schleswig-Holstein, 
Kiel, Germany) an overview of all plasmids can be found in Table 3-4. 
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Table 3-4. Plasmids used throughout this study. 
Backbone Insert Origin Citation 
pcDNA3 HA-DAPK2 wild-type Prof Adi Kimchi  (Inbal et al., 2000) 
pcDNA3 HA-DAPK2 K42A See above See above 
pcDNA™4/TO HA-DAPK2 wt 
Sub-cloned from 
pcDNA3 using 
BamHI and XhOI 
restriction sites. 
 
pcDNA™4/TO HA-DAPK2 K42A See above  
pGL3 DR5 full-length promoter Prof Spencer Gibson  (Shetty et al., 2002) 
pGL3 DR5 promoter-intron wild-type See above See above 
pGL3 DR5 promoter-intron  NF-κB mutated See above See above 
pRL Renilla Luciferase Control Reporter Vector Promega  
pNF-κB-Luc pNF-κB-Luc Clontech   
pcDNA3 FLAG-BCL-XL Dr Ingram Iaccarino   
pcDNA3 empty Invitrogen (now Life Technologies)  
pcDNA™4/TO empty See above  
 
3.2.15 Luciferase Assays 
 
Cells were transfected with siRNA oligonucleotides as described earlier. 
Twenty-four h later, cells were co-transfected with 100 ng of pNF-κB-Luc, DR5 
full length promoter Firefly-luciferase pGL3, DR5 promoter-intron wild-type (wt) 
Firefly-luciferase pGL3, or DR5 promoter-intron NF-κB mutated (mt) 
Firefly-luciferase pGL3 constructs and 10 ng of CMV promoter Renilla-luciferase 
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pRL construct using Attractene Transfection Reagent. The day after, both 
Firefly- and Renilla-luciferase activities were quantified using the Dual-Glo® 
Luciferase Assay System according to the manufacturer’s 
instructions. Luminescence was detected using a PHERAstar Plus plate reader. 
The measured luminescence for Firefly luciferase activity was normalised to that 
of Renilla luciferase. 
 
3.2.16 Crystal violet cell survival assay 
 
Crystal violet is a dye that stains cellular proteins and DNA (Bonnekoh et al., 
1989, Yang et al., 2001, Lu et al., 2009). Here, it was used to quantify cell 
survival, thus to discriminate between detached (dead) and attached cells 
(presumably alive) quantifying the number of life cells on the cell culture plate. 
For cell survival assays, cells were transfected as described earlier and 24 h later 
re-plated into 96-well plates at a density of 2x104 cells per well. The following day 
cells were treated with TRAIL, TNF-α, FAS-IgM, cisplatin or H2O2 for 24 h. Cells 
were then fixed using methanol and stained as follows: Cells were washed in 
PBS, and fixed and stained with 100 µl per well 0.5% (w/v) crystal violet in 25% 
(v/v) methanol for 30 min. The plates were then thoroughly washed with water, 
dried o/n and the dried dye dissolved in 10% (v/v) acetic acid for 30 min by 
incubating on a horizontal shaker. In the next step crystal violet stain was 
quantified by measuring the absorbance at 595 nm using a SunriseTM microplate 
absorbance reader. Values were normalised to the untreated samples and each 
experiment was performed in triplicates.  
! !
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4.1 Introduction  
 
Despite the effort and resources invested in cancer research, cancer remains a 
serious public health problem. Most patients are treated surgically and/or with 
combinations of a systemic treatment with chemotherapeutic drugs, antibodies 
and small molecule inhibitors. The big disadvantage of systemic tumour therapy 
is that most treatments affect the body as a whole and do not target the 
tumorigenic cells and tissues specifically. Further, although patients generally 
respond well to the various types of tumour therapy, they frequently develop 
resistance to it. This poses a challenge to their treatment and calls for more 
tumour specific and alternative approaches to be developed. Indeed, much 
excitement was generated in the mid nineties when TRAIL was identified (Wiley 
et al., 1995, Pitti et al., 1996, Sanchez-Perez et al., 2002, Kirienko et al., 2010). 
In contrast to chemotherapeutic and small molecule-based strategies, TRAIL-
based therapies directly and specifically targeted cancer cells with relatively weak 
side effects. However, the use of TRAIL itself, or TRAIL agonistic antibodies, in 
experimental tumour therapy has been frequently confronted with the 
development of resistance to TRAIL-based treatments that often arises during 
the course of therapy (Mellier et al., 2010). Here, we report a novel approach to 
overcome resistance to TRAIL-mediated cell death, based on the depletion of 
death associated protein kinase (DAPK) 2 by siRNAs. Silencing DAPK2 resulted 
in re-sensitisation of resistant cancer cells to TRAIL. 
 
TRAIL is a death receptor (DR) ligand that signals through DR4 and DR5, two 
members of the TNF receptor family [(Sawyers, 2004, Strachan et al., 1999), 
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reviewed in (Gonzalvez and Ashkenazi, 2010)]. DR5 has two isoforms that differ 
by 29 amino acids and which are functionally indistinguishable (Sawyers, 2004, 
Screaton et al., 1997). TRAIL binding activates primarily the extrinsic apoptotic 
pathway (Figure 1-4). The formation of ligand/receptor complexes leads to the 
assembly of a multi-protein DISC, which in the case of TRAIL is typically 
composed of FADD, the initiator caspases, caspase-8 and caspase-10 and/or c-
FLIP. The initiator caspases subsequently proteolytically cleave effector 
caspases, such as caspase-3, caspase-6 and/or caspase-7 thereby activating 
them. This leads to the destruction of key cellular components such as the 
cytoskeleton, nucleus and DNA, and the appearance of typical features of 
apoptosis such as membrane blebbing and nuclear shrinkage. TRAIL can also 
activate intrinsic apoptotic pathways via BID and thus involve mitochondria 
(Figure 1-4). By virtue of preferentially killing tumour cells, TRAIL is seen by 
many as a ‘magic bullet’ against cancer cells. Some cancer cells, however, are 
resistant, or develop resistance, to TRAIL-induced apoptosis. Several resistance 
mechanisms have been described but do not account for all cases of resistance 
[reviewed in (Mellier et al., 2010) and (van Dijk et al., 2013)], suggesting that 
additional but yet unidentified mechanisms exist. Deregulation at the receptor, 
DISC and mitochondria level have all been described, and the involvement of 
MAPKs and PARP1 have also been suggested (Azijli et al., 2013, Yuan et al., 
2013). Here we show that DAPK2 can be used as a target to overcome 
resistance to TRAIL-induced apoptosis. 
 
DAPK2 (also known as DRP-1) belongs to the DAPK family, which comprises a 
number of proteins regulated by calcium (Ca2+)/calmodulin (CaM) that are 
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involved in death-inducing pathways. The three main members (DAPK1, DAPK2 
and DAPK3) share a high degree of homology in the kinase domain but vary 
greatly outside this key region (Figure 1-9, described in detail in 1.8). The most 
studied protein is the founder molecule DAPK1, which has been implicated in 
Interferon-γ, FAS ligand, TNF-α and ceramide-induced cell death, amongst 
others [reviewed in (Bialik and Kimchi, 2006)]. The gene is often methylated in 
tumour cells and is thought to be a tumour suppressor (Raval et al., 2007). 
DAPK3 (also known as ZIPK) lacks the Ca2+/CaM regulatory domain, is 
characterised by a nuclear localisation signal (NLS) and has been described as a 
tumour suppressor and to be involved in cardiovascular pathologies [reviewed in 
(Usui et al., 2014)]. DAPK2 is a much smaller protein than DAPK1 (42 versus 
120 kDa); it lacks ankyrin repeats, and, critically, the death domain (Figure 1-9). 
Evidence for a pro-apoptotic role is largely based on its ability to induce 
apoptosis-like cell morphology upon overexpression (Puente et al., 2006, Inbal et 
al., 2000, Breasted and New-York Historical Society. Library., 1930). Moreover, 
siRNA mediated depletion of DAPK1 has recently been shown to re-sensitise 
TRAIL-resistant endometrial carcinoma cells to TRAIL-induced apoptosis 
suggesting in some circumstances an anti-apoptotic role of DAPK1 (Bai et al., 
2010). We thus hypothesized that endogenous DAPK2 may under some 
circumstances have anti-apoptotic properties and provide cancer cells with pro-
survival cues.  !! ! !
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4.2 Results !
4.2.1 DAPK2 depletion sensitises resistant cells to TRAIL-induced 
apoptosis 
 
The DAPK2 molecule lacks a recognisable death motif. We, therefore, asked 
what the contribution of endogenous DAPK2 to cell death induced by different 
apoptotic triggers was. For these studies, we used U2OS osteosarcoma cells and 
A549 NSCLC cells, two cell lines with different mutational backgrounds that have 
been extensively characterised in our laboratory (Shiloh et al., 2013, Watling et 
al., 2008). Both osteosarcoma and NSCLC are solid tumours that have been 
described to frequently develop resistance to TRAIL-based treatments (Locklin et 
al., 2007, Voortman et al., 2007) and indeed, the two model cell lines used here, 
U2OS and A549, have been previously reported to be resistant to TRAIL-
mediated apoptosis (Mirandola et al., 2006, Zhuang et al., 2010).  
 
RNAi was used to modulate the levels of DAPK2 in U2OS and A549 cells. 
Although most experiments described in this Thesis used a pool of siRNAs, the 
specificity of each individual siRNA oligonucleotide was analysed meticulously. 
Molecules targeting different regions of DAPK2, efficiently reduced DAPK2 
protein levels without affecting protein levels of DAPK1 and DAPK3 (Figure 4-1a, 
b, c, note: knockdown of DAPK3 in U2OS better visible in a, but siDAPK2 
Dharmacon_5 was not loaded). Of note, U2OS lysates did not contain detectable 
levels of DAPK1 protein when compared to A549 cell lysates loaded on the same 
gel (Figure 4-1a + b). Using qPCR we further established that DAPK1 cDNA was 
only amplified after more then 30 PCR cycles, indicating very low, to non-
detectable mRNA expression levels of DAPK1 in U2OS cells. Evaluating the 
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effect of DAPK2 depletion on DAPK3 was not trivial as the polyclonal 
DAPK3/ZIPK (279-298) antibody (Calbiochem) detects multiple bands and 
siRNA-mediated knockdown of DAPK3 was not as efficient as siRNA-mediated 
depletion of DAPK1 and DAPK2. However, a DAPK3 specific band was identified 
by knocking down DAPK3 itself and it could be seen in all blots on Figure 4-1 
(can be easiest detected in Figure 4-1a, disappears in the 10th lane, siDAPK3). 
 
Off-target effects associated with oligonucleotides 1 and 5 were, however, 
observed.  These were thus excluded from our analyses and a pool containing 
only oligonucleotides 3 and 4 were used throughout the study (henceforth 
referred to as siDAPK2). To further validate the effect of DAPK2 depletion we 
purchased a custom made Dharmacon DAPK2 siRNA oligonucleotide that 
specifically targeted the DAPK2 3’UTR as well as a DAPK2 siRNA from an 
alternative supplier (QIAGEN) (Hs_DAPK2_11 FlexiTube siRNA) also targeting 
the DAPK2 3’UTR. This supplier uses an algorithm completely different from the 
one used by Dharmacon to select its sequences. Reassuringly, this siRNA 
yielded results identical to those shown by the other siRNAs. Both of the 3’UTR 
targeting siRNAs were specific to DAPK2 and did not target DAPK1 or DAPK3 
(Figure 4-1a, b, c). Cells transfected with a non-targeting siRNA pool (siNS) 
were used as controls in all experiments presented in this Thesis and that 
involved RNAi. 
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Figure 4-1. Deconvolution of DAPK2 siRNAs used in this study and their effect on other 
members of the DAPK family. 
U2OS (a + b) or A549 (c) cells were left untransfected or were transfected with non-targeting 
siLuc, siNS, different DAPK2 siRNA oligonucleotides, siDAPK1 or siDAPK3 as indicated in the 
figure. Forty-eight h after transfection effects of each individual oligonucleotide, effects on 
DAPK1, DAPK2 and DAPK3 protein levels were assessed by SDS-PAGE/western blotting. 
U2OS cells (a + b) did not express detectable amounts of DAPK1 protein, lysates of 
untransfected A549 cells with equal amount of protein were loaded as control. HSP90 served 
as loading control. Data is representative of two independent repeats. 
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To assess the contribution of endogenous DAPK2 to cell death induced by 
different apoptotic triggers, the siDAPK2 pool (consisting of oligonucleotide 3* 
and 4*, henceforth referred to as siDAPK2) was used to deplete endogenous 
levels of DAPK2. As shown in Figure 4-2, in contrast to the non-targeting siRNA 
pool (siNS), siDAPK2 efficiently downregulated DAPK2 mRNA and protein levels 
in U2OS (Figure 4-2a) and A549 (Figure 4-2f) cells. To study cell death, cells 
were transfected with either siNS or siDAPK2, 24 h later re-plated into 96 well 
plates and the next day challenged with TRAIL (Figure 4-2b and g), cisplatin 
(Figure 4-2c and h), hydrogen peroxide (H2O2) (Figure 4-2d and i) and TNF-α 
(Figure 4-2e and j) for 24 h. Cell death levels were assessed using crystal violet 
viability assays. Crystal violet is a dye that stains cellular proteins and DNA 
(Bonnekoh et al., 1989, Yang et al., 2001, Lu et al., 2009) and it can be used to 
measure cell survival by discriminating between detached (dead) and attached 
cells (presumably alive) in cell culture plates. The susceptibility of cells with near 
to none DAPK2 expression was compared to that of control cells (siNS). Data 
from three independent experiments (each with technical triplicates) is shown as 
the mean percentage of live cells ± standard error of the mean (SEM) (Figure 
4-2). U2OS were readily killed by cisplatin (Figure 4-2c) and oxidative stress 
(Figure 4-2d), which was not dependent on DAPK2. A549 were less susceptible 
than U2OS to the killing effects of cisplatin (Figure 4-2h), or H2O2 (Figure 4-2i) 
but, as for U2OS cells, the induction of apoptosis was also independent of 
DAPK2 expression levels. As reported previously, U2OS and A549 were 
resistant to DR-mediated cell death induced by TRAIL (Figure 4-2b and g, black 
bars) or TNF-α (Figure 4-2e and j, black bars). Both cell types could not be 
sensitized to TNF-α-induced death by silencing DAPK2 (Figure 4-2e and j, green 
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bars). In contrast, reducing the levels of DAPK2 significantly sensitised U2OS 
and A549 cells to TRAIL-induced cell death (Figure 4-2b and g, green bars), 
suggesting that DAPK2 potentially functioned as an inhibitory molecule that 
modulated TRAIL signalling.  
 
The effect of DAPK2 depletion on sensitisation to TRAIL-induced apoptosis was 
further validated using a different cell death assay, which involved quantifying  
DNA hypoploidy (Figure 4-3). U2OS and A549 were transfected with either 
siDAPK2 or siNS and 48 h post-transfection challenged with TRAIL for 6 h. As for 
the crystal violet viability assays, DNA hypoploidy measurement with propidium 
iodide (PI) showed significant killing in DAPK2-depleted cells (Figure 4-3c + d 
and h + i) compared to cells transfected with the non-targeting control siRNA 
(Figure 4-3a + b and f + g). Cell cycle profiles are graphically summarised in bar 
charts (Figure 4-3e and j). 
 
 
 
 
 
 
 
 
Depletion of DAPK2 sensitises tumour cells to TRAIL-induced apoptosis 
 
! 122!
 
Figure 4-2. Knockdown of DAPK2 sensitises U2OS and A549 cells to TRAIL-induced cell 
death. 
U2OS (a - e) and A549 (f - j) cells were transfected with either siNS, or DAPK2 siRNA. Forty-
eight h after transfection knockdown efficiency was determined by SDS-PAGE/western blotting 
and qPCR (a + f). Data represent mean ± SEM of three independent experiments. Statistical 
analyses were done using Student’s t-test (paired, one tailed) (*** p< 0.005). For cell survival 
assays (U2OS, b - e and A549, g - j), cells were re-plated into 96 well plates at a density of 
2x104 cells per well 24 h after siRNA transfection. The following day cells were treated with the 
indicated concentrations of TRAIL (b + g), cisplatin (c + h), H2O2 (d + i) and TNF-α (e + j) for 
24 h. Cells were then fixed using methanol and stained with crystal violet. Crystals were 
dissolved in 10% (v/v) acetic acid and quantified by measuring the absorbance at 595 nm. 
Values were normalised to the untreated samples. Data represent mean ± SEM of three 
independent experiments performed in triplicates. Statistical analyses were done using two-
way ANOVA test (*** p< 0.005). 
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Figure 4-3. Silencing DAPK2 sensitises TRAIL resistant cancer cell lines to TRAIL-
induced cell death. 
U2OS and A549 cells were transfected with either siNS, or siDAPK2. Forty-eight h after 
transfection U2OS (a - e) and A549 (f - j) cells were treated with TRAIL (100 ng/ml) for 6 h. 
Cells were then fixed with ethanol, incubated with RNase A and PI. Cell sub-populations were 
analysed using FlowJo software. Representative cell cycle profiles of three independent 
experiments are shown in histograms (1 - d and f - i) and summarised graphically in bar charts 
(e + j). Data is representative of two independent repeats. 
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4.2.2 The effect of sensitisation to TRAIL upon DAPK2 depletion was 
validated by deconvoluting the siRNA pools and by using additional 
siRNAs 
 
The experiments demonstrating a sensitisation of U2OS and A549 cells to 
TRAIL-induced apoptosis upon DAPK2 depletion were carried out using a pool of 
siGENOME DAPK2 oligonucleotides 3 and 4 (siDAPK2), as validation 
experiments demonstrated that siDAPK2 oligonucleotides 1 and 5 had off-target 
effects. To further validate these findings and exclude any additional potential off-
target effects still unidentified, sensitisation experiments described in Figure 4-2 
were repeated using the individual siDAPK2 oligonucleotides 3 and 4, a custom 
made 3’UTR-specific DAPK2 siRNA from Dharmacon and another one from 
QIAGEN (Hs_DAPK2_11 FlexiTube). Cells were transfected with either siNS or 
single siDAPK2 oligonucleotides, 24 h later re-plated into 96 well plates and the 
next day, challenged with TRAIL. Cell death levels were assessed using crystal 
violet cell viability assays. The susceptibility of DAPK2-depleted cells was 
compared to that of siNS-transfected cells. Data from three independent 
experiments (each with three technical replicates) are shown as the mean 
percentage of live cells ± SEM (Figure 4-4). As demonstrated earlier, U2OS and 
A549 were resistant to DR-mediated cell death induced by TRAIL when 
transfected with siNS. (Figure 4-4a - j, black bars). Consistent with the results 
obtained using the siDAPK2 pool, U2OS and A549 cells were readily killed when 
DAPK2 was depleted from cells following transfection with individual siGENOME 
DAPK2 oligonucleotides 3 or 4 (Figure 4-4a + b, f + g). Reassuringly, 
transfection of U2OS and A549 cells with the 3’UTR specific DAPK2 siRNAs also 
sensitised to TRAIL-induced apoptosis (Figure 4-4c + d, h + i), providing further 
evidence in favour of the notion that the sensitisation to TRAIL-induced apoptosis 
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is a specific effect resulting from DAPK2 knockdown. Interestingly, when 
comparing the effect of sensitisation to TRAIL upon DAPK2 knockdown between 
U2OS and A549 cells, U2OS exhibited a stronger sensitivity to TRAIL treatment 
with significant cell death at a TRAIL concentration as low as 1 ng/ml (Figure 
4-4a - d). A549 cells however required a concentration of at least 10 ng/ml of 
TRAIL to induce significant killing (Figure 4-4f - i). This suggested that A549 
cells possessed an inhibitory mechanism, which protected them from TRAIL that 
was not fully overcome by solely depleting DAPK2.  
 
To additionally exclude the possibility that the transfection of cells with siRNA 
oligonucleotides per se induced sensitisation to TRAIL-induced apoptosis, further 
control experiments were performed. Cells were transfected with siRNA against 
Luciferase (siLuc). This targeted the luciferase gene, which can be found in the 
common eastern firefly (Photinus pyralis) and is not expressed in mammalian 
cells. Cells were left untransfected (Untr), or they were transfected with either 
siNS or siLuc, and cell death was assessed using crystal violet assay as 
described before. As shown in Figure 4-4e and j, transfection of U2OS and A549 
cells with siLuc (purple bars) yielded in results identical to transfection with siNS 
(black bars) but there was no evidence for significantly increased sensitisation to 
TRAIL-induced apoptosis. These results were almost identical to cells that were 
left untransfected (Untr, grey bars), which also exhibited resistance to TRAIL 
induced apoptosis. 
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Taken together these data strongly supported the initial observation and 
suggested that depletion of DAPK2 specifically sensitised TRAIL resistant U2OS 
and A549 cells to TRAIL-induced apoptosis.   
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Figure 4-4. Validation of siRNA oligonucleotide molecules that target different 
sequences of DAPK2 mRNA, designed using different algorithms. 
U2OS (a - e) or A549 (f - j) cells were transfected with non-targeting siNS or siLuc, different 
DAPK2 siRNA oligonucleotides or left untransfected (Untr), as indicated in the figure. Forty-
eight h after transfection cell survival in response to TRAIL ligation was measured using crystal 
violet viability assays. For that purpose, 24 h after transfection cells were re-plated into 96-well 
plates at a density of 2x104 cells per well. The following day, cells were treated with the 
indicated concentrations of TRAIL for 24 h. Cells were then fixed using methanol and stained 
with crystal violet. Crystals were dissolved in 10% (v/v) acetic acid and quantified by measuring 
the absorbance at 595 nm. Values were normalised to the untreated samples. Data represent 
mean ± SEM of at least three independent experiments, performed in triplicate. Statistical 
analyses were done using two-way ANOVA test (** p<0.01, *** p< 0.005). !! !
U2OS 
0 1 10 100 500
0
50
100
150
*** siDAPK2 Dharmacon 3
 
siNS
*** *** ***
[TRAIL] (ng/ml)
Ce
ll 
su
rv
iv
al
 (
%
)
0 1 10 100 500
0
50
100
150
Ce
ll 
su
rv
iv
al
 (
%
)
[TRAIL] (ng/ml)
*** siDAPK2 Qiagen 11 
siNS
*** *** ***
0 1 10 100 500
0
50
100
150
0 1 10 100 500
0
50
100
150
0 1 10 100 500
0
50
100
150
0 1 10 100 500
0
50
100
150
[TRAIL] (ng/ml)
[TRAIL] (ng/ml)
[TRAIL] (ng/ml)
[TRAIL] (ng/ml)
Ce
ll 
su
rv
iv
al
 (
%
)
Ce
ll 
su
rv
iv
al
 (
%
)
Ce
ll 
su
rv
iv
al
 (
%
)
Ce
ll 
su
rv
iv
al
 (
%
)
siDAPK2 Dharmacon 3
 
siNS
*** *** ***
siDAPK2 Qiagen 11
 
siNS
** *** ***
siDAPK2 Dharmacon 3’UTR
 
siNS
*** *** ***
siDAPK2 Dharmacon 4
 
siNS
*** *** ***
0 1 10 100 500
0
50
100
150
*** siDAPK2 Dharmacon 3’UTR
 
siNS
*** *** ***
Ce
ll 
su
rv
iv
al
 (
%
)
n.s.
n.s.
n.s.
n.s.
Ce
ll 
su
rv
iv
al
 (
%
)
a)
b)
c)
[TRAIL] (ng/ml)
d)
0 1 10 100 500
0
50
100
150
[TRAIL] (ng/ml)
siDAPK2 Dharmacon 4
 
siNS
*** *** *** ***
A549
f)
g)
i)
h)
0 1 10 100 500
0
50
100
150
siLuc
 
siNS
Untr 
[TRAIL] (ng/ml)
Ce
ll 
su
rv
iv
al
 (
%
)
0 1 10 100 500
0
50
100
150
siLuc
 
siNS
Untr 
[TRAIL] (ng/ml)
Ce
ll 
su
rv
iv
al
 (
%
)
e) j)
 
Depletion of DAPK2 sensitises tumour cells to TRAIL-induced apoptosis 
 
! 128!
4.2.3 Downregulation of DAPK2 sensitises cells to TRAIL-induced 
apoptosis via increased apoptotic signalling 
 
Having observed that U2OS and A549 cells were more susceptible to TRAIL-
induced cell death after DAPK2 knockdown, we next asked what the molecular 
consequences of DAPK2 silencing were. Accordingly, cells were transfected with 
siDAPK2, as before, treated with TRAIL for varying periods of time as indicated, 
and proteins extracted and separated on a polyacrylamide gel (Figure 4-5). 
Western blot membranes were subsequently probed with antibodies specific to 
key molecules known to be activated downstream of TRAIL. TRAIL-induced 
apoptosis was studied over a period of 1-24 h. Focus was given to earlier time 
points (up to 4 h) as caspase activation is generally a rapid event in cells 
sensitive to TRAIL. Caspase-8 and caspase-10 are two initiator caspases 
downstream of DRs and were thus analysed first. Activation of caspase-8 was 
faster and stronger in siDAPK2-transfected cells than in control cells (siNS) 
(Figure 4-5a + d), as seen by both the emergence of smaller caspase fragments 
(43, 41 and 18 kDa) and the reduction of the full-length 55 kDa protein. Indeed, in 
cells transfected with siNS, caspase-8 cleavage 1 h after TRAIL treatment (100 
ng/ml) was much weaker in siNS-transfected cells than in cells transfected with 
siDAPK2. Activation of caspase-8 leads to cleavage of the effector caspase-3 
and subsequent degradation of molecules such as PARP, which ultimately 
results in cellular demise. Accordingly, DAPK2 silencing also resulted in 
increased caspase-3 (Figure 4-5b and e) and PARP cleavage (Figure 4-5c and 
f). In addition, the reduction of BID expression and increased caspase-9 
cleavage after DAPK2 silencing indicated the recruitment of the intrinsic apoptotic 
pathway (Figure 4-5a + d and b + e). Collectively, these data suggested that 
 
Depletion of DAPK2 sensitises tumour cells to TRAIL-induced apoptosis 
 
! 129!
DAPK2 inhibited caspase activation downstream of TRAIL by interfering with 
both the extrinsic and intrinsic apoptosis pathways.  
 
!
Figure 4-5. Knockdown of DAPK2 increases apoptotic extrinsic and intrinsic apoptotic 
signalling in response to TRAIL treatment. 
Molecular events of TRAIL-induced apoptosis (a - f) were assessed by SDS-PAGE/western 
blotting. Forty-eight h after A549 and U2OS cells were transfected with siNS and siDAPK2, 
cells were treated with TRAIL (100 ng/ml) for the indicated time points. Activation of the 
extrinsic and intrinsic pathways was assessed by SDS-PAGE/qualitative western using 
cleavage of BID and caspase-8 (a + d), caspase-9 and caspase-3 (b + e) and PARP (c + f) as 
read-outs.  Lamin B, α-Tubulin, β-Actin and HSP90 served as loading controls. Data is 
representative of at least three independent repeats. !! !
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4.2.4 siDAPK2 mediated sensitisation to TRAIL-induced apoptosis is 
independent of c-FLIP 
 
Having observed that DAPK2-depleted U2OS and A549 cells were more 
susceptible to TRAIL-induced apoptosis and that there was a concomitant more 
pronounced activation of the effector caspase in these cells, we next asked what 
could cause this increased activation of caspase-8. As described earlier, c-FLIP 
possesses strong homology to caspase-8 with its two DEDs in the N-terminus 
and it is, in fact, a major inhibitor of the extrinsic cell death pathway. Accordingly, 
cells were transfected with siNS or siDAPK2 oligonucleotides and mRNA, as well 
as protein, was extracted to assess the cellular levels of c-FLIP in response to 
DAPK2 knockdown. As depicted in Figure 4-6a + b, RNAi-mediated DAPK2 
depletion did not alter mRNA induction of c-FLIP in U2OS or A549 cells. 
Consistently, protein levels of the c-FLIP isoforms c-FLIPL, c-FLIPγ and c-FLIPs 
were also unaffected by DAPK2 knockdown (Figure 4-6c + d). Suggesting that 
DAPK2 depletion mediated sensitisation to TRAIL-induced apoptosis is 
independent of the modulation of c-FLIP. 
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Figure 4-6. Silencing DAPK2 does not affect the levels of c-FLIP. 
U2OS (a + c) and A549 (b + d) cells were transfected with either siNS or DAPK2 siRNA. Forty-
eight h after transfection the levels of c-FLIP mRNA were analysed by qPCR (a + b). qPCR 
data represent mean ± SEM of three independent experiments with duplicate samples. 
Statistical analysis was done using Student’s t-test (paired, one tailed). Protein expression 
levels of c-FLIP were evaluated by quantitative western blotting (c + d) blots shown are 
representative of three independent experiments yielding identical results.  
 
4.2.5 DAPK2 silencing leads to the upregulation of DR5 and DR4 mRNA, 
key receptors for TRAIL-induced apoptosis 
 
The involvement of both the extrinsic and intrinsic cell death pathways, 
evidenced by increased activation of caspase-8 and increased cleavage of the 
downstream molecules, such as caspase-9 and BID, suggested that knocking 
down DAPK2 affected an upstream event common to both arms of the TRAIL 
apoptotic pathway (Figure 1-4). As both pathways are activated via the 
engagement of TRAIL receptors, the effect of DAPK2 depletion on the levels of 
TRAIL-receptor expression was assessed. It is known that TRAIL can induce cell 
death via either of its two receptors, namely DR4 and DR5. In addition, there are 
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also the so-called decoy receptors, DcR1 and DcR2, which can compete with 
DR4 and DR5 for ligand binding. Hence, the ratio of TRAIL decoy to DRs also 
determines the responsiveness of cells to TRAIL (Merino et al., 2006). A fifth 
receptor named OPG has been identified but its activity so far has not been 
linked to TRAIL-induced apoptosis. All receptor types have been described in 
1.4.2 and depicted in Figure 1-3). To assess receptor levels in U2OS and A549 
cells, cells were transfected with siDAPK2 or siNS, and mRNA levels of TRAIL 
receptors were assessed by qPCR. Transfection of U2OS and A549 cells with 
siDAPK2 led to the induction of DR5 mRNA (Figure 4-7a + d), one of the 
receptors through which TRAIL can signal to kill. DR4, the second death-inducing 
receptor was not expressed in U2OS cells but was expressed in A549 and its 
mRNA levels were also increased after silencing DAPK2 (Figure 4-7d). 
Messenger RNA levels of the decoy receptors DcR1 and DcR2 were neither 
elevated in U2OS, nor in A549 cells (Figure 4-7b + e). Interestingly, the mRNA 
levels of the soluble receptor OPG showed the trend of an increase in U2OS 
cells, (Figure 4-7c) but remained unaffected after DAPK2 depletion in A549 cells 
(Figure 4-7f). These data suggested that the sensitisation of TRAIL-resistant 
U2OS and A549 cells to TRAIL-induced apoptosis was possibly modulated by 
the increased expression of DRs.  ! !
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Figure 4-7. Knockdown of DAPK2 induces expression of DR4 and DR5 mRNA. 
U2OS (a - c) and A549 (d - f) cells were transfected with either siNS or siDAPK2 
oligonucleotides. Forty-eight h after transfection RNA was harvested and DR5 (U2OS, A549) (a 
+ d), DR4 (A549) (d), DcR1 (U2OS, A549), DcR2 (U2OS, A549) (b + e) and OPG (U2OS, 
A549) (c + f) mRNA levels were analysed by qPCR. qPCR data represent mean ± SEM of at 
least three independent experiments with technical duplicate samples. Statistical analysis was 
done using Student’s t-test (paired, one tailed) (* p<0.05, *** p< 0.005). !! !
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4.2.6 DAPK2 silencing induces protein expression of DR4 and DR5.  
 
Having observed a clear upregulation of DR mRNA levels upon DAPK2 
depletion, DR5 in U2OS and both DR4 and DR5 in A549 cells, we sought to 
establish if this mRNA induction translated into protein expression. The induction 
of DR5 was analysed using SDS-PAGE/quantitative western blotting in both cell 
lines. DR5 has two isoforms that differ by 29 amino acids and which are 
functionally indistinguishable, as described earlier. The antibody used here 
recognises both isoforms and the identity of DR5 was further confirmed using 
DR5-specific RNAi. Silencing of DAPK2 did not only significantly increase DR5 
mRNA levels as shown in Figure 4-7; it significantly induced DR5 protein 
expression in U2OS and A549 cells (Figure 4-8). Densitometric analyses of 
western blots, normalising DR5 expression levels to the housekeeping gene 
HSP90 and siNS transfected cells, revealed an protein level increase of 
approximately three fold in U2OS for both DR5 isoforms and an increase of 
around five fold of DR5S  and approximately four fold of DR5L in A549 cells. 
(Figure 4-8a + c). To analyse the cell surface expression of DR4 and DR5 upon 
DAPK2 knockdown, unpermeabilised U2OS and A549 cells were stained with DR 
specific, fluorophore-coupled, antibodies. As opposed to the quantification of total 
DR protein levels using SDS-PAGE/quantitative western blotting, this technique 
specifically captures the levels of extracellular and thus potentially functional 
DRs. As shown in Figure 4-8 (b + d) RNAi-mediated DAPK2 silencing led to a 
two - three fold induction of DR5 surface expression in U2OS and A549 cells, 
RNAi targeting DR5 served as a control. Furthermore, the surface expression of 
DR4 was increased in A549 cells upon RNAi-mediated DAPK2 knockdown and, 
here too, siDR4 served as a control for antibody specificity. 
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Figure 4-8. DAPK2 silencing leads to the upregulation of DR5 and DR4, key receptors 
for TRAIL. 
U2OS (a + b) and A549 (c - e) cells were transfected with either siNS, or siDAPK2 for 48 h. 
Proteins were isolated and the level of DR expression was assessed by western blotting (a + 
c), or flow cytometry (b, d, e). Densitometric analyses of western blots were plotted as fold 
change of DR5 expression relative to the siNS control. Data represent mean ± SEM of three 
independent experiments. Statistical analyses were done using one-way ANOVA test (* p< 
0.05, ** p<0.01, *** p< 0.005). Cell surface expression was quantified using geometric means 
of three independent experiments and plotted as fold change of surface expression. Statistical 
analysis was done using Student’s t-test (paired, one tailed) (* p< 0.05, ** p<0.01). 
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4.2.7 The effect of DR4 and DR5 upregulation upon DAPK2 knockdown 
was validated by deconvolution and additional siRNAs 
 
To further validate the finding that DR expression was induced specifically in 
response to DAPK2 depletion and not due to an off-target effect, the siDAPK2 
pool was deconvoluted as before and additional siDAPK2 oligonucleotides used. 
The latter included the custom made Dharmacon 3’UTR-specific DAPK2 siRNA 
mentioned previously and the Hs_DAPK2_11 FlexiTube siRNA from QIAGEN. 
U2OS and A549 cells were transfected with individual siDAPK2 oligonucleotides 
or siNS as control, and cell surface DR expression was assessed by flow 
cytometry. As depicted in Figure 4-9 depletion of DAPK2 by each of the siRNA 
oligonucleotides significantly increased the surface expression of DR5 in U2OS 
cells. The same result was obtained in A549 cells (Figure 4-10a - d) where cell 
surface expression of DR5 was induced upon transfection with each of the 
individual siDAPK2 oligonucleotides. In addition, in A549 cells, the knockdown of 
DAPK2 using each of the single siRNAs also led to upregulation of DR4 surface 
expression (Figure 4-10e - h).  
 
As shown in Figure 4-11 the upregulation of DR5 surface expression upon 
DAPK2 knockdown was further compared to the effect of the additional non-
targeting siRNA oligonucleotides, such as siRNA siLuc and cells that were left 
untransfected (Untr). Depletion of DAPK2 using the siDAPK2 pool specifically 
induced expression of DR5 in U2OS (Figure 4-11a) and A549 cells (Figure 
4-11b), as shown before. Leaving cells untransfected or transfecting them with 
siLuc did not cause any detectable/significant change in DR5 surface expression 
compared to the siNS control. Taken together, these data thus suggest that 
 
Depletion of DAPK2 sensitises tumour cells to TRAIL-induced apoptosis 
 
! 137!
siDAPK2-induced sensitisation to TRAIL was accompanied by, and likely to be 
modulated via, upregulation of DR receptors. 
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Figure 4-9. Validation of different siRNA oligonucleotide molecules for their ability to 
induce DR5 expression in U2OS cells. 
U2OS cells were transfected with non-targeting siNS, or different DAPK2 siRNA 
oligonucleotides, as indicated in the figure. Flow cytometry was used to assess the levels of 
DR5 (a - d). Data represent mean ± SEM of at least three independent experiments. Cell 
surface expression was quantified using geometric means of those independent experiments 
and plotted as fold change of surface expression in relation to siNS. Statistical analysis was 
done using Student’s t-test (paired, one tailed) (* p< 0.05, ** p<0.01, *** p< 0.005). !
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Figure 4-10. Validation of different siRNA oligonucleotide molecules for their ability to 
induce DR5 and DR4 expression in A549 cells.  
A549 cells were transfected with non-targeting siNS, or different DAPK2 siRNA 
oligonucleotides, as indicated in the figure. Flow cytometry was used to assess the levels of 
DR5 (a - d) and DR4 (e - h). Data represent mean ± SEM of at least three independent 
experiments. Cell surface expression was quantified using geometric means of those 
independent experiments and plotted as fold change of surface expression in relation to siNS. 
Statistical analysis was done using Student’s t-test (paired, one tailed) (* p< 0.05, ** p<0.01, *** 
p< 0.005). 
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Figure 4-11. Upregulation of DR5 expression is specific to DAPK2 depletion.  
U2OS and A549 cells were transfected with non-targeting siNS and siLuc, siDAPK2 and siDR5 
oligonucleotides or left untransfected (Untr), as indicated. Flow cytometry was used to assess 
the levels of DR5 (a + b). Data represent mean ± SEM of at least three independent 
experiments. Cell surface expression was quantified using geometric means of those 
independent experiments and plotted as fold change of surface expression in relation to siNS. 
Statistical analysis was done using Student’s t-test (paired, one tailed) (* p< 0.05, ** p<0.01, *** 
p< 0.005). !!
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predicted, downregulation of DR5 slightly increased resistance of U2OS or A549 
to TRAIL-induced death (Figure 4-12a + c). In contrast, the downregulation of 
DAPK2 sensitised cells, as shown previously, provided that the expression of 
DR5 was not downregulated (compare cells transfected with siDAPK2/siNS 
versus siDAPK2/siDR5). This suggested that the upregulation of DR5 following 
silencing of DAPK2 was indeed critical to sensitise the resistant cells to 
apoptosis. A549 cells also express DR4 and double knockouts of DR4 and 
DAPK2 suggested that in these cells DR4 was partially required to sensitise 
A549 cells to TRAIL-induced apoptosis. The effect does not seem to be as 
pronounced as that seen when DR5 was silenced and, despite the trend shown, 
it was not statistically significant (Figure 4-12d). At higher concentrations of 
TRAIL, DR5 knockdown did not fully reverse the phenotype, suggesting that in 
these cells DR4 might be engaged to overcome impaired DR5 expression 
(Figure 4-12c + d).  
 
Indeed, silencing of DR5 would almost certainly reverse the phenotype observed 
when DAPK2 was silenced, as this is a key receptor for TRAIL. To study whether 
DR5 upregulation was the crucial step in siDAPK2-induced sensitisation to 
TRAIL, we titrated siDR5 (Figure 4-13a), measured its impact on DR5 protein 
expression (Figure 4-13a + b) and established the concentration at which only 
the DAPK2 RNAi effect was reverted, which was deemed to be 1.25 nM (Figure 
4-13a). By co-transfecting siDAPK2 (20 nM) and siDR5 (1.25 nM) in U2OS cells, 
which only express DR5, we were able to revert the induction of DR5 levels. 
Furthermore, reverting DR5 levels successfully impaired siDAPK2-mediated 
TRAIL sensitisation (Figure 4-13c) and thus confirms the data shown in (Figure 
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4-12a + c). Overall, these findings strongly support the role of DR induction in 
siDAPK2-induced TRAIL sensitisation. In particular DR5 seemed to be the key 
molecule which was upregulated in response to DAPK2 knockdown and which, 
when reverted to its initial level can no longer facilitate TRAIL-induced apoptosis. 
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Figure 4-12. In the absence of DR5, siDAPK2 can neither sensitise U2OS, nor A549 to 
TRAIL-induced apoptosis. 
Double knockdowns were carried out in U2OS (a + b) and A549 (c - e) cells. For this purpose, 
U2OS and A549 cells were transfected with 40 nM of: siNS+siNS, siDR5+siNS, 
siDAPK2+siNS, siDR5+siDAPK2 (a + c) and siNS+siBID and siBID+siDAPK2 (e). A549 cells 
were also transfected with siNS+siDR4 and siDR4+siDAPK2 (d). Twenty-four h after 
transfection cells were re-plated into 96 well plates at a density of 2x104 cells per well. The 
following day cells were treated with TRAIL for 24 h at the indicated final concentrations. Cells 
were methanol-fixed and stained with crystal violet. Staining was dissolved in acetic acid and 
quantified by measuring the absorbance at 595 nm. Values were normalised to the untreated 
samples. Data represent mean ± SEM of three independent experiments performed in 
triplicates. Statistical analysis was done using two-way ANOVA test (* p< 0.05, ** p<0.01, *** 
p< 0.005). Forty-eight h after transfection and re-plating, RNA was harvested and double 
knockdown efficiency was confirmed (b + e). DAPK2 DR4 and DR5 mRNA levels were 
analysed by qPCR, data represent mean ± SD of one representative experiment with technical 
duplicate samples. !! !
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Figure 4-13. Titration of DR5 siRNA sufficient to block TRAIL-induced apoptosis in U2OS 
cells.  
(a) U2OS cells were transfected with either siNS, siLuc (both controls for RNAi off-target 
effects), siDAPK2 or with siDAPK2 (20 nM) concomitantly with siDR5 (0.31-20 nM) for 48 h. 
DR5 expression was measured by flow cytometry and cell surface expression quantification 
performed as before. Co-transfection of U2OS cells with 1.25 nM siDR5 and 20 nM siDAPK2 
abolished siDAPK2-mediated DR5 induction. (b) The effect of co-transfection was also 
assessed using quantitative western blotting, which confirmed the results obtained by flow 
cytometry. [The shadow bands seen in the DAPK2 panel correspond to DR5, since the 
membrane was probed for with this antibody after being stripped from the anti-DR5 antibody.] 
(c) To assess the impact of reverting the siDAPK2-mediated effects on DR5 protein levels on 
cell survival after TRAIL U2OS cells were transfected with either siDAPK2 (20 nM) and siNS 
(1.25 nM), or siDAPK2 (20 nM) and siDR5 (1.25 nM). Cells were re-plated into 96-well plates at 
a density of 2x104 cells per well 24 h after siRNA transfection and treated the following day with 
the indicated concentrations of TRAIL for another 24 h. Cells were methanol-fixed and stained 
with crystal violet. Staining was dissolved in acetic acid and quantified by measuring the 
absorbance at 595 nm. Values were normalised to the untreated samples. Data represent 
mean ± SEM of three independent experiments performed in triplicates. Statistical analysis was 
done using two-way ANOVA test (* p< 0.05, ** p<0.01, *** p< 0.005). !! !
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4.2.9 TRAIL downstream signalling differs significantly between U2OS and 
A549 cells. 
 
Having established that siDAPK2-mediated sensitisation to TRAIL-induced 
apoptosis was caused by upregulation of DR5 and, to some extent DR4; further 
experiments were carried out to more fully understand downstream processes.  
BID is a pro-apoptotic member of the BCL-2 family and part of a well-known 
amplification loop downstream of TRAIL, which in some cells is required to 
induce death. It has been shown that the cell type determines how BID operates: 
BID cleavage can provide an amplification loop for the apoptotic signal as in type 
I cells, where the main mechanism is mediated by extrinsic apoptotic signalling, 
or as in type II cells, it serves as the primary mechanism of TRAIL-induced 
apoptosis, as described in 1.4.3. 
 
U2OS and A549 cells were transfected with all permutations of siRNA to a final 
concentration of 40 nM: siNS/siNS, siDAPK2/siNS, siBID/siNS and 
siDAPK2/siBID. Downregulation of BID per se did not impact significantly on the 
susceptibility of U2OS or A549 to TRAIL-induced death (Figure 4-14a and c). In 
U2OS cells, the downregulation of DAPK2 sensitised cells, as shown previously, 
and siBID did not have an impact on the sensitisation process (Figure 4-14a 
compare cells transfected with siDAPK2/siNS versus siDAPK2/siBID). 
Interestingly, in A549 cells siBID rescued siDAPK2 mediated sensitisation to 
TRAIL (Figure 4-14c, compare cells transfected with siDAPK2/siNS versus 
siDAPK2/siBID), suggesting that A549 require a mitochondrial amplification loop.  
These results indicated that the induction of TRAIL-induced apoptosis in U2OS 
cells downstream of DR signalling was fundamentally different to A549 cells. 
 
Depletion of DAPK2 sensitises tumour cells to TRAIL-induced apoptosis 
 
! 146!
While U2OS cells showed characteristics of type I cells with a dispensable 
mitochondrial amplification loop, A549 behaved like type II cells by depending on 
the mitochondrial amplification of TRAIL-induced apoptosis. To validate the 
finding that the mitochondrial amplification loop was indeed dispensable in U2OS 
cells, mitochondrial amplification of extrinsic apoptotic signalling was blocked by 
overexpressing the anti-apoptotic BCL-2 family member, BCL-XL. The impact of 
BCL-XL overexpression on DAPK2 and BCL-XL protein endogenous levels in 
U2OS cells was addressed using a plasmid with a BCL-XL expression cassette 
and an empty vector as a control, in combination with transfection of siDAPK2 or 
siNS oligonucleotides (Figure 4-15a). Interestingly, overexpression of BCL-XL did 
not rescue siDAPK2-induced TRAIL sensitisation in U2OS cells (Figure 4-15b + 
c). Hence, the mitochondrial amplification loop seems to be dispensable when 
inducing apoptosis via TRAIL in DAPK2 depleted U2OS cells. Overall, these 
findings reveal different signalling process in U2OS and A549 cells downstream 
of DR activation. The fact that amplification via BID is of fundamentally different 
importance in the two cell lines studied lends further support to the hypothesis 
that siDAPK2-induced sensitization to TRAIL is mediated at the receptor level. !
 
Depletion of DAPK2 sensitises tumour cells to TRAIL-induced apoptosis 
 
! 147!
!
Figure 4-14. In the absence of BID, siDAPK2 can sensitise U2OS but not A549 to TRAIL-
induced apoptosis. 
Double knockdowns were carried out in U2OS (a) and A549 (c) cells. For this purpose, cells 
were transfected with 40 nM of the following siRNA mixtures: siNS+siNS, siDAPK2+siNS, 
siNS+siBID and siBID+siDAPK2. Twenty-four h after transfection cells were re-plated into 96 
well plates at a density of 2x104 cells per well. The following day cells were treated with TRAIL 
for 24 h at the indicated final concentrations. Cells were methanol-fixed and stained with crystal 
violet. Staining was dissolved in acetic acid and quantified by measuring the absorbance at 595 
nm. Values were normalised to the untreated samples. Data represent mean ± SEM of three 
independent experiments performed in triplicates. Statistical analysis was done using two-way 
ANOVA test (* p< 0.05, ** p<0.01, *** p< 0.005). Forty-eight h after transfection and re-plating, 
RNA was harvested and double knockdown efficiency was confirmed (b + d). DAPK2 and BID 
mRNA levels were analysed by qPCR, data represent mean ± SD of one representative 
experiment with duplicate samples. !
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Figure 4-15. Overexpression of BCL-XL does not rescue siDAPK2-mediated sensitisation 
of U2OS cells to TRAIL. 
(a) U2OS cells were transfected with either siNS, or siDAPK2 in combination with an ‘empty’ 
pcDNA3 control vector (EV), or with a pcDNA3 BCL-XL expression plasmid, and the 
knockdown and over-expression efficiencies determined by quantitative western blotting. Cells 
transfected with the empty vector (b), or with the BCL-XL-expressing vector (c) were re-plated 
into 96-well plates at a density of 2x104 cells per well 24 h after siRNA transfection. The 
following day cells were treated with the indicated concentrations of TRAIL for 24 h and cell 
death assessed using crystal violet assays, as described before. Values were normalised to 
the untreated samples. Data represent mean ± SEM of two independent experiments 
performed in triplicate. Statistical analyses were done using two-way ANOVA test (* p< 0.05, ** 
p<0.01, *** p< 0.005). ! !
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4.2.10 Depletion of DAPK2 also sensitises U2OS and A549 cells to FAS 
ligand-induced apoptosis 
 
The process by which TRAIL binds to DR4 and DR5 and leads to caspase 
cleavage and apoptosis are very similar to another receptor of the TNFR family, 
known as FasR (also known as CD95). This receptor, however, can only be 
ligated by the death-inducing ligand FasL (also known as CD95L). In contrast to 
TRAIL, which specifically targets tumour cells, FasL induces apoptosis in a 
variety of tissues as described earlier in the Introduction. Interestingly, the 
upregulation of c-FLIP has been described as a common mechanism of FasL-
resistance, as is the case for TRAIL. Given the high degree of signalling overlap 
between TRAIL- and FasL, we asked whether the lack of DAPK2 also affected 
the cells susceptibility to FasL-mediated apoptosis. To induce FasL-mediated 
apoptosis, we used an anti-Fas IgM antibody that is capable of clustering FasR, 
thus mimicking FasL-induced apoptosis (henceforth referred to as FasL) 
(Yonehara et al., 1989). U2OS and A549 cells were transfected with siNS, 
siDAPK2 and siFLIP, which served as a positive control for sensitisation to FasL-
induced apoptosis. As shown in Figure 4-16a, DAPK2 knockdown sensitised 
U2OS cells to FasL-induced apoptosis, just like what was observed for c-FLIP, a 
known inhibitor of Fas-induced death. Interestingly, in A549 cells (Figure 4-16e) 
neither siDAPK2, nor siFLIP-sensitised cells to FasL-induced apoptosis. As what 
was seen for mRNA upregulation of DR4 and DR5 in response to DAPK2 
knockdown (Figure 4-7a + d), we found significantly elevated levels of FasR 
mRNA upon DAPK2 depletion in both cell lines studied (Figure 4-16b + f). 
Upregulation of FasR messenger RNA levels also translated into increased 
surface FasR protein expression (Figure 4-16c + g), which was further confirmed 
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using additional DAPK2 siRNAs (Figure 4-16d + h). Given the differential 
response to FasL in DAPK2-depleted U2OS and A549 cells, the levels of the 
FasL decoy receptor (DcR3); a putatively soluble protein which expression levels 
have been described to negatively correlate with FasL-induced cell death was 
assessed (Li et al., 2007). Interestingly, DcR3 mRNA expression levels were 
decreased upon DAPK2 knockdown in U2OS cells (Figure 4-16b), whereas 
DcR3 mRNA levels remained unaffected in A549 cells (Figure 4-16f), suggesting 
that DcR3 levels might correlate with cellular sensitivity to FasL-induced cell 
death. These results indicated that, besides sensitising U2OS and A549 cells to 
TRAIL-induced apoptosis, DAPK2 knockdown could also sensitise cells to FasL-
induced cell death. However, sensitization to FasL seems to be associated not 
only with the upregulation of its corresponding receptor, FasR, but also with 
significant downregulation of its decoy receptor, DcR3. On the face of it, it seems 
that the way depletion of DAPK2 leads to Fas-sensitisation is a process 
fundamentally different from that that led to the sensitization to TRAIL, where 
decoy receptors appeared unimportant.  
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Figure 4-16. Depletion of DAPK2 sensitises U2OS but not A549 cells to FAS-induced 
apoptosis. 
U2OS (a + b) or A549 (e + f) cells were transfected with non-targeting siNS, siDAPK2 and 
siFLIP, as indicated in the figure. Forty-eight h after transfection cell survival rates in response 
to FAS-IgM were measured using crystal violet viability assays. For cell survival assays (a + e), 
24 h after transfection, cells were re-plated into 96-well plates at a density of 2x104 cells per 
well. The following day, cells were treated with the indicated concentrations of TRAIL for 24 h. 
Cells were then fixed using methanol and stained with crystal violet. Crystals were dissolved in 
10% (v/v) acetic acid and quantified by measuring the absorbance at 595 nm. Values were 
normalised to the untreated samples. Data represent mean ± SEM of at least three 
independent experiments, performed in triplicate. (Legend continued on the next page) 
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(Continued from last page) Statistical analyses were done using two-way ANOVA test (* 
p<0.05, ** p<0.01, *** p< 0.005). Forty-eight h after transfection and re-plating, RNA was 
harvested and c-FLIP, FasR and DcR3 mRNA levels were analysed by qPCR. c-FLIP qPCR 
data represent mean ± SD of one representative experiments with duplicate samples, FASR 
and DcR3 qPCR data represent mean ± SEM of at least three independent experiments with 
duplicate samples. Statistical analysis was done using Student’s t-test (paired, one tailed) (* 
p<0.05, ** p<0.01, *** p< 0.005). U2OS (c + d) or A549 (g + h) cells were transfected with non-
targeting siNS, or different DAPK2 siRNA oligonucleotides, as indicated in the figure. Flow 
cytometry was used to assess the levels of FasR (c, d, g and h). For U2OS cells, data 
represent mean ± SEM of two independent experiments (d), whereas for A549 cells, data 
represent mean ± SEM of three independent experiments (h). Cell surface expression 
quantification was done using geometric means of those independent experiments and plotted 
as fold change of surface expression in relation to siNS. Statistical analysis was done using 
Student’s t-test (paired, one tailed) (* p< 0.05, ** p<0.01, *** p< 0.005). 
 
4.3 Discussion 
 
DAPK1 was the first member of the DAPK family to be identified by Adi Kimchi in 
the mid-nineties (Deiss et al., 1995). DAPK1 is a serine/threonine kinase with a 
well-defined death domain, implicated in apoptotic pathways triggered by diverse 
stimuli(Shiloh et al., 2013). DAPK2 is a much smaller kinase, with approximately 
80% of homology to DAPK1 in the kinase domain, a dimerization domain but with 
no discernible death domain(Inbal et al., 2000) (Figure 1-9). Most reports on 
DAPK2 involve exogenously expressed, and thus overexpressed, DAPK2. We 
hypothesised that depending on the cellular content and expression levels of 
DAPK2 this kinase would work either as a pro- or anti-apoptotic protein. 
 
Death-inducing ligands of the TNF superfamily have been a focus of translational 
cancer research for the last 20 years. Due to their potentially tumour-eliminating 
characteristics, work has been specifically focused on TNF-α, FasL (CD95) and 
TRAIL. Whereas TNF-α and FasL have proven to cause significant and 
potentially life-threatening side effects when administered systemically 
(MacEwan, 2002, Nagata, 1997), TRAIL had a promising debut as a therapeutic 
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agent. In contrast to TNF-α and FasL, TRAIL specifically induced cell death in 
transformed cells whereas exhibiting little to none systemic toxicity (Kirienko et 
al., 2010). It soon became clear that numerous cancer cells that readily died after 
the initial treatment quickly acquired resistance to TRAIL (Sanchez-Perez et al., 
2002), hindering the development of successful clinical applications. Several 
resistance mechanisms have been described since, such as downregulation of 
TRAIL receptors and upregulation of the inhibitory molecule c-FLIP, to mention 
but the most prominent ones. Much effort has thus focused on overcoming this 
resistance. To date, the most successful ways to overcome TRAIL resistance 
involve synergistic pro-apoptotic treatments and/or the induction of ROS (Mellier 
and Pervaiz, 2012, Ganten et al., 2004). Additional strategies that focus on 
specific re-sensitisation of tumour cells to TRAIL, potentially with few side effects, 
are thus highly desirable. Recently, siRNA mediated depletion of DAPK1 has 
been shown to re-sensitise TRAIL-resistant endometrial carcinoma cells to 
TRAIL-induced apoptosis suggesting in some circumstances an anti-apoptotic 
role for DAPK1 (Bai et al., 2010).  
 
Here, we have shown using crystal violet-based cell survival assays that RNAi-
mediated depletion of another DAPK family member, DAPK2, compared to a 
non-targeting control siNS (Figure 4-2a + f), specifically sensitises U2OS and 
A549 cells to TRAIL-induced apoptosis (Figure 4-2b + g). The findings seemed 
bona fide since multiple DAPK2 siRNAs with different targeting sequences did 
not cross-targeted other DAPK family members (Figure 4-1). Interestingly, in 
cells depleted of DAPK2 there is no sensitisation to a wide range of other 
apoptotic stimuli (Figure 4-2c - e and h - j). These results were further confirmed 
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by measuring DNA hypoploidy (Figure 4-3), which can be used as a readout for 
apoptosis.  Deconvolution of the siDAPK2 pool and two additional unrelated 
DAPK2 siRNAs validated these initial observations and ascribed the effects to 
specific silencing of DAPK2 (Figure 4-4a - d and f - i). In addition, a second non-
specific siRNA (siLuc) confirmed that the observed sensitisation is not an 
unspecific response to the transfection with siRNA oligonucleotides (Figure 4-4e 
and j).  
 
Downregulation of DAPK2 leads to TRAIL-mediated activation of both extrinsic 
and intrinsic death pathways, which is quicker in A549 cells than in U2OS cells 
(Figure 4-5). Interestingly, activation of the intrinsic signalling, which includes a 
mitochondrial amplification loop, appears dispensable in U2OS cells (Figure 
4-14a and Figure 4-15) but represents a crucial part of TRAIL-induced apoptosis 
upon DAPK2 depletion in A549 cells (Figure 4-14c). Many mechanisms of 
TRAIL-resistance and strategies to overcome these involve the DISC complex, 
including down-regulation of c-FLIP, which mimics caspase-8 and thus inhibits its 
binding to the DISC (Ganten et al., 2004). Inhibition of anti-apoptotic members of 
the BCL-2 family, such as BCL-2 and BCL-XL, has also been shown to re-
sensitise TRAIL-resistant cancer cells to TRAIL-induced apoptosis (Sinicrope et 
al., 2004, Huang and Sinicrope, 2008). There was no change on FLIP levels 
upon siDAPK2 (Figure 4-6) and overexpressing BCL-XL had no impact on 
DAPK2-mediated sensitisation of U2OS to TRAIL (Figure 4-15), suggesting that 
these molecules are unlikely factors of TRAIL resistance that can be overcome 
by silencing DAPK2. However, perhaps the most prominent mechanism to 
overcome TRAIL-resistance is the up-regulation of its receptors, DR4 and/or 
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DR5. DAPK2 depletion leads to a significant increase of DR5 mRNA levels in 
U2OS and A549 cells (Figure 4-7a + d). In A549 cells, silencing DAPK2 also 
increases the expression of DR4 mRNA levels (Figure 4-7d). Such mRNA 
upregulation translated into significantly increased levels of total DR5 protein in 
U2OS and A549 cells (Figure 4-8a + c), as well as increased cell surface 
expression of DR5 in U2OS and A549 cells (Figure 4-8b + d and Figure 4-11a + 
b) and DR4 in A549 cells (Figure 4-8e). Deconvolution and use of two additional 
siDAPK2 oligonucleotides revealed that depletion of DAPK2 specifically induces 
protein expression of DR5 in U2OS and A549 cells and DR4 in the A549 cell line 
(Figure 4-9 and Figure 4-10). The upregulation of DRs is one of the most 
common mechanisms leading to the re-sensitisation of resistant cells to TRAIL-
induced apoptosis. Several combination treatments and methods combining 
TRAIL-agonists and compounds have been described leading to the induction of 
DRs and thus re-sensitisation to TRAIL-induced apoptosis. These strategies 
range from co-treatment with DNA damaging agents (Naka et al., 2002), 
(Mendoza et al., 2008) to the use of proteasome inhibitors (Liu et al., 2008b, Liu 
et al., 2007). However, other possible receptor-associated mechanisms of 
sensitisation such as a shift in the ratio between DcRs and DRs (Prasad et al., 
2011) or a change of DR formation in lipid rafts (Delmas et al., 2004, Psahoulia et 
al., 2007) have been described. Simultaneous knockdowns of DAPK2/DR5 in 
U2OS and A549 as well as DAPK2/DR4 in A549 cells reveals that, in both cell 
lines, DR5 is the main receptor for inducing TRAIL-mediated apoptosis (Figure 
4-12). To test whether the observed induction of DR5 is sufficient for re-
sensitisation and to exclude other potential sensitising processes, siDR5 was 
titrated and a concentration of siDR5 was established, capable of reverting the 
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DAPK2 RNAi mediated induction of DR5 (1.25 nM). These experiments were 
carried out in U2OS cells, as they do not express DR4 (Figure 4-13a + b), thus 
simplifying the results’ interpretation. Co-transfection of siDAPK2 (20 nM) and 
siDR5 (1.25 nM) successfully rescues cells from siDAPK2 mediated TRAIL-
sensitisation, suggesting that the TRAIL-resensitised phenotype of DAPK2-
depleted cells is dependent on the upregulation of its key receptor DR5.  
Having already established that depletion of DAPK2 did not impact on the 
sensitisation to TNF-α (Figure 4-2e + j) further investigations into the effect of 
DAPK2 knockdown on sensitisation to FasL were carried out. For that purpose, 
an anti-FAS IgM antibody that was first described in 1989 (Yonehara et al., 1989) 
and that is capable of clustering FasR, thus mimicking FasL-induced apoptosis 
(Figure 4-16) (henceforth referred to as FasL) was used. Our analysis revealed 
that under certain conditions DAPK2 depleted cells can also be sensitised to 
FasL-induced cell death. Interestingly, DAPK2 depleted U2OS cells are 
significantly sensitised to FasL-induced apoptosis to the same extent as U2OS 
cells with silenced c-FLIP (Figure 4-16a), whereas no sensitising effect is 
observed in A549 cells, which is also not sensitised to FasR by simply using 
RNAi against siFLIP (Figure 4-16e). As for the upregulation of DR5 and/or DR4 
upon DAPK2 knockdown, FasR mRNA and surface-protein levels are also 
elevated in U2OS and A549 cells after transfection with siDAPK2 (Figure 4-16). 
Interestingly, mRNA of the soluble FasL decoy receptor, DcR3, is significantly 
downregulated in U2OS cells, whereas no such effect is observed in A549 cells 
(Figure 4-16b + f).  
 
 
Depletion of DAPK2 sensitises tumour cells to TRAIL-induced apoptosis 
 
! 157!
It thus seems likely that the mechanisms of sensitisation to FasL-induced cell 
death and TRAIL-induced cell death in DAPK2-depleted cells are essentially 
different. Under the experimental conditions used here, siDAPK2 leads to a 
significant downregulation of the FasR decoy receptor DcR3 transcript in U2OS 
cells (Figure 4-16b). Previously, it has been shown that the expression of DcR3 
inversely correlates with the sensitivity to FasL-induced apoptosis (Li et al., 
2007). This could explain the selective sensitivity of DAPK2 depleted U2OS cells 
to FasL. This is in contrast to DAPK2-depleted A549 cells, which remain resistant 
to FasL-induced cell death even after depletion of the well-described intracellular 
Fas signalling inhibitor c-FLIP (Figure 4-16e and f) (Scaffidi et al., 1999).  
 
Overall, our work suggests that inhibition of DAPK2 in combination with TRAIL or 
TRAIL mimics may provide an alternative, novel approach to overcome TRAIL-
resistance and may ultimately open new avenues for treatments of certain types 
of malignancies. Interestingly, DAPK2 depletion seems to induce expression of a 
variety of death receptors e.g. DR4, DR5 and FasR. This increased expression is 
facilitated most likely via a common transcription factor. Interestingly, DR4, DR5 
and FasR share, amongst others, the transcription factor p53 (Liu et al., 2004), 
(Shetty et al., 2005, Muller et al., 1998) and can all be induced by members of 
the NF-κB-family of transcription factors (Mendoza et al., 2008, Shetty et al., 
2005, Chan et al., 1999). The potential role and/or activation of these factors 
upon DAPK2 depletion will be described in Chapter 5. !
! !
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5.1 Introduction 
 
In Chapter 4. it has been shown that the depletion of DAPK2 sensitises TRAIL-
resistant U2OS and A549 cells to TRAIL-induced apoptosis (Figure 4-2). It was 
further demonstrated that the siRNA-mediated knockdown of DAPK2 induced the 
upregulation of DR4, DR5 and FasR at the mRNA and protein level (Figure 4-7 
and Figure 4-8). Sensitisation to TRAIL-induced apoptosis was mainly facilitated 
by upregulation of DR5, as reverting DR5 levels to the levels of siNS-transfected 
cells rescued the sensitisation to TRAIL in U2OS cells (Figure 4-12 and Figure 
4-13). Besides transcriptional induction, it has been shown that DR5 can be 
upregulated via mRNA stabilisation or by an increase in protein stability. 
Treatment with the proteasome inhibitor PS-341 (Bortezomib or Velcade®) has 
been shown to induce DR5 via mRNA stabilisation at the 3′-untranslated region 
(Kandasamy and Kraft, 2008). Treatment with the plant flavonoid Quercetin has 
been described to increase protein stability but not mRNA stability of DR5 (Jung 
et al., 2010). In this chapter we sought to elucidate the mechanism(s) behind 
siDAPK2-mediated upregulation of DR5. Classical experiments were performed 
to assess the mRNA and protein stability of DR5 in DAPK2 depleted cells. 
Having established that the induction of DR5 in cells after DAPK2 depletion 
occurred at the transcriptional level, based on published work, we focused on the 
role of the transcription factors p53 and the NF-κB on the induction of DR5. The 
transcription factor p53, which has been described as the so-called ‘guardian of 
the genome’ (Lane, 1992), is a central regulator of the DNA damage response 
and is frequently mutated in cancer cells (Muller and Vousden, 2013). Tightly 
regulated by its ubiquitin ligase MDM2, p53 is activated by various types of 
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cellular stress (e.g. DNA damage, metabolic stress and ROS [reviewed in (Lakin 
and Jackson, 1999, Liu et al., 2008a, Puzio-Kuter, 2011)]) and it has been 
described to regulate the transcription of DRs and FasR. These receptors can be 
upregulated by p53 in response to DNA damaging agents such as 5-fluoruracil 
(5-FU) and cisplatin, or the inhibitor of p53’s E3 ubiquitin ligase, Nutlin-3 (Henry 
et al., 2012, Meijer et al., 2013, Vassilev et al., 2004). When incorrectly regulated, 
the NF-κB family of transcription factors has been linked to many pathological 
conditions, especially cancer and inflammation [reviewed in (Karin et al., 2002, 
Lawrence, 2009)]. Similar to p53, activation of NF-κB upon treatment with 
etoposide, phorbol myristate acetate (PMA) and ionomycin (PMA/I) (Chan et al., 
1999), or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Singh et al., 2007) 
(Mendoza et al., 2008) has  been shown to activate DR5, DR4 or FasR. To 
understand further the events downstream of siRNA-mediated depletion of 
DAPK2 and upstream of DR mRNA upregulation, we studied the role of p53 and 
NF-κB in siDAPK2-mediated TRAIL sensitisation and established that NF-κB is 
absolutely required for siDAPK2-mediated sensitisation to TRAIL-induced cell 
death whilst p53 is dispensable. We thus investigated the regulation of NF-κB by 
DAPK2 and, in the process, identified DAPK2 as a potential novel regulator of 
NF-κB signalling. !  
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5.2 Results 
5.2.1 Increased DR5 expression following DAPK2 knockdown is 
transcriptionally regulated and not due to altered mRNA or protein 
stability 
 
To gain insight into the mechanism underlying the upregulation of DR5 mRNA 
and protein levels in response to DAPK2 knockdown, mRNA transcription and 
protein translation were inhibited and mRNA and protein stability assessed 
(Figure 5-1). Transcription was blocked by treating cells with actinomycin D (Act-
D), a polypeptide antibiotic (Waksman et al., 1946), which prevents transcription 
by intercalating with DNA at the transcription initiation complex and thereby 
preventing mRNA elongation (Sobell, 1985). The experimental procedure for 
analysing DR5 mRNA stability is represented schematically (Figure 5-1a). Cells 
were treated with Act-D as indicated 48 h after transfection with either siNS or 
siDAPK2 oligonucleotides. Gene expression analysis was performed by qPCR, 
using HPRT and GAPDH as housekeeping genes. Fold change was calculated 
by normalising mRNA expression to samples that were not treated with Act-D for 
each transfection individually. As shown in Figure 5-1 (b + c), no significant 
difference in the mRNA stability of siNS or siDAPK2-transfected cells was 
observed. Interestingly, the DR5 mRNA half-life (50% of mRNA transcript) in 
U2OS cells was approximately 240 min, whereas it was longer than the time 
range assessed in A549 cells. To analyse protein stability, translation was 
blocked by cycloheximide (CHX) an inhibitor of the elongation phase of 
eukaryotic translation (Obrig et al., 1971, Schneider-Poetsch et al., 2010), which 
blocks translation and thus de novo protein synthesis, was used. The 
experimental procedure for analysing DR5 protein stability is represented 
schematically (Figure 5-1d). Cells were treated with CHX as indicated 48 h after 
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transfection with either siNS or siDAPK2 oligonucleotides. DR5 protein levels 
were measured over time using SDS-PAGE/quantitative western blotting followed 
by densitometric analysis, where each value was normalised to the 
corresponding HSP90 loading control. Fold change was calculated by 
normalising protein expression of each set of transfections to samples that were 
not treated with CHX. For these analyses the DR5L isoform was used. As 
depicted in Figure 5-1 (e + f), protein stability remained the same in U2OS and 
A549 cells regardless of DAPK2 expression levels. Protein half-life was 
approximately 1 h in both cell lines. There was a trend towards a shorter half-life 
in DAPK2-depleted cells in relation to siNS-transfected cells, which was not 
statistically significant. In short, the depletion of DAPK2 led to an up-regulation of 
DR5 mRNA and protein levels, which was not mediated by an increase in mRNA 
or protein stability, and which is consistent with a transcriptional effect. 
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Figure 5-1. DR5 increased expression following the knockdown of DAPK2 is 
transcriptionally regulated and not due to alterations on mRNA or protein stability. 
The experimental procedure for analysing DR5 mRNA stability is represented schematically in 
(a). RNA stability was determined after RNAi against DAPK2 by inhibiting RNA synthesis with 
actinomycin D (Act-D) over the time periods indicated in the figure (b, c). Experimental 
procedures used to analyse DR5 protein stability are represented in (d). Protein synthesis was 
inhibited using cycloheximide (CHX) after 48 h transfection with siNS and siDAPK2 (e, f). DR5 
protein levels were measured over time using SDS-PAGE/western blotting followed by 
densitometric analysis, where each value was normalised to the corresponding HSP90 loading 
control. For these analyses the DR5L isoform was used. The data represent the mean of three 
independent experiments ± SEM and no significant changes were detected using a two-way 
ANOVA test. I am grateful to Ms Sarah Stöcker for her contribution to these experiments. 
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5.2.2 DAPK2 depletion mediated sensitisation to TRAIL is independent of 
p53 
 
Investigations into the role of p53 in siDAPK2-mediated upregulation of DR 
mRNA and sensitisation to TRAIL were also carried out. For that purpose, p53 
mRNA levels in U2OS and A549 cells were measured, as p53 itself is one of the 
first transcriptional targets of p53 as part of a positive feedback loop (Deffie et al., 
1993). As shown in Figure 5-2, RNAi-mediated depletion of DAPK2 in either 
U2OS or A549 cells did not lead to transcriptional induction of p53 mRNA. The 
cell cycle regulator p21 (CIP1/WAF1), one of the most studied and most 
immediate transcriptional targets of p53, can also provide a readout for p53 
activation since it is mostly, but not exclusively, activated by p53 (Macleod et al., 
1995). Interestingly, although p53 mRNA was not upregulated, there was a 
statistically significant ~2-fold upregulation of p21 mRNA in response to DAPK2 
knockdown in U2OS and A549 cell (Figure 5-2a and b). 
 
 
Figure 5-2. Depletion of DAPK2 does not affect p53 mRNA expression levels but induces 
its target p21. 
U2OS (a) and A549 (b) cells were transfected with either siNS or siDAPK2 RNA 
oligonucleotides. Forty-eight h after transfection RNA was harvested, and p53 and p21 mRNA 
levels were analysed by qPCR. Data represent mean ± SEM of four independent experiments 
with duplicate samples. Statistical analysis was done using Student’s t-test (paired, one tailed) 
(*** p< 0.005). 
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To further test whether p53 was involved in DAPK2 depletion-induced 
sensitisation to TRAIL-mediated apoptosis, p53-null prostate cancer PC3 cells 
and p53-mutated bladder carcinoma T24 cells were used. Whereas PC3 is a 
prostate adenocarcinoma cell line that lacks both p53 alleles, T24 cells carry a 
p53 mutant allele with an in-frame deletion of the TAC triplet encoding tyrosine 
126 (Table 3-1) that leads to impaired activation of p53 upon induction of DNA 
damage (Konstantakou et al., 2009). As shown in Figure 5-3 (a + c), transfection 
of PC3 or T24 cells with siDAPK2 successfully downregulated DAPK2 protein 
levels. Interestingly, PC3 as well as T24 were readily sensitive to TRAIL-induced 
apoptosis at a concentration of more than 100 ng/ml (Figure 5-3b + d, black 
bars). Depletion of DAPK2 in p53-null PC3 cells, or in p53-mutated T24 cells led 
to a significant further increase in sensitivity towards TRAIL-induced apoptosis 
(Figure 5-3b + d, black bars versus green bars).  
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Figure 5-3. Knockdown of DAPK2 sensitises PC3 and T24 cells to TRAIL-induced cell 
death, in a p53-independent manner. 
PC3 (a, b) and T24 (c, d) cancer cells were transfected with either siNS, or DAPK2 siRNA. 
Forty-eight h after transfection knockdown efficiency was determined by SDS-PAGE/western 
blotting (a, c). Data represent mean ± SEM of three independent experiments. For cell survival 
assays (PC3, b and T24, d), cells were re-plated into 96 well plates at a density of 2x104 cells 
per well 24 h after siRNA transfection. The following day cells were treated with the indicated 
concentrations of TRAIL for 24 h. Cells were then fixed using methanol and stained with crystal 
violet. Crystals were dissolved in 10% (v/v) acetic acid and quantified by measuring the 
absorbance at 595 nm. Values were normalised to untreated control samples. Data represent 
mean ± SEM of three independent experiments performed in triplicates. Statistical analyses 
were done using two-way ANOVA test (* p< 0.05, ** p<0.01, *** p< 0.005). 
 
Despite the fact that p53 itself was not found to be transcriptionally activated 
(Figure 5-2a + b, left graph), the data suggest that p53 was likely activated upon 
siRNA-mediated depletion of DAPK2, as, mRNA levels of p21 were upregulated 
by two-fold (Figure 5-2a + b, right graph). However, further experiments with 
p53-null PC3 and p53-mutated T24 cells revealed that wild-type, fully functional, 
p53 was dispensable for the molecular mechanism involved in the sensitization of 
these cells to TRAIL-induced apoptosis (Figure 5-3b + d). This suggested that 
while p53 might be transcriptionally activated in response to DAPK2 knockdown, 
it was not crucial for the observed sensitisation. 
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5.2.3 Depletion of DAPK2 activates the NF-κB-family of transcription 
factors 
 
Given the fact that cellular p53 was dispensable to sensitise cells to TRAIL-
induced apoptosis, the induction/activation of other transcription factors known to 
be involved in the regulation of the TNF receptor superfamily was analysed. As 
described earlier, the induction of DR4, DR5 and FasR has been linked not only 
to p53 but also the NF-κB-family of transcription factors. Experiments using 
NF-κB luciferase reporter assays to detect potential NF-κB activation in response 
to DAPK2 depletion were, therefore, performed. U2OS and A549 cells were 
transfected with either siNS or siDAPK2 and 24 h later with pNF-κB-Luc reporter 
Firefly-luciferase and CMV promoter/Renilla-luciferase plasmids. Forty-eight h 
later, luminescence was detected and normalised to the internal transfection 
control and to siNS. Interestingly, a significant increase in pNF-κB-Luc reporter 
activity in U2OS and A549 cells depleted of DAPK2 compared to siNS was 
observed (Figure 5-4). 
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Figure 5-4. NF-κB is transcriptionally active in response to DAPK2 depletion. 
Luciferase assays were performed to assess the transcriptional activity of NF-κB in response to 
DAPK2 knockdown in U2OS (a) and A549 (b). RNAi-mediated DAPK2 depletion was induced 
24 h prior to co-transfection with a pNF-κB-Luc reporter Firefly-luciferase and a CMV promoter/ 
Renilla-luciferase constructs. Twenty-four h later, both Firefly- and Renilla-luciferase activities 
were measured. Data were analysed by normalising the Firefly-luciferase to the luminescence 
obtained for the Renilla-luciferase construct. Data represent mean ± SEM of three independent 
experiments performed in triplicates. Statistical analysis was done using Student’s t-test 
(paired, two tailed) (* p< 0.05). I am grateful to Ms Marina L. Georgiou for her contribution to 
the luciferase assays. 
 
NF-κB signalling is highly complex and different members assemble into different 
dimers that then participate in canonical and non-canonical signalling pathways. 
The canonical pathway tends to involve NF-κB1 (p105/p50) and RELA (p65) or 
cREL, whereas the non-canonical pathway is thought to involve primarily NF-κB2 
(p100/p52) and RELB. This distinction is not absolute and a great deal of 
signalling specificity is determined by the cell type and cellular environment 
(Ghosh and Karin, 2002, Tergaonkar, 2006). To further understand the effect of 
DAPK2 knockdown on NF-κB signalling, qPCR analyses of all five human NF-κB 
family members, namely NF-κB1, NF-κB2, RELA, RELB, and cREL were 
performed. U2OS and A549 cells were transfected with either siNS control or 
siDAPK2, and 48 h later RNA was harvested, reverse transcribed, and qPCR 
performed. These analyses revealed that the mRNA expression of NF-κB family 
members such as NF-κB1, NF-κB2 and RELB was strongly induced (2-3 fold) in 
both cell lines in response to DAPK2 knockdown (Figure 5-5). In addition, RELA 
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and cREL were found to be slightly but significantly upregulated in U2OS cells 
but not in A549 cells. Taken together, these results suggested that RNAi-
mediated genetic ablation of DAPK2 led to the activation of NF-κB responses 
and to the transcriptional upregulation of NF-κB-family transcription factors. 
 
 
Figure 5-5. mRNA levels of NF-κB family members are upregulated in response to 
siDAPK2. 
U2OS (a) and A549 (b) cells were transfected with either siNS or siDAPK2 RNA 
oligonucleotides. Forty-eight h after transfection RNA was harvested and NF-κB mRNA levels 
were analysed by qPCR. Data represent mean ± SEM of at least three independent 
experiments with duplicate samples. Statistical analysis was done using Student’s t-test 
(paired, one tailed) (* p< 0.05, ** p<0.01, *** p< 0.005). 
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5.2.4 Elevated transcription of NF-κB in response to siDAPK2 translates 
into increased protein expression.  
 
Using luciferase reporter assays it was established that the RNAi-mediated 
ablation of DAPK2 induced the NF-κB response. Indeed, in response to DAPK2 
knockdown, the transcription of NF-κB1, NF-κB2 and RELB was strongly induced 
in both U2OS and A549 cells. In addition, RELA and cREL were also significantly 
upregulated in U2OS cells. To elucidate whether the elevated mRNA levels also 
translated into increased NF-κB activation, cells were transfected as before and 
proteins were extracted and separated on a polyacrylamide gel. Western blot 
membranes were then probed with antibodies specific to NF-κB1, NF-κB2, RELA 
and the activating phosphorylation of RELA (pS536). Protein expression analysis 
revealed that p100 and p52 (NF-κB2) were induced (Figure 5-6c + d) in 
response to DAPK2 knockdown, whilst p105 (NF-κB1) levels remained 
unchanged, with a slight increase in its proteolytic cleavage as demonstrated by 
a 1.5 and 2-fold increase in p50 expression in U2OS and A549 cells, respectively 
(Figure 5-6a + b). Importantly, RELA was robustly phosphorylated on S536 in 
both cell lines (Figure 5-6e + f). This suggested that the transcriptional 
upregulation at the mRNA level of NF-κB1 and NF-κB2 led to increased protein 
expression in DAPK2-depleted cells. Consistent with the mRNA results (Figure 
5-5a and b), NF-κB2 was more strongly induced than NF-κB1 and no changes in 
the levels of total RELA protein were detectable. However, RELA was strongly 
phosphorylated on S536. These results suggest that in response to DAPK2 
knockdown both branches of NF-κB signalling (canonical and non-canonical) 
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were engaged with phosphorylated RELA S536 as part of the canonical NF-κB 
activation and upregulated NF-κB2 as part of the non-canonical activation. 
 
 
Figure 5-6. NF-κB family members are upregulated at the protein level in response to 
DAPK2 depletion. 
U2OS (a, c, e) and A549 (b, d, f) cells were transfected with either siNS or DAPK2 siRNA. 
Forty-eight h after transfection the expression levels of NF-κB1 (a, b), NF-κB2 (c, d), RELA 
pp65-S536 and RELA (e, f) were evaluated by SDS-PAGE/western blotting. Lamin-B and 
HSP90 served as loading controls. Blots shown are representative of three independent 
experiments. I am grateful to Ms Marina L. Georgiou for her contribution to the western blots. 
 
5.2.5 NF-κB activation induces the transcription of a variety of NF-κB 
target genes 
 
In Chapter 4., it was shown that the TNFR family members DR5 and FASR were 
transcriptionally induced in both U2OS and A549 cells upon DAPK2 depletion, as 
was DR4 in DAPK2-depleted A549 cells. Subsequent experiments revealed that 
NF-κB mRNA was induced (Figure 5-5), protein translated (Figure 5-6) and this 
was transcriptionally active in DAPK2-depleted cells (Figure 5-4). Additional 
probing into the transcriptional activation of NF-κB target genes and NF-κB 
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signalling-associated genes was thus carried out. U2OS and A549 cells were 
transfected with siNS and siDAPK2, mRNA was harvested, reverse transcribed 
and gene expression was analysed by qPCR, as before. Results for NF-κB target 
genes that are commonly used as readouts for NF-κB-activation as well as genes 
that are associated with NF-κB signalling but have not been shown to be induced 
by NF-κB directly are depicted in Figure 5-7. The death inducing ligand TNF-α, 
as well as its corresponding receptor, tumour necrosis factor receptor (TNFR) 2, 
have both been described as NF-κB target genes and are often activated as part 
of a positive feedback loop in response to cytokine stimulation (Perrot-Applanat 
et al., 2011, Hamilton et al., 2011). Interestingly, TNF-α mRNA levels were also 
significantly upregulated (2-fold) in U2OS and A549 cells (Figure 5-7a + b), 
whilst the levels of TNFR2 remained unaffected in U2OS cell (Figure 5-7a) but 
were strongly upregulated (> 6-fold) in A549 cells (Figure 5-7b). The 
transcription of the death-inducing ligand TRAIL itself, whose signalling and 
downstream killing mechanism are the main focus of this study, has also been 
described as an NF-κB-target gene (Baetu et al., 2001, Matsuda et al., 2005). 
Interestingly mRNA levels of TRAIL were not affected in U2OS, or A549 cells 
(Figure 5-7a + b). The effect of siDAPK2-mediated NF-κB activation on the 
transcription of cyclooxygenase-2 (COX2) and SOD2, both described as NF-κB 
targets, was also assessed (Xu et al., 1999, Yamamoto et al., 1995). COX2, also 
known as prostaglandin-endoperoxide synthase 2, is involved in the production of 
prostaglandins and it has been shown to trigger pro-inflammatory responses 
upon NF-κB-mediated induction (Ulivi et al., 2008). SOD2 is the mitochondrial 
member of the SOD family and has been to exhibit have anti-oxidative and anti-
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inflammatory effects (Zelko et al., 2002, Hernandez-Saavedra et al., 2005, 
Velarde et al., 2012). SOD2 expression was significantly increased in both cell 
lines, with a stronger activation in A549 cells than in U2OS cells (Figure 5-7a + 
b). COX2, however, was only induced in response to DAPK2 depletion in A549 
cells (Figure 5-7a + b). The opposite was true for the receptor-interacting serine/ 
threonine-protein kinase (RIPK) 2, another NF-κB target gene (Matsuda et al., 
2003) which has also been associated with activation of NF-κB in response to T-
cell receptor signalling (Ruefli-Brasse et al., 2004), as it was elevated in U2OS 
but not in A549 cells (Figure 5-7a + b). 
 
To probe further into the specificity of the transcriptional response in DAPK2-
depleted cells, the mRNA levels of TNFR1 and RIPK1 were also measured. Both 
genes have been associated with NF-κB signalling (Wajant and Scheurich, 2011, 
O'Donnell et al., 2007) but, critically, have not been described as NF-κB 
response genes. Neither of these genes was significantly affected by DAPK2 
depletion-mediated induction of NF-κB (Figure 5-7c + d). We further assessed 
the mRNA levels of the proto-oncogene c-JUN, which has been described 
previously to be activated in parallel with NF-κB (Kharkwal et al., 2012, Sanchez-
Perez et al., 2002), shown to directly interact with NF-κB and to increase the 
DNA-binding capacity of NF-κB (Wolter et al., 2008, Stein et al., 1993). As shown 
in Figure 5-7 (c + d) it was modestly upregulated in DAPK2 depleted U2OS and 
A549 cells and this was statistically significant. Together the data show that the 
depletion of DAPK2 led to the transcriptional upregulation of previously described 
NF-κB target genes and that the response was not totally identical in U2OS and 
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A549 cells, since some genes appear to be activated in one but not the other cell 
line. Moreover, genes that have been associated with NF-κB signalling, but have 
not been so far described as NF-κB targets, remained unaffected by DAPK2 
knockdown-induced NF-κB activation in either of the studied cell lines. 
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Figure 5-7. Effect of DAPK2 depletion on the induction of NF-κB-response and NF-κB-
associated genes. 
U2OS (a + c) and A549 (b + d) cells were transfected with either siNS or siDAPK2 RNA 
oligonucleotides. Forty-eight h after transfection RNA was harvested and mRNA levels of NF-
κB target genes and NF-κB signalling associated genes were analysed by qPCR. Data 
represent mean ± SEM of at least three independent experiments with duplicate samples. 
Statistical analysis was done using Student’s t-test (paired, one tailed) (* p< 0.05, ** p<0.01, *** 
p< 0.005).  
TNF-Į TNF-Į
 
TNFR2TNFR2
0.0
0.5
1.0
1.5
2.0
2.5 *
0
1
2
3
4 *
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
TRAIL TRAIL
 
SOD2SOD2
0.0
0.5
1.0
1.5
2.0
siN
S
siD
AP
K2
 
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
m
R
N
A
 fo
ld
 c
ha
ng
e
siN
S
siD
AP
K2
 
siN
S
siD
AP
K2
 
0.0
0.5
1.0
1.5
COX2 COX2 RIPK2RIPK2
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
siN
S
siD
AP
K2
 
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
m
R
N
A
 fo
ld
 c
ha
ng
e
siN
S
siD
AP
K2
 
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
0
1
2
3
TNFR1 TNFR1 RIPK1
0.0
0.5
1.0
1.5
siN
S
siD
AP
K2
 
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
m
R
N
A
 fo
ld
 c
ha
ng
e
siN
S
siD
AP
K2
 
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
RIPK1
m
R
N
A
 fo
ld
 c
ha
ng
e
0.0
0.5
1.0
1.5
m
R
N
A
 fo
ld
 c
ha
ng
e
0
2
4
6
0.0
0.5
1.0
1.5
2.0
m
R
N
A
 fo
ld
 c
ha
ng
e
0.0
0.5
1.0
1.5
m
R
N
A
 fo
ld
 c
ha
ng
e
*
* **
a) b)
c) d)
*
NFț% signalling associated genes
A549 U2OS
NFț% response genes
c-JUN
0.0
0.5
1.0
1.5
2.0 **
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
 
c-JUN
0.0
0.5
1.0
1.5 ***
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e
0.0
0.5
1.0
1.5
2.0
0
2
4
6
8
siN
S
siD
AP
K2
 
m
R
N
A
 fo
ld
 c
ha
ng
e **
 
DAPK2 depletion leads to the upregulation of DRs via NF-B-family activation 
 
! 176!
5.2.6 Activation of NF-κB is causal for the sensitisation of U2OS and A549 
cells to TRAIL in response to DAPK2 depletion 
 
The absence of DAPK2 in U2OS and A549 cells sensitised these otherwise 
resistant cells to TRAIL-induced cell death via upregulation of DR5 and/or DR4 in 
what appeared to be a NF-κB-dependent manner. We hypothesised that if NF-κB 
activation was critical for the sensitisation, then knocking down its components 
should lead to a reversal of this phenotype. Cell survival assays were performed 
and RNAi against NF-κB1, NF-κB2, RELA and RELB with or without targeting 
DAPK2 concomitantly used to falsify the hypothesis. The efficiency of the double 
knockdown experiments was validated using qPCR (Figure 5-8c + f and Figure 
5-9c + f). As depicted in Figure 5-8a, U2OS cells with silenced DAPK2 became 
resistant to TRAIL again only when NF-κB1 was absent. In contrast, A549 cells 
became resistant when either NF-κB1 or NF-κB2 was silenced (Figure 5-8d + e). 
Despite its strong phosphorylation (Figure 5-6e + f), RELA was redundant and 
its absence per se did not prevent DAPK2 silencing from sensitising U2OS or 
A549 cells to TRAIL-induced apoptosis (Figure 5-9a + d). Interestingly, silencing 
RELB did not effect the sensitisation of U2OS cells to TRAIL-mediated death 
(Figure 5-9b), but it partially blocked sensitisation of A549 cells (Figure 5-9e). 
Together the data suggested that NF-κB1 was necessary for the re-sensitization 
to TRAIL in DAPK2 depleted U2OS cell, whereas NF-κB1, NF-κB2 and RELB 
were involved in the re-sensitisation process of A549 cells. The canonical NF-κB 
pathway involves NF-κB1 (p105/p50) and RELA (p65), whereas the non-
canonical pathway primarily involves NF-κB2 (p100/p52) and RELB. Thus, the 
absence of DAPK2 seems to activate both the canonical and the non-canonical 
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NF-κB pathway, and the activation seems to be different in U2OS and A549 
cells. 
 
 
Figure 5-8. NF-κB1 and/or NF-κB2 are necessary for the sensitisation to TRAIL-induced 
cell death seen after DAPK2 silencing.  
Double knockdowns were carried out in U2OS (a, b, c) and A549 (d, e, f) cells. For this 
purpose, cells were transfected with 40 nM of the following siRNA mixes: siNS+siNS, 
siDAPK2+siNS, siNS+NF-κB1 and siBID+NF-κB2. Twenty-four h after transfection cells were 
re-plated into 96 well plates at a density of 2x104 cells per well. The following day cells were 
treated with TRAIL for 24 h at the indicated final concentrations (U2OS: a, b; A549: d, e). Cells 
were methanol-fixed and stained with crystal violet. Staining was dissolved in acetic acid and 
quantified by measuring the absorbance at 595 nm. Values were normalised to the untreated 
samples. Data represent mean ± SEM of three independent experiments performed in 
triplicates. Statistical analysis was done using two-way ANOVA test (* p< 0.05, ** p<0.01, *** 
p< 0.005). Forty-eight h after transfection and re-plating, RNA was harvested and double 
knockdown efficiency was confirmed (U2OS: c; A549: f). DAPK2, NF-κB1 and NF-κB2 mRNA 
levels were analysed by qPCR, data represent mean ± SEM of three independent experiments 
with duplicate samples. 
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Figure 5-9. RELA and RELB are dispensable for the sensitisation to TRAIL-induced cell 
death seen after DAPK2 silencing. 
Double knockdowns were carried out in U2OS (a, b, c) and A549 (d, e, f) cells. For this 
purpose, cells were transfected with 40 nM of the following siRNA mixes: siNS+siNS, 
siDAPK2+siNS, siNS+RELA and siBID+RELB. Twenty-four h after transfection cells were re-
plated into 96 well plates at a density of 2x104 cells per well. The following day cells were 
treated with TRAIL for 24 h at the indicated final concentrations (U2OS: a, b; A549: d, e). Cells 
were methanol-fixed and stained with crystal violet. Staining was dissolved in acetic acid and 
quantified by measuring the absorbance at 595 nm. Values were normalised to the untreated 
samples. Data represent mean ± SEM of three independent experiments performed in 
triplicates. Statistical analysis was done using two-way ANOVA test (* p< 0.05, ** p<0.01, *** 
p< 0.005). Forty-eight h after transfection and re-plating, RNA was harvested and double 
knockdown efficiency was confirmed (U2OS: c; A549: f). DAPK2, RELA and RELB mRNA 
levels were analysed by qPCR, data represent mean ± SEM of three independent experiments 
with duplicate samples. 
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5.2.7 Absence of DAPK2 leads to the NF-κB-mediated upregulation of DR5 
 
Human DR5 is an NF-κB target gene, which possesses a NF-κB binding site in 
the first intronic region (Shetty et al., 2005) (depicted in Figure 5-10a). The effect 
of RNAi-mediated DAPK2 depletion on the activation of the DR5 promoter was 
investigated using luciferase reporter constructs. Accordingly, U2OS and A549 
cells were transfected with either siNS or siDAPK2 and 24 h later with DR5 
promoter pGL3 Firefly-luciferase constructs and CMV promoter/Renilla-luciferase 
plasmids. Forty-eight h later, luminescence was detected and normalised to the 
internal transfection control and to siNS. The DR5 promoter plasmids used in this 
study are schematically represented in Figure 5-10a. The full-length DR5 
promoter plasmid spans over the whole promoter region of the DR5 gene from 
1200 base pairs (bp) upstream of the transcription start site (TSS) to 2400 bp 
downstream into the gene and has been cloned into pGL3 vector. The other two 
constructs cover a smaller area of the DR5 promoter, mainly the intronic region of 
the DR5 promoter but include the well-characterised p53 and NF-κB binding sites 
of the human DR5 gene (Shetty et al., 2005) (Figure 5-10a). One of these 
promoter-intron plasmids contains a mutation of the NF-κB binding site (referred 
to as promoter-intron mt), which has been shown to abrogate NF-κB-mediated 
DR5 transcription (Shetty et al., 2005). The other second promoter-intron plasmid 
carries the wild-type sequence of the NF-κB binding site (referred to as promoter-
intron wt). The DR5 promoter was clearly engaged upon transfection of both cell 
types with siDAPK2 (Figure 5-10b + c and f + g), and this engagement was 
abrogated if the NF-κB binding site on this promoter was mutated (Figure 5-10c 
+ g, compare wt and mt), indicating the absolute requirement for NF-κB in 
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siDAPK2-mediated DR5 upregulation. All of the applied DR5 promoter luciferase 
constructs also contain the p53-binding site, which in case of the mutated NF-κB 
binding site (Figure 5-10c + g) was unable to compensate for the lack of NF-κB 
and promote full DR5 transcription. This was another piece of evidence lending 
further support to the hypothesis that DAPK2 depletion mediated re-sensitisation 
to TRAIL-induced cell death independently of p53 through mechanism(s) that 
relied on the activation of NF-κB.  
 
NF-κB activation was clearly required for the transcriptional induction of DR5 in 
DAPK2 depleted cells. Further experiments, however, were carried out to verify 
these results by using RNAi against NF-κB1 with or without targeting DAPK2 
concomitantly and assessing its effect on DR5 mRNA and protein levels. NF-κB1 
was chosen, as previous double knockdown experiments revealed that RNAi-
mediated depletion of NF-κB1 abrogated the re-sensitising effect of DAPK2 
knockdown in both U2OS and A549 cells (Figure 5-8a + d). As shown in Figure 
5-10 (d + h) depletion of DAPK2 significantly induced DR5 mRNA in both cell 
lines, as described earlier. In contrast, knockdown of NF-κB1 on its own only had 
a small effect on DR5 mRNA levels in U2OS cells and none on the levels in 
A549. However, the combinatory knockdown of DAPK2 and NF-κB1 (compare 
green and purple bars) reverted the induction of DR5 in the absence of DAPK2. 
Importantly, these results were reproducible at the protein level (Figure 5-10e + 
i) where the induction of DR5 protein expression in response to DAPK2 depletion 
was reverted by simultaneous downregulation of NF-κB1 and DAPK2. 
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Figure 5-10. The transcription factor NF-κB is a critical component of DR5 expression 
and is necessary for the induction of DR5 after DAPK2 silencing. 
The DR5 locus and plasmids used for DR5 promoter analyses are represented in (a). As 
before, DAPK2 depletion was initiated in U2OS (b + c) and A549 cells (f + g) 24 h prior to co-
transfection with the DR5 full-length promoter (b, f), DR5 promoter-intron wild-type (wt) or NF-
κB mutated (mt) (c, g) plasmid Firefly-luciferase pGL3 construct and a CMV promoter/Renilla-
luciferase construct. Twenty-four h later, both Firefly- and Renilla-luciferase activities were 
measured. Data were analysed by normalising the Firefly-luciferase to the luminescence 
obtained for the Renilla-luciferase activity. Data represent mean ± SEM of three independent 
experiments. Statistical analysis was done using Student’s t-test (paired, two tailed) (* p< 0.05, 
*** p< 0.005). U2OS (d + e) and A549 (h + j) cells were transfected with either siNS or the 
following siRNA 1:1 mixes: siNF-κB1+siNS, siDAPK2+siNS, siDAPK2+ NF-κB1 (40 nM in 
total). Forty-eight h after transfection RNA and proteins were isolated and levels of DR5 mRNA 
(d + h) and protein were measured (e + i). I am grateful to Ms Marina L. Georgiou for her 
contribution to the luciferase assays. 
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5.2.8 Dissecting the upstream mechanisms leading to the activation of 
NF-κB in absence of DAPK2 
 
DAPK2 depletion induced the activation of a NF-κB transcriptional response 
leading to the induction of a variety of NF-κB target genes, including DR5, which 
subsequently re-sensitised otherwise resistant cells to TRAIL-induced apoptosis. 
To gain a more dynamic insight into the NF-κB activation kinetics in DAPK2-
depleted cells and gain further insight into the mechanisms upstream of such 
activation, a series of experiments were carried out using the death inducing 
ligand TNF. Besides activating the MAPK pathway and inducing extrinsic 
apoptosis, the third main pathway initiated by TNF-α is the activation of NF-κB 
(Wajant et al., 2003). As neither U2OS nor A549 were sensitive (or could be 
sensitised) to TNF-α-induced cell death by silencing DAPK2 (Figure 4-2), TNF-α 
was used to induce NF-κB signalling and study the effect of DAPK2 knockdown 
on the latter. Briefly, activation of NF-κB through TNF-α occurs as follows: IκBα 
inhibits NF-κB signalling by masking the nuclear localisation sequence of NF-κB 
transcription factors and thereby inhibiting nuclear translocation and DNA binding 
(Perkins, 2000). Downstream processes upon binding of TNF-α to TNFR1 
remove this blockage (Pahl, 1999). Ligation of TNF-α to TNFR1 induces a 
conformational change in the intracellular domain of the receptor; leading to the 
recruitment of TRADD to its death domain. TRADD functions as an adaptor 
molecule for the binding of TRAF2 and RIPK1 (Hsu et al., 1996a, Hsu et al., 
1996b). TRAF2 is needed for the recruitment of the IκB kinase (IKK) complex, 
whereas RIPK1 activates the IKKs by phosphorylation (Devin et al., 2000). The 
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activated IKK complex subsequently phosphorylates IκBα, induces its 
proteasomal degradation and activates NF-κB (Karin, 1999). 
 
U2OS and A549 cells were transfected with either siNS or siDAPK2 as described 
before, treated with TNF-α for varying periods of time as indicated, and proteins 
were extracted and separated on a polyacrylamide gel. Western blot membranes 
were subsequently probed with antibodies specific to NF-κB key molecules 
known to be activated downstream of TNF-α. The results for U2OS cells and 
A549 cells are shown in Figure 5-11 (a + b), respectively, and are very similar in 
both cell lines. Transfection of U2OS or A549 with siDAPK2 caused a decrease 
of IκBα protein levels, and to the activation of NF-κB. The reduction of IκBα was 
already detectable independently of any stimulation with TNF-α, in untreated 
samples transfected with siDAPK2 when compared to cells transfected with a 
non-targeting siRNA control. However, de novo synthesis of IκBα was also 
reduced in response to TNF-α, (compare the TNF-α 30 min and 120 min time 
point with and without siDAPK2). It must be pointed out that DAPK2 and IκBα 
have very similar sizes. As the DAPK2 blot was done after the WB membranes 
were probed for IκBα, the signal from the IκBα antibody was still picked up when 
the membranes were re-probed for DAPK2. As described earlier (Figure 5-6e + 
f) absence of DAPK2 lead to increased baseline phosphorylation of RELA on 
S536. This was clearly independent of TNF-α, which in A549 cells was only 
visible after a long exposure of the WB (Figure 5-11b). Comparing the 120 min 
time point of TNF-α stimulation in siNS and siDAPK2 cells, the phosphorylation 
of RELA S536 in DAPK2-depleted cells was slightly increased, hinting towards a 
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prolonged activation of RELA S536 phosphorylation in DAPK2-depleted cells. 
Changes in total RELA levels in response to TNF-α, especially visible in A549 
cells (Figure 5-11b), were unlikely to be caused by protein degradation as the 
timeframe here would be too short. More likely, the signal for phosphorylated 
RELA in A549 cells was so strong that it was difficult to fully strip the membrane 
and masked the RELA signal when the membrane was re-probed for total RELA. 
Furthermore, no changes in the total levels of IKK-α, part of the IKK complex 
were observed in either U2OS, or A549 cells. Taken together, it seemed that 
DAPK depletion led to chronic phosphorylation of RELA S536, independent of 
extrinsic NF-κB activation, which was accompanied by a chronic degradation of 
IκBα. 
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Figure 5-11. Effect of DAPK2 depletion on molecular NF-κB signalling events 
downstream of TNF-α  stimulation. 
U2OS (a) and A549 (b) cells were transfected with siNS and siDAPK2. Forty-eight h later, cells 
were treated with TNF-α (10 ng/ml) for the indicated time points. NF-κB signalling events were 
assessed by SDS-PAGE/western blotting. IκBα degradation, levels of RELA pS536 and total 
RELA used as readouts. Knockdown of DAPK2 was confirmed by SDS-PAGE/western blotting. 
HSP90 served as loading control. Blots shown are representative of two independent 
experiments. I am grateful to Ms Maria M. Misterek for her contribution to these western blots. 
 
5.2.9 Effect of DAPK2 overexpression on the activation of NF-κB by TNF-α 
 
The absence of DAPK2 led to a chronic decrease of IκBα and subsequently 
chronic increase of RELA S536 phosphorylation independent of extrinsic NF-κB 
stimulants. To shed further light into the role of DAPK2 in the regulation of NF-κB 
tetracycline-inducible U2OS cells, which contained either wild-type (HA-
DAPK2.wt) or kinase-dead DAPK2 (HA-DAPK2.K42A) constructs were 
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generated. We wanted to assess whether overexpression of DAPK2 led to the 
opposite phenotype observed after DAPK2 knockdown. As DAPK2 is a protein 
kinase we also wanted to assess whether over-expression of a kinase mutant 
DAPK2, a so-called dominant-negative protein, would mimic the effect of DAPK2 
siRNA on NF-κB. Single cell clones for DAPK2 wt and kinase-dead were 
produced as described in detail in 3.2.2. The expression of DAPK2 constructs 
was induced with DOX 24 h prior to the exposure to TNF-α. Treatment with TNF-
α for varying periods of time was performed as indicated. Western blot 
membranes were subsequently probed with antibodies specific to NF-κB key 
molecules known to be activated downstream of TNF-α. Wild-type DAPK2 was 
successfully overexpressed upon treatment with DOX with no leaky expression of 
HA-DAPK2 present in untreated cells (Figure 5-12a). Overexpression of DAPK2 
without TNF-α stimulation seemed to slightly decrease basal levels of IκBα 
protein expression (compare 0 min time point of TNF-α stimulation - and + DOX 
treatment). More pronounced was the effect of DAPK2 overexpression on the 
phosphorylation of RELA S536. When DAPK2 was present in excess, TNF-α 
induced phosphorylation of RELA S536 was dampened (compare 5 min and 30 
min time point of TNF-α stimulation - and + DOX treatment). Total levels of RELA 
remained unaffected and visible differences were most likely caused by 
antibodies for phosphorylated RELA masking the total RELA signalling.  
 
As for the U2OS TetR cells overexpressing wild-type DAPK2, kinase-dead 
DAPK2 was successfully overexpressed upon DOX stimulation and no 
background expression was detectable (Figure 5-12b). Similarly to U2OS cells 
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transfected with siDAPK2 (Figure 5-11a), an increased baseline phosphorylation 
of RELA S536, independent of TNF-α stimulation, was observed. 
Overexpression of kinase-dead DAPK2 did not exert a significant impact on the 
kinetics of RELA S536 phosphorylation. Interestingly, basal IκBα protein levels 
remained unaffected upon overexpression of kinase dead DAPK2, whereas after 
120 min of TNF-α stimulation the IκBα de novo synthesis appeared delayed, with 
is consistent with data obtained in the absence of DAPK2 (Figure 5-11a + b). 
Taken together, overexpression of wild-type DAPK2 dampened TNF-α mediated 
activation of NF-κB, as assessed by using phosphorylation of RELA S536 as a 
readout. When overexpressed, kinase-dead DAPK2 induced basal 
phosphorylation of RELA S536, as seen after siRNA-mediated depletion of 
DAPK2. However, the effect on IκBα was less pronounced in these cells than in 
cells depleted of DAPK2 after RNAi. Thus, the overexpression of wild-type 
DAPK2 inhibited the activation of NF-κB, whereas overexpression of kinase-dead 
DAPK2 partially mimicked the results obtained by knocking down DAPK2, 
leading to the phosphorylation of RELA S536. !  
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Figure 5-12. Overexpression of wild-type and kinase dead DAPK2 affects NF-κB 
signalling events downstream of TNF-α  stimulation. 
U2OS TetR HA-DAPK2.wt (wild type) (a) and U2OS TetR HA-DAPK2.K42 (kinase dead) (b) 
cells were stimulated with transfected with doxycycline (DOX) (10 ng/ml). Twenty-four h later, 
cells were treated with TNF-α (10 ng/ml) for the indicated time points. NF-κB signalling events 
were assessed by SDS-PAGE/western blotting. IκBα degradation, levels of RELA pS536 and 
total RELA were used as readouts. Overexpression of HA-DAPK2 was confirmed by SDS-
PAGE/western blotting. HSP90 served as loading control. Blots shown are representative of 
three independent experiments. I am grateful to Ms Maria M. Misterek for her contribution to 
these western blots. 
 
So far, all data provided evidence for cross-talk between NF-κB and DAPK2, with 
the lack of DAPK2 leading to basal activation of NF-κB (Figure 5-11) and DAPK2 
overexpression suppressing NF-κB signalling (Figure 5-12a). To analyse the 
effect that NF-κB activation had on the expression levels of DAPK2, U2OS and 
A549 cells were incubated with TNF-α to induce the activation of NF-κB, as 
before. The effect of NF-κB activation on DAPK2 protein levels was studied over 
a time period of up to 72h. The levels of DAPK2 in U2OS cells were greatly 
decreased after 72 h of stimulation with TNF-α (Figure 5-13a), whereas in A549 
cells a strong reduction of DAPK2 levels was already detectable after a period of 
48 h (Figure 5-13b). These results should be considered preliminary as the 
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experiment was only carried out once. Taken at face value though, the results 
suggested, that DAPK2 was directly affected in response to the activation of NF-
κB by TNF-α and lent further support to the concept that DAPK2 is a novel 
inhibitory protein for activation of NF-κB. 
 
The founding member of the DAPK-family has been associated with various 
types of induced cell death and it has been found to be directly associated with 
the TNF-α receptor TNFR1, the adaptor molecule TRADD and, more 
interestingly, with the adaptor molecule FADD, which plays an important role in 
TRAIL-induced apoptosis (Henshall et al., 2003). DAPK2 has only been 
described to directly interact with transforming growth factor β receptor 1 
(TGFBR1). To assess the possibility of a direct interaction between DAPK2 and 
the TRAIL receptor DR5, co-immunoprecipitation was performed. Due to the lack 
of suitable DAPK2 antibodies, expression of HA-tagged DAPK2 was induced in 
U2OS TetR HA-DAPK2.wt cells and HA-DAPK2 was precipitated using beads 
covalently coupled to an anti-HA antibody. Membranes were probed with a DR5 
antibody (rabbit), revealing an interaction between DAPK2 and DR5 (Figure 
5-14, compare lane five - DOX with lane six + DOX). As a control, membranes 
were additionally probed with a HA-specific mouse antibody, showing the specific 
induction and precipitation of HA-DAPK2 in DOX-treated cells.  
 
Taken together these data suggest that DAPK2 was likely to play an important 
role in the regulation of NF-κB signalling, as its downregulation induced the 
activation of NF-κB upstream of IκBα and its overexpression clearly inhibited the 
activation of RELA in response to TNF-α-induced NF-κB. Moreover, the 
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overexpression of a kinase-dead DAPK2 partially mimicked knocking down 
DAPK2, as it also led to the basal phosphorylation of RELA. DAPK2 itself was 
clearly downregulated upon chronic activation of NF-κB, supporting the 
hypothesis of DAPK2 functioned as an upstream inhibitor of NF-κB signalling. 
The direct interaction with DR5 suggested that DAPK2 might interact with 
upstream modulators of TRAIL-induced apoptosis and/or activators of NF-κB.  
 
Figure 5-13. Effect of prolonged TNF-α  stimulation on DAPK2 stability. 
U2OS (a) and A549 (b) cells were treated with TNF-α (10 ng/ml) for the indicated time points. 
Levels of DAPK2 in response to TNF-α stimulation were assessed by SDS-PAGE/western 
blotting. HSP90 served as loading control. The experiment was performed once. 
 
 
 
Figure 5-14. DAPK2 directly interacts with DR5. 
U2OS TetR HA-DAPK2.wt cells were treated with doxycycline (DOX) at a concentration of 10 
ng/ml to induce the expression of HA-DAPK2. Twenty-four h later, cells were lysed and 
incubated overnight with either beads that were covalently bound to anti HA antibodies or 
uncoupled beads. The next day input samples (1/10 of the pull down) and pull down samples 
were assessed by SDS-PAGE/western blotting. The membrane was subsequently probed with 
DR5 and anti-HA antibodies. HSP90 served as loading control for the input samples. Blots 
shown are representative of two independent experiments. 
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5.3 Discussion 
 
In Chapter 4. it was shown that the depletion of DAPK2 by RNAi sensitised 
resistant cancer cell lines to TRAIL-induced apoptosis, but not to a wide variety of 
other death stimuli. It was additionally shown that the sensitising effect was due 
to the upregulation of DR5 and, in some cell lines, also DR4. Moreover, DAPK2 
knockdown induced the expression of FasR and it sensitised U2OS cells to FasL-
induced cell death.  
 
Induction of all these receptors both at the mRNA and protein level led to the 
hypothesis that a common transcription factor was likely activated in response to 
DAPK2 knockdown and that this was responsible for inducing the transcription of 
DR4, DR5 and FasR. The transcription factor p53, as well as the NF-κB-family of 
transcription factors have both been described to be involved in the transcription 
of DR4, DR5 and FasR. To gain further insight into the mechanisms of siDAPK2-
mediated sensitisation to TRAIL-induced apoptosis, we focused on the role of 
p53 and the NF-κB transcription factors. It has been previously described that 
DRs cannot only be induced through increased transcription but also via mRNA 
stabilization (Kandasamy and Kraft, 2008) or increased protein stability (Jung et 
al., 2010). DR induction leads to an increase of the number of receptor molecules 
on the cell surface thus overcoming the threshold required to sensitise cells to 
TRAIL cytotoxicity. As U2OS cells do not express DR4 and silencing DAPK2 led 
to the upregulation of DR5 in both U2OS and A549 cells (Figure 4-8), we 
focused on the regulation of DR5 induction/expression upon DAPK2 depletion. 
Using classical biochemical assays we were able to show that depletion of 
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DAPK2 did not increase the mRNA (Figure 5-1b + c) or protein (Figure 5-1e + f) 
stability of DR5. However, DR5 and DR4 mRNAs were elevated after silencing 
DAPK2 (Figure 4-7), suggesting that inhibition of DAPK2 led to the 
transcriptional regulation of DRs. As mentioned earlier, the well-studied DR5 
receptor gene is regulated by a variety of transcription factors, such as p53 and 
NF-κB. We discovered that DAPK2 knockdown did not lead to a transcriptional 
induction of p53 mRNA. However, the cell cycle regulator p21 (CIP1/WAF1), one 
of the most studied and immediate transcription targets of p53 often used as a 
readout for p53 activation (Macleod et al., 1995), was upregulated when DAPK2 
was silenced (Figure 5-2a + b). The fact that DAPK2 silencing could also 
sensitise p53-mutated T24 colon cancer cells and p53-null prostate cancer PC3 
cells argues against the absolute requirement for p53 (Figure 5-3). However, it 
has been shown that the functions of p53-transcription factor family members 
p63 and p73 have certain redundancies with p53.  Isoforms of p73 and p63 have 
also been shown to induce apoptosis in response to DNA damage (Ramadan et 
al., 2005, Petitjean et al., 2008) and both are capable of inducing p21 
(CIP1/WAF1) (Levrero et al., 2000). Furthermore it has been shown that p21 can 
also be activated by NF-κB (Basile et al., 2003). We therefore focused on the 
activation of NF-κB upon DAPK2 depletion. Using NF-κB luciferase reporter 
assays it was shown that NF-κB is transcriptionally active in response to DAPK2 
knockdown (Figure 5-4). This is interesting, as NF-κB plays an ambiguous role in 
TRAIL signalling. For example, there are reports suggesting an anti-apoptotic 
role for NF-κB, involving the up-regulation of the DcR1 (Bernard et al., 2001), or 
of anti-apoptotic BCL-XL (Zender et al., 2005), whereas other reports suggest a 
pro-apoptotic role due to the induction of DR4 or DR5 (Mendoza et al., 2008, 
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Shetty et al., 2005). Interestingly, binding of TRAIL to DcR2, that contains a 
truncated DD, has been shown to activate NF-κB, which then initiates a negative 
feedback loop protecting cells from TRAIL-induced apoptosis (Degli-Esposti et 
al., 1997a). NF-κB signalling is highly complex and different members assemble 
in different dimers that then participate in canonical and non-canonical signalling 
pathways. Canonical pathways have been described to involve NF-κB1 
(p105/p50) and RELA (p65) and the non-canonical pathway is thought to involve 
primarily NF-κB2 (p100/p52) and RELB. Distinction between these pathways is 
not absolute and much depends on the cellular environment and specific cell type 
(Tergaonkar, 2006). Further analyses using qPCR and SDS-PAGE/western 
blotting revealed that components of the canonical (RELA and NF-κB1) as well 
as components of the non-canonical (NF-κB2) pathways were transcriptionally 
upregulated upon DAPK2 depletion in both cell lines studied (Figure 5-5). RELA, 
an important factor of the canonical NF-κB activation was found to be 
consistently phosphorylated in response to RNAi-mediated DAPK2 depletion. 
Proteolytic processing of NF-κB1 p105 to NF-κB1 p50 seemed to be unaffected 
in U2OS cells (Figure 5-6a) but was slightly increased in A549 cells (Figure 
5-6b). NF-κB1 p100 was found to be significantly processed in both cell lines 
studied (Figure 5-6c + d). Overall, DAPK2 depletion induced the activation of 
NF-κB-family transcription factors without specifically activating the canonical or 
non-canonical signalling branch. Further analysis of NF-κB target genes, that 
have previously been used as readouts for NF-κB activation, revealed a 
differential expression upon DAPK2 knockdown in U2OS compared to A549 
cells. TNF-α and SOD2, however, were induced in both cell lines. Interestingly, c-
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JUN, which has often been found to be co-activated with NF-κB was also 
induced after DAPK2 silencing (Figure 5-7) 22, 45. To unravel the complex role of 
NF-κB in TRAIL signalling, we then performed double knockdown experiments 
(Figure 5-8 and Figure 5-9). By analysing the effect of TRAIL on U2OS and 
A549 cells transfected with siRNA targeting DAPK2 concomitantly with siRNAs 
directed against NF-κB family members, we identified NF-κB1 as key molecules 
responsible for a sensitisation to TRAIL-induced apoptosis in response to DAPK2 
depletion (Figure 5-8a + b). Interestingly, in A549 cells, knockdown of NF-κB2 
and RELB in combination with DAPK2 also resulted in a partial rescue. 
Remarkably, RELA (p65), which was consistently phosphorylated on S536, did 
not seem to be involved in the siDAPK2 mediated sensitisation to TRAIL (Figure 
5-8e, Figure 5-9e). It thus appears that U2OS cells require mainly the activation 
of the NF-κB canonical pathway, whereas A549 cells require the activation of 
both the canonical and non-canonical pathways. It is still unclear why this is, but 
it is fair to assume that, due to distinct cellular environments in these two cell 
lines, silencing DAPK2 leads to the formation of different NF-κB dimers which are 
nevertheless capable of resulting in an identical biological response, namely 
upregulation of DR5. As described in Chapter 4, the fact that A549 seems to also 
require BID to be fully sensitised to TRAIL after DAPK2 silencing may be related 
to the partial requirement for NF-κB2/RELB. It is also possible that NF-κB2 
and/or RELB are required to induce DR4, which is not expressed in U2OS cells. 
In 2005, Shetty and colleagues characterised the specific NF-κB binding site in 
the first intron of the DR5 gene. Indeed, using DR5 promoter luciferase 
constructs with either wild type or mutated NF-κB consensus sites (Figure 5-10a) 
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we established the necessity of NF-κB as a transcription factor required for the 
induction of DR5 in response to DAPK2 depletion (Figure 5-10c + g). Recently, 
Yoo and colleagues have suggested that DAPK1 can function as a repressor for 
NF-κB activation (Yoo et al., 2012). Additionally, NF-κB activation downstream of 
T cell receptor signalling is increased in DAPK1 knockout T cells (Chuang et al., 
2008). Moreover, DAPK1 has been found to interact with the TNF-α receptor 
TNFR1 (Henshall et al., 2003), NEMO [also known as inhibitor of nuclear factor 
kappa-B kinase subunit gamma (IKK-γ)] (Fenner et al., 2010) and the adaptor 
molecule FADD, which plays a crucial role in TRAIL-induced apoptosis (Henshall 
et al., 2003). As all DAPK family members are thought to form multi-protein 
complexes (Gozuacik and Kimchi, 2006), the activation of NF-κB proteins upon 
DAPK2 knockdown is likely to be caused by at least some of the same molecular 
events described for DAPK1. DAPK2 has only been described to directly interact 
with TGFBR1. Here, we showed that DAPK2 directly interacts with the TRAIL-
receptor DR5 (Figure 5-14), which immediately suggests the possibility that 
DAPK2 may be part of a multi-protein complex influencing signalling downstream 
of DRs.  
 
Interestingly, Yukawa and co-workers (Li et al., 2004) showed, using a high 
concentration of siDAPK1, that downregulation of DAPK1 in endometrial cancer 
cells led to cell death. They hypothesised that this was due to the induction of 
TRAIL, DR4 and DR5 mRNAs. In contrast to their findings for DAPK1, we did not 
observe an induction of TRAIL (Figure 5-7) or DcR expression (Figure 4-7), nor 
did we observe apoptosis 48 h post-siDAPK2 transfection. What we did observe 
after knocking down DAPK2, as they did for DAPK1, was the upregulation of DR4 
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and DR5, depended on the activation of NF-κB and on the integrity of NF-κB1 
proteins (p50 and p105). Overall these observations suggests that DAPK2 is a 
potential novel modulator of NF-κB signalling, possibly associated with the multi-
protein complex downstream of TNFR family members. The proposed model is 
depicted in Figure 5-15.   ! !
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Figure 5-15. DAPK2 is a novel modulator of TRAIL-induced apoptosis. 
Death receptor ligation by TRAIL primarily activates the extrinsic apoptotic pathway. TRAIL 
binding induces DISC formation. Activation of the initiator Caspases-8/10 leads to proteolytic 
cleavage and activation of downstream effector caspases, such as Caspase-3, which 
eventually culminates in apoptosis. TRAIL can also activate the intrinsic apoptotic pathway via 
BID. This involves depolarisation of the mitochondrial membrane potential via BAK and BAX, 
followed by cytochrome c release and downstream activation of Caspase-9. Resistance 
mechanisms can occur at many different stages of the cascade. c-FLIP can inhibit the 
activation of initiator caspases within the extrinsic pathway, XIAP can block the action of 
effector caspases and anti-apoptotic members of the BCL-2 family, such as BCL-XL and BCL-
2, which are known inhibitors of the intrinsic apoptosis pathway. Depletion of DAPK2 triggers 
the activation of NF-κB and leads to NF-κB-mediated induction of DR5 mRNA and to an 
increase in DR5 protein levels. The increase in the number of DR5 molecules presumably 
overcomes the inhibition threshold and lead to the re-sensitisation of cancer cells to TRAIL-
induced apoptosis. 
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6.1 Introduction 
 
DAPK2 shares a high level of homology within its kinase domain with the other 
two DAPK family members, DAPK1 and DAPK3 (Figure 1-9). DAPK1 has been 
linked to key events in autophagy and it has been, more recently, implicated in 
mitochondrial maintenance (Shang et al., 2005) and metabolism (Mor et al., 
2012). As described earlier, DAPK2 is significantly smaller than DAPK1 and it 
lacks the ankyrin repeats region, the cytoskeletal binding domain and the death 
domain, all of which are part of DAPK1’s unique protein structure (Deiss et al., 
1995). Several biological roles and functions have been ascribed to DAPK2 and, 
perhaps surprisingly, they often coincide with those of DAPK1. Indeed, it would 
appear that, like DAPK1, DAPK2 is also involved in the formation of autophagic 
vesicles (Cohen et al., 1997, Inbal et al., 2002), modulation of receptor induced 
cell death (Inbal et al., 2000, Lin et al., 2007) and several modes of intrinsic 
apoptotic cell death(Inbal et al., 2002). Whereas epigenetic silencing of DAPK1 
has been reported in many different human cancers (Esteller et al., 2001, 
Katzenellenbogen et al., 1999), DAPK2 appears to be silenced mainly in 
haematological disorders (Rizzi et al., 2007). Most approaches used for studying 
the role of DAPK2 have, so far, relied on using tagged versions of this molecule 
and it is, therefore, still unclear whether these functions are also carried out by 
the native protein, when DAPK2 is expressed at much lower, endogenous, levels 
(Further discussed in 1.8.1.)  
 
DAPK1 has been shown to regulate mitochondrial integrity and to modulate the 
mitochondrial membrane potential (Shang et al., 2005) but, to the best of our 
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knowledge, no work has been carried out in this respect with regards to DAPK2. 
Since DAPK1 and DAPK2 appear to share many functions and both are thought 
to reside, at least partially, in the mitochondria, we hypothesised that DAPK2 
depletion was also likely to regulate mitochondrial metabolism, which may also 
explain how silencing DAPK2 leads to NF-κB activation (Chapter 5.). 
Mitochondrial dysfunction is characterised by the induction of ROS in the cell 
(Turrens, 2003). Ultimately, dysfunctional mitochondria can no longer be 
powerhouses of use to the cell and are, therefore, targeted for degradation. 
Alternatively, their membrane can depolarise leading to the release of 
cytochrome c, which is part of a well-studied apoptotic process (Liu et al., 1996). 
As in previous chapters, depletion of DAPK2 through RNAi was carried out in 
both U2OS osteosarcoma and A549 NSCLC cells. In DAPK2-depleted cells there 
was an increase in the levels of intracellular ROS, such as peroxide (H2O2) and 
superoxide anion (O2•-), mitochondrial depolarisation and severely impaired 
mitochondrial metabolism. The data thus suggested that DAPK2 exerted 
metabolic and mitochondria-regulating functions, which have not been described 
to date and that, can explain why this kinase is downregulated in several 
haematological malignancies (Humbert et al., 2014, Rizzi et al., 2007, Tur et al., 
2009).  
 
6.2 Results  
6.2.1 RNAi-mediated ablation of DAPK2 induces oxidative stress and 
activates mitogen-activated protein kinases (MAPKs) 
 
Although DAPK2 is structural significantly different from DAPK1, their kinase 
domains are highly homologous (80%) (Bialik and Kimchi, 2006) (Figure 1-9). In 
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order to determine whether DAPK2 modulated the level of cellular oxidative 
stress in U2OS and A549 cells were transfected as in previous chapters. 
Oxidative stress was studied by flow cytometry in cells transfected with siNS, 
siDAPK2 or challenged with H2O2, which was used as a positive control for the 
production of ROS. General oxidative stress was analysed using the 
chloromethyl 2',7'-dichlorodihydrofluorescein diacetate (CM-H2DCFDA, 
henceforth referred to as DCFDA) probe (Figure 6-1a + b and e + f) and 
superoxide production was assessed using the dihydroethidium (DHE) probe 
(Figure 6-1c + d and g + h). The fluorescence of cells transfected with siDAPK2 
or treated with H2O2 was compared to that of control cells (siNS). The histograms 
depict typical cell profiles obtained in each experiment and the bar charts on the 
right conglomerate mean percentage of fluorescence normalised to control cells 
± SEM from three independent experiments. Both DAPK2 depletion and H2O2 
treatment resulted in an increase in general oxidative stress in U2OS (Figure 
6-1a + b) and A549 (Figure 6-1e + f) cells. The same was observed with regards 
to the generation of superoxide, which was elevated upon siDAPK2 depletion 
and upon treatment with H2O2 in both U2OS (Figure 6-1c + d) and A549 cells 
(Figure 6-1g + h). 
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Figure 6-1. Depletion of DAPK2 induces oxidative stress. 
U2OS (a - d) and A549 (e - h) cells were transfected with either siNS, or DAPK2 siRNA for 48 
h and oxidative stress was detected by flow cytometry. Cells were also treated with H2O2 (0.5 
mM, 24 h), which was used as a positive control for ROS production. The DCFDA probe was 
used to detect general ROS in U2OS (a + b) and A549 cells (e + f), whereas O2•- anions were 
detected in U2OS (c + d) and A549 cells (g + h) using the DHE probe. Staining intensity was 
quantified using geometric means of three independent experiments and plotted as fold change 
in relation to the siNS-transfected cells. Statistical analysis was done using Student’s t-test 
(paired, one tailed) (* p< 0.05, ** p<0.01).  
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Having observed a clear induction of ROS (H2O2 and O2•-) upon silencing 
DAPK2, we asked whether this led to the activation of mitogen-activated protein 
kinases (MAPKs), which are known to be activated by oxidative stress as part of 
a pro-survival response (Son et al., 2013). Therefore, U2OS and A549 cells were 
transfected with either siNS or with siDAPK2, proteins were extracted and then 
analysed by SDS-PAGE. Quantitative western blots in Figure 6-2 confirmed the 
efficiency of the knockdown of DAPK2 in U2OS (Figure 6-2a) and A549 (Figure 
6-2c) cells, when compared to the control siNS-transfected cells. Western blot 
membranes were also probed with antibodies raised against the phosphorylated 
forms of ERK1/2, p38 and JNK. Depletion of DAPK2, when compared to the siNS 
control, led to clear phosphorylation/activation of ERK1/2 (Thr202/Tyr204) and 
JNK (Thr183/Tyr185) in U2OS and A549 cells, whereas phosphorylation of p38 
(Thr180/Tyr182) was only observed in U2OS cells but not in A549 lung cancer 
cells (Figure 6-2a versus c). Superoxide anion (O2•−) is a potentially damaging 
free radical, which is converted into less reactive hydrogen peroxide (H2O2) by 
enzymes of the superoxide dismutase (SOD) family. To analyse the effect of 
DAPK2 depletion on the expression of SOD1, which is the predominant 
cytoplasmic SOD, and mitochondrial SOD2, cells were transfected as before and 
RNA was subsequently extracted. There was significant, albeit small (<1.5-fold), 
up-regulation of both SOD1 and SOD2 mRNA in U2OS cells (Figure 6-2b). In 
contrast, in A549 cells, SOD1 mRNA was not induced but SOD2 mRNA was 
greatly increased (>4-fold) (Figure 6-2d).  
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Figure 6-2. DAPK2 depletion induces phosphorylation of MAPKs and transcription of 
SODs. 
U2OS (a - b) and A549 (c - d) cells were transfected with either siNS, or DAPK2 siRNA. Forty-
eight h after transfection, the efficacy of DAPK2 silencing and phosphorylation of ERK1/2, JNK 
and p38 were assessed by SDS-PAGE/western blotting using Lamin B and HSP90 as loading 
controls (a, c), and the induction of SOD1 and SOD2 mRNA was measured by qPCR (b, d). 
Data represent mean ± SEM of three independent experiments. Statistical analyses were done 
using Student’s t-test (paired, one tailed) (* p< 0.05). I am grateful to Ms Marina L. Georgiou for 
her contribution to the western blots and Ms Sarah Stöcker for performing the qPCR 
experiments. 
 
6.2.2 DAPK2 knockdown increases the levels of mitochondrial O2•− and 
leads to spontaneous mitochondrial membrane depolarisation  
 
Silencing DAPK2 in two different cell lines led to up-regulation of cellular ROS, 
activation of MAPKs and upregulation of mitochondrial SOD2, whereas SOD1 
was only slightly upregulated in one of the cell lines (U2OS). We, therefore, 
asked whether the source of oxidative stress were mitochondria. Indeed, the 
production of ATP by oxidative phosphorylation is a major source for 
mitochondrial ROS, and mitochondrial proton and electron leaks can impact on 
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mitochondrial coupling efficiency and lead to increased production of 
mitochondrial ROS (Balaban et al., 2005). MitoSOX™ Red was used to assess 
mitochondrial O2•− levels since it selectively targets mitochondria and is 
exclusively oxidised by O2•− (Figure 6-3). Cells were transfected as before and 
treatments with H2O2 or the mitochondrial complex I inhibitor 1-methyl-4-
phenylpyridinium (MPP+) iodide served as positive controls for the experiment. 
Unsurprisingly, treatment of U2OS (Figure 6-3a) and A549 cells (Figure 6-3d) 
with either H2O2 or MPP+ increased the levels of mitochondrial O2•−. As 
hypothesised, RNAi-mediated depletion of DAPK2 resulted in a small but 
statistically significant increase of mitochondrial O2•− in U2OS (Figure 6-3b + c) 
and A549 cells (Figure 6-3e + f) compared to siNS-transfected control cells. 
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Figure 6-3. DAPK2 knockdown triggers mitochondrial O2•− production. 
U2OS (a - c) and A549 (d - f) cells were transfected with either siNS, or DAPK2 siRNA. Forty-
eight h later, mitochondrial O2•− levels were assessed using the MitoSOX™ Red probe.  U2OS 
(a) and A549 (d) cells were also treated with H2O2 (0.5 mM) or MPP+ (1 mM) for 24 h, which 
were used as positive controls. The average of geometric means of four independent 
experiments was plotted as fold change (siNS versus siDAPK2) (c, f). Statistical analysis was 
done using Student’s t-test (paired, two tailed) (* p< 0.05). 
 
Another potential source for cellular ROS is the endoplasmic reticulum (ER) 
where the transcription factor CCAAT-enhancer-binding protein homologous 
protein (CHOP) is specifically activated upon ER stress (Nishitoh, 2012). 
Tunicamycin was used to induce ER stress (Kaufman, 1999), which triggered the 
expression of CHOP in both U2OS (Figure 6-4a) and A549 cells (Figure 6-4b). 
In contrast, DAPK2 knockdown did not lead to an increase in CHOP expression 
in either of the cell lines (Figure 6-4a + b).  
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Figure 6-4. Depletion of DAPK2 does not induce the expression of CHOP. 
U2OS (a) and A549 (b) cells were transfected with either siNS, or DAPK2 siRNA. Forty-eight h 
later, ER stress was assessed by SDS-PAGE/western blotting using CHOP expression as a 
readout. The induction of CHOP protein following treatment with tunicamycin for 24 h (0.5 
µg/ml) served as positive control for CHOP induction and HSP90 expression was used as a 
loading control. Blots shown are representative of three independent experiments. 
 
It is thought that elevated levels of mitochondrial O2•− can be both a cause and a 
consequence of mitochondrial depolarisation (Wang et al., 2012b), which is 
involved in apoptosis and inflammation(Lum and Nagley, 2003, Heiskanen et al., 
1999). To study the effect of DAPK2 depletion on mitochondrial membrane 
potential (Δψm), the JC-1 probe, which forms red fluorescing aggregates at 
hyperpolarized mitochondrial membranes and green-fluorescing monomers at 
depolarised membranes, was used. U2OS and A549 cells were transfected with 
either siNS, or siDAPK2 and, as a control for Δψm depolarisation, cells were 
treated with carbonyl cyanide 3-chlorophenylhydrazone (CCCP), and then 
analysed by flow cytometry (Figure 6-5c + e and i + k). By gating the depolarised 
population that resulted from CCCP treatment, two distinct populations were 
identified: one with intact mitochondria and another that exhibited increased 
green fluorescence and thus harboured cells with depolarised mitochondria. 
Depletion of DAPK2 led to approximately 50% more depolarised mitochondria in 
both U2OS (Figure 6-5a + b) and A549 cells (Figure 6-5g + h), when compared 
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to siNS-transfected control cells. This pattern can also be seen in histograms 
measuring fluorescence in the green channels (FITC, ~525 nm) (Figure 6-5d + e 
and j + k). After normalising the absolute fluorescence of cells upon DAPK2 
knockdown to that of siNS-transfected cells and applying appropriate statistical 
analyses (detailed in figure’s legend), a significant overall increase in green 
fluorescence, a read-out for decreased Δψm, was measured in both cell lines 
(Figure 6-5f + l), suggesting that DAPK2 ablation led to an increase in 
mitochondria spontaneously depolarising. !  
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Figure 6-5. RNAi-mediated ablation of DAPK2 increases the rate of spontaneous 
mitochondrial membrane depolarisation. 
U2OS (a - f) and A549 (g - l) cells were transfected with either siNS, or siDAPK2. Forty-eight h 
after transfection cells were incubated with JC-1 and the fluorescence of J-aggregates, or 
monomers was measured in red and green fluorescence channels by flow cytometry. CCCP 
(50 µM) was used to induce complete mitochondrial depolarisation (c, i) and to set appropriate 
gates in U2OS (a - c) and A549 cells (g - i) used for the quantification of mitochondrial 
depolarisation following transfection with siNS (a, g), or siDAPK2 (b, h). Overall green 
fluorescence (FITC) data are also presented in histograms (U2OS: d, e; A549: j, k). Staining 
intensity was quantified using geometric means of three independent experiments and plotted 
as fold change (f, l). Data represent mean ± SEM of three independent experiments and the 
statistical analysis was done using Student’s t-test (paired, one tailed) (* p< 0.05).  
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Activation of DAPK1 has been linked to a decrease in Δψm upon treatment with 
mitochondrial complex inhibitors (Shang et al., 2005). As shown in Figure 6-6, 
when compared to cells transfected with the non-targeting control (siNS), A549 
cells depleted of DAPK2 had reduced DAPK1 phosphorylated on S308, which is 
an inactivating phosphorylation event that modulates DAPK1 activity.  
 
 
Figure 6-6. Depletion of DAPK2 reduces the phosphorylation of DAPK1. 
A549 cells were transfected with either siNS, or DAPK2 siRNA. Forty-eight h later, DAPK1 
phosphorylation was assessed by SDS-PAGE/western blotting. When compared to cells 
transfected with siNS, DAPK2-depleted A549 cells were less phosphorylated on DAPK1 S308, 
which is an inactivating phosphorylation event that modulates DAPK1 activity. Blots shown are 
representative of three independent experiments. I am grateful to Ms Maria M. Misterek for her 
contribution to this experiment. 
 
This suggested that silencing DAPK2 led to the activation of DAPK1. 
Interestingly, U2OS cells did not express DAPK1 protein or mRNA (as described 
in 4.2.1, Figure 4-1), which suggested that although the depolarisation of 
mitochondria in A549 cells might be associated with activation of DAPK1, in 
U2OS cells the observed reduction in Δψm was likely due to another molecular 
event. 
 
6.2.3 Altered mitochondrial integrity leads to metabolic changes 
 
The increase in mitochondrial O2•− production and the increase in spontaneous 
mitochondrial depolarisation suggested that mitochondria were a likely source of 
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ROS generated upon DAPK2 knockdown. The data were consistent with a 
significant impairment of mitochondrial integrity in response to DAPK2 depletion 
and, in the case of A549 lung cancer cells, activation of DAPK1. The metabolic 
consequences of these mitochondrial alterations in DAPK2-depleted U2OS and 
A549 cells were, therefore, investigated next.  
 
Eukaryotic cells use two key metabolic pathways for the generation of ATP 
(Figure 1-11). Both pathways start with glycolysis as the first step of glucose 
metabolism, converting one glucose molecule into two molecules of pyruvate with 
gain of two ATP molecules. Aerobic respiration involves the transport of pyruvate 
into the mitochondria and mitochondrial respiration downstream of glycolysis 
through the tricarboxylic acid (TCA) /Krebs cycle, which yields another thirty four 
ATP molecules/molecule of glucose (giving a total of thirty six ATP molecules) 
(Rich, 2003). Anaerobic respiration includes glycolysis and the fermentation of 
pyruvate to lactate, a metabolic pathway that bypasses mitochondrial respiration, 
and is predominantly up-regulated in cancer cells in the so-called Warburg effect, 
which, somewhat counter intuitively, cancer cells use to produce most of their 
energy (Warburg, 1956, Bialik and Kimchi, 2006). 
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Figure 6-7. Simplified cartoon of cellular metabolism pathways. 
Simplified cartoon depicting cellular metabolism pathways with glycolysis as the first step of 
glucose breakdown, and oxidative phosphorylation and anaerobic respiration as subsequent 
steps. 
 
A Seahorse was used to determine changes in aerobic and anaerobic 
respiration. This powerful instrument measures the oxygen consumption rate 
(OCR), an accurate indicator of mitochondrial respiration, as well as the 
extracellular acidification rate (ECAR), which is an indirect measurement of lactic 
acid production (Figure 1-11). Cells were transfected as before, and OCR and 
EACR were determined under basal-conditions in siDAPK2- or siNS-transfected 
cells. The EACR in siDAPK2-tranfected cells, measured in mpH/min, was 
normalised to that in siNS-transfected control cells. No statistically significant 
changes in EACRs were detected between siNS- and siDAPK2-transfected 
U2OS (Figure 6-8a), or A549 (Figure 6-8g) cells, suggesting that silencing 
DAPK2 does not skew metabolism in these cells towards anaerobic respiration. 
OCR was measured in pMoles/min and normalised as described above for EACR 
measurements. In contrast to what was seen for EACR, there was a significant 
decrease in OCRs by mitochondria upon DAPK2 knockdown in both U2OS 
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(Figure 6-8b) and A549 (Figure 6-8h) cells, suggesting that DAPK2 modulated 
mitochondrial respiration but not anaerobic respiration.  
 
Figure 6-8. The absence of DAPK2 leads to a reduction of oxidative phosphorylation in 
U2OS and A549 cells. 
To quantify cellular metabolic processes, U2OS (a - f) and A549 (g - l) cells were transfected 
with either siNS, or DAPK2 siRNA. Forty-eight h after transfection cells were analysed using a 
Seahorse Analyser. ECAR, an indirect measurement of lactic acid production, is depicted as 
fold change of mpH/min and normalised to siNS control in U2OS (a) and A549 cells (g). OCR, 
which can be used to determine mitochondrial respiration, is shown as fold change of pmol/ 
min and normalised to siNS control in U2OS (b) and A549 cells (h). Forty-eight h after siRNA 
transfection NAD+, NADH, NADP+ and NADPH levels were analysed using colorimetric assays 
in U2OS (c - f) and A549 cells (i - l). Treatment with MPP+ (1 mM, 24 h) served as a positive 
control. Data represent mean ± SEM of three independent experiments, statistical analyses 
were done using Student’s t-test (paired, one tailed) (* p<0.05, ** p<0.01). I am grateful to Ms 
Marina L. Georgiou for performing this experiment. 
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To investigate further the consequences of DAPK2 depletion on cellular 
metabolism, levels of the coenzymes nicotinamide adenine dinucleotide (NAD+) 
and nicotinamide adenine dinucleotide phosphate (NADP+), as well as their 
corresponding reduced forms (NADH and NADPH, respectively), were analysed. 
During glycolysis and the TCA cycle, each glucose molecule leads to the 
reduction of six NAD+ to NADH, which are then oxidised during oxidative 
respiration to produce ATP (Rich, 2003). In contrast to NADH, NADPH is not 
involved in metabolic processes but it has an important role in the regeneration of 
oxidised glutathione (GSH). GSH is a key antioxidant in cells, thus protecting 
them against cellular ROS, such as free radicals and peroxides (Kirsch and De 
Groot, 2001). Colorimetric assays were used to determine the levels of NAD+ and 
NADH, as well as NADP+ and NADPH. MPP+ was used to inhibit oxidative 
phosphorylation and increase the levels of NAD+ and NADH, and thus as a 
control. As shown for U2OS (Figure 6-8c + d) and A549 cells (Figure 6-8i + j), 
MPP+ treatment increased the levels of NAD+ and NADH (albeit in A549 cells, the 
increase in NADH was very small and not statistically significant). However, 
NAD+/NADH levels remained unaffected by DAPK2 knockdown. Interestingly, the 
levels of NADP+ and NADPH in U2OS cells (Figure 6-8e + f) were slightly 
decreased upon silencing DAPK2 (only statistically significant for NADP+ where a 
20% decrease was consistently measured across experiments), whereas there 
was no detectable change in A549 cells (Figure 6-8k + l). It thus appears that 
RNAi-mediated ablation of DAPK2 affected oxidative phosphorylation without 
substantially impacting on NAD+/NADH, or NADP+/NADPH metabolism. 
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6.2.4 Depletion of DAPK2 leads to decreased glutathione levels and 
induction of NRF2 
 
Having established that genetic ablation of DAPK2 led to changes in cellular 
oxidative stress, mitochondrial respiration, activation of stress kinases and up-
regulation of SODs in two distinct cancer cell types, we next asked what effect 
down-regulation of DAPK2 had on the levels of GSH. GSH functions as an 
electron donor for reducing reactions and it is involved in the reduction of cellular 
ROS (Pompella et al., 2003, Brigelius-Flohe and Maiorino, 2013). In fact, the 
generation of oxidised GSH (in the form of GSSG) is tightly linked to 
mitochondrial oxidative phosphorylation, whereby NADPH reduces GSSG to 
GSH. To assess total levels of GSH levels by colorimetry, cells were transfected 
as described earlier.  Subtle, but highly statistically significant, down-regulation of 
GSH levels upon DAPK2 knockdown were detected and this was more prominent 
in U2OS (Figure 6-9a) than in A549 cells (Figure 6-9d). 
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Figure 6-9. Ablation of DAPK2 leads to decreased GSH levels and, in U2OS cells, to the 
induction of NRF2 mRNA. 
U2OS (a - c) and A549 (d - f) cells were transfected with either siNS, or siDAPK2 the levels of 
GSH were analysed using a colorimetric assay 24 h later (a, d). NRF2 (b, e) and KEAP1 (c, f) 
mRNA levels were assessed by qPCR. Data represent mean ± SEM of at least three 
independent experiments and the statistical analyses were done using Student’s t-test (paired, 
one tailed) (* p<0.05, ** p<0.01, *** p< 0.005). I am grateful to Ms Emily Chater for performing 
the GSH assay and Ms Sarah Stöcker for performing the qPCR experiments. 
 
The question was whether such small reductions in GSH levels were sufficient to 
induce nuclear factor (erythroid-derived 2)-like 2 (NFE2L2/NRF2), a latent 
transcription factor responsible for the transcription of a multitude of key 
antioxidants that can protect cells from oxidative stress. NRF2 is known to bind to 
the so-called antioxidant response element (ARE), leading to transcriptional 
activation of GSH synthesising enzymes and other antioxidant enzymes, such as 
SOD1 and SOD2, which were up-regulated upon DAPK2 silencing (Figure 6-2b 
+ d). After U2OS and A549 cells were transfected with siDAPK2 or siNS, RNA 
and proteins were extracted and the levels of NRF2 and its key-regulating 
ubiquitin ligase kelch-like ECH-associated protein 1 (KEAP1) analysed. 
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Interestingly, NRF2 mRNA levels were significantly elevated in U2OS cells 
(Figure 6-9b), but not in A549 cells (Figure 6-9e). KEAP1 was not induced in 
either U2OS (Figure 6-9c), or A549 cells (Figure 6-9f).  
 
6.2.5 The mitochondrial-associated function of DAPK2 is likely to be 
kinase mediated !
The data thus far suggested that the increase in intracellular ROS caused by 
downregulating DAPK2 was due to an impairment of mitochondrial functions. In 
order to understand how DAPK2 preserved mitochondrial integrity, the relevance 
of DAPK2’s kinase domain was investigated. For that purpose, tetracycline (Tet)-
inducible U2OS cell lines (U2OS-TetR) containing HA-tagged DAPK2 constructs 
that were either wild-type (HA-DAPK2.wt), or kinase-dead (HA-DAPK2.K42A), 
described earlier (Inbal et al., 2002), were used. The caveat with this approach 
was that it was impossible to express the constructs at endogenous levels. 
Indeed, over-expression of wild-type DAPK2 is known to be sufficient to induce 
apoptotic features, such as membrane blebbing and nuclear fragmentation (Inbal 
et al., 2002). As such, this approach could not be used as an alternative 
experimental method to revert the phenotype observed after silencing DAPK2 
using RNAi. It did, however, enable the analysis of the role of the kinase domain 
on the regulation of intracellular oxidative stress. 
 
Expression of the transgene was induced in HA-DAPK2.wt cells (Figure 6-10a) 
and HA-DAPK2.K42A cells (Figure 6-10c) using doxycycline (DOX) and ROS 
levels were measured using the DCFDA probe. Overexpression of wild-type 
DAPK2, rather than leading to reduced oxidative stress, led to an increase in 
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general ROS production (Figure 6-10b), but importantly this was not observed if 
cells overexpressed a kinase-dead DAPK2 mutant (Figure 6-10d). The 
overexpressed kinase dead mutant (HA-DAPK2.K42A) did not behave as a 
dominant negative and did not mimic the phenotype caused by DAPK2 depletion 
seen after RNAi. This might be due to the fact that, in this cell system, the cells 
still expressed endogenous wild-type DAPK2. 
 
 
Figure 6-10. Effect of wild-type (wt) and kinase-dead (K42A) DAPK2 overexpression on 
oxidative stress. 
The expression of HA-tagged wild-type (wt), or HA-tagged kinase-dead (K42A) DAPK2 in 
U2OS-TetR cells was induced using doxycycline (10 ng/ml). HA-DAPK2 (a) and HA-
DAPK2.K42A (c) expression was verified by SDS-PAGE/western blotting. The impact of wild-
type (b) or kinase-dead (d) DAPK2 overexpression have on oxidative stress was analysed as 
described earlier using the DCFDA probe. 
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To eliminate the endogenous wild-type DAPK2 in the inducible cell model, 
3’UTR-specific siRNAs were used. These molecules target exclusively 
endogenous DAPK2 (Figure 6-11). Cells were transfected with either siNS or 
custom made Dharmacon DAPK2 siRNA oligonucleotide that specifically 
targeted the DAPK2 3’UTR (described in 117 and shown in Figure 4-1) and, in 
order to induce the expression of HA-DAPK2.K42A, cells were stimulated with 
DOX as they were being transfected. As shown in Figure 6-11a, siDAPK2-3’UTR 
specifically targeted endogenous DAPK2 and did not impact on the expression of 
kinase dead DAPK2, which was detected using an anti-HA antibody. Having 
established a cell system where it was possible to efficiently down-regulate 
endogenous DAPK2 and concomitantly overexpress a kinase dead DAPK2 
mutant, enabled studying the effect of kinase-dead DAPK2 on the generation of 
general ROS. Consistent with our previous results (Figure 6-1a), depletion of 
wild-type DAPK2 without (Figure 6-11c, grey line) or with overexpression of 
kinase-dead DAPK2 (Figure 6-11c, dotted black line), using siDAPK2-3’UTR, led 
in both cases to a significant increase in ROS (Figure 6-11c and d). The 
overexpression of kinase-dead DAPK2, importantly, actually led to a significantly 
higher level of oxidative stress in U2OS cells than the wild-type endogenous 
protein (Figure 6-11d). In control cells transfected with siNS, the level of 
oxidative stress was the same regardless of the presence or absence of HA-
DAPK2.K42A (Figure 6-11c). Collectively, our data thus suggest that DAPK2 
kinase activity is important for preserving mitochondria’s integrity and protecting 
cells from oxidative stress. 
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Figure 6-11. Effect of kinase-dead (K42A) DAPK2 overexpression on oxidative stress in 
cells that are depleted of endogenous DAPK2. 
The expression of HA-tagged kinase-dead (K42A) DAPK2 in U2OS-TetR cells was induced 
using doxycycline (10 ng/ml). To eliminate endogenous DAPK2 and study the effect of the 
kinase-dead DAPK2 mutant individually, U2OS TetR cells containing the HA-DAPK2.K42A 
construct were transfected with either siNS, or siDAPK2-3’UTR and concomitantly stimulated 
with doxycycline (10 ng/ml). Targeted knockdown of endogenous DAPK2 and overexpression 
of HA-DAPK2.K42A were then assessed by SDS-PAGE/western blotting (a). The effect of the 
kinase dead DAPK2 mutant overexpression, in the presence (b, grey line) and absence (c, 
dotted black line) of endogenous DAPK2, on oxidative stress was quantified by flow 
cytometry with the DCFDA probe (b, c). Data were plotted as fold change of DCFDA 
fluorescence of U2OS TetR cell transfected with siDAPK2-3’UTR without doxycycline 
treatment (d). Statistical analysis was done using one-way ANOVA test (** p<0.01, *** p< 
0.005). 
 
 
 
 
0 103 105104102
0
20
40
60
80
100
Fluorescence intensity (FITC) 
DAPK2 wt
c) 
DAPK2 wt knockdown +
HA-DAPK2.K42A
DAPK2 wt knockdown
0 103 105104102
0
20
40
60
80
100
Fluorescence intensity (FITC) 
b) 
DAPK2 wt
DAPK2 wt +
HA-DAPK2.K42A
+ Doxycycline
42 kDaHA-DAPK2.K42A
siNS
siDAPK2
3’UTRUntr
- Doxcycyline
siNS
siDAPK2
3’UTRUntr
a) 
55 kDaĮ7XEXOLQ
DAPK2 42 kDa
Unspecific band
DAPK2
Unspecific band
(long exposure)
(short exposure)
42 kDa
0.0
0.5
1.0
1.5
Fo
ld
 c
ha
ng
e 
D
C
FD
A 
in
te
ns
ity
DAPK2 wt
DAPK2 wt + HA-DAPK2.K42A
DAPK2  wt knockdown
DAPK2  wt knockdown + 
HA-DAPK2.K42A
***
***
**
d) 
M
ax
im
um
 D
C
FD
A 
S
ig
na
l (
%
)
M
ax
im
um
 D
C
FD
A 
S
ig
na
l (
%
)
 
DAPK2 Regulates Oxidative Stress in Cancer Cells by Preserving Mitochondrial Function 
 
! 221!
6.2.6 Discussion 
 
Although DAPK1, DAPK2 and DAPK3 are structurally different, recent analyses 
have revealed that DAPK2 and DAPK3 evolved from DAPK1 around the 
development of jawed vertebrates (Shoval et al., 2011). DAPK1 regulates 
mitochondrial integrity(Shang et al., 2005) and metabolic processes (Mor et al., 
2012). Given the common ancestry and sequence homology within DAPKs’ 
kinase domains, common mechanisms of action and functional redundancy have 
been postulated, which invoke the formation of a so-called ‘death-associated 
multi-protein complex’ (Gozuacik and Kimchi, 2006). Indeed, all three have been 
associated with apoptotic processes and are thought to be potential tumour 
suppressors (Bialik and Kimchi, 2006).  
 
Here, we showed that depletion of DAPK2 results in ROS generation in U2OS 
and A549 cells (Figure 6-1a, c, e, g) and, phosphorylation/activation of MAPKs 
(Figure 6-2a and c), and induction of SODs (Figure 6-2b and d). Mitochondrial 
SOD2 was induced more than cytosolic SOD1, suggesting that in the absence of 
DAPK2 (Figure 6-2b and d), ROS were produced by mitochondria(Turrens, 
2003). Additional experiments support this hypothesis (Figure 6-3) and indicate 
that the ER was an unlikely additional ROS source (Figure 6-4). Silencing 
DAPK2 led to increased spontaneous mitochondrial depolarisation (Figure 6-5) 
and, in A549 cells, to the activation of DAPK1 (Figure 6-6), thought to be a Δψm 
sensor involved in cytoskeletal rearrangements responsible for mitochondrial 
transport mechanisms (Shang et al., 2005). Apart from the homology on the 
kinase domain, DAPK1 and DAPK2 have also been reported to heterodimerise 
(Gozuacik and Kimchi, 2006). It is thus reasonable to assume that they may 
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operate in a similar fashion with regards to mitochondrial maintenance, sensing 
the mitochondrial membrane potential and leading to downstream processes of 
mitophagy and mitochondrial degradation, which result in faulty mitochondria. 
Interestingly, neither overexpression of DAPK1, nor DAPK2 has been shown to 
induce mitochondrial depolarisation (Inbal et al., 2002).  
 
DAPK2 knockdown led to significantly reduced oxidative phosphorylation without 
affecting lactic acid fermentation (Figure 6-8a + g and b + h). This suggested a 
fundamental role for DAPK2 in the regulation of mitochondrial metabolism and/or 
maintenance. This, in turn, raises the question of how these cells maintain their 
energy supply, as without increased lactic acid fermentation (ECAR), DAPK2-
depleted cells are unlikely to be compensating the decrease in oxidative 
phosphorylation via anaerobic respiration (Figure 1-11). Consistent with this, no 
significant changes in NAD+/NADH and/or NADP+/NADPH upon DAPK2 silencing 
were seen (Figure 6-8c - f and i - l). All experiments were performed 48 h post-
RNAi. Thus, eventual cellular compensatory mechanisms, such as increased 
glycolytic rate or lactic acid production, may not yet be detectable. For example, it 
has been shown that inhibition of the mitochondrial electron transport by low 
doses of ethidium bromide causes NADH accumulation, halts the TCA cycle and 
drives cells towards anaerobic glucose metabolism, but these results were 
obtained after 4 days of mitochondrial electron transport inhibition (Noda et al., 
2002).  
 
The ROS increase and mitochondrial depolarisation were accompanied by a 
small, but statistically significant, GSH decrease (Figure 6-9a and d) and, in 
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U2OS cells by the transcriptional induction of the ‘master regulator of antioxidant 
responses’ NRF2 (Gorrini et al., 2013) (Figure 6-9b). There was no induction of 
NRF2 in A549 cells (Figure 6-9e) and the levels of KEAP1 mRNA, an NRF2 
regulator, remained unchanged in both cell lines (Figure 6-9c + f). 
 
Overexpression of HA-tagged wild-type DAPK2 per se increased the levels of 
intracellular ROS in U2OS cells (with endogenous DAPK2), whereas kinase-dead 
DAPK2 did not (Figure 6-10). The overexpression of the kinase-dead mutant, in 
the absence of endogenous DAPK2, led to increased oxidative stress in U2OS 
cells and this was greater than that seen with the wild-type protein (Figure 6-11). 
Collectively, these data indicate that DAPK2 kinase activity is important for 
preserving mitochondrial integrity and protecting cells from oxidative stress. 
 
DAPK2 is emerging as a tumour suppressor in several types of cancer cells, 
especially in acute promyelocytic leukaemia (APL), a subtype of acute 
myelogenous leukaemia (AML), which responds to treatment with all-trans 
retinoic acid (ATRA) (Rizzi et al., 2007). This is interesting, as ATRA is known to 
up-regulate DAPK2 expression. Given the role of ROS in the aetiology of AML 
(Rassool et al., 2007), downregulation and/or loss of DAPK2 is likely to benefit 
emerging cancer cells, by leading to deregulated mitochondria, increase in 
cellular ROS and, thus, genomic instability. Indeed, somatic mitochondrial 
mutations and accumulated mitochondrial damage have been linked to AML 
development (He et al., 2003). Despite it relatively small size and straightforward 
structural features, DAPK2 appears to be a double-edge sword, depending on 
cellular context and, presumably, interaction partners. Indeed, earlier, we have 
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shown that downregulation of endogenous DAPK2 sensitises multiple cancer cell 
types to TRAIL-induced apoptosis. This is due to ability to activate NF-κB, which 
is another multi-faceted protein that, curiously, can also be activated by oxidative 
stress. 
 
We have thus identified a completely novel role for DAPK2 in the regulation of 
mitochondrial integrity, as its absence leads to mitochondrial depolarisation and 
increased oxidative stress. This may be a mechanism by which, depending on 
the intracellular context, DAPK2 can act as a tumour suppressor gene. 
Importantly, as the effect of DAPK2 silencing on mitochondrial respiration is 
conserved between mesenchymal U2OS cells and epithelial A549 cells, it is likely 
that our findings can be further extended to additional cell lineages and 
malignancies. Time will tell. !
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7.1 General Discussion !
7.1.1 Overview !
TRAIL is a member of the TNF ligand superfamily and has been described to be 
involved in innate anti-tumour surveillance. By binding to its corresponding 
receptors DR4 and DR5, TRAIL has been shown to selectively induce cell death 
in tumours cells without affecting ‘normal’ tissue. Experimental cancer therapies 
using TRAIL-receptor agonists (TRAs) have proven promising in preclinical work 
and have made it into phase II clinical trials. Unfortunately, their success has 
been hindered for a variety of reasons. In contrast to homotrimeric TRAIL, many 
TRAs are antibody based and are only capable of clustering two DRs, whereas 
TRAIL induces clustering of three DRs, leading to a stronger activation of 
extrinsic apoptosis pathways. Moreover, it was described that many initially 
TRAIL sensitive cells develop resistance to TRAIL-induced apoptosis and several 
strategies have been developed to attempt to overcome this resistance, including 
the concomitant use of chemotherapeutic drugs or proteasome inhibitors. Despite 
good re-sensitising effects triggered by these agents in an in vitro setting, these 
findings were not reproduced in a clinical environment. To enable the success of 
TRAIL-based therapies in the clinic more powerful TRAs and more sophisticated 
and/or novel strategies are currently being developed, as they are clearly needed 
to overcome TRAIL-resistance in the clinic.  
 
Previous work carried out in Dr. Costa-Pereira’s laboratory by Dr. Sutton and Dr. 
Fonseca revealed that RNAi-mediated depletion of DAPK2 resulted in the 
sensitisation of TRAIL-resistant U2OS osteosarcoma cells to TRAIL-induced 
apoptosis (Figure 2-1C). The sensitisation was reported to be specific, as 
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DAPK2 did not sensitise cells to other cytotoxic agents such as taxol and H2O2 
(Figure 2-1A and B) or to apoptosis triggered by the death-inducing cytokine 
TNF-α (Figure 2-1D). The aim of my Ph.D. project, therefore, was to elucidate 
the underlying molecular mechanism(s) leading to the sensitisation of TRAIL-
resistant cancer cells to TRAIL-induced cell death.  
 
7.1.2 RNAi-mediated depletion of TRAIL specifically sensitises cancer 
cells to TRAIL-induced cell death 
 
In 4.2.1 we established that the siRNA oligonucleotides used throughout this 
work specifically targeted DAPK2 without affecting the protein levels of the other 
DAPK-family members, namely DAPK1 or DAPK3 (Figure 4-1). We further 
established that U2OS cells did not express detectable amounts of DAPK1. By 
using a pool of two siRNA oligonucleotides we confirmed the initial observation 
that DAPK2 depletion sensitised U2OS cells to TRAIL-induced apoptosis (Figure 
4-2a - e). We extended these findings to the NSCLC cell line A549, another solid 
tumour cell line that has recently been reported as resistant to TRAIL-induced 
apoptosis (Figure 4-2f - j). As for U2OS cells, RNAi-mediated depletion of 
DAPK2 in A549 cells sensitised these to TRAIL-induced apoptosis but not to 
other cytotoxic agents. To further validate that RNAi-mediated DAPK2 depletion 
could sensitise cancer cells to TRAIL-induced apoptosis, cells were transfected 
with additional four siRNA oligonucleotides. As shown in Figure 4-4, each 
individual DAPK2-targeting siRNA oligonucleotide sensitised U2OS and A549 
cells to TRAIL-induced apoptosis. These results not only afforded further support 
to the initial findings but they also excluded the possibility that the sensitisation to 
 
General Discussion and Future Perspective 
 
! 228!
TRAIL-induced apoptosis was caused by a potential RNAi-mediated off-target 
effect.  
 
7.1.3 Sensitisation to TRAIL-mediated apoptosis requires the upregulation 
of DRs 
 
Molecular pathways leading to TRAIL-induced apoptosis in DAPK2-depleted 
U2OS and A549 cells were analysed further using SDS-PAGE/western blotting, 
which revealed that DAPK2-depleted cells, in response to TRAIL, showed a 
stronger activation of the executioner caspase, caspase-8 (Figure 4-5). We 
sought to unravel the molecular background leading to this stronger activation. 
As depicted in Figure 1-5 a common mechanism of resistance to TRAIL includes 
the downregulation of its corresponding receptors, or the upregulation of the 
protease-deficient caspase homolog, c-FLIP. We hypothesised that DAPK2 
depletion might revert such processes and thus further analysed the effect of 
RNAi-mediated DAPK2 depletion on the levels of DR4, DR5 and c-FLIP. While 
we did not observe any changes in c-FLIP mRNA or protein levels (Figure 4-6), 
we did detect a significant increase in DR4 and DR5 mRNA (Figure 4-7) and 
protein expression (Figure 4-8) in response to RNAi-mediated DAPK2 depletion. 
To further validate that the depletion of DAPK2 specifically upregulated TRAIL’s 
DRs, we performed single knockdowns with four different DAPK2-targeting 
siRNA oligonucleotides. As expected, each one of these single oligonucleotides 
induced the expression of these DRs (Figure 4-9 and Figure 4-10).  
 
After establishing that DAPK2 depletion induced the expression of DRs, we 
asked whether this upregulation per se led to re-sensitisation of cells towards 
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TRAIL-induced apoptosis. For this purpose, we used U2OS cells as they only 
expressed DR5. By using double knockdowns combining different siRNA 
oligonucleotides we were able to target DAPK2 and DR5 concomitantly. We 
initially titrated the amount of DR5 siRNA that reverted the DR5 induction in 
response to DAPK2 knockdown (Figure 4-13a). Remarkably, co-transfection of 
1.25 nM siDR5 with 20 nM siDAPK2 was sufficient to rescue U2OS cells from 
TRAIL-induced apoptosis in response to DAPK2 knockdown (Figure 4-13c), 
suggesting that the induction of DR expression was the main driver for the 
sensitisation towards TRAIL-induced apoptosis.  
 
Given the fact that activation of TRAIL DRs and the FasR exhibit a high degree of 
signalling similarities and signalling components, we also assessed the effect of 
DAPK2 depletion on FasL-triggered apoptosis. Interestingly, we found that 
silencing DAPK2 sensitised U2OS cells towards FasL, whereas A549 remained 
resistant (Figure 4-16). Curiously, knockdown of DAPK2 resulted in the induction 
of FasR mRNA and increased protein levels in both cell lines, suggesting that 
A549 cells may have an additional inhibitory molecule that will need to be 
targeted before they can succumb to the cytotoxic effects of FasL. We further 
discovered that U2OS cells, that become sensitive to FasL-induced apoptosis in 
response to DAPK2 depletion, also showed a reduction of FasL decoy receptor 
DcR3 mRNA levels (Figure 4-16b). Thus, the upregulation of FasR per se might 
not have been the actual cause of the sensitisation to FasL-induced apoptosis, 
instead it might have been the repression of DcR3, which would the explain why 
U2OS cells become sensitive to DAPK2-mediated FasL-induced apoptosis.  
 
 
General Discussion and Future Perspective 
 
! 230!
7.1.4 RNAi-mediated depletion of DAPK2 induces NF-κB 
 
Having established that inhibition of DAPK2 led to the selective sensitisation to 
TRAIL in U2OS and A459 cells and that this was mediated by the upregulation of 
its corresponding receptors, we analysed some of the underlining mechanisms 
causing such an induction. To measure the potential increase of mRNA and/or 
protein stability, we used classical biochemical assays that revealed that neither 
mRNA nor protein stability was affected in response to RNAi-mediated DAPK2 
depletion (Figure 5-1). Given the increased mRNA levels for DR4, DR5 and 
FasR in response to DAPK2 knockdown, we then focused on potential 
transcription factors causing such induction. A thorough literature research 
revealed that the transcription factor p53 and the NF-κB family of transcription 
factors were likely candidates as both were previously described to be involved in 
the induction of DR4, DR5 and FasR transcripts. Although we did not detect 
elevated p53 mRNA levels in response to DAPK2 knockdown, the observed that 
the transcription of p21, one of it most immediate p53 target genes, was elevated 
(Figure 5-2). The use of p53 mutant T24 bladder carcinoma and p53-null 
prostate carcinoma PC3 cells (Figure 5-3) established that both cell lines were 
readily sensitised to TRAIL-induced apoptosis after DAPK2 knockdown despite 
their altered p53 status. Therefore, we concluded that p53 per se was 
dispensable for siDAPK2-mediated sensitisation to TRAIL. As mentioned before, 
the NF-κB family of transcription factors had also been described to activate the 
transcription of DRs and FasR. By using NF-κB luciferase reporter assays we 
showed that NF-κB was transcriptionally active in DAPK2 depleted cells (Figure 
5-4) and qPCR experiments revealed that NF-κB family members were induced 
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at the mRNA and/or protein level (Figure 5-5 and Figure 5-6). Further 
investigation into the transcriptional activation of NF-κB target genes revealed 
that several were upregulated in response to RNAi-mediated DAPK2 depletion 
(Figure 5-7). Remarkably, the transcription of the TNF-α receptor and NF-κB 
target gene TNFR2 was elevated in A549 cells, whereas the transcription of the 
second TNF-α receptor TNFR1 remained unaffected, however this was not 
observed in U2OS cells (Figure 5-7). TNFR2 has been previously described as a 
NF-κB target gene (Santee and Owen-Schaub, 1996). However, to the best of 
our knowledge, so far TNFR1 has not been reported to be transcriptionally 
regulated by NF-κB. As described in 1.6, TNFR2 does not contain a DD and is 
therefore incapable of inducing apoptosis. In contrast to TNFR1, which can 
activate extrinsic apoptotic signalling and pro-survival cues via NF-κB. As shown 
in Figure 4-2 RNAi-mediated depletion of DAPK2 had no effect on the sensitivity 
of A549 cells towards TNF-α, which could readily be explained by the unaltered 
expression of TNFR1 and the elevated expression of the pro-survival receptor, 
TNFR2.  
 
In 2010, Bai et al. described that RNAi-mediated depletion of the DAPK-family 
member DAPK1 in endometrial carcinoma cells resulted in their sensitisation to 
TRAIL-induced apoptosis (Bai et al., 2010). The authors proposed that this was 
driven by the induced secretion of TRAIL itself and the induction of DR4, DR5 
and TRAIL expression. They also reported on an induced expression of FasR 
and DcR1. Given the great homology of DAPK1 and DAPK2 in their kinase 
domain (Figure 1-9) it is likely that depletion of either kinase could induce similar 
cellular changes leading to the expression of DR4, DR5 and FasR in a 
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comparable way. Indeed, as described earlier we found elevated levels of DR4, 
DR5 and FasR in DAPK2 depleted cells. However, in contrast to these 
observations, we detected no induction of DcR1 or TRAIL mRNA in either of the 
studied cell lines (Figure 4-7 and Figure 5-7). 
 
7.1.5 Activation of NF-κB is necessary for the sensitisation to TRAIL 
 
Having established a clear activation of NF-κB in response to DAPK2 knockdown 
we investigated whether or not this activation was causal for the upregulation of 
DRs and sensitisation to TRAIL-induced apoptosis. Therefore, double knockdown 
experiments were carried out, where NF-κB family members and DAPK2 were 
concomitantly targeted. As depicted in Figure 5-8, depletion of NF-κB1, a key 
molecule of the canonical NF-κB branch, rescued the siDAPK2-induced 
sensitisation to TRAIL in U2OS and A549 cells. Depletion of NF-κB2, a key 
molecule of the non-canonical branch in combination with DAPK2 depletion led to 
a partial rescue only in A549 cells. Knockdown of RELB and DAPK2 resulted in a 
partial rescue only in A549 cells, whereas knockdown of RELA had no effect on 
the siDAPK2-mediated sensitisation to TRAIL. These observations clearly 
suggested that the activation of NF-κB was crucial for the sensitisation of U2OS 
and A549 cells to TRAIL-induced apoptosis. To verify previous reports stating 
that NF-κB activation induces the transcription of DR5 (Shetty et al., 2005), we 
used DR5 promoter luciferase constructs to demonstrate that RNAi-mediated 
depletion of DAPK2 induced the transcriptional activation of DR5. Furthermore, 
DR5 promoter luciferase constructs containing a mutated NF-κB-binding site 
remained inactivated in DAPK2-depleted cells (Figure 5-10). Together, these 
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results provide compelling evidence for a direct requirement of NF-κB for the 
induction of DR5 in DAPK2-depleted cells and furthermore sensitisation to 
TRAIL-induced apoptosis.   
 
In 2008, Chuang et al. reported that DAPK1 modulates T cell receptor 
(TCR) -induced NF-κB signalling in T cells. The authors reported that 
RNAi-mediated depletion of DAPK1 or overexpression of kinase dead (K42A) 
DAPK1 resulted in increased TCR activation and basal RELA phosphorylation. 
They proposed that DAPK1 functions by affecting the translocation of IKK 
proteins into lipid membrane rafts (Chuang et al., 2008). Moreover, in 2012 Yoo 
et al. reported that overexpression of DAPK1 in ovarian cancer cells inhibited the 
expression of NF-κB target genes and proposed that DAPK1 functions as an NF-
κB repressor downstream of TNF-α (Yoo et al., 2012). Given the previously 
described sensitisation of endometrial carcinoma cells to TRAIL-induced 
apoptosis and their induced expression of NF-κB response genes such as DR4, 
DR5, TRAIL and DcR1 in response to RNAi-mediated DAPK1 depletion, we 
explored the possibility that DAPK2 might exhibit similar effects on NF-κB. 
 
By carrying out experiments using TNF-α to induce NF-κB signalling, we 
discovered that DAPK2-depleted U2OS and A549 cells have decreased basal 
levels of IκBα, resulting in a delayed activation of NF-κB (RELA S536 
phosphorylation) (Figure 5-11). In contrast, the overexpression of wild type 
DAPK2 reduced the levels of IκBα but it also ‘dampened’ the activation of NF-κB 
(as assessed by measuring RELA S536 phosphorylation). Interestingly, the 
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overexpression of a kinase dead DAPK2 (K42A) resulted in elevated levels of 
basal RELA S536 phosphorylation in both cell lines (Figure 5-12b).  These 
results were in agreement with previous work carried out with DAPK1 by Chuang 
et al. 2008. It is worth while pointing out that the majority of our work was carried 
out in U2OS cells that as shown in Figure 4-1a and b do not express detectable 
amounts of DAPK1 protein. The A549 cells did express detectable levels of 
DAPK1 and these were unaffected upon RNAi-mediated depletion of DAPK2 
(Figure 4-1c). However, DAPK2 depletion resulted in an activating de-
phosphorylation of DAPK1 S308 in A549 cells (Figure 6-6), potentially to 
compensate for the loss of DAPK2. These findings open the possibility that 
DAPK2 and DAPK1 may, in fact, exhibit similar effect(s) on the regulation of NF-
κB. 
 
The question thus remains as to how downregulating DAPK2 leads to the 
activation of NF-κB, which is vital to sensitise otherwise resistant cells to TRAIL-
mediated death. Clearly, the involvement of NF-κB in TRAIL signalling is complex 
and highly cell type- and context-dependent and DAPK2 appears to regulate an 
upstream component of NF-κB signalling. Such a component could be the NF-κB 
negative regulator, IκB. As described above, silencing DAPK2 led to its 
disappearance.  This then poses the question of why IκB is being degraded with 
the most immediate hypothesis being its phosphorylation by an IKK complex, 
coupled to the TRAIL receptor complex. Remarkably, Chuang et al. reported that 
depletion of DAPK1 or overexpression of kinase dead DAPK1 resulted in a 
stronger recruitment of IKK-α and IKK-β into lipid rafts. Spatial accumulation of 
the IKK complex proteins activates the phosphorylation and subsequent 
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degradation of IκB, which could be enhanced in DAPK2-depleted and kinase 
dead DAPK2-overexpressing cells. This indicates a potential involvement of 
DAPK1 and DAPK2s kinase domain in the regulation of IKK proteins. Such 
regulation may occur via RIPK and/or TRADD (Liu et al., 2008a). Interestingly, 
the increased basal phosphorylation of RELA upon DAPK2 knockdown was more 
pronounced in U2OS cells, compared to A549 cells (Figure 5-11), which could 
potentially be explained by a compensatory mechanism of activated DAPK1 in 
A549 cells.  
 
Perhaps the interaction of DAPK2 with DR5 (Figure 5-14) enabled it to act as a 
‘plug’ that effectively stops cells from ‘inadvertently’ succumbing to TRAIL. 
Removing DAPK2 may free binding sites on the receptor complex necessary to 
couple the pathway to the initiator caspases and accumulation of the IKK 
complex which can also be activated downstream of DRs. It is also possible that 
the interaction between NF-κB signalling components and DAPK2 occurs in the 
cytoplasm rather than at the membrane level and, again, IKKs and IκB are the 
most likely interaction partners. Another possibility is that DAPK2 represses NF-
κB activation by, for example, protecting the cell from cellular stress, which is 
known to activate NF-κB. Whichever way DAPK2 silencing leads to NF-κB 
activation, NF-κB activation seemed to lead to the degradation of DAPK2 in 
response to a classical NF-κB activator such as TNF-α (Figure 5-13). What is 
intriguing is why the output of the TRAIL stimulus is death considering NF-κB 
also leads to the activation of key survival genes. The balance must thus rest on 
the faster caspase activation observed following DAPK2 silencing and on the 
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NF-κB-mediated induction of DR5 and/or DR4. As mentioned above, 
overexpression of DAPK2 was able to suppress the TNF-α mediated activation of 
NF-κB. Overexpression of DAPK2 did not, however, revert the phenotype 
observed upon DAPK2 knockdown, as IκB also decreased. The latter was 
consistent with the findings of Yoo et al. who found IκB to be downregulated in 
response to DAPK1 overexpression (Yoo! et! al.,! 2012). A model that shows our 
understanding of the effect of DAPK2 depletion on the regulation of TRAIL-
induced apoptosis is depicted in Figure 5-15. 
 
7.1.6 Deregulation of the mitochondria in response to DAPK2 silencing is 
likely to be independent of the mechanism that sensitises resistant 
cancer cells to TRAIL 
 
RNAi-mediated depletion of DAPK2 also induced significant metabolic changes 
in the mitochondrion. By using ROS specific probes, we found that the levels of 
cellular ROS, particularly superoxide, were elevated in DAPK2 depleted U2OS 
and A549 cells (Figure 6-1). Indeed, a number of stress kinases and anti-
oxidative enzymes were elevated in cells upon DAPK2 knockdown (Figure 6-2). 
Further analyses revealed that these cellular changes most likely originated from 
the mitochondria. By using mitochondria specific probes we showed that DAPK2-
depleted cells contained elevated levels of superoxide in their mitochondria 
(Figure 6-3) and that their membranes spontaneously depolarised (Figure 6-5). 
These alterations had further functional consequences on the mitochondria and 
resulted in a decreased rate of oxidative phosphorylation in DAPK2-depleted 
cells (Figure 6-8). Interestingly, DAPK1 has also been previously shown to 
regulate mitochondrial integrity and to modulate the mitochondrial membrane 
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potential. More specifically, inhibition of mitochondrial complex proteins was 
reported to induce activating de-phosphorylation of DAPK1 S308. It was thus 
proposed that DAPK1 plays a crucial role in maintaining mitochondria integrity 
and in the recycling of mitochondria with low Δψm (Shang et al., 2005). The 
ROS-inducing effect of DAPK2 depletion is further enhanced when kinase dead 
DAPK2 is overexpressed (Figure 6-11), which ultimately suggests that the 
DAPK2 effect on the mitochondria is kinase mediated. Given the high sequence 
homology between the kinase domain of DAPK1 and DAPK2 (Figure 1-9) it is 
hardly surprising that their kinase dependent functions may overlap and thus  
both proteins may affect mitochondrial maintenance via their kinase activity. 
 
Remarkably, other scientists have previously reported that challenging cancer 
cells with several compounds could induce oxidative stress in these cells and 
sensitise them to TRAIL-induced apoptosis. For example, treatment of different 
types of cancer cells with compounds such as cardamomin, an experimental anti-
inflammatory drug, 20(S)-ginsenoside Rg3, a steroidal saponin that has been 
shown to sensitise resistant cells to several chemotherapeutic drugs, or 
indomethacin, a non-steroidal anti-inflammatory drug, resulted in increased 
intracellular ROS levels and re-sensitisation to TRAIL-induced apoptosis (Yadav 
et al., 2012, Lee et al., 2013, Tse et al., 2014). All of these compounds 
specifically activated the ER stress response gene CHOP which resulted in the 
transcriptional induction of DRs and thereby re-sensitisation to TRAIL-induced 
apoptosis. Other authors reported that induction of ROS using andrographolide, a 
diterpenoid lactone isolated from a traditional herbal medicine Andrographis 
paniculata, or γ-Tocotrienol, a member of the vitamin E family, led to p53-
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mediated upregulation of DRs (Zhou et al., 2008, Kannappan et al., 2010). 
Remarkably, the use of the uncoupler of oxidative phosphorylation CCCP 
resulted in an increased sensitisation to TRAIL via increased intrinsic apoptotic 
signalling (Izeradjene et al., 2005). 
 
Given the various reports linking ROS generation to sensitisation to TRAIL-
induced apoptosis, there was the possibility that depletion of DAPK2 induced 
ROS through deregulation of mitochondrial maintenance, which then turned 
U2OS and A549 cells sensitive to the killing effects of TRAIL. However, in 
contrast to previous reports, under the experimental conditions used throughout 
my PhD we did not detect induction of the transcription factor CHOP (Figure 6-4) 
and we demonstrated that p53 was not essential for the siDAPK2-mediated 
sensitisation to TRAIL (Figure 5-3). Moreover, in 2014 Tse et al. showed that the 
re-sensitisation of cancer cells to TRAIL-induced apoptosis in response to ROS 
induced using indomethacin involved the inhibition of NF-κB (Tse et al., 2014). In 
contrast, here, we have demonstrated that NF-κB activation plays a crucial role in 
the sensitisation to TRAIL. The relationship between NF-κB and ROS is rather 
complex. It has been reported that NF-κB pro-survival cues can be activated in 
response to ROS induction thereby promoting the transcription of antioxidant 
genes such as SOD2 (Jones et al., 1997). However, NF-κB has also been shown 
to induce cellular ROS by upregulating the expression of COX2 or the NADPH 
oxidase 2 (NOX2) (Deng et al., 2003, Anrather et al., 2006). Therefore, it is 
possible that increased levels of cellular ROS triggered the induction of NF-κB 
that was seen in response to RNAi-mediated depletion of DAPK2. In contrast, we 
found that the overexpression of DAPK2 ‘dampened’ the activation of NF-κB 
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(Figure 5-12a), but it was also accompanied by an increase of cellular ROS 
(Figure 6-10a). Our data thus suggest that the induction of NF-κB in response to 
DAPK2 knockdown and mitochondrial alterations seen likely represent two 
independent events.  
 
7.2 Limitations of the work 
7.2.1 Are in vitro studies ‘physiological enough’? 
 
The most concerning limitation of any work carried out with cell lines is that some 
findings may not translate into the in vivo setting. Unfortunately, we were unable 
to obtain DAPK2-null cells, which would have allowed us to exclude the remote 
possibility that the observed phenotypes were caused by the methods used to 
either increase or decrease. The first report of a DAPK2 knockout mouse was 
only reported this year (Guay et al., 2014), which is why it was not possible to 
utilise any DAPK2-negative mouse embryonic fibroblasts (MEFs) to help further 
understand the role of DAPK2 in NF-κB signalling and mitochondrial regulation. 
 
7.2.2 RNAi-mediated depletion: the ideal method? 
 
All experiments carried out during this PhD involved RNAi-mediated depletion of 
relevant target genes 48 h after siRNA-transfection. This time point allowed the 
efficient knockdown of targeted genes. However, for some particular experiments 
a more prolonged downregulation of DAPK2 would potentially have given further 
insights into DAPK2 molecular roles. Especially the effect of DAPK2 on 
mitochondrial metabolism would have been easier to analyse with a prolonged 
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DAPK2 depletion. Unfortunately, several attempts to create inducible small 
hairpin (sh) DAPK2-expressing cell lines that target DAPK2 and would have 
allowed a sustained DAPK2 depletion were unsuccessful. Newer methods using 
the CRISPR/Cas system may help to remedy this and it is certainly something 
that should be explored as a priority, as it may have a significant impact on the 
understanding of DAPK2 biology.  
 
7.3 Future perspectives !
7.3.1 Understanding the role of DAPK2’s kinase domain in TRAIL-
induced apoptosis 
 
Throughout this work the majority of observations were made using siRNAs, 
which target endogenous DAPK2. To understand whether the kinase domain of 
DAPK2 was involved in the modulation of NF-κB or mitochondria viability, cells 
were transfected with a kinase dead DAPK2, which is thought to mimic the effect 
of depleting this enzyme. When analysing the effect of kinase dead DAPK2 on 
NF-κB, we overexpressed kinase dead DAPK2 in U2OS TetR cells and assessed 
the effect of overexpressing this molecule on REL phosphorylation (Figure 
5-12b). Unfortunately, our initial attempts to mimic the effect of DAPK2 depletion 
on the sensitisation to TRAIL by overexpressing kinase dead DAPK2 were 
unsuccessful, most likely due to the expression of endogenous DAPK2, as 
overexpression of kinase dead DAPK2 lead only to a slight induction of RELA 
phosphorylation. Further experiments, as those shown in Figure 6-11, should be 
carried out, where a 3’UTR specific siRNA oligonucleotide was used to deplete 
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endogenous DAPK2 and only assess the effects of the exogenously 
overexpressed protein.  
 
7.3.2 How does DAPK2 regulate NF-κB? 
 
Despite the clear-cut data showing that downregulation of DAPK2 led to the 
activation of NF-κB, the precise way by which DAPK2 expression regulates the 
activity of NF-κB remains elusive. It remains a possibility that DAPK2 actually 
directly interacts with NF-κB family members and, apart from the obvious co-
immunoprecipitation experiments; more wide-ranging experiments with tandem 
affinity purification (TAP) could be used to identify interaction partners, followed 
by co-immunoprecipitations to verify potential findings. If these experiments 
reveal direct interactions between DAPK2 and NF-κB family members or their 
upstream regulators, interaction studies should be carried out to map down the 
exact interaction domains. These finding could make a significant difference to 
our current understanding of DAPK2 biology and its potential role as a 
therapeutic target.  
 
7.3.3 How does DAPK2 regulate the mitochondria? 
 
Experiments carried out during this PhD aimed at analysing the relations of 
DAPK2 and the mitochondria focused solely on mitochondrial changes upon 
DAPK2 knockdown. Further experiments analysing the activation status, and 
indeed cellular localisation, of DAPK2 in response to mitochondrial stress should 
be carried out to further analyse the potentially protective effect of DAPK2 on the 
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mitochondria. As DAPK2 must be dephosphorylated on S308 to become active, 
specific antibodies, raised against this epitope, could provide valuable 
information about the activation status of DAPK2 in response to mitochondrial 
stress and greatly facilitate the analyses. Furthermore, future work should include 
an analysis of the induction and/or stabilisation of DAPK2 in response to 
mitochondrial changes.  
 
7.3.4 Dynamics of DAPK2: where is the protein located? 
 
To date, the vast majority of reports analysing the function of DAPK2 have been 
based on overexpression studies. This is the reason why, for most of our 
experiments, we chose to manipulate endogenous DAPK2 using RNAi 
methodologies but which are also not without their own intrinsic problems. The 
exception to this were experiments carried out to ascertain certain properties of a 
kinase dead DAPK2, in which case, as others, we too made use of 
overexpressing systems,  
 
To gain further insight into the physiological role of DAPK2, future work should 
include the analysis of the cellular location(s) of endogenous DAPK2 using high-
resolution microscopy. Due to the lack of suitable good quality antibodies, 
fluorescence tagged versions of DAPK2 might be needed as a strategy to 
overcome this issue. By using advanced imaging techniques, such as förster 
resonance energy transfer (FRET), one could analyse the proximity of DAPK2 to 
members of the NF-κB family, or mitochondrial proteins and monitor their 
interactions in response to extracellular stimulations. 
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7.3.5 DAPK2 as a therapeutic target 
 
This work has revealed that DAPK2 is a potential therapeutic clinical target in 
combination with TRAs. For potential clinical application(s), DAPK2-specific 
kinase inhibitors should be tested for their ability to mimic the effect of RNAi-
mediated DAPK2 depletion. In 2014 Geering et al. published the first research 
article focusing on leucocyte biology using a DAPK2 specific inhibitor. Atempts 
should be made to source this inhibitor, which should then be used in further 
studies to analyse the effect of DAPK2 kinase inhibition on the regulation of NF-
κB and mitochondrial maintenance. 
7.3.6 Role of siDAPK2-induced ROS in the activation of NF-κB 
 
Unfortunately, attempts to scavenge cellular ROS levels using N-acetylcysteine 
(NAC) and assessing the effect of reduced cellular ROS levels on the re-
sensitisation to TRAIL-induced apoptosis were so far unsuccessful. This was 
most likely due to the length of the assay required for the RNAi-mediated 
depletion of DAPK2 (48 h). After 48 h higher doses of NAC exhibited a 
considerable amount of toxicity, whereas lower doses were unable to prevent the 
siDAPK2-induced induction of ROS. Further experiments making use of less 
toxic and more sophisticated ROS scavengers should be carried out to further 
understand the potential role of ROS in the activation of NF-κB and re-
sensitisation of resistant cancer cells to TRAIL-induced apoptosis in response to 
RNAi-mediated depletion of DAPK2.  !!
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7.3.7 Unravelling of the DAPK1-DAPK2 interactome !
This thesis provides persuasive evidence for a role of DAPK2 in the regulation of 
NF-κB and maintenance of mitochondria viability. Previous reports have also 
suggested the involvement of DAPK1 in the regulation of NF-κB and have 
postulated that DAPK1 is a potential sensor for the Δψm. As shown in Figure 
4-1, U2OS cells did not express detectable amounts of DAPK1, whereas A549 
did and this was de-phosphorylated, and thus presumably activated, upon 
DAPK2 knockdown (Figure 6-6). This suggests that DAPK1 might have been 
activated in A549 cells to compensate for the loss of DAPK2. Therefore, further 
experiments should analyse the possibility of a direct interaction between both 
kinases and ascertain whether these kinases are capable of cross-
phosphorylating each other. For this purpose, co-immunoprecipitation 
experiments and mapping of interaction domains, together with FRET and other 
high-resolution imaging techniques, could be carried out to provide an 
understanding of their complex relationship  !  
 
General Discussion and Future Perspective 
 
! 245!
7.4 Final conclusion 
 
The kinase domain of DAPK2 and DAPK1 share strong sequence homology, 
which makes it reasonable to assume that they share substrates. Clearly our 
understanding of how DAPK2 regulates and interacts with NF-κB, as well as its 
precise role in mitochondria metabolism, is in its infancy and much remains to be 
understood. As a regulator of NF-κB, DAPK2 is probably part of a multi-protein 
complex that is likely to be in relative proximity to membrane receptors, 
associated with upstream mediators of NF-κB, which may include proteins such 
as DAPK1. The disappearance of DAPK2 may disturb the balance of signalling 
components within or associated with this complex, thereby leading to the 
activation of NF-κB. As a mitochondrial regulator, DAPK2 is also likely to be part 
of a larger protein network that may be involved in processes such as the 
recycling of ‘faulty’ mitochondria. Overall, work carried out during my PhD point 
towards DAPK2 being an important mitochondrial regulator and potentially a 
clinical target to overcome TRAIL resistance. Indeed, DAPK2 inhibition in 
combination with TRAIL or TRAs may provide an alternative, novel, approach to 
overcome TRAIL-resistance by virtue of activating the pro-apoptotic facet of the 
NF-κB response. It is encouraging to think that it may ultimately open up new 
avenues for treatments of certain types of malignancies.  
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DAPK2 is a novel modulator of TRAIL-induced
apoptosis
CR Schlegel1, A-V Fonseca1,2, S Sto¨cker1,3, ML Georgiou1, MB Misterek1,4, CE Munro1, CR Carmo1,5, MJ Seckl1
and AP Costa-Pereira*,1
Targeting molecules involved in TRAIL-mediated signalling has been hailed by many as a potential magic bullet to kill cancer
cells efficiently, with little side effects on normal cells. Indeed, initial clinical trials showed that antibodies against TRAIL
receptors, death receptor (DR)4 and DR5, are well tolerated by cancer patients. Despite efficacy issues in the clinical setting,
novel approaches to trigger TRAIL-mediated apoptosis are being developed and its clinical potential is being reappraised.
Unfortunately, as observed with other cancer therapies, many patients develop resistance to TRAIL-induced apoptosis and there
is thus impetuous for identifying additional resistance mechanisms that may be targetable and usable in combination therapies.
Here, we show that the death-associated protein kinase 2 (DAPK2) is a modulator of TRAIL signalling. Genetic ablation of DAPK2
using RNA interference causes phosphorylation of NF-jB and its transcriptional activity in several cancer cell lines. This then
leads to the induction of a variety of NF-jB target genes, which include proapoptotic DR4 and DR5. DR4 and DR5 protein
expression is correspondingly increased on the cell surface and this leads to the sensitisation of resistant cells to TRAIL-
induced killing, in a p53-independent manner. As DAPK2 is a kinase, it is imminently druggable, and our data thus offer a novel
avenue to overcome TRAIL resistance in the clinic.
Cell Death and Differentiation (2014) 21, 1780–1791; doi:10.1038/cdd.2014.93; published online 11 July 2014
Despite the effort and resources invested in cancer research,
cancer remains a serious public health problem.Most patients
are treated surgically, with chemotherapeutic drugs and/or
antibodies and small molecule inhibitors. Patients generally
respond well to the initial therapy but frequently develop
resistance to it. This poses a challenge to their treatment and
calls for alternative approaches to be developed. Indeed,
much excitement was generated in the mid-1990s when
tumour necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) was identified.1–4
TRAIL is a death receptor (DR) ligand that signals through
DR4 and DR5, two members of the TNF receptor family.5–7
DR5 has two isoforms that differ by 29 amino acids and which
are functionally indistinguishable.5,8 TRAIL ligation activates
primarily the extrinsic apoptotic pathway. The formation of
ligand/receptor complexes leads to the assembly of a multi-
protein death-inducing signalling complex (DISC), which in
the case of TRAIL is typically composed of the adaptor Fas-
associated death domain, caspase-8, caspase-10 and/or
c-FLIP. These initiator caspases proteolytically cleave
effector caspases such as caspase-3, caspase-6 and/or
caspase-7 thereby activating them. This leads to the destruc-
tion of key cellular components and the appearance of typical
features of apoptosis. TRAIL can also activate intrinsic
apoptotic pathways via BID and thus involve mitochondria.
By virtue of preferentially killing tumour cells, TRAIL is seen by
many as a ‘magic bullet’ against cancer cells. Some cancer
cells, however, are resistant, or develop resistance, to
TRAIL-induced apoptosis. Several resistance mechanisms
have been described but they do not account for all cases
of resistant cells,9 suggesting that additional as yet
unidentified mechanisms exist. Deregulation at receptor,
DISC and mitochondria levels have all been described, and
the involvement of mitogen-activated protein kinases and
poly-(ADP-ribose) polymerase 1 (PARP1) have also been
suggested. Here we show that death-associated protein
kinase 2 (DAPK2) can be used as a target to overcome
resistance to TRAIL-induced apoptosis.
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DAPK2 (also known asDRP-1) belongs to the DAPK family,
which comprises a number of serine/threonine kinases
regulated by calcium/calmodulin that are involved in death-
inducing pathways. The three main members (DAPK1–3)
share a high degree of homology in the kinase domain but
vary greatly outside this key region. The most studied protein
is the founder molecule DAPK1, which has been implicated in
interferon-g, FAS ligand, TNF-a and ceramide-induced cell
death, among others.10 The gene is often methylated in
tumour cells and it is thought to be a tumour suppressor.11
DAPK2 is a much smaller protein than DAPK1 (42 versus
120 kDa), it lacks ankyrin repeats and, critically, the death
domain (Supplementary Figure S1). Accordingly, evidence for
a proapoptotic role is largely based on its ability to induce
apoptosis-like cell morphology upon overexpression.12–14
We thus hypothesised that endogenous DAPK2 may under
some circumstances have antiapoptotic properties and
provide cancer cells with prosurvival cues.
Results
DAPK2 depletion sensitises resistant cells to TRAIL-
mediated apoptosis. As DAPK2 lacks a recognisable death
motif, we asked what the contribution of endogenous DAPK2
to cell death induced by different apoptotic triggers was. We
used U2OS osteosarcoma cells and A549 non-small-cell
lung cancer cells as examples of two cancer cell lines with
different mutational backgrounds and which have been
extensively characterised in our laboratory.15,16 RNA inter-
ference (RNAi) was used to modulate the levels of DAPK2 in
these cells. A pool of short interfering (si) oligonucleotides
targeting different regions of DAPK2 (henceforth, siDAPK2),
which were validated by deconvolution (Supplementary
Figure S2), efficiently reduced DAPK2 mRNA and protein
levels in U2OS (Figure 1a) and A549 (Figure 1g) cells. Cells
were transfected with siDAPK2, challenged with TRAIL
(Figures 1b and h), cisplatin (Figures 1c and i), hydrogen
peroxide (H2O2) (Figures 1d and j), TNF-a (Figures 1e and k),
taxol or etoposide (not shown), and cell death levels
assessed using crystal violet viability assays. Cells trans-
fected with a non-targeting siRNA pool (siNS) were used as
controls in all experiments. The susceptibility of cells with
near-to-none DAPK2 expression was compared with that of
control cells. Data from three independent experiments (each
with triplicate samples) are shown as the mean percentage of
live cells±S.E.M. (Figure 1). U2OS were readily killed by
cisplatin (Figure 1c), oxidative stress (Figure 1d), etoposide
and taxol (not shown), and this was not dependent on
DAPK2. A549 were less susceptible than U2OS to the killing
effects of cisplatin (Figure 1i) or H2O2 (Figure 1j), but, as for
U2OS cells, the induction of apoptosis was also independent
of DAPK2 expression levels. As many other tumour cells,
U2OS and A549, were resistant to DR-mediated cell death
induced by TRAIL (Figures 1b and h, black bars) or TNF-a
(Figures 1e and k). Both cell types could be sensitised to
TNF-a-induced death by inhibiting protein synthesis using
cycloheximide (CHX) (not shown), but sensitisation to TNF-a
was not achieved by silencing DAPK2 (Figures 1e and k).
In contrast, reducing the levels of DAPK2 significantly
sensitised U2OS and A549 cells to TRAIL-induced cell death
(Figures 1b and h, green bars), suggesting that DAPK2
functioned as an inhibitory molecule that modulated TRAIL
signalling. Cell death was also assessed by measuring DNA
hypoploidy (Supplementary Figure S3), which yielded similar
results to those shown in Figures 1b and h.
Downregulation of DAPK2 leads to sensitisation to
TRAIL-induced apoptosis via increased apoptotic
signalling. Having observed that U2OS and A549 cells
were more susceptible to TRAIL-induced cell death after
DAPK2 knockdown, we asked what the molecular conse-
quences of DAPK2 silencing were. Cells were transfected as
before, treated with TRAIL for varying periods of time, and
proteins extracted and separated by sodium dodecyl
sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE)
(Figures 1f and l). Western blot (WB) membranes were
subsequently probed with antibodies specific to molecules
activated downstream of TRAIL. TRAIL-induced apoptosis
was studied over a period of 1–24 h and we chose to focus on
earlier time points as caspase activation is generally a rapid
event in cells sensitive to TRAIL. Caspase-8 and -10 are two
initiator caspases downstream of DRs and were thus
analysed first. Caspase activation was faster and stronger
in siDAPK2-transfected cells than in control cells (siNS)
(Figures 1f and l), as seen by both the emergence of smaller
caspase fragments (43, 41 and 18 kDa) and also by the
reduction in the full-length 55 kDa protein. Indeed, caspase-8
cleavage 1 h after TRAIL treatment was much weaker in
siNS-transfected cells than in cells transfected with siDAPK2.
The same was observed for caspase-10 (not shown).
Activation of caspase-8 leads to activation of the effector
caspase-3 and subsequent degradation of molecules such
as PARP, which ultimately results in cellular demise.
Accordingly, DAPK2 silencing also resulted in increased
caspase-3 and PARP cleavage (Figures 1f and l). In addition,
the reduction of BID expression and increased caspase-9
cleavage after DAPK2 silencing indicated the recruitment of
the intrinsic apoptotic pathway (Figures 1f and l). Collectively,
these data suggest that DAPK2 inhibited caspase activation
downstream of TRAIL by interfering both with the extrinsic
and intrinsic apoptosis pathways.
DAPK2 silencing leads to the upregulation of DR5, a key
receptor for TRAIL-induced apoptosis. The evidence for
the involvement of both these pathways suggested that
DAPK2 affected an upstream event common to both arms of
TRAIL apoptotic pathways. Accordingly, transfection of
U2OS and A549 cells with siDAPK2 led to the upregulation
of DR5 (Figures 2a–d), one of the receptors through which
TRAIL can signal to kill. DR4 was not expressed in U2OS
cells (not shown) but it was expressed in A549 and its
expression was also increased after silencing DAPK2
(Figure 2e). The greatly enhanced expression of DR4 and
DR5 was analysed both by SDS-PAGE/quantitative WB
(qWB) (Figures 2a and c) and by flow cytometry
(Figures 2b, d and e). Silencing DAPK2 had no effect
on the mRNA levels of any of the three TRAIL decoy
receptors: DcR1 (TRAIL-R3/TRID/TNFRSF10C),17 DcR2
(TRAIL-R4/TRUNDD/TNFRSF10D)17 and osteoprotegerin
(OPG/TNFSF11)18 (not shown). Interestingly, it also
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Figure 1 Knockdown of DAPK2 increases apoptotic signalling and sensitises resistant cancer cell lines to TRAIL-induced cell death. U2OS (a–e) and A549 (g–k) cells
were transfected with either siNS or DAPK2 siRNA. Forty-eight hours after transfection knockdown efficiency was determined by SDS-PAGE/WB and qPCR
(a and g). Data represent mean±S.E.M. of three independent experiments. Statistical analyses were carried out using Student’s t-test (paired, one-tailed) (***Po0.005). For
cell survival assays (U2OS in b–e and A549 in h–k), cells were replated into 96-well plates at a density of 2! 104 cells per well 24 h after siRNA transfection. The following
day, cells were treated with the indicated concentrations of TRAIL (b and h), cisplatin (c and i), H2O2 (d and j) and TNF-a (e and k) for 24 h. Cells were then fixed using
methanol and stained with crystal violet. Crystals were dissolved in 10% (v/v) acetic acid and quantified by measuring the absorbance at 595 nm. Values were normalised to
the untreated samples. Data represent mean±S.E.M. of three independent experiments performed in triplicate. Statistical analyses were carried out using two-way ANOVA
test (***Po0.005). Molecular events of TRAIL-induced apoptosis (f and l) were assessed by SDS-PAGE/WB. Forty-eight hours after A549 and U2OS cells were transfected
with siNS and siDAPK2, cells were treated with TRAIL (100 ng/ml) for the indicated time points. Activation of the extrinsic and intrinsic pathways were assessed by WB using
cleavage of BID, caspase-8, caspase-9, caspase-3 and PARP as read-outs. Lamin B, a-tubulin and HSP90 served as loading controls
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had no impact on the induction or expression of c-FLIP
(Supplementary Figure S4), effectively ruling out the induc-
tion of FLIP in the upregulation of DR5 and DR4, and,
therefore, in the sensitisation process.
In the absence of DR5, DAPK2 can neither sensitise
U2OS nor A549 cancer cells to TRAIL-induced apoptosis.
The upregulation of DR5 may have been necessary but not
sufficient for the sensitisation to TRAIL-induced apoptosis
observed after silencing DAPK2 (Figure 1). To determine its
relevance, knockdowns targeting concomitantly DAPK2 and
DR5 were performed. As controls, cells were transfected with
siNS, siDR5 or siBID. BID is part of a well-known amplifica-
tion loop downstream of TRAIL, which in some cells is
required to induce death. Cells were transfected with all
permutations of siRNA, as indicated. Downregulation of DR5
per se did not impact on the susceptibility of U2OS or A549 to
TRAIL-induced death (Figures 3a and c). In contrast, the
downregulation of DAPK2-sensitised cells, as shown pre-
viously, provided that the expression of DR5 was not
downregulated (compare cells transfected with siDAPK2/
siNS versus siDAPK2/siDR5). However, silencing DR5
would almost certainly revert the phenotype observed
when DAPK2 was silenced, as this is a key receptor for
TRAIL. We, therefore, titrated siDR5 (Figure 3f), measured
its impact on DR5 protein expression (Figures 3f and g) and
established the concentration at which only the DAPK2
RNAi effect was reverted (1.25 nM). Co-transfection
of U2OS cells with siDAPK2 (20 nM) and siDR5
(1.25 nM) impaired siDAPK2-mediated TRAIL sensitisation
(Figure 3h), thus backing up the data shown in Figures 3a
and c. This suggested that the upregulation of DR5
following silencing of DAPK2 was critical to sensitise
resistant cells to apoptosis. A549 cells also express DR4
and double knockouts of DR4 and DAPK2 suggested that
DR4 was partially required to sensitise them to TRAIL-
induced apoptosis. The effect does not seem to be as
pronounced as that seen when DR5 was silenced and,
despite the trend shown, it was not statistically significant
(Figure 3d). At higher concentrations of TRAIL, DR5
knockdown did not fully revert the phenotype, suggesting
that in these cells DR4 might be engaged to overcome
impaired DR5 expression (Figures 3c and d). Interestingly,
double knockdown of DAPK2 and BID (Supplementary
Figure S8) demonstrated that A549 cells required a BID
amplification loop for sensitisation (Figure 3e), whereas
U2OS cells did not (Figure 3b). Overexpression of BCL-XL
in U2OS cells further indicated that BID was not involved in
the sensitisation to TRAIL achieved in U2OS cells after
RNAi against DAPK2 (Supplementary Figure S5).
Increased DR5 expression following DAPK2 knockdown
is transcriptionally regulated and not due to altered
mRNA or protein stability. Having established that DR5
upregulation was a key event during DAPK2-mediated
sensitisation to TRAIL-induced death in A549 and U2OS,
we sought to establish within this context how DR5
expression was regulated. Using qPCR, we observed that
silencing DAPK2 upregulated the levels of DR5 mRNA in
both cell lines (Figures 4a and b). We then conducted classic
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Figure 2 DAPK2 silencing leads to the upregulation of DR5 and DR4, key
receptors for TRAIL. U2OS (a and b) and A549 (c–e) cells were transfected with
either siNS or siDAPK2 for 48 h. Proteins were isolated and the level of DR
expression was assessed by WB (a and c) or flow cytometry (b, d and e).
Densitometric analyses of WBs were plotted as fold change of DR expression
relative to the siNS control. Data represent mean±S.E.M. of three independent
experiments. Statistical analyses were carried out using one-way ANOVA test
(*Po0.05, **Po0.01 and ***Po0.005). Cell surface expression quantification was
carried out using geometric means of three independent experiments and plotted as
fold change of surface expression. Statistical analysis was carried out using
Student’s t-test (paired, one-tailed) (*Po0.05 and **Po0.01)
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experiments with actinomycin D (Figure 4c), which blocks
transcription or CHX (Figure 4f), which blocks translation and
thus de novo protein synthesis. Neither DR5 mRNA
stability (Figures 4d and e) nor the protein’s half-life
(Figures 4g and h) were significantly altered by reducing
the expression levels of DAPK2. The data are therefore
consistent with a transcriptional effect.
NF-jB is phosphorylated and transcriptionally active
when DAPK2 is downregulated. DR5 is transcriptionally
regulated by the tumour suppressor p53 and by NF-kB.19
Upon silencing DAPK2, there was no change in p53 mRNA
levels and both prostate cancer PC3 cells, which are p53 null,
and bladder cancer T24 cells, which have an inactivating
mutation in p53, can be sensitised to TRAIL by downregulating
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Figure 3 In the absence of DR5, siDAPK2 can neither sensitise U2OS nor A549 to TRAIL-induced apoptosis. Double knockdowns were carried out in U2OS (a and b) and
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transfection, cells were replated into 96-well plates at a density of 2! 104 cells per well. The following day cells were treated with TRAIL for 24 h at the indicated final
concentrations. Cells were methanol-fixed and stained with crystal violet. Staining was dissolved in acetic acid and quantified by measuring the absorbance at 595 nm. Values
were normalised to the untreated samples. Data represent mean±S.E.M. of three independent experiments performed in triplicate. Statistical analysis was carried out using
two-way ANOVA test (*Po0.05, **Po0.01 and ***Po0.005). (f) U2OS cells were transfected with either siNS, siLuc (both controls for RNAi off-target effects), siDAPK2 or
with siDAPK2 (20 nM) concomitantly with siDR5 (0.31–20 nM) for 48 h. DR5 expression was measured by flow cytometry and cell surface expression quantification carried out
as before. Co-transfection of U2OS cells with 1.25 nM siDR5 and 20 nM siDAPK2 abolished siDAPK2-mediated DR5 induction. (g) The effect of co-transfection was also
assessed using quantitative WB, which confirmed the results obtained by flow cytometry. (The shadow bands seen in the DAPK2 panel correspond to DR5, as the membrane
was probed for with this antibody after being stripped from the anti-DR5 antibody.) (h) To assess the impact of reverting the siDAPK2-mediated effects on DR5 protein levels
on cell survival after TRAIL, U2OS cells were transfected with either siDAPK2 (20 nM) and siNS (1.25 nM), or siDAPK2 (20 nM) and siDR5 (1.25 nM). Cells were replated into
96-well plates at a density of 2! 104 cells per well 24 h after siRNA transfection and treated the following day with the indicated concentrations of TRAIL for another 24 h. Cell
viability was assessed as in (a–e)
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DAPK2 (Supplementary Figure S6). These data suggested
that p53 was not necessary to sensitise TRAIL-resistant cells
to TRAIL-induced apoptosis and we thus focused on NF-kB.
Protein expression analysis of NF-kB components by SDS-
PAGE/qWB demonstrated that p100 and p52 (NF-kB2) were
induced (Figures 5c and d), whereas p105 (NF-kB1) levels
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Figure 4 DR5 increased expression following the knockdown of DAPK2 is transcriptionally regulated and not due to alterations on mRNA or protein stability. U2OS
(a, d and g) and A549 (b, e and h) cells were transfected with either siNS or siDAPK2. Forty-eight hours after transfection, RNA was harvested and DR5 (U2OS, A549) and
DR4 mRNA (A549) levels were analysed by qPCR (a and b). The experimental procedure for analysing DR5 mRNA stability is represented schematically in (c). RNA
stability was determined after RNAi against DAPK2 by inhibiting RNA synthesis with actinomycin D (Act-D) over the time periods indicated in the figure (d and e).
Experimental procedures used to analyse DR5 protein stability are represented in (f). Protein synthesis was inhibited using cycloheximide (CHX) after 48 h transfection
with siNS and siDAPK2 (g and h). DR5 protein levels were measured over time using quantitative WB followed by densitometric analysis, where each value was
normalised to the corresponding HSP90 loading control. For these analyses, the DR5l isoform was used. The data represent the mean of three independent
experiments±S.E.M. and no significant changes were detected using a two-way ANOVA test
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remained unchanged, with a slight increase in its proteolytic
cleavage as demonstrated by a 1.5- and 2-fold increase in p50
expression in U2OS and A549 cells, respectively (Figures 5a
and b). Importantly, RELA (p65/NF-kB3) was robustly
phosphorylated on S536 in both cell lines (Figures 5e and f).
This suggested that NF-kB was transcriptionally active when
DAPK2 was downregulated, which was confirmed using
luciferase reporter assays (Figures 5g and h). Further
analysis of NF-kB target genes by qPCR, which also included
induction of NF-kB components, further corroborated that
NF-kB was activated following RNAi against DAPK2. Indeed,
silencing DAPK2 led to robust induction of TNF-a, c-JUN,
NF-kB1, NF-kB2 and RELB, and, although modest, to an
increase in RELA and c-REL mRNA levels (Figures 5i and j).
The data are thus consistent with NF-kB having a critical role
in the aforementioned sensitisation.
NF-jB transcriptionally regulates DR5 expression and
leads to sensitisation of osteosarcoma and non-small-
cell lung cancer cells to TRAIL-induced apoptosis. The
absence of DAPK2 in U2OS and A549 cells sensitised these
otherwise resistant cells to TRAIL-induced cell death in what
appeared to be an NF-kB-dependent manner. We hypothe-
sised that if NF-kB activation was critical for the sensitisation,
then knocking down its components should lead to a reversal
of this phenotype. We, therefore, performed RNAi against
NF-kB1, NF-kB2 or RELA with or without targeting DAPK2
concomitantly (Figure 6 and Supplementary Figure S8) and
observed that U2OS cells with silenced DAPK2 became
resistant to TRAIL again only when NF-kB1 was absent
(Figures 6a and c–e). In contrast, A549 cells became
resistant when either NF-kB1 or NF-kB2 was silenced
(Figures 6f and h–j). Despite its strong phosphorylation,
RELA was redundant and its absence per se did not prevent
DAPK2 silencing from sensitising U2OS or A549 cells to
TRAIL-induced apoptosis. Interestingly, silencing RELB was
also without an effect on the sensitisation of U2OS cells to
TRAIL-mediated death but it partially blocked sensitisation of
A549 cells (Supplementary Figures S7 and S8). Taken
together, these data indicate that DAPK2 may be a core,
upstream, modulator of TRAIL signalling and that targeting
it may affect multiple resistance pathways. We further
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Figure 5 NF-kB is transcriptionally active upon knockdown of DAPK2. U2OS
(a, c, e, g and i) and A549 (b, d, f, h and j) cells were transfected with either siNS or
DAPK2 siRNA. Forty-eight hours after transfection, the expression levels of NF-kB1
(a and b), NF-kB2 (c and d), RELA pp65-S536 and RELA (e and f) was evaluated
by qWB. Lamin-B and HSP90 served as loading controls. Blots shown are
representative of three independent experiments yielding identical data. Luciferase
assays were performed to assess the transcriptional activity of NF-kB in response to
DAPK2 knockdown in U2OS (g) and A549 (h). RNAi-mediated DAPK2 depletion
was induced 24 h before co-transfection with a pNF-kB-Luc reporter Firefly
luciferase and a CMV promoter/Renilla-luciferase constructs. Twenty-four hours
later, both Firefly- and Renilla-luciferase activities were measured. Data were
analysed by normalising the Firefly luciferase to the luminescence obtained for the
Renilla-luciferase construct. Data represent mean±S.E.M. of three independent
experiments performed in triplicate. Statistical analysis was carried out using
Student’s t-test (paired, two-tailed) (*Po0.05). The effect of DAPK2 depletion on
the transcription of NF-kB target genes in U2OS (i) and A549 (j) cells was assessed
by qPCR after RNAi against DAPK2, which was carried out as described previously.
Statistical analysis was carried out using Student’s t-test (paired, one-tailed)
(*Po0.05, **Po0.01 and ***Po0.005)
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analysed the importance of NF-kB activation in DR5 transcrip-
tion using luciferase reporter assays (Figure 6k). The DR5
promoter was engaged upon cell transfection with siDAPK2
(Figures 6l and n), and this engagement was abrogated
if the NF-kB binding site on this promoter was abolished
(Figures 6k, m and o), indicating an absolute requirement for
NF-kB in siDAPK2-mediated DR5 upregulation.
Discussion
As DAPK2 shares B80% of homology to DAPK1 in the
kinase domain but has no discernible death domain12
(Supplementary Figure S1), we hypothesised that depending
on the cellular content and expression levels of DAPK2
this kinase would work either as a pro- or antiapoptotic
protein. Here, we have shown that RNAi-mediated depletion
of DAPK2 (Figures 1a and g) specifically sensitises
U2OS and A549 cells to TRAIL-induced apoptosis
(Figures 1b and h), but not to a wide range of other
apoptotic stimuli (Figures 1c–e and i–k).
Downregulation of DAPK2 leads to TRAIL-mediated
activation of both extrinsic and intrinsic death pathways
(Figure 7), and this is quicker in A549 cells than in U2OS
cells (Figures 1f and l). Interestingly, activation of the intrinsic
signalling appears dispensable in U2OS cells (Figure 3b and
Supplementary Figure S5) but represents a crucial part of
TRAIL-induced apoptosis upon DAPK2 depletion in A549
cells (Figure 3e). Many mechanisms of TRAIL resistance and
strategies to overcome these involve the DISC complex,
including downregulation of c-FLIP.20 Inhibition of BCL-2/
BCL-XL has also been shown to resensitise cells to TRAIL-
induced apoptosis.21,22 There was no change on FLIP upon
siDAPK2 (Supplementary Figure S4) and overexpressing
BCL-XL had no impact on DAPK2-mediated sensitisation of
U2OS to TRAIL (Supplementary Figure S5), suggesting that
these molecules are factors of TRAIL resistance that are
unlikely to be surpassed by silencing DAPK2. Perhaps, the
most prominent mechanism to overcome TRAIL resistance is
the upregulation of its receptors, DR4 and/or DR5. DAPK2
depletion leads to a significant increase of DR5 protein in
U2OS and A549 cells (Figures 2a–d). In A549 cells, it also
increases the expression of DR4 (Figure 2e). Such receptor
upregulation is essential for the sensitisation of U2OS and
A549 cells to TRAIL-induced apoptosis following downregula-
tion of DAPK2 (Figure 3).
DR expression can be induced by several chemicals, which
can cause either their mRNA stabilisation23 or transcriptional
upregulation by various transcription factors.19,24 DR induc-
tion leads to an increase in the number of receptor molecules
on the cell surface, thus overcoming the threshold required to
sensitise cells to TRAIL cytotoxicity. As U2OS cells do not
express DR4 and silencing DAPK2 leads to the upregulation
of DR5 in both U2OS and A549 cells (Figure 2), we focused on
the regulation of DR5 induction/expression upon DAPK2
depletion. We showed that depletion of DAPK2 does not
increase the mRNA (Figures 4c–e) or protein (Figures 4f–h)
stability of DR5. However, DR5 and DR4mRNAs are elevated
after silencing DAPK2 (Figures 4a and b), suggesting that
inhibition of DAPK2 leads to the transcriptional regulation
of DRs.
DR5 is regulated by a variety of transcription factors such as
p53 and NF-kB.19 The fact that DAPK2 silencing can also
sensitise p53-mutated (mt) T24 colon cancer cells and
p53-null prostate cancer PC3 cells rules out the absolute
requirement for p53 (Supplementary Figure S6). In contrast,
activation of NF-kB (Figure 5) is absolutely essential (Figure 6
and Supplementary Figures S7 and S8). This is interesting as
NF-kB has an ambiguous role in TRAIL signalling. For
example, there are reports suggesting an antiapoptotic role
for NF-kB, involving the upregulation of DcR125 or of
antiapoptotic BCL-XL,
26 whereas other reports suggest a
proapoptotic role due to the induction of DR4 or DR5.19,24
Interestingly, binding of TRAIL to DcR2 has been shown to
activate NF-kB, which then initiates a negative feedback loop
protecting cells from TRAIL-induced apoptosis.27 Using an
NF-kB reporter plasmid, we were able to show that NF-kB is
transcriptionally active in both U2OS and A549 cells following
DAPK2 knockdown (Figures 5g and h). RELA is phosphory-
lated on S536 (Figures 5e and f), and NF-kB1 and NF-kB2 are
upregulated (Figures 5a–d) in response to DAPK2 knock-
down. NF-kB signalling is highly complex and different
members assemble in different dimmers, which then partici-
pate in canonical and non-canonical signalling pathways.
Canonical pathways tend to involve NF-kB1 and RELA,
whereas the non-canonical pathway is thought to involve
primarily NF-kB2 and RELB. This distinction is not absolute
and a great deal of signalling specificity is determined by the
cell type and cellular environment.28 Indeed, NF-kB1, NF-kB2
and RELB were robustly induced in response to RNAi against
DAPK2 both in U2OS and A549 cells, and there was a hint of
an induction of RELA and c-REL (Figures 5i and j). To unravel
the complex role of NF-kB in TRAIL signalling, we performed
double-knockdown experiments (Figure 6). By analysing the
effect of TRAIL on U2OS and A549 cells transfected with
siDAPK2 concomitantly with siRNAs directed against NF-kB
family members, we identified NF-kB1 as key molecules
responsible for sensitisation to TRAIL-induced apoptosis in
response to DAPK2 depletion. Interestingly, in A549 cells,
knockdown of NF-kB2 and RELB in combination with
DAPK2 also resulted in a partial rescue (Figure 6i and
Supplementary Figure S7b). It thus appears that U2OS cells
require mainly the activation of the NF-kB canonical
pathway, whereas A549 cells require activation of both the
canonical and non-canonical pathways. It is still unclear why
this is but it is fair to assume that, due to distinct cellular
environments in these two cell lines, silencing DAPK2 leads
to the formation of different NF-kB dimers, which are
nevertheless capable of resulting in an identical biologic
response, namely upregulation of DR5. The fact that A549
seem to also require BID to be fully sensitised to TRAIL
after DAPK2 silencing may be related to the partial
requirement for NF-kB2/RELB. It is also possible that
NF-kB2 and/or RELB are required to induce DR4,
which is not expressed in U2OS cells. Using DR5 promoter
luciferase constructs with either wild-type (wt) or NF-kB-mt
consensus sites, we established the necessity of NF-kB as a
transcription factor required for the induction of DR5 in
response to DAPK2 depletion. Recently, Yoo et al.29
suggested that DAPK1 could function as a repressor
for NF-kB activation.29 Additionally, NF-kB activation
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downstream of T-cell receptor signalling is increased in
DAPK1-knockout cells.30 As all DAPKs are thought
to form multiprotein complexes,31 the activation of NF-kB
proteins upon DAPK2 knockdown is likely to be caused
by at least some of the same molecular events described
for DAPK1. Different NF-kB family members can thus
differentially regulate TRAIL receptors, which is reflected
by sensitisation to TRAIL following DAPK2 silencing
being dependent on NF-kB1 in U2OS and A549 cells and
by the additional requirement of NF-kB2 and RELB in
A549 cells.
The question thus remains how downregulating DAPK2
leads to the activation of NF-kB (Figure 5), vital to sensitising
resistant cells to TRAIL-mediated death (Figure 6). The
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involvement of NF-kB in TRAIL signalling is highly cell
context-dependent and DAPK2 likely regulates an upstream
component of NF-kB signalling. Such a component may be
the NF-kB-negative regulator, IkB. Indeed, silencing DAPK2
leads to its disappearance (not shown), which is probably the
main cause for the activation of NF-kB. This then poses the
question of why IkB is being degraded and the most
immediate hypothesis is that it is being phosphorylated by
IKKs, coupled to the TRAIL receptor complex. Such coupling
may occur via RIP and/or TRADD.32 Perhaps, DAPK2
Figure 6 The transcription factor NF-kB is a critical component of DR5 expression and is necessary for the sensitisation to TRAIL-induced cell death seen after DAPK2
silencing. U2OS (a–e, l and m) and A549 (f–j, n and o) cells were transfected with either siNS or the following siRNA 1 : 1 mixes: siNF-kB1þ siNS, siDAPK2þ siNS and
siDAPK2þNF-kB1 (40 nM in total). Forty-eight hours after transfection, RNA and proteins were isolated and levels of DR5 mRNA (a and f) and protein were measured (b and g).
For mRNA, data represent mean±S.E.M. of two independent experiments in U2OS cells (a) and three independent experiments in A549 (f). Statistical analyses were carried out
using Student’s t-test (paired, two-tailed) (*Po0.05). For protein, DR5 levels and knockdown verification were achieved with qWB, using lamin B as a loading control. Cell survival
analyses in response to TRAIL after the double knockdowns were carried out in U2OS and A549 cells that were transfected with either siNS or the following siRNA 1:1 mixes:
siNF-kB1þ siNS, siDAPK2þ siNS, siDAPK2þNF-kB1 (c and h), siNSþ siNF-kB2, siDAPK2þ siNF-kB2 (d and i) and siNSþ siRELA, siDAPK2þ siRELA (e and j).
Twenty-four hours after transfection, cells were replated into 96-well plates at a density of 2! 104 cells per well and treated with TRAIL for 24 h at the indicated final concentrations
the day after. Crystal violet viability assays were carried out as described previously. Values were normalised to the untreated samples. Data represent mean±S.E.M. of three
independent experiments performed in triplicate. Statistical analysis was carried out using two-way ANOVA test (*Po0.05, **Po0.01 and ***Po0.005). Plasmids used for DR5
promoter analyses are represented in (k). As before, DAPK2 depletion was initiated 24 h before co-transfection with the DR5 full-length promoter (l and n), DR5 promoter-intron wt
or NF-kB-mt (m and o) plasmid Firefly-luciferase pGL3 construct and a CMV promoter/Renilla-luciferase construct. Twenty-four hours later, both Firefly- and Renilla-luciferase
activities were measured. Data were analysed by normalising the Firefly luciferase to the luminescence obtained for the Renilla-luciferase activity. Data represent mean±S.E.M.
of three independent experiments. Statistical analysis was carried out using Student’s t-test (paired, two-tailed) (*Po0.05 and ***Po0.005)
Figure 7 DAPK2 is a novel modulator of TRAIL-induced apoptosis. Death receptor ligation by TRAIL primarily activates the extrinsic apoptotic pathway. TRAIL binding
induces DISC formation. Activation of the initiator caspases-8/10 leads to proteolytic cleavage and activation of downstream effector caspases such as caspase-3, which
eventually culminates in apoptosis. TRAIL can also activate the intrinsic apoptotic pathway via BID. This involves depolarisation of the mitochondrial membrane potential via
BAK and BAX, followed by cytochrome c release and downstream activation of caspase-9. Resistance mechanisms can occur at many different stages of the cascade. c-FLIP
can inhibit the activation of initiator caspases within the extrinsic pathway, XIAP can block the action of effector caspases and antiapoptotic members of the BCL-2 family, such
as BCL-XL and BCL-2, which are known inhibitors of the intrinsic apoptosis pathway. Depletion of DAPK2 triggers the activation of NF-kB and leads to NF-kB-mediated
induction of DR5 mRNA and to an increase in DR5 protein levels. The increase in the number of DR5 molecules presumably overcomes the inhibition threshold and lead to the
resensitisation of cancer cells to TRAIL-induced apoptosis
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interacts with the TRAIL receptor complex and it acts as a
‘plug’ that stops cells from ‘inadvertently’ succumbing to
TRAIL. Removing DAPK2 may free binding sites necessary
to couple the pathway to the initiator caspases and to NF-kB.
It is also possible that the interaction between NF-kB
signalling components and DAPK2 occurs in the cytoplasm
rather than at the membrane with IKKs and IkB being the
most likely interactors. DAPK2 may alternatively repress
NF-kB by, for example, protecting the cell from cellular
stress, known to activate NF-kB. Whichever way DAPK2
silencing leads to NF-kB activation, NF-kB activation per se,
in response to a classic NF-kB activator such as TNF-a,
leads to the degradation of DAPK2 (not shown). What is
intriguing is why the output of the TRAIL stimulus is death, as
NF-kB also leads to the activation of key survival genes. The
balance must thus rest on the faster caspase activation
observed following DAPK2 silencing and on the NF-kB-
mediated induction of DR5 and/or DR4. Clearly, our under-
standing of how DAPK2 and NF-kB interact is in its infancy
and much remains to be understood.
Overall, our work suggests that inhibition of DAPK2 in
combination with TRAIL or TRAIL mimics may provide an
alternative, novel, approach to overcome TRAIL resistance
via activating proapoptotic functions of the NF-kB response,
and may ultimately open new avenues for treatments of
certain types of malignancies.
Materials and Methods
Cell culture. U2OS and A549 cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% (v/v) foetal calf serum (FirstLink, Wolverhampton,
UK), 2 mM L-glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin (Sigma-
Aldrich, St. Louis, MO, USA) in a humidified atmosphere of 10% CO2 at 37 1C.
TRAIL and TNF-a were from PeproTech (London, UK) and all other chemicals
were from Sigma-Aldrich.
Antibodies. Anti-DAPK2 was purchased from Epitomics (Burlingame, CA,
USA). Antibodies against DR5, NF-kB1 (p50, p105), NF-kB2 (p52, p100), RELA
(p65), phosphorylated RELA (pp65-S536), BID, PARP, BCL-XL, caspase-3,
caspase-8 and caspase-9 were bought from Cell Signaling Technology
(Cambridge, UK). The antibodies against b-actin, a-tubulin and Flag were
obtained from Sigma-Aldrich and the one against HSP90 was from NeoMarkers
(Fremont, CA, USA). The antibody against lamin B was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Secondary antibodies were from Dako
(Glostrup, Denmark). For flow cytometry, the antibody against DR5 was
from eBioscience (Hatfield, UK) and the one against DR4 was from Abcam
(Cambridge, UK).
RNAi. RNAi was performed as described before16 using Lipofectamine
RNAiMax (Invitrogen, Paisley, UK). Briefly, cells plated at 2.5! 105 in 6-well
plates were left untransfected or were transfected with either 20 nM AllStars
negative control siRNA (Qiagen, Hilden, Germany) or 20 nM siGENOME pooled
siRNA (Dharmacon, Lafayette, CO, USA) to DAPK2 (oligonucleotides 3 and 4),
DR4, DR5, BID, NF-kB1, NF-kB2 and RELA (pool of four oligonucleotides)
(Supplementary Table SI). A custom-made siDAPK-30-UTR oligonucleotide
from Dharmacon and another 30-UTR-targeting siDAPK2 oligonucleotide from
Qiagen (Hs_DAPK2_11 FlexiTube siRNA) were also used. For double
knockdowns, equal amounts of AllStars negative control and/or targeting
siRNA were mixed to a final concentration of 40 nM. To avoid variability in cell
numbers, 24 h after transfection, cells were counted and replated at identical
numbers. Cells were then treated and analysed as described in the figures
using the methods described below.
Cell survival assays. Cells were plated in triplicate in 96-well plates (2! 104
cells per well) and treated the next day with different concentrations of TRAIL,
cisplatin, H2O2 or TNF-a for 24 h, as indicated in the figures. Cell survival was
assessed using crystal violet staining. For that purpose, cells were washed in
phosphate-buffered saline (PBS), and fixed and stained with 0.5% (w/v) crystal
violet in 25% (v/v) methanol for 30min. The plates were then thoroughly washed
with water, dried and the dried dye dissolved in 10% (v/v) acetic acid. The
absorbance was measured at 595 nm in a spectrophotometer. Apoptosis was also
determined by studying cell cycle profiles: cells were washed two times with PBS
and fixed with ice-cold 70% (v/v) ethanol for 30min. After two additional washing
steps, cells were incubated with 20 mg/ml ribonuclease A (Qiagen) and stained
with 50mg/ml PI for 15min in the dark. Cells were processed using a flow
cytometer and the data were analysed using FlowJo version 8.8.7 (Tree Star Inc.,
Ashland, OR, USA).
Western blotting. Proteins were extracted using radioimmunoprecipitation
assay buffer (RIPA; 50mM Tris-HCl (pH 7.4), 0.5% (v/v) NP-40, 150 mM NaCl,
1 mM EDTA, 1mM Na3VO4 and ‘cOmplete and Mini, EDTA-free protease inhibitor
cocktail’, the latter used as instructed by the manufacturer; Roche, Mannheim,
Germany). Concentrations were determined using a Bradford assay according to
the manufacturer’s instructions. They were then analysed by SDS-PAGE/qWB.
Membranes were blocked and secondary antibodies diluted in 5% (w/v)
non-fat milk/TBS-Tween-20 and primary antibodies were dissolved in 5% (w/v)
BSA/TBS-Tween-20. WBs were analysed using the quantitative luminescence
system Fusion SOLO (Analis, Ghent, Belgium). Densitometric analysis was
performed using Image Studio Lite software (LI-COR Biosciences, Lincoln, NE,
USA) (http: //www.licor.com/islite).
Flow cytometry. Cells were incubated with anti-DR4-FITC or anti-DR5-PE for
1 h at 4 1C, washed five times with cold PBS and fixed with 1% (w/v)
p-formaldehyde. Cells were analysed using a FACS Canto (Becton Dickinson,
Franklin Lakes, NJ, USA) and data were analysed with FlowJo Version 8.8.7.
Geometric means were used for the analyses.16
Real-time PCR. Gene expression analysis was carried out by quantitative
two-step reverse transcription PCR. Reverse transcription was performed using
total RNA and the High Capacity cDNA Reverse Transcription kit (Life Technologies,
Carlsbad, CA, USA), using random hexamers. qPCR was carried out using the
Fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) with
specific primer pairs (Supplementary Table SII). For each target mRNA analysed,
2.5ml of Fast SYBR Green Master Mix, 0.5mM of each primer pair and 2 ml of
cDNA in deionised water (5 ng/ml) were mixed in 384-well plates in duplicates
using Matrix Equalizer Electronic Multichannel Pipetters (Thermo Fisher Scientific,
Waltham, MA, USA). qPCR was carried out on an ABI PRISM 7900HT (Applied
Biosystems) using the following settings: initial activation of 20 s at 95 1C, 40
cycles; denaturation for 1 min at 95 1C; annealing/extension for 20 s at 60 1C; final
melting curve was carried out for 15 s at 95 1C and then 15 s at 60 1C.
Quantification of target messages was performed using qbasePLUS software
(Biogazelle, Ghent, Belgium). HPRT and GAPDH were the reference genes used
for normalisation.
Co-transfection of adherent cells with siRNA and DNA. Co-
transfection was performed using Attractene transfection reagent (Qiagen). Briefly,
cells plated at density of 4! 105 in 6-well plates were transfected with either
40 nM AllStars negative control siRNA or 40 nM siDAPK2 and 1.2mg DNA of
empty vector control, or pCDNA3.BCL-XL plasmid, which was kindly provided by
Dr. Ingram Iaccarino (Institute of Human Genetics, University Hospital Schleswig-
Holstein, Kiel, Germany). Protein expression was analysed by qWB and cell death
using crystal violet assays.
Plasmids. The DR5 full-length promoter pGL3 construct and DR5 promoter-
intron wt and NF-kB-mt pGL3 constructs were kindly provided by Professor
Spencer Gibson (University of Manitoba, Winnipeg, MB, Canada). pNF-kB-Luc
reporter vector was from Clontech (Saint-Germain-en-Laye, France). The BCL-XL
expression plasmid was a gift from Dr. Ingram Iaccarino (Institute of Human
Genetics, University Hospital Schleswig-Holstein, Kiel, Germany).
Luciferase assays. Cells were transfected with siRNA oligonucleotides as
described above. Twenty-four hours later, cells were co-transfected with 100 ng
of pNF-kB-Luc, DR5 full-length promoter Firefly-luciferase pGL3, DR5
promoter-intron wt Firefly-luciferase pGL3 or DR5 promoter-intron NF-kB-mt
Firefly-luciferase pGL3 constructs and 10 ng of CMV promoter Renilla-luciferase
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pRL construct using Attractene transfection reagent (Qiagen). The day after,
both Firefly- and Renilla-luciferase activities were quantified using the Dual-Glo
Luciferase Assay System (Promega, Madison, WI, USA) according to the
manufacturer’s instructions. Luminescence was detected using a PHERAstar
Plus plate reader (BMG Labtech, Ortenberg, Germany). The measured luminescence
for Firefly-luciferase activity was normalised to that of Renilla luciferase.
mRNA and protein stability. Cells were transfected with siRNA
oligonucleotides as before. Forty-eight hours after transfection cells were treated
with 5 mg/ml actinomycin D for 1–4 h. Subsequently, RNA was isolated using an
RNeasy Mini Kit (Qiagen) following the manufacturer’s instructions. Gene
expression analysis was performed by qPCR as described before, using HPRT
and GAPDH as housekeeping genes. For protein stability, cells were incubated
with CHX for 2, 4 or 6 h and protein measured by SDS-PAGE/qWB using the
Fusion SOLO quantitative luminescence system (PEQLAB, Erlangen, Germany).
Statistical analysis. Mean±S.E.M. of three independent experiments were
calculated. Statistical tests were carried out as indicated in each figure legend
using GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA).
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DAPK2 regulates oxidative stress in cancer cells by
preserving mitochondrial function
CR Schlegel1, ML Georgiou1, MB Misterek2, S Stöcker3, ER Chater1, CE Munro1, OE Pardo1, MJ Seckl1 and AP Costa-Pereira*1
Death-associated protein kinase (DAPK) 2 is a serine/threonine kinase that belongs to the DAPK family. Although it shows
significant structural differences from DAPK1, the founding member of this protein family, DAPK2 is also thought to be a putative
tumour suppressor. Like DAPK1, it has been implicated in programmed cell death, the regulation of autophagy and diverse
developmental processes. In contrast to DAPK1, however, few mechanistic studies have been carried out on DAPK2 and the
majority of these have made use of tagged DAPK2, which almost invariably leads to overexpression of the protein. As a
consequence, physiological roles of this kinase are still poorly understood. Using two genetically distinct cancer cell lines as
models, we have identified a new role for DAPK2 in the regulation of mitochondrial integrity. RNA interference-mediated depletion
of DAPK2 leads to fundamental metabolic changes, including significantly decreased rate of oxidative phosphorylation in
combination with overall destabilised mitochondrial membrane potential. This phenotype is further corroborated by an increase in
the production of mitochondrial superoxide anions and increased oxidative stress. This then leads to the activation of classical
stress-activated kinases such as ERK, JNK and p38, which is observed on DAPK2 genetic ablation. Interestingly, the generation of
oxidative stress is further enhanced on overexpression of a kinase-dead DAPK2 mutant indicating that it is the kinase domain of
DAPK2 that is important to maintain mitochondrial integrity and, by inference, for cellular metabolism.
Cell Death and Disease (2015) 6, e!; doi:10.1038/cddis.2015.31; published online xx xxx 2015
Death-associated protein kinase (DAPK) 2 shares a high level
of homology within its kinase domain with the other two DAPK
family members, DAPK1 (DAPk) and DAPK3 (ZIPK/DLK).
Since the identification of DAPK1 by the Kimchi and co-
workers1 numerous studies have shown that DAPK1 functions
as a tumour suppressor, is linked to key events in autophagy
and is involved in mitochondrial maintenance2 and
metabolism.3 DAPK2, which was characterised in 1999,4 is
significantly smaller than DAPK1, and it lacks ankyrin repeats,
the cytoskeletal binding domain and the death domain, all of
which are part of DAPK1’s unique structure.1 Several
functions have been ascribed to DAPK2 and they often
coincide with those of DAPK1. Like DAPK1, DAPK2 is also
involved in the formation of autophagic vesicles,5,6 modulation
of receptor induced cell death7–9 and several modes of
intrinsic apoptotic cell death.6 While epigenetic silencing of
DAPK1 has been reported in many different human
cancers,10,11 DAPK2 appears to be silenced mainly in
haematological disorders,12 although it has been shown to
modulate TRAIL-induced apoptosis in several cancer cell lines
of non-haematological origin.9 Most approaches used for
studying the role of DAPK2 used tagged DAPK2 and it is,
therefore, still unclear whether these functions are also carried
out by the native protein, expressed at much lower, endogen-
ous, levels.
DAPK1 has been shown to regulate mitochondrial integrity
and tomodulate themitochondrial membrane potential2 but, to
the best of our knowledge, no work has been carried out in this
respect with regard to DAPK2. Since DAPK1 and DAPK2
appear to share many functions and both are thought to
reside, at least partially, in the mitochondria, we hypothesised
that DAPK2 depletion regulated mitochondrial metabolism.
Mitochondrial dysfunction is characterised by the induction of
reactive oxygen species (ROS) in the cell.13 Ultimately,
dysfunctional mitochondria can no longer be powerhouses
of use to the cell and are, therefore, targeted for degradation.
Alternatively, their membranes can depolarise leading to the
release of cytochrome c, an early apoptotic process.14 Using
two distinct cancer cell types, namely U2OS osteosarcoma
and A549 non-small cell lung cancer cells,9,15 we show
that DAPK2 depletion increases the levels of intracellular
ROS, leads to mitochondrial depolarisation and impairs
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mitochondrial metabolism. DAPK2 thus exerts metabolic and
mitochondria-regulating functions, which have not been
described to date and that can explain why it is downregulated
in haematological malignancies,12,16,17 and involved in
modulating death-inducing signalling in solid tumours.9
Results
RNAi-mediated ablation of DAPK2 induces oxidative
stress and activates mitogen-activated protein kinases.
Although DAPK2 is structurally significantly different from
DAPK1, their kinase domains are highly homologous.18 As
DAPK1 has been shown to be involved in mitochondrial
regulation,2 we asked whether DAPK2 could also modulate
the level of cellular oxidative stress. For that purpose, DAPK2
was targeted with a pool of short interfering (si) RNA
oligonucleotides (henceforth referred to as siDAPK2), pre-
viously validated in our laboratory (Supplementary Figure S1)9.
U2OS osteosarcoma and A549 lung cancer cells were
transfected with either a control non-targeting siRNA oligo-
nucleotide (siNS) or with siDAPK2 and proteins were
analysed by sodium dodecyl sulphate-PAGE electrophoresis
(SDS-PAGE). Quantitative western blots (qWB) in Figure 1
show the efficiency of the knockdown of DAPK2 in U2OS
(Figure 1a) and A549 (Figure 1e) cells, when compared with
the control siNS-transfected cells.
Oxidative stress was studied by flow cytometry in cells
transfected with siNS, siDAPK2 or challenged with H2O2
(positive control for the production of ROS). General oxidative
stress was analysed using the chloromethyl 2ʹ,7ʹ-dichlorodihy-
drofluorescein diacetate (CM-H2DCFDA, henceforth referred
to as DCFDA) probe (Figures 1c and g) and superoxide
production was assessed using the dihydroethidium (DHE)
probe (Figures 1d and h). The fluorescence of cells
transfected with siDAPK2 or treated with H2O2 was compared
to that of control cells (siNS). The histograms depict typical cell
profiles obtained in each experiment and the bar charts on the
right conglomerate mean percentage of fluorescence normal-
ised to control cells±S.E.M. from three independent experi-
ments. Both DAPK2 depletion and H2O2 treatment resulted in
an increase in general oxidative stress in U2OS (Figure 1c)
and A549 (Figure 1g) cells. The same was observed with
regard to the generation of superoxides, which was elevated
on siDAPK2 depletion and on treatment with H2O2 in both
U2OS (Figure 1d) and A549 cells (Figure 1h).
Having observed a clear induction of ROS (H2O2 and O2
•− )
on silencing DAPK2, we asked whether this led to the
activation of mitogen-activated protein kinases (MAPKs),
which are known to be activated by oxidative stress as part
of a pro-survival response.19 Hence, WBmembranes (Figures
1a and e) were probed with antibodies raised against the
phosphorylated forms of ERK1/2, p38 and JNK. Depletion of
DAPK2, when compared with the siNS control, led to clear
phosphorylation/activation of ERK1/2Thr202/Tyr204 and
JNKThr183/Tyr185 in U2OS and A549 cells, whereas phosphor-
ylation of p38Thr180/Tyr182 was only observed in U2OS cells but
not in A549 lung cancer cells (Figure 1a versus Figure 1e).
Superoxide anion (O2
•− ) is a potentially damaging free
radical, which is converted into less reactive hydrogen
peroxide (H2O2) by enzymes of the superoxide dismutase
(SOD) family. To analyse the effect of DAPK2 depletion on the
expression of SOD1, the predominant cytoplasmic SOD, and
mitochondrial SOD2, cells were transfected as before and
RNAwas subsequently extracted. Therewas significant, albeit
small (o1.5-fold), upregulation of both SOD1 and SOD2
mRNA in U2OS cells (Figure 1b). In contrast, in A549 cells,
SOD1 mRNA was not induced but SOD2 mRNA was greatly
increased (greater than fourfold; Figure 1f).
DAPK2 knockdown increases the levels of mitochondrial
O2•− and leads to spontaneous mitochondrial membrane
depolarisation. Silencing DAPK2 in two different cell lines
led to upregulation of cellular ROS, downstream activation of
MAPKs and upregulation of mitochondrial SOD2, whereas
SOD1 was only slightly upregulated in one of the cell lines
(U2OS). We, therefore, asked whether the source of oxidative
stress were mitochondria. Indeed, the production of ATP by
oxidative phosphorylation is a major source for mitochondrial
ROS, and mitochondrial proton and electron leaks can impact
on mitochondrial coupling efficiency and lead to increased
production of mitochondrial ROS.20 MitoSOX Red (Molecular
Probes) was used to assess mitochondrial O2
•− levels since it
selectively targets mitochondria and is exclusively oxidised
by O2
•− (Figure 2). Cells were transfected as before and
treatments with H2O2 or the mitochondrial complex I inhibitor
1-methyl-4-phenylpyridinium (MPP+) iodide served as posi-
tive controls for the experiment. Unsurprisingly, both treat-
ments increased the levels of mitochondrial O2
•− (Figures 2a
and e). As hypothesised, RNA interference (RNAi)-mediated
depletion of DAPK2 resulted in a small but statistically
significant increase of mitochondrial O2
•− in U2OS (Figures
2b and c) and A549 cells (Figures 2f and g) compared with
siNS-transfected cells.
Another potential source for cellular ROS is the endoplas-
mic reticulum (ER) where the transcription factor CCAAT-
enhancer-binding protein homologous protein (CHOP) is
specifically activated on ER stress.21 To induce ER stress
we used tunicamycin,22 which induced the expression of
CHOP in both U2OS (Figure 2d) and A549 cells (Figure 2h). In
contrast, DAPK2 knockdown did not increase CHOP expres-
sion in either cell line (Figures 2d and h).
Elevated levels of mitochondrial O2
•− can be both a cause
and a consequence of mitochondrial depolarisation,23 which
is involved in apoptosis and inflammation.24,25 To study the
effect of DAPK2 depletion on mitochondrial membrane
potential (Δψm), the JC-1 probe was used. U2OS and A549
cells were transfected with either siNS, or siDAPK2 and, as a
control for Δψm depolarisation, cells were treated with
carbonyl cyanide 3-chlorophenylhydrazone (CCCP), and
then analysed by flow cytometry. Two distinct cell populations
were identified after gating the depolarised population that
resulted from CCCP treatment: one with intact mitochondria
and another that harboured cells with depolarised mitochon-
dria. Depletion of DAPK2 led to ~ 50% more depolarised
mitochondria in both U2OS (Figures 3a–c) and A549 cells
(Figures 3g–i), when compared with control cells. This
pattern can also be seen in the histograms in Figures 3d, e,
j and k. After normalising the absolute fluorescence of cells
on DAPK2 knockdown to that of siNS-transfected cells,
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Figure 1 DAPK2 depletion induces oxidative stress, phosphorylation of MAPKs and transcription of SODs. U2OS (a–d) and A549 (e–h) cells were transfected with either
siNS or DAPK2 siRNA. Forty-eight hours after transfection, the efficacy of DAPK2 silencing and phosphorylation of ERK1/2, JNK and p38 were assessed by SDS-PAGE/qWB
using Lamin B and HSP90 as loading controls (a and e), and the induction of SOD1 and SOD2 mRNAwas measured by qPCR (b and f). Data represent mean± S.E.M. of three
independent experiments. Statistical analyses were done using Student’s t-test (paired, one tailed) (Po0.05). Oxidative stress was detected by flow cytometry. Cells were
transfected with siNS or siDAPK2 for 48 h, and H2O2 treatment (0.5 mM, 24 h) was used as a positive control for ROS production. The DCFDA probe was used to detect general
ROS in U2OS (c) and A549 cells (g), whereas O2•− anions were detected in U2OS (d) and A549 cells (h) using the DHE probe. Staining intensity was quantified using geometric
means of three independent experiments and plotted as fold change in relation to the siNS-transfected cells. Statistical analysis was done using Student’s t-test (paired, one tailed)
(*Po0.05, **Po0.01)
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a significant overall increase in green fluorescence, a read-
out for decreased Δψm, was measured in both cell lines
(Figures 3f and l), suggesting that DAPK2 ablation increased
spontaneous mitochondria depolarisation. This was con-
firmed using tetramethylrhodamine ethyl ester (TMRE),
another mitochondrial probe (Figure 4).
Treatment with mitochondrial complex inhibitors leads to the
activation of DAPK1 and a decrease in Δψm2. As shown in
Figure 3m A549 cells depleted of DAPK2 have reduced
DAPK1 phosphorylated on S308, which is an inactivating
phosphorylation event that modulates DAPK1 activity. This
suggested that silencing DAPK2 led to the activation of
0 103 105104102
0 103 105104102 0 103 105104102
0 103 105104102
0
20
40
60
80
100
M
ax
im
um
 M
ito
SO
X 
Si
gn
al
 (%
) 
M
ax
im
um
 M
ito
SO
X 
Si
gn
al
 (%
) 
M
ax
im
um
 M
ito
SO
X 
Si
gn
al
 (%
) 
M
ax
im
um
 M
ito
SO
X 
Si
gn
al
 (%
) 
Fluorescence intensity
H2O2
siNS
MPP+
H2O2
siNS
MPP+
0
20
40
60
80
100
Fluorescence intensity
siDAPK2
siNS siNS
siN
S
siD
AP
K2 siN
S
siD
AP
K2
0.0
0.5
1.0
1.5
2.0
*
Fo
ld
 c
ha
ng
e 
M
ito
SO
X
Fo
ld
 c
ha
ng
e 
M
ito
SO
X
 in
te
ns
ity
 in
te
ns
ity
0
20
40
60
80
100
Fluorescence intensity
siDAPK2
0
20
40
60
80
100
Fluorescence intensity
0.0
0.5
1.0
1.5
*
DAPK2
HSP90
si
N
S
si
D
AP
K2
CHOP 27 kDa 
42 kDa 
90 kDa 
Tu
ni
ca
m
yc
in
DAPK2
HSP90
si
N
S
si
D
AP
K2
CHOP 27 kDa 
42 kDa 
90 kDa 
Tu
ni
ca
m
yc
in
unspecific band unspecific band
U2OS cells A549 cells
Figure 2 DAPK2 knockdown triggers mitochondrial O2•− production. U2OS (a–d) and A549 (d–h) cells were transfected with either siNS or DAPK2 siRNA. Forty-eight hours
later, mitochondrial O2
•− levels were assessed using the MitoSOX Red probe. U2OS (a and b) and A549 (e and f) cells were also treated with H2O2 (0.5 mM) or MPP+ (1 mM),
which were used as positive controls, for 24 h. The average of geometric means of four independent experiments was plotted as fold change (siNS versus siDAPK2) (c and g).
Statistical analysis was done using Student’s t-test (paired, two tailed) (*Po0.05). ER stress was assessed 48 h after siRNA transfection by SDS-PAGE/qWB using CHOP
expression as a read-out (d and h). The induction of CHOP protein following treatment with tunicamycin (0.5 μg/ml) served as positive control and HSP90 expression was used as
a loading control
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DAPK1. Interestingly, U2OS cells did not express DAPK1
protein or mRNA (data not shown). Thus, although mitochon-
drial depolarisation in A549 cells might be associated with
activation of DAPK1, in U2OS cells this is unlikely.
Altered mitochondrial integrity leads to metabolic
changes. The increase in mitochondrial O2•− production
and spontaneous mitochondrial depolarisation after DAPK2
silencing suggested that mitochondria were the likely source
of ROS. The data were consistent with a significant
impairment of mitochondrial integrity in response to DAPK2
depletion and, in the case of A549 lung cancer cells,
activation of DAPK1. The metabolic consequences of these
mitochondrial alterations in DAPK2-depleted cells were,
therefore, investigated next.
Eukaryotic cells use two key metabolic pathways for ATP
generation (Figure 5a). Both pathways start with glycolysis
as the first step of glucose metabolism, converting one
glucose molecule into two molecules of pyruvate with gain of
two ATP molecules. Aerobic respiration involves the trans-
port of pyruvate into the mitochondria and mitochondrial
respiration downstream of glycolysis through the tricarboxylic
acid (TCA)/Krebs cycle, which yields another thirty four ATP
molecules/molecule of glucose.26 Anaerobic respiration
includes glycolysis and the fermentation of pyruvate to
lactate, a metabolic pathway that bypasses mitochondrial
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Figure 3 Genetic ablation of DAPK2 increases the rate of spontaneous mitochondrial membrane depolarisation using the JC-1 probe. U2OS (a–f) and A549 (g–m) cells were
transfected with either siNS or siDAPK2. Forty-eight hours after transfection cells were incubated with JC-1 and the fluorescence of J-aggregates or monomers was measured in
red and green fluorescence channels by flow cytometry. CCCP (50 μM) was used to induce complete mitochondrial depolarisation (c and i) and to set appropriate gates in U2OS
(a–c) and A549 cells (g–i) used for the quantification of mitochondrial depolarisation following transfection with siNS (a and g), or siDAPK2 (b and h). Overall green fluorescence
(FITC) data is also presented in histograms (U2OS: d and e; A549: j and k). Staining intensity was quantified using geometric means of three independent experiments and
plotted as fold change (f and l). Data represent mean± S.E.M. of three independent experiments and the statistical analysis was done using Student’s t-test (paired, one tailed)
(*Po0.05). The phosphorylation of DAPK1 on Ser308 and DAPK1 expression levels were analysed in A549 lung cancer cells by SDS-PAGE/qWB, using HSP90 as a loading
control (m)
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respiration, and is predominantly upregulated in cancer cells
(Warburg effect), which cancer cells use to produce most of
their energy.18,27
Changes in aerobic and anaerobic respiration were
analysed by measuring the oxygen consumption rate (OCR),
an accurate indicator of mitochondrial respiration, and the
extracellular acidification rate (ECAR), an indirect measure-
ment of lactic acid production, with a Seahorse XF96 analyser
(Seahorse Bioscience, North Billerica, MA, USA; Figure 5).
OCR and EACR were determined under basal conditions in
siDAPK2- or siNS-transfected cells. The EACR in siDAPK2-
tranfected cells, measured inmpH/min, was normalised to that
in siNS-transfected control cells. No statistically significant
changes in EACRs were detected between siNS- and
siDAPK2-transfected U2OS (Figure 5b), or A549 (Figure 5h)
cells, suggesting that silencing DAPK2 did not skew metabo-
lism in these cells towards anaerobic respiration. OCR was
measured in pMoles/min and normalised as described above
for EACR measurements. In contrast to what was seen for
EACR, there was a significant decrease in OCRs by
mitochondria on DAPK2 knockdown in both U2OS
(Figure 5c) and A549 (Figure 5i) cells, suggesting that DAPK2
modulated mitochondrial respiration but not anaerobic
respiration.
To investigate further the consequences of DAPK2
depletion on cellular metabolism, levels of the coenzymes
nicotinamide adenine dinucleotide (NAD+) and nicotinamide
adenine dinucleotide phosphate (NADP+), as well as their
corresponding reduced forms (NADH and NADPH, respec-
tively), were analysed. During glycolysis and the TCA cycle,
each glucose molecule leads to the reduction of six NAD+ to
NADH, which are then oxidised during oxidative respiration to
produce ATP.26 In contrast to NADH, NADPH is not involved
in metabolic processes but it has an important role in the
regeneration of oxidised glutathione (GSH), a key antioxidant
in cells.28 Colorimetric assays were used to determine the
levels of NAD+ and NADH, as well as NADP+ and NADPH.
MPP+ was used to inhibit oxidative phosphorylation and
increase the levels of NAD+ and NADH. As shown for U2OS
(Figures 5d and e) and A549 cells (Figures 5j and k), the
control MPP+ treatment increased the levels of NAD+ and
NADH (albeit in A549 cells the increase in NADH was small
and not statistically significant). However, NAD+/NADH
levels remained unaffected by DAPK2 knockdown. Interest-
ingly, the levels of NADP+ and NADPH in U2OS cells (Figures
5f and g) appeared slightly decreased on silencing DAPK2,
whereas there was no detectable change in A549 cells
(Figures 5l and m). The data thus suggested that RNAi-
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Figure 4 Measurement of spontaneous mitochondrial membrane depolarisation after transfection with siDAPK2 using the TMRE probe. U2OS (a–c) and A549 (d and e) cells
were transfected with either siNS or siDAPK2. Forty-eight hours after transfection cells were incubated with TMRE and the fluorescence intensity in the red fluorescence channel
(PE) was measured by flow cytometry. CCCP (50 μM) was used to induce mitochondrial depolarisation (b and e). Staining intensity was quantified using geometric means of
three independent experiments and plotted as fold change (c and e). Data represent mean±S.E.M. of three independent expQ8 eriments and the statistical analysis was done using
Student’s t-test (paired, one tailed) (*Po0.05, **Po0.01)
DAPK2 regulates oxidative stress
CR Schlegel et al
6
Cell Death and Disease
MP
P+siN
S
siD
AP
K2
OCR
O
C
R
 (F
ol
d 
C
ha
ng
e)
siD
AP
K2
**
siD
AP
K2
*
OCR 
EC
AR
 (F
ol
d 
C
ha
ng
e)
siD
AP
K2
ns
EACR 
EC
AR
 (F
ol
d 
C
ha
ng
e)
siN
S
siN
S
siD
AP
K2
0.0
0.5
1.0
1.5
ns
EACR
Glucose
Glucose
Glycolysis
Pyruvate Lactate
TCA
cycle
NADH
ATP
CO2
H2O2
O2
ATP
OCR
ECAR
Anaerobic
NADH NADH NAD
+
Cellular Respiration Model
0.0
0.5
1.0
1.5
2.0
2.5
0
1
2
3
4
NA
D+
 (F
ol
d 
ch
an
ge
)
NA
DP
+  (
Fo
ld
 c
ha
ng
e)
NA
DP
+  (
Fo
ld
 c
ha
ng
e)
NA
DH
 (F
ol
d 
ch
an
ge
)
NA
DP
H 
(F
ol
d 
ch
an
ge
)
NA
DP
H 
(F
ol
d 
ch
an
ge
)
NA
D+
 (F
ol
d 
ch
an
ge
)
NA
DH
 (F
ol
d 
ch
an
ge
)
0
1
2
3
4
NADH
NADP+ NADPH NADP+ NADPH
NAD+ NADH
U2OS cells A549 cells
p=0.0504
**
p=0.0744
*
p=0.0881
NAD+
O
C
R
 (F
ol
d 
C
ha
ng
e)
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
siN
S
siN
S
0.0
0.5
1.0
1.5
2.0
2.5
MP
P+siN
S
siD
AP
K2
MP
P+siN
S
siD
AP
K2
MP
P+siN
S
siD
AP
K2
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
siN
S
siD
AP
K2 siN
S
siD
AP
K2 siN
S
siD
AP
K2 siN
S
siD
AP
K2
Figure 5 The absence of DAPK2 leads to reduced oxidative phosphorylation in U2OS and A549 cells. (a) Simplified cartoon depicting cellular metabolism pathways with
glycolysis as the first step of glucose breakdown, and oxidative phosphorylation and anaerobic respiration as subsequent steps. To quantify cellular metabolic processes, U2OS
(b–g) and A549 (h–m) cells were transfected with either siNS or DAPK2 siRNA. Forty-eight hours after transfection cells were analysed using a Seahorse Analyser. ECAR, an
indirect measurement of lactic acid production, is depicted as fold change of mpH/min and normalised to siNS control in U2OS (b) and A549 cells (h). OCR, which can be used to
determine mitochondrial respiration, is shown as fold change of pmol/min and normalised to siNS control in U2OS (c) and A549 cells (i). Forty-eight hours after siRNA
transfection, NAD+, NADH, NADP+ and NADPH levels were analysed using colorimetric assays in U2OS (d–g) and A549 cells (j–m). Treatment with MPP+ (1 mM, 24 h) served
as a positive control. Data represent mean± S.E.M. of three independent experiments, statistical analyses were done using Student’s t-test (paired, one tailed) (*Po0.05,
**Po0.01)
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mediated ablation of DAPK2 affected oxidative phosphoryla-
tion without substantially impacting on NAD+/NADH or
NADP+/NADPH metabolism.
Depletion of DAPK2 leads to decreased GSH levels and
induction of NRF2. Having established that genetic ablation
of DAPK2 led to changes in cellular oxidative stress,
mitochondrial respiration, activation of stress kinases and
upregulation of SODs in two distinct cancer cell types, we
next asked what effect downregulation of DAPK2 had on the
levels of GSH, which functions as an electron donor and is
involved in the reduction of cellular ROS.29,30 In fact, the
generation of oxidised GSH (GSSG) is tightly linked to
mitochondrial oxidative phosphorylation, whereby NADPH
reduces GSSG to GSH. To assess total GSH level, cells were
transfected as described earlier and a subtle, but statistically
significant, downregulation of GSH levels on DAPK2 knock-
down was detected, which was more prominent in U2OS
(Figure 6a) than in A549 cells (Figure 6e).
The question was whether such small reductions in GSH
levels were sufficient to induce nuclear factor (erythroid-
derived 2)-like 2 (NFE2L2/NRF2), which is responsible for the
transcription of a multitude of antioxidants that protect cells
from oxidative stress. NRF2 binds to the antioxidant response
element, leading to transcriptional activation of GSH synthe-
sising enzymes and other antioxidant enzymes, such as
SOD1 and SOD2, which were upregulated on DAPK2
silencing (Figures 1b and f). After U2OS and A549 cells were
transfected with siDAPK2 or siNS, RNA and proteins were
extracted and the levels of NRF2 and its ubiquitin ligase kelch-
like ECH-associated protein 1 (KEAP1) analysed. Interest-
ingly, NRF2 mRNA levels were significantly elevated in U2OS
cells (Figure 6b), but not in A549 cells (Figure 6f). KEAP1 was
not induced in either U2OS (Figure 6c) or A549 cells
(Figure 6g).
The mitochondrial-associated function of DAPK2 is likely
to be kinase mediated. The data thus far suggested that the
increase in intracellular ROS caused by downregulating
DAPK2 was due to an impairment of mitochondrial functions.
To understand how DAPK2 preserved mitochondrial integrity,
the relevance of DAPK2’s kinase domain was investigated.
For that purpose, tetracycline (Tet)-inducible U2OS cell lines
(U2OS-TetR) containing HA-tagged DAPK2 constructs that
were either wild-type (HA-DAPK2.wt) or kinase-dead (HA-
DAPK2.K42A)6 were used. The caveat with this approach is
that it was impossible to express the constructs at endogen-
ous levels and overexpression of DAPK2 is sufficient to
induce apoptotic features.6 This approach could not thus be
used experimentally to rescue the phenotype observed after
RNAi targeting DAPK2. It did, however, enable analysis of the
role of the kinase domain on the regulation of intracellular
oxidative stress.
Transgene expression was induced in HA-DAPK2.wt
(Figure 7a) and HA-DAPK2.K42A cells (Figure 7c) using
doxycycline (Dox) and ROS levels were measured using
DCFDA. As expected from previously published work, over-
expression of wild-type DAPK2, rather than leading to reduced
oxidative stress, led to an increase in general ROS production
(Figure 7b), but importantly this was not observed if cells
overexpressed a kinase-dead DAPK2 mutant (Figure 7d).
The overexpressed kinase-deadmutant (HA-DAPK2.K42A)
did not behave as a dominant-negative and did not mimic the
phenotype caused by DAPK2 silencing (Figure 7d). This might
be due to the cells still expressing endogenous wild-type
DAPK2. To eliminate the endogenous wild-type DAPK2 in the
inducible cell model, 3′UTR-specific siRNAs were used.
These molecules exclusively target endogenous DAPK2
(Figures 7e–h).9 Cells were transfected with either siNS or 3′
UTR-specific DAPK2 siRNA (henceforth siDAPK2–3′UTR)
and to induce HA-DAPK2.K42A expression cells were
stimulated with Dox as they were being transfected. As shown
in Figure 7e, siDAPK2–3′UTR specifically targeted endogen-
ous DAPK2 and did not impact on the expression of kinase-
dead DAPK2, which was detected using an anti-HA antibody.
Having established a cell system where it was possible to
efficiently downregulate endogenous DAPK2 and concomi-
tantly overexpress a kinase-dead DAPK2 mutant enabled
studying the effect of kinase-dead DAPK2 on the generation of
general ROS. Consistent with our previous results (Figure 1c),
depletion of wild-type DAPK2 without (Figure 7g, grey line) or
with overexpression of kinase-dead DAPK2 (Figure 7g, dotted
line), using siDAPK2–3′UTR, led in both cases to a significant
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A549 cells
siD
AP
K2
0.0
0.5
1.0
1.5
2.0
2.5
Fo
ld
 in
du
ct
io
n 
m
R
N
A
Fo
ld
 in
du
ct
io
n 
m
R
N
A
*
NRF2
0.0
0.5
1.0
1.5
R
el
at
iv
e 
G
SH
 le
ve
ls
R
el
at
iv
e 
G
SH
 le
ve
ls
siN
S
siD
AP
K2siN
S
siN
S
siD
AP
K2
***
GSH
siN
S
siD
AP
K2
NRF2
0.0
0.5
1.0
1.5
Fo
ld
 in
du
ct
io
n 
m
R
N
A
Fo
ld
 in
du
ct
io
n 
m
R
N
A
siN
S
siD
AP
K2
KEAP1
KEAP1
Un
tr
siD
AP
K2
***
GSH
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
Figure 6 Ablation of DAPK2 leads to decreased GSH levels, and in U2OS cells to
the induction of NRF2 mRNA. U Q92OS (a–c) and A549 (d–f) cells were transfected with
either siNS or siDAPK2, and the levels of GSH were analysed using a colorimetric
assay 24 h later (a and d). NRF2 (b and e) and KEAP1 (c and f) mRNA levels were
assessed by qPCR. Data re Q10present mean± S.E.M. of at least three independent
experiments and the statistical analyses were done using Student’s t-test (paired, one
tailed) (*Po0.05, **Po0.01, ***Po0.005)
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Figure 7 Effect of wild-type (wt) and kinase-dead (K42A) DAPK2 overexpression on oxidative stress. The expression of HA-tagged wild-type (wt) or HA-tagged kinase-dead
(K42A) DAPK2 in U2OS-TetR cells was induced using doxycycline (10 ng/ml). HA-DAPK2 (a) and HA-DAPK2.K42A (c) expression was verified by SDS-PAGE/qWB. The impact
of wild-type (b) or kinase-dead (d and f) DAPK2 overexpression on oxidative stress was analysed as described earlier using the DCFDA probe. To eliminate endogenous DAPK2
and study the effect of the kinase-dead DAPK2 mutant individually, U2OS-TetR cells containing the HA-DAPK2.K42A construct were transfected with either siNS or siDAPK2–3′
UTR and concomitantly stimulated with doxycycline (10 ng/ml). Targeted knockdown of endogenous DAPK2 and overexpression of HA-DAPK2.K42A were then assessed by
SDS-PAGE/qWB (e). The effect of the kinase-dead DAPK2 mutant overexpression, in the presence (f, grey line) and absence (g, dotted black line) of endogenous DAPK2, on
oxidative stress was quantified by flow cytometry with the DCFDA probe (f and g). Data were plotted as fold change of DCFDA fluorescence of U2OS-TetR cell transfected with
siDAPK2–3′UTR without doxycycline treatment (h). Statistical analysis was done using one-way ANOVA test (**Po0.01, ***Po0.005)
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increase in ROS (Figures 7g and h). The overexpression of
kinase-dead DAPK2, importantly, actually led to a significantly
higher level of oxidative stress in U2OS cells than the wild-type
endogenous protein (Figure 7h). In control cells transfected
with siNS, the level of oxidative stress was the same
regardless of the presence or absence of HA-DAPK2.K42A
(Figure 7f). Collectively, our data suggested that DAPK2
kinase activity was important for preserving mitochondria’s
integrity and protecting cells from oxidative stress.
Discussion
Although DAPK1–3 are structurally different, both DAPK2 and
DAPK3 evolved from DAPK1,31 which regulates mitochondrial
integrity2 and metabolic processes.3 Given the common
ancestry and sequence homology within DAPKs’ kinase
domains, common mechanisms of action and functional
redundancy have been postulated.32 Indeed, all three have
been associated with apoptotic processes and thought to be
potential tumour suppressors.18
Here we show that depletion of DAPK2 results in ROS
generation (Figures 1c, d, g and h), induction of SODs (Figures
1b and f) and phosphorylation/activation of MAPKs (Figures
1a and e). Mitochondrial SOD2 was induced more than
cytosolic SOD1 (Figures 1b and f), suggesting that in the
absence of DAPK2, increased levels of ROS were produced
by mitochondria.13 Additional experiments support this
hypothesis (Figures 2a–c and e–g) and indicate that the ER
is an unlikely additional ROS source (Figures 2d and h).
Silencing DAPK2 leads to increased spontaneous mitochon-
drial depolarisation (Figures 3a–l and Figure 4), and in A549
cells to the activation of DAPK1 (Figure 3m), thought to be a
Δψm sensor involved in cytoskeletal rearrangements respon-
sible for mitochondrial transport mechanisms.2 DAPK1 and
DAPK2 have also been reported to heterodimerise.32 It is thus
reasonable to assume that they may operate similarly with
regard to mitochondrial maintenance, sensing the mitochon-
drial membrane potential and leading to downstream pro-
cesses of mitophagy and mitochondrial degradation, which
result in faulty mitochondria. Interestingly, neither overexpres-
sion of DAPK1 nor DAPK2 has been shown to induce
mitochondrial depolarisation.6 Immunofluorescence analyses
using MitoTracker Red did not suggest any obvious mitochon-
drial morphological changes in cells devoid of DAPK2 (data
not shown).
DAPK2 knockdown leads to significantly reduced oxidative
phosphorylation without affecting lactic acid fermentation
(Figures 5b, c, h and i). This suggests a fundamental role for
DAPK2 in the regulation of mitochondrial metabolism and/or
maintenance. This, in turn, raises the question of how these
cells maintain their energy supply, without increased lactic
acid fermentation, DAPK2-depleted cells are unlikely to be
compensating the decrease in oxidative phosphorylation via
anaerobic respiration (Figure 5a). Consistent with this, no
significant changes in NAD+/NADH and/or NADP+/NADPH on
DAPK2 silencing are seen (Figures 5d–g and j–m). All
experiments were performed 48 h post RNAi. Thus, eventual
cellular compensatory mechanisms, such as increased
glycolytic rate or lactic acid production, may not yet be
detectable. For example, it has been shown that inhibition of
the mitochondrial electron transport by low doses of ethidium
bromide for 4 days causes NADH accumulation, halts the TCA
cycle and drives cells towards anaerobic glucose
metabolism.33
The ROS increase and mitochondrial depolarisation were
accompanied by a small, statistically significant, GSH
decrease (Figures 6a and e), and in U2OS cells by the
induction of NRF2 (Figure 6b). There was no induction of
NRF2 in A549 cells (Figure 6f) and the levels of KEAP1, a
NRF2 regulator,34 remained unchanged in both cell lines
(Figures 6c and g). SOD2 protein expression levels, unlike
what was observed at the mRNA level, did not vary with the
downregulation of DAPK2 expression. In fact, the expression
of GCLC, GPX1, GSTpi and GSS, enzymes involved in GSH
metabolism, did not change significantly either on RNAi
against DAPK2 (data not shown). These data thus suggest
that it is their enzymatic activity that matters, which is
corroborated by the GSH quantification shown in Figures 6a
and e, used as an indirect read-out for these enzymes.
Overexpression of HA-tagged wild-type DAPK2 per se
increases the levels of intracellular ROS in U2OS cells (with
endogenous DAPK2), whereas kinase-dead DAPK2 does not
(Figures 7a–d). In contrast, as previously shown,6 over-
expression of wild-type DAPK2 does not induce mitochondrial
ROS (data not shown). Interestingly, overexpression of the
kinase-dead mutant, in the absence of endogenous DAPK2,
leads to increased oxidative stress and this is greater than that
seen with the wild-type protein (Figures 7e–h). Collectively,
these data indicate that DAPK2 kinase activity is important for
preserving mitochondrial integrity and protecting cells from
oxidative stress.
DAPK2 is emerging as a tumour suppressor in several types
of cancer cells, especially in acute promyelocytic leukaemia,
which responds to treatment with all-trans retinoic acid
(ATRA).12 This is interesting as ATRA leads to increased
DAPK2 expression. Given the role of ROS in the aetiology of
AML,35 downregulation and/or loss of DAPK2 likely benefits
cancer cells by leading to deregulated mitochondria,
increased cellular ROS and, thus, genomic instability. Indeed,
somatic mitochondrial mutations and accumulated mitochon-
drial damage have been linked to AML development.36
Despite its relatively small size and straightforward structural
features, DAPK2 appears to be a double-edge sword,
depending on cellular context and interaction partners.
Indeed, recently, we have shown that downregulation of
endogenous DAPK2 activates NF-κB and sensitises multiple
cancer cell types to TRAIL-induced apoptosis but not to other
cytotoxic stimuli.9 NF-κB, another multi-faceted protein, can
also be activated by oxidative stress but TRAIL-induced
apoptosis appears to be independent of oxidative stress since
it can be blocked by caspase inhibitors (Supplementary Figure
S2), but these inhibitors do not impair the production of ROS
(Supplementary Figure S3) or mitochondrial depolarisation
(Supplementary Figure S4) seen after DAPK2 depletion.
Experiments using U2OS cells that express LC3–GFP (an
autophagy readout) suggest that depletion of DAPK2 also
affects autophagy, as in these cells nutrient starvation leads to
an increase in the expression of LC3I (data not shown). It is still
unclear if this directly impairs mitochondrial recycling, leading
to the accumulation of ‘faulty’ mitochondria, and if it
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contributes for the oxidative stress measured here. This is
entirely consistent with a novel report by Kimchi and co-
workers,37 where it is shown that DAPK2 is a novel mTORC1
kinase and therefore a novel regulator of autophagic pro-
cesses. How this relates to the regulation of NF-κB9 remains
under scrutiny.
We have thus identified a novel role for DAPK2 in the
regulation of mitochondrial integrity, as its absence leads to
mitochondrial depolarisation and increased oxidative stress.
This may be a mechanism by which, depending on the
intracellular context, DAPK2 can act as a tumour suppressor
gene. Importantly, as the effect of DAPK2 silencing on
mitochondrial respiration is conserved betweenmesenchymal
U2OS cells and epithelial A549 cells, it is likely that our
findings can be further extended to additional cell lineages and
malignancies.
Materials and Methods
Cell culture. U2OS and A549 cells were grown in Dulbecco’s Modified Eagle’s
medium (DMEM) supplemented with 10% (v/v) foetal calf serum (FCS) (FirstLink,
Wolverhampton, UK), 2 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml
streptomycin (henceforth referred to as ‘complete DMEM’), in a humidified
atmosphere of 10% CO2 at 37 °C.Q2 The U2OS-TetR cell line was provided by
Johnsen and co-workers38 and cultured in full DMEM media supplemented with
5 μg/ml blasticidine S hydrochloride. All chemicals were from SigQ3 ma-Aldrich, unless
otherwise specified.
Plasmids. N-terQ4 minal HA-tagged wild-type and kinase-dead (K42A) DAPK2
pcDNA3 plasmids were kindly provided by Kimchi and co-workers.6 Both constructs
were sub-cloned using BamHI and XhoI restriction sites into a pcQ5 DNA4/TO vector,
which is part of the Tet-inducible mammalian expression system, T-REx System
(Life Technologies, Paisley, UK).
Generation of stable inducible cell lines. HA-tagged DAPK2 wild-type
and kinase-dead (K42A) constructs, cloned into the pcDNA4/TO vector, were
linearised using the restriction enzyme PvuI (New England Biolabs, Hitchin, UK)
and transfected into U2OS-TetR cells using Lipofectamine 2000 (Life Technologies),
as instructed by the manufacturer. Forty-eight hours later, cells were re-plated and
incubated with complete DMEM supplemented with 5 μg/ml blasticidine S
hydrochloride and 500 μg/ml Zeocin (Life Technologies). Individual clones were
isolated using cloning cylinders and tested for induction of the transgene and
background expression by SDS-PAGE/qWB. For each construct, at least five
inducible clones were generated and tested.
Antibodies. The anti-DAPK2 antibody was purchased from Epitomics
(Burlingame, CA, USA); anti-phospho-DAPK1 (Ser308) and DAPK1 from Abcam
(Cambridge, UK); antibodies against phospho-ERK1/2 (Thr202/Tyr204), phospho-
p38 MAPK (Thr180/Tyr182), phospho-JNK (Thr183/Tyr185) and CHOP from Cell
Signaling Technology (Cambridge, UK); antibodies against HA, β-actin and α-
tubulin from Sigma-Aldrich; anti- HSP90 (HSP86) from NeoMarkers (Fremont, CA,
USA); antibodies against ERK1/2 and Lamin B were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Anti-mouse and anti-rabbit secondary antibodies were from
DAKO (Glostrup, Denmark) and the anti-goat antibody was from Sigma-Aldrich.
RNA interference. RNAi was performed using Lipofectamine RNAiMax (Life
Technologies), essentially as described in ref. 39. For forward siRNA transfection
cells, plated at a density of 2.5 × 105 in six-well plates, were left untransfected, or
were transfected with either 20 nM AllStars non-targeting control siRNA (siNS)
(Qiagen, Hilden, Germany), 20 nM of a siDAPK2 pool (siRNA oligonucleotides 3
and 4 from Dharmacon, Lafayette, CO, USA) or with either of two different 3′UTR-
specific siRNAs (from Dharmacon or Qiagen). Cells were then treated and analysed
as described in the figures using methods described below. Reverse siRNA
transfections were carried out in 10 cm dishes using 5 × 105 cells in suspension
(8 ml). Cells were left untransfected or were mixed with transfection reagent and
either 20 nM siNS or siDAPK2. All siRNA oligonucleotide sequences are listed on
Supplementary Table SI.
Protein expression analysis. Proteins were extracted using radioimmuno-
precipitation assay buffer (50 mM Tris-HCl pH 7.4; 0.5% (v/v) NP-40, 150 mM NaCl,
1 mM EDTA, 1 mM Na3VO4 and cOmplete and Mini, EDTA-free protease inhibitor
cocktail, the latter used as instructed by the manufacturer (Roche, Mannheim,
Germany)). Concentrations were determined using a Bradford assay according to
the manufacturer’s instructions (BioRad, Hercules, CA, USA). They were then
analysed by SDS-PAGE/ qWB. Membranes were blocked using 5% (w/v) non-fat
milk/TBS-Tween 20, which was the buffer also used to dilute secondary antibodies.
Primary antibodies were diluted in 5% (w/v) BSA/ TBS-Tween 20. WBs were
analysed using the quantitative luminescence system FUSION Solo (PEQLAB,
Sarisbury Green, UK). Images were analysed using Image Studio Lite software (LI-
COR Biosciences, Lincoln, NE, USA) (www.licor.com/islite). The WB images have
been cropped for clarity purposes: that has in no way altered the essence of the
data obtained in three independent experiments.
Detection of oxidative stress by flow cytometry. Cells were cultured
in six-well plates and transfected with siRNA oligonucleotides as described before,
or treated with 0.5 mM H2O2 for 24 h, which was used as a positive control for ROS
production. General ROS were detected using CM-H2DCFDA ( Q6Molecular Probes,
Life Technologies; referred throughout the text as DCFDA). For that purpose, cells
were incubated with 10 μM DCFDA dissolved in pre-warmed PBS for 30 min at 37 °
C. Cells were then trypsinised, resuspended in complete DMEM, washed twice with
PBS and analysed by flow cytometry. Cellular superoxide anions were detected
using DHE (Molecular Probes) 48 h after transfection. Essentially, cells were
trypsinised, resuspended in complete DMEM, washed twice with PBS, incubated in
10 μM DHE dissolved in pre-warmed PBS for 15 min and analysed by flow
cytometry. Mitochondrial superoxide anions were measured using the MitoSOX Red
mitochondrial superoxide indicator. Briefly, cells were transfected as described
earlier, or they were treated for 24 h with 1 mM MPP+, or with 0.5 mM H2O2, the
latter two used as positive controls. Forty-eight hours later, cells were washed with
PBS and incubated for 10 min at 37 °C in the dark with 5 μM MitoSOX Red reagent
diluted in pre-warmed PBS. Samples were subsequently washed twice with PBS
before being analysed. Depolarised mitochondria were quantified using the
MitoProbe 5ʹ,6,6ʹ-tetrachloro-1,1ʹ,3,3ʹ-tetraethylbenzimidazolylcarbocyanine iodide
(JC-1) Assay Kit and Tetramethylrhodamine, ethyl Ester, perchlorate (TMRE;
Molecular Probes). For JC-1 staining, 48 h after transfection, cells were trypsinised,
resuspended in complete DMEM, washed twice with PBS and incubated with 2 μM
JC-1 dissolved in pre-warmed PBS at 37 °C, 10% CO2 for 15 min and analysed by
flow cytometry. TMRE staining was performed as follows: 48 h after transfection
cells were incubated with 100 nM TMRE dissolved in pre-warmed complete DMEM
at 37 °C, 10% CO2 for 10 min and analysed by flow cytometry. To induce complete
mitochondrial depolarisation, the protonophore CCCP (50 mM) was used for 5 min
prior to the incubation of cells with JC-1 and TMRE.
All flow cytometry analyses were performed using a FACS Canto (Becton
Dickinson, Franklin Lakes, NJ, USA) and data mining was done using FlowJo (Tree
Star, Inc., Ashland, OR, USA). Fluorescence geometric means were used for the
analyses and samples were normalised to siNS-transfected control cells, essentially
as described earlier.39
Induction of ER stress. ER stress was induced using the glycosylation
inhibitor tunicamycin (0.5 μg/ml, 24 h) and monitored by SDS-PAGE/qWB using
CHOP expression as a read-out.
Real-time quantitative PCR. Gene expression analysis was done by
quantitative two-step reverse transcription PCR. Reverse transcription was
performed using total RNA and a High Capacity cDNA Reverse Transcription kit
(Life Technologies), using random hexamers. Quantitative PCR (qPCR) was done
using the Fast SYBR Green Master Mix (Life Technologies) with specific primer
pairs (Supplementary Table SII). For each target mRNA analysed, 2.5 μl of Fast
SYBR Green Master Mix, 0.5 μM of each primer pair and 2 μl of cDNA in deionised
water (5 ng/μl) were mixed in 384-well plates in duplicates using Matrix Equalizer
Electronic Multichannel Pipetters (Thermo Fisher Scientific, Loughborough, UK).
qPCR was carried out on an ABI PRISM 7900HT (Applied Biosystems, Foster City,
CA, USA) using the following settings: initial activation of 20ʺ at 95 °C, 40 cycles;
denaturation for 1ʹ at 95 °C; annealing/extension for 20ʺ at 60 °C; final melting curve
was carried out for 15ʺ at 95 °C and then for 15ʺ at 60 °C. Quantification of target
messages was performed using qbasePLUS software (Biogazelle, Ghent, Belgium).
HPRT and GAPDH were the reference genes used for normalisation.
DAPK2 regulates oxidative stress
CR Schlegel et al
11
Cell Death and Disease
Metabolic analyses. Metabolic measurements were done in real-time, non-
invasively, using a Seahorse XF96 analyser, which measured the OCR and the ECAR
under basal conditions in siDAPK2- or siNS-transfected cells. A cell titration assay
was used to determine a suitable cell plating density for both A549 and U2OS cells.
For the experiment proper, 0.5 × 106 cells were plated per 10 cm dish and reverse
transfected on day 1 as previously described. Forty-eight hours post transfection, cells
were re-plated into the XF96 microplates (Seahorse Bioscience; 4 × 104 cells per
100 μl per well) and incubated overnight at 37 °C. The XF calibration solution was
added into the XF sensor cartridge and was also incubated at 37 °C overnight but
without CO2. The next day, prior to the assay, complete DMEM was replaced with an
XF AsQ7 say Medium Modified DMEM (1 g/ml glucose, pH 7.4) and cells were incubated
at 37 °C for 1 h without CO2. Analyses were performed according to the
manufacturer’s instructions using eight measurements that the instrument recorded
for OCR (nmoles/min) and ECAR (mpH/min) pertaining to each well. Results were
analysed using the provided XFe Wave software (Seahorse Bioscience).
GSH colorimetric assay. Cells (2.5 × 105 per well in 6-well plates) were
transfected with siRNA oligonucleotides as described earlier. Cell lysates were collected
and sonicated in 50 mM PBS per 1 mM EDTA. Protein concentrations were determined
using a Bradford assay, according to the manufacturer’s instructions, which enabled
subsequent normalisation of each sample so that the final protein concentration was
1 μg/μl. GSH levels in each sample were quantified using the Glutathione Assay Kit
from BioAssay Systems (Hayward, CA, USA), as per the manufacturer’s protocol.
NADH and NADPH assay. Reverse siRNA transfections were carried out in
10-cm dishes using 5 × 105 cells in suspension. As positive control, cells were
treated for 24 h with 1 mM of MPP+. Forty-eight hours after transfection, NADP/
NADPH levels for each sample were quantified using the NADP/NADPH assay kit
(Abcam) and NAD/NADH levels using the NAD/NADH assay kit (BioVision, San
Francisco, CA, USA), according to the two manufacturers’ protocols.
Statistical analysis. Mean± S.E.M. of at least three independent experiments
were used throughout. ANOVA or t-test statistical analyses were carried out as
indicated in each figure legend using GraphPad Prism (GraphPad Software Inc.,
San Diego, CA, USA).
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